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Bone metastases are common in malignancy and cause morbidity.  However, assessing 
treatment response of bone metastases with morphological changes is insensitive, variable and 
lacks specificity.  This thesis reports initial recruitment data from three prospective trials, 
examining the potential role of functional imaging methods as early biomarkers of response and 
prognosis.  Breast and prostate cancer patients with bone metastases had 18F-Fluoride Positron 
Emission Tomography (PET) and Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) 
before treatment and again at 8-12 weeks following treatment commencement.  Clinical response 
outcomes were appraised up to 24 weeks.  For both imaging methods, there were significant 
differences in the parameters between breast and prostate metastases reflecting different bone 
metastasis pathophysiology of these tumours, and significant intra-patient inter-lesion 
heterogeneity was evident. 18F-Fluoride per-lesion analysis (62 lesions) identified:  an increase in 
SUVmax (p=0.048predicted for treatment response, a lower SUVmean/max/peak/entropy/Ki and higher 
SUVenergy before treatment were significantly associated with OS benefit (all p<0.05) and higher 
%ΔSUVmean/max/peak/entropy/Ki, and lower %ΔSUVenergy at 8 weeks were significantly associated with 
an OS benefit (all p<0.05).  DW-MRI per-lesion analysis (92 lesions) identified a higher %ΔADC 
predicted for treatment response (p=0.029) and a lower baseline ADC is prognostic of OS 
(p<0.05).    Per-patient analyses (18F-Fluoride PET n=12; DW-MRI n=20) yielded less predictive 
and prognostic value, and have demonstrated the significant impact of VOI definition methods on 
the 18F-Fluoride quantification.  Whole-body methods have been developed for DW-MRI and 18F-
Fluoride PET to enable quantification of the heterogeneous skeletal metastatic burden; whole-
body parameters were not more predictive or prognostic than per-patient analyses.  DW-MRI and 
18F-Fluoride PET have shown potential as early imaging biomarkers of treatment response and 
prognosis for bone metastases in breast and prostate cancer, and significant methodological 
factors have been considered, aiming to achieve practical clinical utility of these techniques. 
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Chapter 1  Introduction 
1.1 Bone Metastases 
Bone is a common site for metastatic spread, and results in significant morbidity.  Advances in 
therapies means patients survive longer with such disease.  Breast and prostate cancers account 
for 80% of metastatic bone disease1, both causing bone metastases in 65-75% of patients1.  85% 
of breast cancer patients at autopsy have bone metastases2, exceeding the incidence identified 
during life with conventional imaging.  
Different cancers have different predilection for bone involvement highlighting the significance of 
the underlying pathophysiology, including molecular and cellular biological characteristics, both 
of the metastatic cells and the tissues they spread to3.  This was recognised by Paget in his 1889, 
‘seed and soil’ hypothesis4.  Most metastatic cells spread to bone via the blood5.  Axial skeletal 
bones contain most of the blood-rich red bone marrow were 90% of deposits are identified6, 
providing a large blood supply and the opportunity for ‘blood stagnation’5. 
Normal bone is in a dynamic state of resorption and remodelling, coordinated by osteoclasts and 
osteoblasts7.  Osteoclasts produce proteolytic enzymes and hydrogen ions in the localised 
environment adjacent to their ruffled border7.  Coupled to bone resorption is new bone formation 
by osteoblasts, which produce the proteins of the bone matrix (primarily type I collagen)7 and 
alkaline phosphatase, which are clinical markers of osteoblastic activity.  This osteoid matrix is 
mineralised with hydroxyapatite crystals. 
Once metastatic cells have become established, factors leading to osteoclast-mediated bone 
destruction are secreted.  Receptor activator of nuclear factor kappa-B (RANK) and its ligand 
(RANKL) are the final common mediators for osteoclast maturation and activation in metastases. 
Growth factors (including transforming growth factor beta (TGF-β), prostaglandin-E, epidermal 
growth factor, tumour necrosis factor and interleukin-17) are then released from the damaged 
bone matrix, further stimulating tumour cell growth, and potentiating the secretion of more bone-
resorbing factors, enhancing osteolysis – the ‘vicious cycle’ of bone metastases8.  TGF-β 
enhances osteoclast formation from precursor cells, inhibits osteoblast differentiation (thereby 
inhibiting new bone formation), and promotes the expression of parathyroid hormone related 
peptide which further enhances bone invasion by the tumour9.  Osteoclast involvement is 
observed in all types of metastatic bone deposit, whether lytic or blastic.  Raised levels of RANKL 
causing cancer-induced osteoclastogenesis result from both the infiltrating immune cells and 
reactive changes within bone, but also RANKL expression has been reported in several tumour 
types, including breast and prostate cancer10.   
Metastatic bone deposits can be primarily osteolytic (50%11), sclerotic (35%11, particularly in 
prostate cancer deposits) or mixed (15%, particularly breast cancers5).  Osteoblast growth factors 
(including TGF-β and platelet-derived growth factor) have been isolated from prostate tumours7, 
and goes some way to explain this particular pattern of bony metastatic spread.  More anaplastic 
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tumours, rapidly growing or those confined to the bone marrow tend to cause less osteoblastic 
stimulation5, and lytic lesions result.  
1.1.1 Prostate Cancer Bone Metastases 
Prostate cancer is the most common cancer affecting men in the developed world and the 
incidence is rising.   In the UK there were 40,460 new cases of prostate cancer diagnosed each 
year between 2008 and 201012, forming nearly 26% of male cancers (excluding non-melanoma 
skin cancers) in England, similar to the incidence of 27% in the USA13.   The age-specific mortality 
and absolute number of deaths from prostate cancer have both been decreasing since 199314. 
Prostate cancer spreads to the bone in approximately 90% of patients with advanced prostate 
cancer15.  The preference for human bone by prostate cancer metastases has been demonstrated 
in animal models16.  Prostate cancer metastases preferentially attach to the endothelium of bone 
marrow through the interaction of chemo-attractants17, including stromal-derived factor-118. 
Koeneman et al.19 raised a hypothesis of ‘oestomimetic’ properties of prostate cancer cells, 
suggesting prostate cancer cells exhibit properties similar to the native bone cells, resulting in dis-
regulation of the normal bone turnover.  Despite the sclerotic clinical findings, prostate cancer 
bone metastases result in increased activity of both osteoclasts and osteoblasts.  
Bisphosphonates have been successfully used to inhibit osteoclast bone degradation, and proven 
reduction in skeletal related events (including pathological fracture)20 in prostate cancer patients.  
Serum markers of bone degradation (including type I collagen C-telopeptides (CTX)) which 
demonstrate enhanced osteoclastic activity are significantly higher in prostate cancer patients21 
Bisphosphonate therapy is effective in reducing bone pain in patients with hormone refractory 
prostate cancer22, suggesting morbidity results from osteoclastic action rather than the more 
clinically evident osteoblastic driven sequelae. 
1.1.2 Breast Cancer Bone Metastases 
Breast cancer is the most common malignancy in women in the UK, with 41523 new diagnoses 
in 201123.  Up to 75% of patients with metastatic breast cancer have bone metastases2,24,25, with 
isolated bone metastases seen in around 20% of patients26.  Osteolytic lesions reflect increased 
bone resorption by the osteoclasts, but the osteoclast formation and activity is regulated by the 
osteoblast27. 
Several bone targeted treatments are now approved for breast cancer patients with bone 
metastases, and are considered as standard of care28-30.  These treatments include 
bisphosphonates and RANKL inhibitors.  Bisphosphonates induce apoptosis of osteoclasts, 
thereby inhibiting bone resorption31.  The RANKL pathway is responsible for the stimulation of 
osteoclasts by osteoblasts; osteoclast precursors express the cell surface receptor RANK which 
can be bound by RANKL expressed on activated osteoblasts.  This interaction is targeted by anti-
RANKL therapies, including Denosumab, a monoclonal antibody targeting the receptor activator 
of RANK-L, preventing activation of RANK on the osteoclast surface.  Denosumab therapy in 
breast and prostate cancer reduces bone resorption, tumour induced bone destruction, and 
skeletal related events32,33.  
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1.1.3 Imaging Bone Metastases 
Bone metastases disrupt the balance between osteoclastic and osteoblastic activity, resulting in 
sclerotic or lytic bone lesions; the effect on bone architecture is identified with conventional 
imaging methods. 
1.1.3.1 Plain X-Rays 
Plain X-rays are frequently used for the initial skeletal assessment.  Plain X-rays are relatively 
insensitive (44-50% less sensitive than skeletal scintigraphy34 for breast cancer bone metastases) 
and only have a limited role in monitoring asymptomatic metastases35, particularly in trabecular 
bone disease with the limited contrast between benign and malignant tissue.  50-70% of bone 
must be lost to be visible on simple plain films36,37  Typically, osteolytic bone lesions will result in 
thinning of the trabeculae with an ill-defined margin on plain X-ray imaging38.  Sclerotic disease 
causes nodular, rounded and commonly well circumscribed lesions secondary to trabeculae 
thickening38. 
Sclerosis is a likely outcome of a treatment response.  This process starts at the periphery of a 
lesion and progresses towards the centre of a lesion38.  However, it may take many months for 
this change to be identified on plain films (typically 3-6 months). 
Plain films still have an important role for identification and assessment of bone metastases, but 
largely to provide confirmatory information for other imaging modalities, or to assess fracture risk. 
1.1.3.2 CT 
Computed tomography (CT) detects bone metastases with a sensitivity of 74% and specificity of 
56%.  Such imaging has advantages over plain-film assessment, with increased contrast, and the 
ability to apply bone-specific algorithms and window widths and levels, the ability to view images 
in multiple planes, and utilisation of the contrast between bone cortex and marrow.  CT can often 
demonstrate bone marrow metastases before cortex bone destruction is demonstrable39.   
1.1.3.3 MRI 
Magnetic Resonance Imaging (MRI) is a term encompassing a range of imaging techniques 
utilising on the phenomenon of nuclear magnetic resonance.  Nuclei of atoms, when exposed to 
a magnetic field, absorb and re-emit electromagnetic radiation.  The energy absorbed and re-
emitted by a nucleus is influenced by the atomic isotope, the local environment of the nucleus, 
and the magnetic field strength.  Not all nuclei resonate at precisely the same frequency because 
the immediate magnetic environment is affected by surrounding subatomic particles, particularly 
electrons; electrons can shield the atomic nuclei from the external applied magnetic field.  This 
discrepancy is exploited to differentiate between tissues. 
For clinical magnetic resonance imaging, a static magnetic field within the scanner causes 
hydrogen nuclei (protons) within the subject to line up along the magnetic field (often referred to 
as the B0 field).  These protons will be aligned directly with the field, or directly counter-aligned 
(i.e. at 180o), but all along the z-axis (along the B0 field).  This process is not quite random, and 
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there is an unequal distribution between these two alignments.  There is a slight bias towards 
protons being aligned in the direction of the B0 field, resulting in a net magnetisation in the 
direction of the magnetic field.  A radio frequency pulse (B1 field) to match the natural resonant 
frequency of protons is applied perpendicular to the B0 field.  This energy is absorbed, raising the 
nuclei to a higher energy state, which knocks the protons out of alignment with the B0 magnetic 
field, and the magnetisation vector rotates by 900 into the x-y axis.  This shift in the magnetisation 
can be detected by the MRI scanner.  
The protons, knocked out of alignment with the primary magnetic field, return to their original 
positions once the radio-frequency pulse has passed.  This process is termed relaxation, and is 
a measure of how quickly the net magnetisation vector returns to its ground state.  There are 
several ways the relaxation process can be described.   
T1 relaxation time is a measure of how fast the net magnetism vector returns to the original state 
in the direction of the B0 field.  During this process the previously excited nuclei return to their low 
energy state, and the energy they gained is lost to the surrounding tissues.   
When the radio-frequency pulse knocks the protons into rotation in the x-y axis, not all the protons 
spin at the same speed; they are out of phase.  T2 relaxation describes how the protons relax 
back into phase along the x-y axis.  This happens quicker than the T1 relaxation.  
Different tissues exhibit different proton densities and have different T1 and T2 relaxation 
characteristics.  Images can be taken emphasising these characteristics by altering variables of 
the scan, including the time between radio frequency pulses.  The more time between pulses, the 
more T1 or longitudinal relaxation is achieved, emphasising T1 signal.  T2 weighed images are 
gained by changing the echo time, which refers to the time between the radio frequency pulse 
and the MR signal sampling. 
On T1-weighted images, bone metastases can be identified as hypo-intense lesions against a 
background of marrow which return a higher signal intensity.  On a T2-weighted sequence, bone 
metastases usually demonstrate T2 hyper-intensity due to their elevated water content38. 
MRI is not without limitations.  Cortical bone has a short T2-relaxation time and is poorly 
characterised with MRI.  Bone with a low marrow content, such as ribs, might be imaged better 
with CT39.   
1.1.3.3.1 Diffusion-Weighted MRI 
The resonance frequency of protons is dependent on the strength of the magnetic field.  If a 
sample is placed in a magnetic-field gradient, the protons within the sample will display a range 
of resonance frequencies.  This characteristic is exploited to enable measurement of the ability 
of water to move freely within a sample. 
Free water molecules have kinetic energy, related to temperature.  This energy, translated into 
movement through thermal convection currents, causes the Brownian motion of particles 
suspended in water.  On the atomic level this means water molecules are always on the move.  If 
there are barriers preventing free movement, water molecule will move less far over a given time 
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than if the molecule has no obstruction to free movement.  At 37oC the average displacement of 
water molecules is 0.6micrometers/ms40.  It is this freedom of random motion of water content in 
tissues measured through ‘apparent diffusivity’, or diffusion weighted imaging, by measuring the 
effective displacement of water molecules over a given time period41.  This can be quantified 
using MR imaging techniques. 
Whereas more simple MR imaging relies on one magnetic field (B0) and a radio frequency pulse 
applied at 90o, diffusion-weighted imaging requires additional magnetic fields, applied as non-
uniform gradients.  The first of these alters the phase of each proton of water molecules, but the 
amount of phase shift is relative to each proton’s position within the B0 field.  The second 
additional gradient pulse is equal in magnitude, but opposite in direction, to the first.  If the proton 
has not moved between these two pulses the net effect will be a complete reversal of the original 
phase shift, termed a ‘re-phasing’, and a full signal is received by the MRI scanner.  However, if 
the proton has moved in-between the first and second pulse gradients then complete re-phasing 
is not achieved; the degree of re-phasing is proportional to the magnitude (and the direction) of 
movement of the proton.   
Where water can move freely one might anticipate more signal loss than where water movement 
is restricted in some way, and this is dependent on the architecture of the tissue being examined42.  
Cancer deposits generally have a higher cell density then benign and normal tissues, and can 
have a higher water and protein content43.  Cancer tissues tend to exhibit restriction of water 
diffusion.  Other factors impacting water diffusivity within tissues include cell density, cell 
nuclear:cytoplasm ratio, integrity of the cellular membranes and the extra-cellular space 
architecture43, the presence of necrosis, and the architecture of the extracellular extravascular 
space. 
The image sensitivity to diffusion is commonly referred to as the b-value.  This b-value can be 
altered by changing the time between the two additional gradient pulses, and by altering the size 
of the gradient.  The greater the b-value, the more sensitive the imaging to diffusion, and smaller 
diffusion differences are detected.  Signal-to-noise ratio (SNR) and the T2-relaxation rates limited 
the interval for diffusion measurement usually within 40-80ms41.  An apparent diffusion coefficient 
(ADC) map is generated using different b-values, typically including one with no diffusion 
weighting.  By combining these maps, it is possible to create an ADC map free of the influencing 
factors other than the movement of water. 
DW-MRI is very sensitive to movement artefact.  Small movements caused by pulsatile 
arteries/arterioles can interfere with measurements, and there are larger patient factors including 
breathing, peristalsis and muscular movements42.  Other artifacts result from areas of large 
variations in magnetic susceptibility, including airspaces in the lungs.  Fat and soft tissue 
interfaces can result with artifacts, but modern DW-MRI imaging is always performed with fat-
suppression, which limits the impact from this.  The skeleton, however, is likely to be less affected 
by organ movement, and by areas of large magnetic field inhomogeneities. 
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1.1.3.3.2 Detection of bone metastases with MRI 
MRI offers an advantage because it is sensitive to early changes within the bone marrow, changes 
occurring before the osteoclastic/osteoblastic response of the bone matrix44 imaged with the other 
techniques. 
MRI techniques have diagnostic advantages over other imaging techniques for characterisation 
of skeletal metastases45-52 and has utility for complementary information to standard scintigraphic 
skeletal evaluation, identifying different lesions to those detected with scintigraphy53.  Technical 
advances in the use of diffusion-weighted MRI imaging have led to its increased use for 
characterising bone metastases.  Calculation of ADC values allows differentiation of benign from 
malignant tissue, e.g. head and neck tumours54 and breast tumours55-57.  Byun et al.58 recorded 
the ADC of spinal metastases, and generated a method to use serial ADC measurements to 
monitor radiotherapy response.  They reported bone metastases with an ADC of 0.780.03x10-3 
mm2/s compared with 0.330.03x10-3 mm2/s of normal marrow.  Following radiotherapy 
treatment, the group reported the ADC increased to 1.22  0.02x10-3 mm2/s, when reviewing the 
23 patients with a symptomatic benefit from radiotherapy; T1 and T2 MRI imaging of the same 
lesions did not identify any changes, suggesting the benefit of using ADC quantification to monitor 
therapy responses58. 
1.1.3.4 Bone Scintigraphy 
99mTechnetium (99mTc)-based bone-specific bisphosphonate-related radiopharmaceuticals, bind 
to the hydroxyapatite crystals mineralising the osteoid matrix created by osteoblasts in response 
to bone damage and normal bone turnover.  This binding is proportional to the local blood flow, 
the osteoblastic activity59 and the efficiency of extraction38.  Imaging changes in osteoblastic 
metabolism confers clear advantages over cross-sectional imaging; 99mTc-MDP bone scintigraphy 
is sufficiently sensitive to detect a 5% change in osteoblastic turnover60, whereas a 50% loss of 
bone mineral may be required for detection on radiographic imaging60.  This translates into a 
sensitivity of 99mTc-MDP scintigraphy of between 70% and 100%60, depending on the type and 
site of the tumour.  Talbot et al. report a sensitivity of 78% and a specificity of 48%61. 
Planar bone scintigraphy can result in false-negative scans of 50%62, particularly for purely lytic 
or early lesions.  Scintigraphy does not identify early marrow involvement, although the bone-
scan can become positive relatively early in the progression of a metastatic lesion as an 
osteoblastic reaction occurs6.  MRI imaging, by contrast, can identify the early marrow oedema 
and other changes indicative of marrow infiltration by tumour6.  A visible osteoblastic response 
may not result from aggressive or purely lytic metastases63; this phenomenon commonly occurs 
in myeloma, and a bone scan is not routinely recommended for evaluating such diseases63. 
Bone scintigraphy is often criticised for having a low specificity60,64 because false-positive findings 
on bone scan are common, particularly in the elderly population who have arthritic changes, but 
are also most at risk of malignancy65.  The sensitivity of planar bone scintigraphy is dependent on 
the anatomic site of bony disease, with a sensitivity for spinal and pelvic deposits of only 40%66.  
Unfortunately, the spine is the most common site of metastatic deposits for prostate cancer67.   
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Single Photon Emission Computed Tomography (SPECT) images can be obtained, improving 
lesion detection and localisation68.  Compared with planar scintigraphy, SPECT has higher 
sensitivity (87% vs. 74%68), specificity (91% vs. 81%68) and greater diagnostic accuracy, 
particularly for vertebral metastases69.  SPECT imaging can provide useful information in the 
evaluation of the spine, skull and pelvis, by increasing contrast resolution5 and allowing 
appreciation of both the three-dimensional anatomy and the pattern of uptake.  It is possible to 
detect more bone lesions with SPECT compared to planar scintigraphy, and by being able to 
accurately locate the position, the differentiation between benign and malignant lesions is more 
accurate59,65.  One study suggested high-resolution vertebral SPECT produced results 
comparable with MRI in detecting vertebral metastases, and superior to MRI in the detection of 
osseous extra-vertebral body metastases70.  The addition of CT to SPECT has improved the 
diagnostic accuracy, and improved inter-observer variation significantly71. 
1.1.3.5 Positron Emission Tomography (PET) 
1.1.3.5.1 Basic principles of PET 
The radiation emission from single photon emitting nuclides has proven, with SPECT, to be a 
valuable diagnostic tool.  The spatial localisation of the tracer accumulation is limited by the 
random direction in which the emitted gamma-rays can travel.  Collimators are used to ensure 
only gamma-rays travelling near perpendicular to the detectors are admitted into the camera, 
providing spatial orientation of the originating decay, minimising the impact of scatter.  However, 
this reduces the efficiency of the imaging system.  Detection of a pair of gamma photons, 
produced at 180o to each other from the same point of origin theoretically eliminates the need for 
a collimator as only ‘paired’ photons are counted.  This is the basis for PET imaging. 
The phenomenon of positron annihilation, resulting in the generation of two high energy photons 
at almost 180o to each other, has revolutionised nuclear functional imaging.  Some radionuclides 
emit positrons during radioactive decay.  Positrons are electrons with a positive charge, and have 
limited penetrating power through tissues.  When these positrons encounter a normal negatively 
charged electron an annihilation reaction occurs during which both particles are converted into 
energy, emitted as two photons, both with energy of 511keV, travelling out in a straight line from 
the focus of annihilation at almost 180o degrees to each other.  Detectors are placed in a ring 
around the body to collect the photons for quantification.  The detection of this pair of electron 
almost simultaneously, but on opposite sides of the detection ring, identifies a line through the 
patient along which the original annihilation reaction occurred.  The point of origin is unlikely to 
be equidistant between the two opposed receptors, and one photon is likely to be detected 
fractionally before it’s pair.  More recent scanning technology has enabled further spatial 
resolution by utilising this ‘time of flight’ discrepancy to identify where along the line creased by 
the two opposed photons the annihilation reaction was likely to have occurred.  The detection of 
the emitted radiation from all around the patient enables 3D reconstruction of the images, and all 
modern PET scanners have an integrated CT scanner - images from both can be superimposed.  
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Alongside the development of the PET/CT imaging technique has been the synthesis of radio-
labelled tracers enabling the targeting of specific tissues, cellular functions or metabolic pathways.  
1.1.3.5.2 Qualitative assessment of PET 
Qualitative analysis of PET images has a significant role in routine clinical care, both at the level 
of diagnosis, and to assess disease response.  After treatment, no abnormal tissue should persist 
if a cure is to be achieved, and no abnormal tracer uptake should be seen.  In this way, PET 
imaging, particularly with 18F-FDG, has a significant role in identifying patients with residual 
disease after therapy.  One well established qualitative assessment standardisation is the 
Deauville Score for recording the chemotherapy response of Hodgkin’s Lymphoma72, using the 
liver and mediastinum to reference abnormal 18F-FDG tracer uptake, with strong predictive 
value73. 
1.1.3.5.3 Quantitative assessment of PET 
Quantification of PET images can provide additional complementary information to the qualitative 
analysis, and is potentially more reproducible.  Lin et al.74 showed greater accuracy in prediction 
of event free survival using SUV quantification of a mid-treatment 18F-FDG PET scan rather than 
a qualitative analysis.  Visual inspection is reader-dependent; a standardised quantification 
approach would be expected to be more repeatable and reliable.  There have been few 
comparisons of the accuracy from visual inspection to quantification techniques (e.g. Lin et al., 
200774).  
There are several ways standardised quantifiable data can be extracted from PET images.  Table 
1-1 summarises the broad methods of image quantification, and compares the merits of each. 
Method Advantage Disadvantage Dependency 
Visual 
Static WB imaging 
No need blood 
sampling 
Short scan times 









Patient factors e.g. 





Static WB imaging 
Semi-quantitative 
analysis 
No need for blood 
sampling 
Ease of calculation 
Numerous methods 
of calculation 
Single view of 
dynamic process 













Low dependency on 
imaging time 






Quality of input 
function 





The SUV is the most widely used semi-quantification parameter used in oncology currently, and 
is the ratio between the radiotracer concentration in a region-of-interest (ROI) and the injected 
activity, at a single time point, normalised for factors affecting the tracer distribution.  This 
correction factor for 18F-FDG PET is normally patient weight (SUVBW), but can be lean body mass 
(SUVLBM), or body surface area (SUVBSA).  These all have purported benefits in certain scenarios, 







 Where r is the radioactivity concentration (kBq/ml) within the 
target lesion, a’ is the decay-corrected amount of injected 
tracer, and w is the weight of the patient (used as a surrogate 
of volume of distribution for the tracer, where 1ml=1g)76 
 
If all the tracer is retained and distributed evenly throughout the patient’s tissues, the SUV will be 
1.  This can be further corrected to the lean body mass of the patient (SUL).  SUL is less 
dependent on body habitus than SUV when compared across the population, and is typically 
more consistent between patients with 18F-FDG because patients which high body mass have 
high normal organ SUVs due to the lack of accumulation of 18F-FDG in adipose tissue in the 
fasting state. 
Many factors influence SUV measurement, including patient preparation factors, fasting and 
blood glucose levels (particularly for 18F-FDG imaging), the time for tracer uptake before the scan 
is acquired, tracer pharmacokinetics, patient movement, and quantification methodologies.  The 
time of scan acquisition, the image processing and attenuation corrections all have can affect the 
SUV77.  The partial volume effect can lead to an underestimation of SUV, and small tumours can 
appear less avid, and therefore perhaps less aggressive, than they truly are78-81.   Random errors 
are introduced into the PET image from image noise.  The lower the tracer uptake and lower the 
resulting measured accumulated activity, the greater the impact from image noise, and the more 
likely significant random errors will be influence quantification.   
It is essential to control and standardise all the scan acquisition and patient preparation 
procedures, to try and ensure methodological consistencies for comparison of quantification 
parameters. 
Although a change in SUV is typically used to provide a rudimentary quantification of a treatment 
response82 there are technical limitations.  SUVs do not take consider the concentration of the 
radiopharmaceutical changing with time, both in terms of plasma concentration and of the kinetics 
of the tracer in the tissue.  These kinetic factors are not necessarily linear, and therefore full 
dynamic information is required to model the underlying transport processes.  
1.1.3.5.4 Semi-Quantification Parameters 
SUVmax is often reported, being the voxel with the highest SUV within the VOI.  This is quick to 
perform on most clinical PET software platforms, is reproducible, and is reported in most clinical 
papers76.  SUVmax has become the SUV parameter of choice, not through technical appraisal, but 
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because of ease of measurement83.  This is despite the known limitations of SUVmax, particularly 
the high dependence on the statistical quality of the images, and the size of the maximal pixel 
used for calculation84.  It is also not representative of the heterogeneity of uptake within a VOI. 
SUVmean is a better measure of the population of voxel values within a target, but is impacted by 
the VOI definition method.  The edge of the lesion is unlikely to be clearly defined or reliably 
delineable; SUVmean is less reproducible than SUVmax. 
SUVpeak is the average SUV usually calculated within a 1cm3 sub-volume of a VOI containing the 
highest average uptake; this VOI may not necessarily contain the single voxel with the highest 
value in the whole target volume.  SUVpeak might be less affected by image noise than SUVmax 
because it is calculated from more than a single voxel.85.  There are many examples of VOI used 
to calculate SUVpeak, varying the VOI size, position and shape85. 
Voxel SUV measurements across a VOI are heterogeneous.  There are a number mathematical 
and statistical ways to describe the distribution of voxel values throughout a volume, describing 
their image heterogeneity or texture.  1st order heterogeneity parameters are further global 
descriptors of the distribution histogram and parameters include kurtosis, skewness, energy and 
entropy.  Energy is a measurement of the uniformity of the distribution; a high value suggests the 
distribution is more uniform.  Entropy is a measure of the randomness of the distribution; a high 
entropy suggests the distribution is spread more widely, and conversely a simple image has a low 
entropy. 
An alternative quantification technique is the direct measurement of focal kinetics of tracers. 
1.1.3.5.5 Kinetic Modelling of PET 
True quantitative assessment of PET imaging is derived from measurement of the kinetics of the 
tracer following injection, providing estimates of absolute indices of tracer uptake and retention in 
the lesions of interest.  
To derive kinetic quantification from PET, Van den Hoff described the following requirements86: 
• A time-activity curve for the blood (i.e. an input function) 
• A time-activity curve for the target tissue (i.e. the tissue response) 
• A knowledge of the underlying physiology 
 
Hawkins described a compartmental model to identify kinetic measurements necessary to 
accurately quantify 18F-fluoride uptake, reflecting movement of the tracer between three 




Figure 1-1: 3-comparment model for kinetic measurements, based on87. Cp = Plasma 
compartment; Ce = Extravascular compartment; Cb = Bound to target; K1 & k2-4 = 1st order 
rate constants describing the potential direction changes between compartments 
Using this model, it is possible to calculate the Ki function which represents the net uptake (or 
influx) of fluoride into bone, reflecting the bone blood flow and the fraction of tracer binding the 
bone mineral 
Ki (ml/min/ml) = K1 x (k3 / (k2+k3) 
Such kinetic modelling still requires assumptions: metabolic processes are at a steady state 
during measurement; there is a homogeneous tracer distribution within each compartment; rate 
constants are independent of tracer concentration (i.e. display 1st order kinetics)88. 
Assumptions are still needed, but calculation of the Ki function, which represents the net influx of 
tracer into the bone mineral compartment, has been shown to be a useful quantification 
measurement independent of changes in tracer kinetics occurring elsewhere in the skeleton, 
providing a more accurate measurement of local bone metabolism89.  This methodology has been 
used to characterise regional bone kinetics in non-malignant disease90,91 and latterly in bone 
metastases89,92. 
Using the compartment model, quantification of PET tracer uptake requires knowledge of the 
activity in the plasma feeding the lesion of interest; this is termed the arterial plasma input function 
(IF).  There are several methods to derive the IF, with continuous or serial arterial sampling being 
the gold standard93.  This, however, has obvious logistical (and patient satisfaction) difficulties.  It 
takes considerable time for the activity concentration of venous plasma to match the arterial side 
and methods of ‘arterialised’ venous blood sampling have been described, with warming of a 
periphery causing venous dilatation and venous shunting of arterial blood94; inaccuracies with this 
technique have been identified77.  Image derived input functions (IDIFs) have been described, 
and these provide close correlation with serial arterial plasma sampling95,96, but require fewer 
blood tests, and the venous blood samples are taken later when the activity (and subsequent 
exposure to staff) is greatly reduced.   
To derive the arterial input function non-invasively a region of interest (ROI) can be placed over 
an artery, and the activity concentration calibrated against venous blood samples obtained at a 
later time when the venous and arterial radioisotope activity concentrations equalise97.  IDIFs 




















1.1.3.5.6 Definition of VOI for PET Quantification 
A VOI is necessary for quantification.  SUV of individual voxels can be measured, but for a whole 
lesion it is possible to describe the distribution of the voxels, e.g. maximum, mean, standard 
deviation.  The definition of the ‘whole lesion’ is fraught with difficulties.  The partial volume effect 
influences lesions, particularly smaller lesions.  SUV parameters have been shown to be 
correlated with lesion size, especially SUVmean98.  Even in larger tumours, if there is heterogeneity 
of uptake, tracer uptake can be underestimated e.g. an active tumour edge with high uptake, but 
a less avid necrotic centre.  The SUV uptake will be inconsistent across such a tumour, but which 
voxels relate to the most biologically relevant tissue is unknown. 
VOI definition is a vital contributor to the validity and repeatability of semi-quantitative 
calculation99-101.  Recognition and delineation are essential tasks for successful segmentation 102, 
aiming to maximise the inclusion of the pathology being interrogated and minimising the inclusion 
of the surrounding tissues not under evaluation. 
Methods proposed for VOI definition include manual delineation, a fixed volume VOI, an iso-
contour based on a percentage of the VOI SUVmax, and more complicated computation and 
statistical approaches adapting the segmentation of the VOI based on the target:background ratio 
or algorithms to analyse voxel relationships.  Attempts have been made to standardise 
methodology, including development of the PERCIST criteria83, but no consensus has been 
reached.  Table 1-2 summarises the most commonly used VOI methods. 
Technique Summary Benefits Limitations 
Manual 
Visual interpretation and 
selection of ROI 
Simple 
Time consuming 
Variations with window 
settings 






Manual placement of fixed 
volume over area of interest 
which may include SUVmax 
Simple 
Will not provide whole 
lesion or reproducible 
metrics 
Thresholding 
Irregular iso-contour based 
on a fixed percentage of 
SUVmax, or fixed absolute 
SUV level, or based on 





Selection of optimal 
threshold 
Sensitive to partial 






utilising target and 












comparing voxel values to 









analysed between target 







Table 1-2: Summary of PET image VOI methods, adapted from Zaidi et al106. 
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Applying segmentation threshold levels to a target lesion is now a frequent approach to improve 
repeatability of PET quantification.  These techniques are usually based on the SUVmax of the 
target and may be affected by image noise.  One key advantage is the near universal ability for 
PET centres to be able to perform this without the requirement for additional complex software.  
The choice of threshold level impacts the calculated lesion parameters significantly84.  Erdi et al. 
identified a threshold of around 40% of SUVmax on 18F-FDG PET images best represented the 
volume of disease as identified on CT107; others used this threshold level for VOI definition for 
delineation of cervical cancer108, non-small cell lung cancer109 and head and neck cancer110.  
Whether this accurately delineates the full tumour lesion is unclear, and histological correlation is 
lacking.  The optimal threshold is likely to be highly dependent on the tumour type, the radiotracer 
and the tumour volume111,112.  Nestle et al. demonstrated up to a 41% difference in the VOI 
generated by a variety of delineation methods, including manual, threshold methods (absolute 
and relative to SUVmax), and adaptive101, when using 18F-FDG PET to delineate lung tumours. 
With the advent of increased computational processing power has come the application of more 
complex adaptive VOI delineation.  Several different techniques have been described, with the 
proffered advantage of being less susceptible to image noise and contrast variations affecting 
more conventional threshold methods113.  Hatt, in 2009 reported a Bayesian statistical image 
segmentation method termed FLAB (fuzzy local adaptive Bayesian)114.  This algorithm was 
designed to improve upon earlier statistical approaches to image segmentation.  They compared 
their model with other algorithm methods and concluded FLAB was superior for lesions less than 
2cm compared to other algorithms, and they reported errors of under 10% for non-spherical 
lesions with inhomogeneous distributions of activity, with high levels of reproducibility with 




1.1.3.5.7 18F-Fluoride PET  
Uptake of 18F-fluoride PET tracers is similar to 99mTc-MDP standard bone scintigraphy, with 
absorption by hydroxyapatite.  The uptake is more rapid because the 18F fluoride ions are not 
bound to plasma proteins115.  Fluoride ions diffuse from the intravascular space into the 
extracellular fluid compartment, and bind onto the bone surface through exchange with the 
hydroxyl groups in the hydroxyapatite crystals of the bone, resulting in fluoroapatite90.  The uptake 
is related to the regional blood flow and to osteoblastic activity; the tracer accumulates in areas 
of osteoblastic activity39.  The increased capillary permeability and increased local blood flow due 
to metastatic deposits in bone consequently mean greater uptake in bony metastases compared 
to normal bone115.  18F-Fluoride PET provides the opportunity to quantify features of the local 
environment to tumour deposits rather than the tumour cell directly, assuming surrogacy of the 
bone environment and tumour cell activity.   
18F-Fluoride PET/CT has a very high sensitivity and specificity (100% and 97% respectively61) for 
the detection of bone metastases.  Bone-specific imaging with 18F-Fluoride PET/CT has shown 
increased diagnostic accuracy when compared with technetium based standard scintigraphy and 
SPECT66, and has the benefit of aiding differentiating between benign and malignant bone 
lesions116.   
1.2 Assessing treatment response of bone metastases 
Accurately and timely response assessment is a clinical priority.  Measuring soft tissue tumours 
in situ is fraught with difficulties.  Even physical measurement of tumours by experienced 
clinicians is hampered by intra- and inter-observer variability117. 
It has been vital in oncology to strive towards a standardisation of response definitions to allow 
universal understanding, and to allow homogeneity for inter- and intra-patient comparison, 
particularly important for clinical trial outcomes.  The standardisation of response criteria has 
passed through several variations and iterations, and there are specific points to consider 
depending on the imaging modality being reviewed.  Qualitative assessment of imaging is still the 
mainstay of oncological response assessments, alongside tumour size measurements, and is the 
only current standard method for assessment of bone metastases. 
The World Health Organisation (WHO) attempted in the 1980s to standardise measurement of 
soft tissue tumour deposits using plain films and bone scans.  These initial criteria were based on 
bi-dimensional measurements118.  These definitions did not create the standardisation desired, 
with up to 40% major disagreements identified119.  A response in bone lesions was to be 
determined by a reduction in size or re-calcification of lytic lesions, a decreased density of blastic 
lesions, and stable disease could not be concluded before 8 weeks due to the slow response of 
bone lesions118,119.  The International Union against Cancer (UICC) criteria for categorising 
treatment response in breast cancer, published in 1977, term bone metastases as ‘evaluable, but 
non-measurable’.  These guidelines suggest objective evaluation of bone lesions using X-rays 
and scintigraphy, including assessment of healing sclerosis of lytic lesion, whether new lesions 
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develop120 This was clearly imperfect, and is not relevant to predominantly sclerotic bone 
metastases, including those from prostate cancer. 
The RECIST criteria followed (version 1.0 in 2000121, version 1.1 in 2009122), and uses the sum 
of the longest diameters.  Response is identified by a change in size of the target lesions, with 
PR defined as ≥30% decrease (but not a complete response) and PD as ≥20% increase122.  These 
criteria still have limitations.  RECIST criteria depend predominantly on the measurement of solid 
tumours.  Bone metastases are not readily measurable. 
The inability to include bony metastases in the RECIST criteria led to the development of a bone-
specific response criteria which took into account the significant advances in imaging technology, 
including findings on plain X-ray, CT and conventional MRI imaging, and skeletal scintigraphy; 
the MD Anderson (MDA) criteria34 includes qualitative assessments of bone metastases.  PET 
and SPECT were not included in the criteria because there was, at the time, no evidence to 
support their application in response assessment of bone metastases34. 
The development of functional imaging methods to image and quantify the underlying tumour cell 
metabolism characteristics raises the need for alternative definitions of response: metabolic 
response criteria.  This is particularly relevant with the development of new anti-cancer therapies 
aiming to have a cytostatic effect, rather than causing tumour cell death and demonstrable tumour 
shrinkage; lack of progression of tumours may be associated with improved outcomes, even when 
a size response has not been identified83. 
Although there has been widespread integration of functional imaging techniques into clinical 
practice, and the availability and cost has fallen significantly, there has been much less integration 
into clinical trial design, principally due to the variation in technique between centres, and a lack 
of consensus on the appropriate treatment response metrics and definitions, and how PET might 
be used as a surrogate endpoint for assessing clinical efficacy of new therapies75,83.  
The EORTC group began the work to bring uniformity to PET response assessment, producing 
their first recommendations in 1999123 (see Table 1-3). 
Progressive Metabolic 
Disease 
An increase in 18F-FDG >25% within tumour region 
defined on baseline scan, or a visible increase 
(>20%) in longest dimension, or the appearance of 
new lesions 
Stable Metabolic Disease 
An increase in tumour SUV of<25% or less than 15% 
with no visible increase in extent of uptake (i.e.<20% 
increase in longest dimension) 
Partial Metabolic Response 
A reduction of minimum 15-25% in tumour 18F-FDG 
SUV after one cycle of chemotherapy and greater 
than 25% after one treatment cycle (25% was a 
useful empirical cut off, but there was no 
reproducibility assessment at this stage).  A reduction 
in the extent of tumour uptake was not a requirement. 
Complete Metabolic 
Response 
No significant uptake of tracer 
Table 1-3:  EORTC recommendations for defining treatment responses using 18F-FDG PET 
(adapted from123). 
Since publication of this initial guidance there have been attempts to standardise the PET scan 
protocols and analysis with an aim of enabling integration of PET scanning into clinical trials. 
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Shankar et al. reported recommendations of a workshop panel where the main factors influencing 
the variation in PET scan technique and quantification were considered75.  The recommendations 
included patient preparation standardisations and advice on scan timings.  Note was made of the 
importance of attenuation correction methods, ROI/VOI definition methods, tracer dose, and 
quantification parameters to be used.  The lack of robust comparative data limited the 
recommendations provided by this group.  SUVmax and SUVpeak were felt to be the most robust 
measurements, but the details around ROI definition, attenuation correction and tracer dose could 
not be resolved75. 
The Netherlands protocol “for standardisation and quantification of 18F-FDG whole-body PET 
studies in multi-centre trials”124 addressed many of these issues, aiming to provide a standard of 
PET scanning enabling consistency between centres.  This group addressed patient preparation, 
methods to match scan statistics, image reconstruction issues, and they devised a multicentre 
quality control phantom.  They also made recommendations about VOI definition and SUV 
calculations124.  Definition of response using SUVs are, however, a further level of complexity still 
lacking consensus. 
The PERCIST criteria83 were a proposed RECIST style approach to standardising definition of 
response using 18F-FDG PET, developing metabolic response definitions reliant on 
standardisation of the scan acquisition and quantification variables known to be influential.  The 
key recommendations are summarised briefly in Table 1-5: 
Variable Recommendation 
SUV normalisation SUL 
Target lesions Hottest single tumour lesion identified 
(highest SUL of maximal 1.2cm ROI in 
tumour). 
Up to 5 measurable lesions (“typically the 
hottest which are typically the largest”) 
Quantification parameters SULpeak; SULmax 
Also record SULmean using 50% and 70% 





Complete resolution of 18F-FDG uptake 
within target lesion 
Partial Metabolic 
Response (PMR) 




Not CMR, PMR or PMD. 
Progressive Metabolic 
Disease (PMD) 
>30% increase in 18F-FDG SULpeak 
OR – visible increase in extent of tracer 
uptake 
OR – new lesions 
Table 1-4: PERCIST key recommendations (Adapted from83). 
The aim of these recommendations was to provide consistency for using 18F-FDG PET in clinical 
trials.  The guidelines do not aim to identify the most discriminating quantification parameters, and 
they do not broach the myriad of PET tracers available in clinical practice, including 18F-Fluoride 
PET, and bone metastases are not specifically identified.  These recommendations are clearly 
not applicable to other functional imaging methods such as DW-MRI. 
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1.3 Imaging treatment response 
1.3.1 Response assessment with scintigraphy 
Assessment of a treatment response with scintigraphy is seen by a qualitative change in the tracer 
uptake.  This has limitations.  Growth of lytic lesions, demonstrating predominantly osteoclastic 
activity, does not result in 99mTcMDP tracer uptake125.  The flare phenomenon is well characterised, 
seen within 4-12 weeks from treatment onset126-128, whereby new bone formation by osteoblastic 
activity in healing bone metastases following a treatment response results in increased tracer 
uptake, which could be misinterpreted as progressive disease(PD)39.  In a group of breast cancer 
patients, a flare response was noted in 35% at a mean time of 3.3 months following start of 
treatment129.  It can take 6 months for a flare response to reduce130, with others reporting 
persistence at 2 years131.  For this reason the Prostate Cancer Working Group (PCWG2) 
guidance on assessing a treatment response in bone metastases from prostate cancer 
recommend a bone scan not before 12 weeks after initiation of therapy, and, if new lesions are 
identified, a confirmatory scan should be repeated 6 or more weeks later (i.e. at 18 weeks), 
delaying confirmation of PD132. 
1.3.2 Imaging Response Assessment with CT 
CT imaging can be used to monitor the sclerotic change in bone metastases following a response 
to treatment.  Quantification using Hounsfield units has tracked the change in reactive sclerosis 
within metastatic deposits after treatment with bisphosphonates133.  Bone metastases can result 
in associated soft tissue extension, which enables RECIST size criteria of response to be applied.  
New lesions can be identified, although the appearance of a sclerotic lesion with treatment can 
often suggest a treatment response in a previously unseen small lytic deposit. 
1.3.3 Imaging Response Assessment with Quantification of PET 
The feasibility of detecting metabolic changes with 18F-FDG PET in extra-cranial tumours 
following treatment was initially shown when monitoring neoadjuvant chemotherapy for breast 
cancer patients134, showing a SUV reduction of up to 50% in primary tumours after 3 months in 
those who responded; responses were noted in SUV measurement after only 8 days of treatment.  
Changes in 18F-FDG SUV are now widely used for monitoring treatment responses for a wide 
variety of tumours, but there is still no consensus on how to standardise and define metabolic 
responses. 
Bone metastases have been an obvious target for research given the poor value of monitoring 
morphological changes to therapy.  Stafford et al. in 2002 reported a 24-patient study of serial 
18F-FDG PET scans for women with bone metastases from breast cancer; changes in SUV 
correlated with the clinical response assessment135.  A 2006 study of spinal metastases treated 
with stereotactic radiosurgery showed changes in 18F-FDG uptake 1 and 6 months following 
treatment correlated with the clinical response136.   
A later study of breast cancer bone metastases with 25 patients clearly demonstrated sequential 
18F-FDG scans showing changes in the tumour activity in bone metastases following treatment, 
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whereas morphological changes were inconsistent137.  Breast cancer bone metastases were 
monitored with 18F-FDG PET before and after treatment by Tateishi et al., reporting in 2008.  A 
significant correlation was identified between increases in CT attenuation with decreases of 18F-
FDG SUV and TLG138.   
Other tracers have also been interrogated.  Lindholm et al. reported in 2009 a study of 13 breast 
cancer patients with bone metastases, imaged with 11C-methionine PET, concluding a significant 
fall in SUV in responding sites of disease139.  More recently, Cook et al. have demonstrated 
sequential 18F-Fluoride measurements of prostate cancer bone metastases before and after 
therapy show correlations between change in SUV and PSA140.  
1.3.4 Imaging Response with DW-MRI 
Most studies demonstrate an increase in tumour ADC values following successful therapy41.  
Following successful therapy, tumour cell death and vascular change in response can precede 
morphological changes, raising the possibility of using DW-MRI as a response biomarker.  An 
increase in ADC following successful treatment has been identified as early as 6-8 days after 
treatment141, preceding measurable tumour regression, and has been histologically attributed to 
an increase of extracellular space141.  There is some uncertainty of the underlying mechanism 
associated with changes in diffusion, but an increase in ADC after therapy for several tumour 
types has been demonstrated, including in breast tissue xenografts after only 2 cycles of 
chemotherapy142.  A National Cancer Institute sponsored consensus meeting in 2008 from the 
Society of Magnetic Resonance in Medicine set out recommendations to try and achieve 
consistency in imaging techniques, analysis and reporting for studies examining response 
assessment with DW-MRI41, with the overall aim of establishing DW-MRI as an imaging 
biomarker. 
A response to radiotherapy of spinal lesions was suggested by Byun et al. in 200258 with repeat 
imaging 6 months after treatment.  The authors however reported an increase in ADC in 23 
patients who had a symptomatic benefit from radiotherapy to the target lesion.  T1 and T2 MRI 
imaging of the same lesions did not detect qualitative changes. 
Further studies demonstrated a rapid increase in ADC following successful therapy, including in 
liver lesions from breast cancer treated with chemotherapy (the investigators could predict a 
response with ADC just 4 days after therapy143, and also in brain tumours treated with 
radiotherapy144.  A low ADC, it is suggested, identifies tumour viability, compared with a relatively 
high ADC secondary to necrosis which would confer radiotherapy resistance144.  Cui et al.145 
monitored ADC changes in patients with hepatic metastases from colorectal or gastric primary 
tumours.  Lesion with a lower pre-therapy ADC were more likely to show a treatment response, 
with ADC noted at 3-7 days.  Significant correlations were identified between the overall reduction 
in size of the lesions and both the pre-treatment ADC and early ADC changes145.  Although a 
different histology, Thoeny et al. in 2005 demonstrated the link between ADC and necrosis.  They 
measured the ADC of rhabdomyosarcomas in rats before and after therapy, and compared the 
imaging quantification with histology.   They showed an increase in ADC two days after therapy 
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correlated with histological necrosis, and a subsequent decrease in ADC nine days after treatment 
corresponded with tumour regrowth146. 
Not all studies have demonstrated value from measuring ADC before treatment.  Manton et al. 
were unable to predict response to neoadjuvant chemotherapy for primary breast cancers using 
baseline ADC measurement147. 
Changes in ADC were noted in primary bone tumours after treatment by Yakushiji et al.148, 
showing a greater change in the ADC in the tumours with more necrosis before treatment.  There 
was, however, no correlation attempted between change in ADC and clinical outcome.  In another 
small study of histologically proven osteosarcoma patients Uhl et al. demonstrated higher ADC 
values in necrotic areas compared to viable tumour149 following chemotherapy treatment.  
Lee et al. used a preclinical model of metastatic prostate cancer to investigate the feasibility of 
using MR diffusion quantification to assess the change in lesions after docetaxel chemotherapy 
treatment150.  Significant increases in ADC were detected seven days after therapy, and 
histological correlation showed previously dense cellular morphology had changed to a bone 
lesion with more heterogeneous density150.  The same team translated this pre-clinical experience 
to a real-life clinical setting, imaging a patient with bone metastases from prostate cancer with 
DW-MRI before initiation of anti-androgen treatment (not chemotherapy), and again at 2 weeks 
and 8 weeks after treatment started.  Clinically the patient responded to therapy, and after 8 
weeks there was an increase in ADC measured, correlating with a decreased PSA suggesting a 
response, but no demonstrable change in size of the bony lesions measured151. 
The first clinical series to demonstrate ADC changes in bone metastases of patients undergoing 
treatment involved 26 patients with prostate cancer bone metastases who had lumbar spine and 
pelvis DW-MRI imaging before chemotherapy and again at 12 weeks following treatment152.  
Using standard response criteria, 8 patients were identified as responders and 15 progressors.  
100 lesions were analysed in total, but there was no significant difference identified in pre-
treatment ADC between responders and progressors.  However, in those patients who responded 
to treatment there was a significant increase in ADC after treatment152.  Interestingly, there was 
also a significant increase in ADC of the lesions measured in those patients who progressed on 
treatment, and there was heterogeneity of ADC response within both responders and non-
responders.  The authors suggested the magnitude of ADC rise was greater in responders, with 
a sensitivity of 75% and specificity of 66.6% for identifying response if a minimum of 25% increase 
in ADC was used as a cut-off.  The attribute the heterogeneity of ADC change to changes within 
the composition of the bone marrow as well as histopathological changes in the tumour.  
Reischauer et al.153 prospectively monitored 9 treatment-naive men with bone metastases from 
prostate cancer with DW-MRI imaging before treatment and again at 1, 2 and 3 months after anti 
androgen therapy was started.  They reported significant increase of ADCmean of metastases, 
even after 1 month153.  Clinically, patients responded, with PSA dropping by more than 90%153.  
These authors also noted a heterogeneous response on functional diffusion maps which showed 
some voxels had a fall in ADC, and more voxels demonstrated this at 3 months after therapy 
compared to the 1-month imaging. 
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Most recently, a group in London reported on their development of a semiautomatic segmentation 
method of whole-body diffusion weighted MRI in an attempt to derive indices of tumour burden154.  
Whole-body diffusion-weighted imaging was performed on 11 patients in total, 4 female patients 
with metastatic breast cancer and 7 male patients with metastatic prostate cancer.  Imaging was 
completed before treatment and then again at between 12 to 38 weeks after therapy was started.  
Response was assessed clinically based on other imaging, clinical assessment and measured 
tumour markers.  The authors developed a semi-automatic segmentation algorithm to select 
areas of bony disease.  Those patients with a treatment response had a significantly larger 
increase in median global ADC compared to non-responders, and the non-responders had a 
significantly larger increase in total diffusion volume (i.e. volume of disease segmented)154.  Non-
responders had a small decrease in median gADC after treatment. 
1.4 Novel imaging approaches for appraisal of bone metastases  
1.4.1 Whole-Body DW-MRI 
A limiting factor in the use of DW-MRI imaging for spinal assessment was the size of the target 
organ; technical advances have been necessary to enable efficient scanning of larger areas to 
include most of the axial skeleton.  One of the earliest approaches to whole-body MRI imaging 
was reported by Steinborn et al. in 1999.  They evaluated the potential diagnostic benefits of a 
whole-body bone-marrow protocol (fast T1-weighted and STIR images) for the detection of bone 
metastases.  They were able to identify 216 lesions in 18 patients; standard bone scans of the 
same patients only identified 159 lesions155. 
Takahara et al.156 were among the first to describe a technique for a more rapid whole-body three-
dimensional diffusion weighted image with background body signal suppression156.  Their 
technique allowed for free breathing, and resulted in a much faster whole-body technique.  Such 
a technique was used for assessment of haematopoiesis in the bone marrow in the same year157. 
Nakanishi et al,158 compared a whole-body DW-MRI technique with standard bone scintigraphy 
for the detection of bone metastases.  The authors reported a sensitivity of 96% and positive 
predictive value of 98% when DW-MRI was used in conjunction with T1 and STIR MRI images158.  
For the same patients, they reported a sensitivity of 96% for skeletal scintigraphy.  This suggested 
DW-MRI imaging of the skeleton was certainly capable of detecting metastatic bone disease 
successfully, but did not suggest superiority to current standard imaging.  This was also concluded 
by Xu et al. the following year using a 3T MRI scanner159.  
The benefit of adding whole-body diffusion weighted MRI to standard MR was considered by 
Takenaka et al.160.  This group also compared DW-MRI with 18F-FDG-PET and standard 
scintigraphy for detecting bone metastases in 115 consecutive non-small cell lung cancer 
(NSCLC), with a 12-month clinical follow up being used as a standard of reference.  They 
concluded the specificity and accuracy of whole-body MR with DWI (95.5% and 96.1% 
respectively) were significantly higher than scintigraphy (reported by the group as 95.5% and 
95.0%); the improvement in specificity was small, but statistically significant.  This benefit came 
from combining whole-body MR with DWI.  They reported integrated a sensitivity of 97% and 
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specificity of 95.4% using 18F-FDG PET/CT.  The authors conclude whole-body DW-MRI is as 
accurate as scintigraphy and/or 18F-FDG PET/CT, with the benefit of reduced radiation 
exposure160.  Similar findings have been found by several other groups50,51,161,162. 
Gutzeit et al.162 compared DW-MRI and skeletal scintigraphy for the detection of bone metastases 
from prostate cancer and breast cancer, prospectively scanning 36 patients in total.  They 
analysed the b=1000s/mm2 images, and separated identified lesions into three categories of 
pathological suspicion.  They concluded a sensitivity for detecting metastatic lesions at 97% 
(82%-100%) if there were more than ten lesions, but only 58% (29%-84%) if there were fewer 
than 5 lesions (scintigraphy 48% (31%-66%) and 67% (35%-89%), respectively).  The authors 
concluded non-superiority of DW-MRI over skeletal scintigraphy.  Patients with a higher burden 
of bony metastatic disease DW-MRI seemed to perform better than a bone scan. 
In 2011 Wu et al. performed a meta-analysis questioning the diagnostic accuracy of whole-body 
MRI for detection of bone metastases163.  This did include a range of MRI techniques, but a 
subgroup analysis was performed for those who had diffusion-weighted imaging (DWI).  The 
authors concluded DWI was sensitive, but led to reduced specificity (pooled sensitivity for DW-
MRI imaging 87.7% (76.3%-94.9%), pooled specificity 86.1% (79.2%-91.4%)) compared to 
whole-body MRI without DWI. 
Elber et al. evaluated methodological aspects of whole-body DWI for staging prostate cancer 
bone metastases164.  They compared the imaging of the identified bone metastases with the level 
of sclerosis identified on corresponding CT scans, concluding superior contrast-to-noise for non-
sclerotic bone metastases compared to the heavily sclerotic lesions.  They also showed densely 
sclerotic lesions were best visualised on T1-weighted MRI imaging, and were noted to have more 
restriction of diffusion164. 
1.4.2 Image Heterogeneity 
The voxels than comprise the three-dimensional imaging of all modern medical imaging 
techniques can be considered as individual packets of information, and offers another possible 
route of image quantification.  Individual voxel information is routinely used when quantifying 
medical imaging.  The SUVmax of PET studies is the most widely used parameter, largely due to 
the ease of acquisition – it is simply recording the value of the voxel with the highest calculated 
SUV within the target VOI.  However, the voxel intensities across a tumour or normal tissue VOI 
are not consistent, and it is not clear which part of a tumour VOI is the most clinically relevant.  
The histogram of voxel information grained from VOI image analysis can be described in several 
ways; the mean and median of the distributions are often reported during clinical studies of PET 
imaging.  DW-MRI imaging favours these as measures of water diffusion within a VOI.  These 
parameters however discard most of the other histogram data, and this data about the image 
heterogeneity may have significant clinical relevance. 
Image heterogeneity analysis has been developed over the past few decades for wide ranging 
applications, from NASA examining satellite images165, through the study of sea ice patterns166 
and the commercial classification of cashew nut kernels167, to the current investigations of 
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possible applications in oncology, there is significant interest in unlocking potential patterns and 
data from images. 
Each individual voxel intensity in medical imaging is the result of numerous interacting factors, 
and there are many ways the voxel intensity distributions can be described and compared, and 
possibly used to reveal clinically relevant information.  The 1st order heterogeneity or texture 
features are the descriptors of the voxel intensity frequency-distribution histogram, including the 
mean and median parameters.  The histogram can be interrogated further; the skewness and 
kurtosis describe the shape of the distribution curve in more detail, where kurtosis is a descriptor 
the sharpness of the peak of the distribution, and skewness is a measure of the symmetry of the 
distribution.  Entropy of an image is used to describe the randomness of an image and energy is 
a measure of voxel uniformity. 
Computational power has enabled image analysis at more complex levels.  The voxel to voxel 
relationships can be interrogated, measuring how often voxels of differing (or similar) intensities 
are related to each other, and in what configuration.  In addition, more complicated fractal pattern 
analysis and Bayesian statistical models can be used to categorise imaging features even further.   
This all has potential clinical utility, possibly allowing interrogation and identification of specific 
tissue architectures and behaviours.  As early as the 1980s there was interest in the fractal nature 
of vasculature168.   Texture analysis has been used to identify neovascularisation169  and 
differentiate between benign and malignant tissue170. 
Texture analysis with has been used to predict cancer treatment responses for a number of 
different soft tissue malignancies and with different imaging modalities, including CT images171 
and MRI scans172.  Texture analysis of soft tissue malignancies have also shown prognostic 
potential, including quantification of CT scans173-177, and PET images178-180.  The predictive and 





Bone metastases are common sequelae of common malignancies, and result in significant 
morbidity.  Patients with prostate and breast cancers, even with bone metastases, have prolonged 
survival, and treatments to further prolong survival and mitigate symptoms from bone metastases 
are vital.  There are now many treatments shown to have excellent clinical value, but assessment 
of treatment response in patients with only bone disease remains a clinical problem.  For this 
reason, bone metastases are excluded from clinical trials, to the detriment of the breast and 
prostate cancer patients with bone predominant disease.  There is an urgent requirement for the 
development of accurate imaging biomarkers for assessment of treatment response in bone 
metastases. 
1.6 Scope and objectives 
This thesis reports the initial data from 3 prospective clinical trials designed to interrogate, 
amongst other functional imaging techniques, 18F-Fluoride PET and DW-MRI for the appraisal of 
bone metastases from breast and prostate cancer, the quantification of treatment response, and 
correlation between the quantification parameters and clinical markers of disease response.  
These studies are, at the time of submission, still recruiting patients; it is beyond the scope of this 
thesis to report on the objectives of these three clinical studies. 
The main objective of this thesis is to identify the best methods for the final analysis of the three 
clinical studies, ensuring accurate and clinically relevant quantification of the images to maximise 
any potential clinical utility. 
The aims of this thesis are: 
18F-Fluoride PET: 
• To investigate iso-contour delineation of volumes of interest for quantification 
• To investigate quantification parameters with a per-lesion analysis for prediction of the 
clinical treatment response assessment, and evaluate the quantification parameters in 
terms of OS and PFS 
• To investigate quantification parameters with a per-patient analysis for prediction of the 
clinical treatment response assessment, and evaluate the quantification parameters in 
terms of OS and PFS 
• To investigate the impact of different VOI methodologies on the quantification parameters 
• To develop a quantification method for the whole-skeletal metastatic burden, and assess 
for predictive and prognostic clinical utility 
DW-MRI: 
• To investigate quantification parameters with a per-lesion analysis for prediction of the 
clinical treatment response assessment, and evaluate the quantification parameters in 
terms of OS and PFS 
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• To investigate quantification parameters with a per-patient analysis for prediction of the 
clinical treatment response assessment, and evaluate the quantification parameters in 
terms of OS and PFS 
• To develop a quantification method for the whole-skeletal metastatic burden, and assess 
for predictive and prognostic clinical utility 
1.7 Hypothesis 
Quantification of the functional imaging techniques will provide more accurate and timely 
assessment of a treatment response of bone metastases compared to current clinical and 
radiological standards. 
1.8 Overview of thesis 
The three prospective clinical studies to which the patients in this thesis were recruited are 
summarised in the Trial Design (Appendix 1). 
The specific methods applied for development of this thesis are described in the Methods and 
Patients (Chapter 2) chapter.  Following explanation of general methods applicable to all studies 
in this thesis follows study-specific methods.  The subsequent technical chapters interrogate 18F-
Fluoride PET and DW-MRI, examining VOI methodologies, and the predictive and prognostic 
value using per-lesion analyses, per-patient analyses and whole-skeletal metastatic burden 
analyses.  These will be detailed in the Methods and Patients chapter.  
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Chapter 2  Methods and Patients 
2.1 Introduction 
Three prospective clinical studies have been designed to interrogate functional imaging methods 
for the assessment of a treatment responses in bone metastases from breast and prostate cancer; 
details can be reviewed in Appendix 1. 
In preparation for full recruitment and final analysis of these studies, the data from the initial 
patients has been used to prepare and interrogate quantification methodologies.  There are 
uncertainties about which quantification parameters might be most predictive and prognostic, how 
to define the quantification volumes of interest (VOIs), and how to define changes between scans. 
At the time of initial data analysis for this thesis, patient recruitment to the three studies had 
supplied sufficient data for analysis of the 18F-Fluoride PET scans and DW-MRI scans.  
2.2 Overall Methods  
2.2.1 Patient Selection 
For all studies, patients were identified with bone predominant metastatic disease, and were 
recruited before embarking on a change in treatment for radiologically confirmed progressive 
bone disease.   
Full details of the clinical studies can be found in the Trials Design (Appendix 1), but have been 
briefly summarised in Table 2-1. 
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FAB-P 
Tumour Group Prostate Cancer 
Treatment Docetaxel chemotherapy 
Imaging 
18F-Fluoride PET/CT, 11C-Choline PET/CT, WB + 
DW-MRI 
Scan Schedule 
Baseline, 8 weeks from initiation of therapy 
(option of 12 week 18F-Fluoride PET/CT scan if 
possible flare noted at 8 weeks) 
End Point 
Clinical assessment of treatment response up to 
24 weeks from treatment initiation 
   
FAB-B 
Tumour Group Breast cancer 
Treatment 
Hormonal therapy +/- 
bisphosphonate/denosumab 
Imaging 
18F-Fluoride PET/CT, 18F-FDG PET/CT, WB + 
DW-MRI 
Scan Schedule 
Baseline, 8 weeks from initiation of therapy 
(option of 12 week 18F-Fluoride PET/CT scan if 
flare noted at 8 weeks) 
End Point 
Clinical assessment of treatment response up to 
24 weeks from treatment initiation 
   
FAB-IE 
Tumour Group Prostate cancer 
Treatment Hormonal therapy/chemotherapy 
Imaging 
99mTc-Maraciclatide Scintigraphy/SPECT/CT, WB 
+ DW-MRI, DCI-MRI 
Scan Schedule Baseline and 12 weeks from initiation of therapy 
End Point 
Clinical assessment of treatment response up to 
24 weeks from treatment initiation 
 
Table 2-1: Summary of FAB-P, FAB-B and FAB-IE 
These studies have Ethics and ARSAC Committee approvals (FAB-P - 12/LO/0830; RPC 
261/3186/28833, FAB-B 12/LO/1801; RPC 261/3186/29516, and FAB-IE 13/LO/0041 RPC 
54/3186/29826 respectively). 
At the time of this initial data analysis, 9 patients had been recruited into FAB-P, 5 into FAB-B, 
and 6 into FAB-IE. 
All patients met the inclusion criteria for each study: patients (aged 18 or over) with confirmed 
skeletal skeletal-predominant metastatic breast/prostate cancer who are treatment naïve, or with 
PD embarking on new systemic anti-cancer treatment; willingness to comply with study visits and 
tests  
Patients with concomitant uncontrolled medical conditions were excluded, along with those 
patients who had contraindications to MR imaging, those patients likely to require palliative 
radiotherapy between study scans, those patients likely to require G-CSF (excluded because of 
the impact on bone marrow activity which can influence DW-MRI imaging quantification). 
Written informed consent was obtained from the patients. 
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2.2.2 Imaging Protocols 
2.2.2.1 18F-Fluoride PET/CT Procedure 
The PET scans were carried out in the PET Centre at St Thomas’ Hospital using a Discovery VCT 
(until Oct 2013) and then a Discovery 710 (both GE Healthcare).  A target administered activity 
of 225MBq was injected (Min 150MBq, Max 250MBq). 
PET scan acquisition was started 60 minutes after injection of the tracer.  Venous blood samples 
were taken at 55 minutes after injection, and at the end of the PET-CT acquisition (90 minutes 
after injection) from the opposite arm to the injected activity.  The exact times of sampling were 
recorded.  0.2ml of whole blood and 0.2ml of serum underwent radiation count sampling, and the 
time of measurement recorded to correct for decay.  The 18F-fluoride PET half body was acquired 
from the lower limbs towards the head in 6-7 frames of 4 minutes each.  PET images were 
reconstructed using ordered-subset expectation maximisation (2 iterations, 20 subsets).  A CT 
scan for attenuation correction was acquired immediately preceding PET acquisition, with a slice 
thickness of 3.27 mm and a voxel size of 4.7 mm, and PET attenuation correction of the PET was 
performed (120kVp, Auto mA). 
2.2.2.2 DW-MRI Imaging Protocol 
All studies were performed on a 1.5T MRI scanner (Magnetom Aera, Siemens, Erlangen, 
Germany) with an 18-channel external phased-array surface coil (Siemens, Erlangen, Germany), 
with an echo-planar spin-echo technique (free breathing, STIR fat suppression), scanning from 
skull-base to mid-thigh).  Table 2-2 summaries the MRI imaging protocol. 










TR(ms) 4.77 336 12990 3500 630 
TE(ms)  2.39 96 67 97 9.8 
FOV 430 430 430 425 425 
Matrix 244*320 128p*256 208p*256 307*384 307*384 
B-value n/a n/a 0,800 n/a n/a 
NEX 1 1 2/5 2 2 
ST(mm) 5 5 5 4 4 
Table 2-2: Summary MRI protocol used for FAB-P, FAB-IE and FAB-B 
2.2.3 Image Quantification  
Image quantification specifics, parameter definitions and VOI definitions will be discussed in the 
separate sections of this chapter which form the methods for the individual results chapters 
reported in this thesis. 
2.2.3.1 18F-Fluoride PET Quantification Parameters for Analysis 
The most commonly parameters are those describing the SUV voxel population within the VOI, 
namely the maximal voxel value (SUVmax), and the mean of the distributions (SUVmean).  SUVmax 
is the most widely used clinical parameter, and is operator-independent, although as a measure 
of a single VOI voxel it may be affected by noise85.  SUVmean and SUVmax have been shown to be 
reproducible181, but the use of average measurements will be dependent on the definition of the 
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VOI, whereas the SUVmax will be unaffected182.  SUVpeak has been developed as an alternative 
less susceptible to image noise, and has been shown to be reproducible85. 
True quantification parameters, measuring the pharmacokinetic movements of the PET 
radioisotope between the physiological compartments.  This compartmental modelling, frequently 
referred to as kinetic modelling, is considered the most accurate way to analyse PET data183.  
Kinetic modelling has required dynamic scanning, taking multiple frames from the point of injection 
alongside arterial blood sampling to measure the time course of the tracer concentration in the 
plasma, used to define the input function for kinetic modelling.   
To derive the arterial input function non-invasively a region of interest (ROI) can be placed over 
an artery, and the activity concentration calibrated against venous blood samples obtained at a 
later time when the venous and arterial radioisotope activity concentrations equalise97.  IDIFs 
have shown good correlation with arterial sampling95,96.  Siddique et al. described in 2012 a 
method to estimate regional bone metabolism from whole-body 18F-Fluoride PET static images, 
and it is this methodology used in this thesis analysis to calculate the regional bone plasma 
clearance function Ki184.  This method uses venous blood sampling to estimate the arterial input 
function by rescaling for injected activity a population residual curve of the 18F-Fluoride bolus peak 
and exponential clearance from the plasma (obtained from a study of 10 patients by Cook et al.97), 
and combining this to the individual patient’s terminal exponential curve measured with the 
venous blood sampling184.  This technique has been shown to have close correlation to invasive 
kinetic modelling with a mean ratio of 1.006 between the static Ki method and the gold-standard 
dynamic Patlak Ki method, 30 minutes after injection, decreasing to 0.965 at 60 minutes184, and 
has a clear methodological advantage of being much less invasive. 
Volumetric parameters have been used to describe the metabolic tumour volume (MTV) of 
tumours, which is the volume of the defined VOI.  This parameter, from 18F-FDG PET has been 
shown to predict the outcome of tumours, including oropharyngeal cancers185.  The product of 
MTV and SUVmean of 18F-FDG PET images is termed the Total Lesion Glycolysis (TLG).  This 
methodology has been applied to 18F-Fluoride imaging where Total Lesion Activity (TLA) = MTV 
x SUVmean. 
SUVentropy and SUVenergy (also known as uniformity) as heterogeneity parameters were 
recommended by Hatt et al. following examination of PET textural features for robustness of 
measurement with respect to the VOI definition method, and limitation of the effect of partial 
volume impact186.   
The following PET quantification parameters have been selected for these studies: 
• SUV Histogram Parameters 
o SUVmean -the average of voxel SUV values within the VOI.  
o SUVmax – the value of the highest value SUV voxel within the VOI.  
o SUVpeak– the maximum average SUV within the hottest 1cm3 sphere within the 
VOI 
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• SUV Volumetric Parameters 
o MTV – Metabolic Tumour Volume is the volume (cm3) of the VOI.   
o TLA – = MTV x SUVmean.  
• SUV Heterogeneity Parameters 
o SUVentropy - SUVentropy is a measure of the randomness of the distribution.  A 
high entropy suggests the distribution is spread more widely; a simple image 
has a low entropy. 




o SUVenergy – SUVenergy is a 1st order histogram heterogeneity measurement of 







L=number of bins (=32) 
P(b)=probability distribution of bin b 
• SUV Kinetic Parameter 
o Ki – As previously described   
2.2.3.2 DW-MRI Quantification Parameters for Analysis 
Most centres report the ADCmean and ADCmedian as standard parameters, and both these have 
been reported in this analysis.  Both describe the VOI ADC histogram, but are affected differently 
by the distribution shape. 
ADCmin was not included in the analysis; initial data showed ADCmin=0 for most lesions, most likely 
because of the impact of image noise.  A similar finding has been reported by other groups. 
The total diffusion volume (tDV) is a parameter reported by other groups187 and is analogous with 
the MTV obtained from PET imaging.  This is the volume of the VOI(s) as defined on extrapolated 
b-value image. 
ADCentropy and ADCenergy heterogeneity parameters have been associated with prostate cancer 
aggressiveness 176,177 and with prediction of treatment response of primary breast tumours172 and 
have been selected for analysis in this study.  
ADC Quantification Features – Definitions  
• ADC Parameters 
o ADCmean -  the average of voxel ADC values within the VOI.  
o ADCmedian - the median of voxel ADC values within the VOI.  
• tDV – total diffusion volume = volume of VOI. 
 
Methods and Patients 
30 
• ADC Heterogeneity Parameters 
o ADCentropy - a measure of the randomness of the distribution.  A high entropy 
suggests the distribution is spread more widely; a simple image has a low 
entropy. 




o ADCenergy –a 1st order histogram heterogeneity measurement of the uniformity 






L=number of bins (=32) 
P(b)=probability distribution of bin b 
2.2.3.3 Quantifying Change in Parameter 
The percentage change (%Δ) in the parameters between scans has been calculated. 
%𝛥 𝑃𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟 = 100 ×  
(𝑃𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟 𝑆𝑐𝑎𝑛 2 − 𝑃𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟 𝑆𝑐𝑎𝑛 1)
𝑃𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟 𝑆𝑐𝑎𝑛 1
  
A %Δ of 50% represents a parameter measured at the second scan 50% larger than the 
baseline scan (baseline scan x 150%) and a second scan parameter smaller than the baseline 
scan will therefore be represented by a negative change. 
2.2.4 Clinical response definitions 
2.2.4.1 Prostate Cancer 
The clinical response to treatment will be made at up to 24 weeks.  Defining PD will be guided by 
the PCWG2 criteria (Tbl.2-2).  Assessment of response will be made by the patient’s primary 
oncologist (blinded to the study results), and a consensus confirmed by a second oncologist. 
Feature Definition of Progression 
PSA 
If PSA decline from baseline 
• ≥25% and ≥2ng/mL above nadir, 
confirmed at least 3 weeks later 
If no PSA decline from baseline 
• ≥25% and ≥2ng/mL after 12 
weeks 
(NB - Ignore early rises in PSA before 12 weeks of 
treatment, unless other evidence of progression) 
Soft Tissue 
Lesions 
As RECIST criteria 
Bone Lesions 
New lesions confirmed on repeat scan at 
least 6 weeks later 
Symptoms 
Clinical suspicion confirmed by 
continuation/progression of symptoms 
with second review at least 3 weeks later 
Table 2-3: Summary of PCGW2 Guidelines for defining progressive disease132 
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2.2.4.2 Breast Cancer 
Radiological assessment will follow MDA criteria34,148 (using bone scintigraphy, CT, MRI or X-ray 
as clinically relevant undertaken at 24 weeks, unless clinically indicated before, in consensus by 
2 radiologists blinded to PET, DW-MRI and clinical response). The standard imaging at Guys & 
St Thomas' Hospitals is by bone scintigraphy complemented with X-rays or CT bone windows at 
6 months. MRI is used additionally in some patients for monitoring vertebral disease but this 
combination is applicable to the MDA assessment criteria. 
2.2.5 Definitions for Response Analysis 
Response (non-progression) – Stable disease or PR/CR (by tumour-specific criteria discussed 
above) sustained at 24 weeks after initiation of therapy.  Stable disease has been included in this 
response group as clinically none-progression of disease is relevant and will be a clinical reason 
to continue a chosen therapy. 
Progression -  Clinically confirmed PD by 24 weeks after starting therapy, determined by the 
imaging criteria above, or by clinical assessment (tumour markers, clinical signs, clinical 
assessment) resulting in cessation of ineffective therapy, or a change of treatment. 
2.2.6 Definitions for Survival Analyses 
Overall survival (OS) is measured as the time, in days, between the date of the first baseline 
scan for the patient until the data of death, or the date of data censor at the last recorded patient 
clinical contact. 
Progression free survival (PFS) is measured as the time, in days, between the date of the first 
baseline scan for the patient until the data of clinically confirmed disease progression by the 
treating clinical team, or the date of data censor at the last recorded patient clinical contact. 
2.2.7 General Statistical Analysis 
All statistical analysis has been completed in IBM SPSS version 23.  Original data was collated 
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2.3 Methods Specific to Results Chapters 
To meet the aims of this analysis, the analysis has been separated into separate sections: 
1- 18F-Fluoride PET 
a. ROI Segmentation 
b. Per-Lesion Analysis – Response Analysis 
c. Per-Lesion Analysis – Survival Analysis 
d. Per-Patient Target Lesion Analysis – Impact of VOI segmentation thresholds 
e. Per-Patient Target Lesion Analysis – Response Analysis and impact of VOI 
segmentation thresholds 
f. Per-Patient Target Lesion Analysis – Survival Analysis 
g. Whole-Body Quantification of Bone Metastases – Methodology, Response 
Analysis and Survival Analysis 
2- DW-MRI 
a. Per-Lesion Analysis – Response Analysis 
b. Per-Lesion Analysis – Survival Analysis 
c. Per-Patient Target Lesion Analysis – Response Analysis  
d. Per-Patient Target Lesion Analysis – Survival Analysis  
e. Whole-Body Quantification of Bone Metastases – Methodology, Response 
Analysis and Survival Analysis 
These specific methods will now be described separately. 
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2.3.1 18F-Fluoride PET Segmentation –SUV threshold for defining the PET 
ROI of bone metastases 
Sclerotic bone metastases can be identified on CT imaging as areas on increased density within 
bone, with clear and often sharp contrast with the surrounding normal bone, and the sclerosis can 
be used as a proxy for tumour cells within the bone.  Taking this assumption, I have worked to 
identify the best relative threshold to apply to an 18F-Fluoride PET ROI containing a bone 
metastasis ensuring the volume closely matches the sclerotic region on CT imaging. 
Patients with bony metastases from prostate cancer had 18F-Fluoride PET scans as part of the 
FAP-P and FAB-IE studies previously described.  The first four of these scans have been used. 
OsiriX (Pixmeo) software was used for ROI definition, for applying the threshold, and for 
calculating the ROI. 
The reference standard is the area of sclerotic change of bone metastasis as identified on the 
non-contrast enhanced CT component of the 18F-Fluoride PET/CT scan.  The largest lesions, 
clearly distinguished from adjacent lesions and from normal surrounding bone were selected, 
ensuring there was also tracer avidity on the fused PET component.  Up to 5 lesions per patient 
were delineated on the CT scans, and a record made of the area of the ROICT. 
Manual ROIPET regions were then drawn around the corresponding tracer avid lesions on the PET 
scan, ensuring a rim of non-avid tissue was included in the ROIPET, and ensuring correct fusion 
with the CT.  
Thresholds relative to the SUVmax were then applied to the ROIPETs.  The threshold was increased 
in stages, making note of the resulting ROIPET area.  This data was plotted graphically, comparing 
the volume of the ROIPET (expressed as % of ROICT volume) against the threshold applied.  The 
line of best fit was applied using Microsoft Excel functionality, and the equation of this best fit line 
was exported.  For each lesion the threshold level when ROIPET matches the corresponding ROICT 
was identified.  The population of lesions can then be interrogated to identify the best threshold. 
Figures 3-1/3-2/3-3/3-4 document all the results, showing the decrease in area of the ROIPETs as 
the relative threshold applied to the ROI is increased.  For many of the lesions this is not a linear 
relationship. 
Methods and Patients 18F-Fluoride PET Segmentation 
34 
 
Figure 2-1: Patient 1.  Comparison of ROIPET to ROICT (%) against the relative threshold 
(%SUVmax) used to delineate ROIPET  
 
 
Figure 2-2: Patient 2.  Comparison of ROIPET to ROICT (%) against the relative threshold 
(%SUVmax) used to delineate ROIPET  
 
Figure 2-3: Patient 3.  Comparison of ROIPET to ROICT (%) against the relative threshold 
(%SUVmax) used to delineate ROIPET  
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Figure 2-4: Patient 4.  Comparison of ROIPET to ROICT (%) against the relative threshold 
(%SUVmax) used to delineate ROIPET  
From the lines of best fit it is possible to calculate the relative threshold needed to ensure ROIPET 
equals ROICT for each lesion.  These data are displayed in the table below.  In this sample the 
mean threshold of ROIPET to match the area of the ROICT is 27%. 
ROI ROICT Area (cm2) 
PET threshold of to match 
ROIPET to ROICT (%SUVmax) 
P1_ROI1 5.393 27.96% 
P1_ROI2 12.618 28.50% 
P1_ROI3 11.268 36.65% 
P1_ROI4 13.804 38.73% 
P2_ROI1 19.414 24.40% 
P2_ROI2 7.309 26.33% 
P2_ROI3 3.398 20.35% 
P2_ROI4 8.981 34.23% 
P2_ROI5 2.438 21.20% 
P3_ROI1 12.721 36.22% 
P3_ROI2 8.139 35.47% 
P3_ROI3 14.063 28.78% 
P3_ROI4 6.378 28.14% 
P3_ROI5 7.866 18.95% 
P4_ROI1 17.232 21.04% 
P4_ROI2 6.351 25.90% 
P4_ROI3 6.491 26.66% 
P4_ROI4 9.74 13.90% 





95% CI 12.70%-41.04% 
Table 2-4: PET threshold calculated to ensure ROIPET=ROICT 
Taking an average of the ideal threshold across these 19 lesions analysed suggested the 
segmentation of the manual PETROI by 27% of SUVmax will, on average, equate best to the ‘gold-
standard’ of the CTROI.   
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2.3.2 18F-Fluoride PET – Per-Lesion Analysis – Response Analysis 
Hypothesis – Quantification parameters will be shown to predict 24-week clinical treatment 
response both from the baseline imaging and from the change between scans. 
VOI definitions  
The largest individually definable bone metastases were selected for VOI definition, ensuring the 
lesions were also definable on DW-MRI sequences.  These same lesions were then identified on 
the second scan, using the baseline scan and CT component of the PET/CT scan to ensure 
anatomical accuracy. 
Manual VOIs were drawn around each lesion on the PET scan using the registered CT image to 
ensure anatomic accuracy.  In-house software (FAST) was used to define the volumes.  The 
manual VOI (VOImanual) was drawn by the same investigator (Dr Benjamin Taylor (author of this 
thesis) Clinical Oncologist with practical radiology experience) to ensure full inclusion of the PET 
avid area within the VOI, and ensuring physiological tracer uptake was excluded (confirmation 
with an experienced Nuclear Medicine physician where necessary).   
An iso-contour of 27% of SUVmax was applied, excluding peripheral voxels of less than 27% 
(VOI27) (see Chapter 2.3.1).   
The same lesion on the second scan was identified using all available clinical imaging modalities 
and the CT component of the PET scan to ensure anatomical accuracy of delineation. 
PET Quantification Features - Definitions 
• SUV Histogram Parameters – SUVmean, SUVmax, SUVpeak 
• SUV Volumetric Parameters - MTV, TLA.   
• SUV Heterogeneity Parameters - SUVentropy, SUVenergy.   
• SUV Kinetic Parameter - Ki. 
The parameters are reported from the baseline scan, the second scan (at 8 weeks), and %Δ. 
Statistical Analyses 
• Comparison of parameters between tumour sub-groups using parametric independent 
samples t-tests (Mann-Whitney U tests if assumptions necessary for a parametric 
approach are not met) 
• Comparison of parameters between the 24-week response groups using independent 
samples t-tests (Mann-Whitney U tests if assumptions necessary for a parametric 
approach are not met) 
Results - See Chapter 3 
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2.3.3 18F-Fluoride PET – Per-Lesion Analysis – Survival Analysis 
Hypothesis – Quantification parameters from the baseline scan and changes in parameters 
between scans will be identified to be associated with OS and PFS. 
VOI definitions - as described in “Per-Lesion Analysis – Response Analysis” section  
PET Quantification Features- as described in “Per-Lesion Analysis – Response Analysis” 
section  
Statistical Analyses 
• OS Analysis 
o Cox regression univariate analysis 
o KM Analysis with log rank analysis 
• PFS Analysis 
o Cox regression univariate analysis 
o KM Analysis with log rank analysis 
Results – See Chapter 4 
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2.3.4 18F-Fluoride Per-Patient Target Lesion Analysis – Impact of VOI 
segmentation thresholds 
Hypothesis – Choice of VOI will have a significant impact on the quantification parameters, and 
it may be possible to identify a method with the lowest variation.  %Δ parameters will less variation 
with VOI method. 
VOI definitions 
Examining the impact of VOI segmentation on quantification is a major component of this analysis, 
and therefore a number VOI definition methods have been developed.   
The largest individually definable bone metastases were selected for VOI definition, ensuring the 
lesions were also definable on DW-MRI sequences.  Up to 5 lesions were identified for each 
patient.  These same 5 lesions were then identified on the second scan. 
Manual VOIs were drawn around each lesion on the PET scan using the registered CT image to 
ensure anatomic accuracy.  In-house software (FAST) was used to define the volumes.  Further 
VOIs were generated based on the SUVmax of each VOImanual, excluding voxels at less than 27% 
(VOI27) (based on preliminary study described elsewhere in this thesis), 40% (VOI40)100,101 and 
50% (VOI50)188 of the VOI SUVmax to create iso-contour SUV threshold VOIs for the baseline 
imaging.  A VOI using a FLAB technique was also created (VOIFLAB)113.  When a volume was 
fragmented into separate volumes by application of an SUV segmentation threshold, the largest 
residual volume was considered as the VOI for quantification to minimise the impact of image 
noise on quantification (greater impact on smaller VOIs). 
A further set of absolute SUV threshold VOIs were created on the second PET scan using the 
absolute SUV thresholds used to create the baseline (BL) scan VOIs (termed VOI27BL, VOI40BL, 
VOI50BL, respectively).  There is no consensus in published literature about how SUV parameters 
based on the whole voxel population of a VOI, or volumetric parameters, might be used to assess 
changes overtime.  Tracer uptake in a VOI is heterogeneous, and therefore using separate iso-
contours on first and second scans may provide misleading SUV volumetric measurements.  An 
absolute contour based on the iso-contour SUV of the baseline scan has therefore been 
investigated. 
e.g.  Baseline Scan – VOI right femur.  VOImanual has 40% of SUVmax threshold applied 
to create VOI40.  For this example, 40% of SUVmax = 4. 
Second Scan – same VOI right femur identified and VOImanual drawn.  An absolute 
SUV threshold of 4 used to create VOI40BL.  In addition, a VOI40 is also generated 
using the iso-contour threshold method.   
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VOImanual VOImanual Manual 
VOI27 VOI27 
Iso-contour VOI40 VOI40 
VOI50 VOI50 
VOIFLAB VOIFLAB Adaptive 
 VOI27BL 
Absolute  VOI40BL 
 VOI50BL 
Table 2-5: Summary of VOI methods used for quantification PET Quantification Features  
When more than one VOI has been identified in a patient the average of the lesions (up to 5) has 
been used for quantification, with the exception of MTV where the sum of up to 5 lesions has 
been calculated. 
• SUV Histogram Parameters – SUVmean, SUVmax, SUVpeak 
• SUV Volumetric Parameters - MTV, TLA.   
• SUV Heterogeneity Parameters - SUVentropy, SUVenergy.   
• SUV Kinetic Parameter - Ki. 
The parameters are reported from the baseline scan, the second scan (at 8 weeks), and %Δ. 
Statistical Analyses 
• Descriptive statistics 
• Comparisons between parameter distributions calculated with each VOI method using a 
parametric repeated measures one-way ANOVA (where the assumptions necessary for 
a parametric approach are not met, a non-parametric Friedman’s Variance test) 
• Comparisons between the tumour groups with Mann-Whitney U tests 
Results – See Chapter 5 
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2.3.5 18F-Fluoride Per-Patient Target Lesion Analysis – Response Analysis 
and Impact of VOI Segmentation Thresholds 
Hypothesis – Quantification parameters from the baseline scan and changes in parameters 
between scans will be identified predict 24-week clinical treatment response. 
VOI definitions 
The VOI were defined as outlined in the previous sections.   
PET Quantification Features – Definitions - as described in “18F-Fluoride Per-Patient Target 
Lesion Analysis – Impact of VOI segmentation thresholds” section 
Statistical Analyses 
• Mann-Whitney U tests to compare distributions of parameters between response groups 
for each VOI method separately. 
Results – See Chapter 6 
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2.3.6 18F-Fluoride Per-Patient Target Lesion Analysis – Survival Analysis 
Hypothesis – Quantification parameters from the baseline scan and changes in parameters 
between scans will be identified to be associated with OS and PFS. 
VOI definitions – as described in “18F-Fluoride Per-Patient Target Lesion Analysis – Impact of 
VOI segmentation thresholds” section.  It was not reasonable to perform survival analyses using 
all VOI methods.  This analysis has been carried out on the VOImanual. 
 
PET Quantification Features – Definitions - as described in “18F-Fluoride Per-Patient Target 
Lesion Analysis – Impact of VOI segmentation thresholds” section 
Statistical Analyses 
• OS Analysis 
o Cox regression univariate analysis 
o KM Analysis with Log Rank Analysis 
• PFS Analysis 
o Cox regression univariate analysis 
o KM Analysis with Log Rank Analysis 
Results – See Chapter 7 
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2.3.7 18F-Fluoride Whole-Body Quantification of Bone Metastases – 
Methodology, Response Analysis and Survival Analysis 
Hypothesis – Parameters representing the whole PET skeletal volume will be quantified.  
Parameters will be identified predicting 24-week treatment response, and prognostic of PFS and 
OS. 
VOI definitions 
A method was developed for this analysis to segment the bony skeleton from the CT component 
of the PET/CT scan, and use this as a mask to identify and isolate the PET data only 
corresponding to the skeleton.  The scans were manually edited to exclude any residual non-
skeletal or physiological PET signal. 
Software for auto-segmentation of the skeleton from the non-skeletal CT data was not available, 
and therefore this methodology was developed using readily available free software (OsiriX, for 
Mac).  Bone is readily distinguished on CT images due to the significant difference in density of 
bone compared to the surrounding tissues. 
The baseline CT components of the PET/CT scans of 3 breast cancer patients and 4 prostate 
cancer patients (the first patients recruited to the studies already described) were used for 
analysis.  Multiple ROIs were drawn within skeletal and non-skeletal tissues, and the Hounsfield 
Unit distribution statistics for each ROI recorded. 
 Skeletal ROI Extra-skeletal ROI 
Mean Hounsfield Unit (HU) 
(95% CI) 
288.88 (262.84-314.92) -4.891 (-16.496-6.714) 
HU Standard Deviation 
(95% CI) 
167.614 (152.988-182.241) 28.804 (26.572-31.035) 
HU Min (95% CI) -56.532 (-78.84 - -34.225) -92.899 (-109.905 - -75.89) 
HU Max (95% CI) 862.771 (816.040-909.502) 
75.827 (63.948-87.707) 
SD=70.834 
Table 2-6: Population statistics of Hounsfield Unit (HU) descriptors for skeletal and extra-
skeletal ROIs. 
To differentiate between skeletal and extra-skeletal tissues a HU threshold greater than the 
maximum HU of extra-skeletal tissue, and ideally less than the minimum HU of skeletal bone 
needs to be identified. 
For this methodology, the threshold selected was the maximum HU of the extra-skeletal ROI 
population, plus 2 standard deviations (where SD of population =70.834). 
Therefore, the threshold identified was 75.827+2(70.834)=217.5. 
This threshold will exclude 95% of extra-skeletal uptake.  Visual inspection identified a good 
segmentation of the skeletal volume. 
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Skeletal Segmentation Method 
The following details the step-by-step CT processing used to segment the skeletal volume, 
creating a mask to be applied to the 18F-Fluoride PET for whole-body skeletal quantification.  
OsiriX was used to prepare the CT scan, removing any non-skeletal component of the CT scan 
with HU>217.5.  In-house software (FAST) was used to create the mask.  The following table 
summarises the steps involved: 
Step Task 
1 CT component of PET scan loaded into OsiriX 
2 All pixels with HU<217.5 set to -1000  
3 Axial CT views – Residual non-skeletal tissue manually removed (teeth, couch, 
urinary tract, bladder, injection site, extra-skeletal physiological signal).  ROIs 
manually drawn around all the residual non-skeletal signal, and all these pixels 
manually set to HU -1000.  ROI data saved. 
4 Re-check axial views, further deletions if necessary.  ROIs of further deletions 
saved. 
5 CT scan closed without saving the deletions. 
6 Clean CT scan re-opened 
7 The saved ROIs were reloaded and the pixels within the ROIs set to -1000.  
This resulted in all the CT image data being saved, apart from the extra-skeletal 
tissue which would not be segmented by the 217.5HU threshold.  OsiriX applies 
a universal threshold algorithm whereby voxels below the threshold but within 
the VOI are also excluded; the FAST software uses an algorithm to apply the 
segmentation to the edges of the VOI, preserving intra-VOI voxels for 
quantification. 
8 The modified CT was then exported in DIACOM format. 
9 FAST software then used.  PET component and CT scan loaded into software. 
10 Mask created from the modified CT scan, but excluding all pixels<217.5 HU.  
This mask was then applied over the fused PET scan, and PET voxels outside 
of the mask excluded from analysis. 
11 Skeletal malignancy was then segmented from the whole skeletal PET volume 
using the 27% iso-contour thresholds based on the SUVmax of the skeletal PET 
volume 
Table 2-7: Preparation of CT-scan for segmentation of whole-skeletal volume which can 
then be used as a mask to select only skeletal 18F-Fluoride PET activity. 
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Figure 2-5 (below) documents one of the study patients (the same patient has also been pictorially 
represented in the discussion of the DW-MRI whole-body methodology), showing the baseline 
bone scan for reference (a), the bony skeleton segmented from the CT data (b), the baseline 18F-
Fluoride PET (c), and the segmented 18F-Fluoride PET after application of the mask and a 27% 
iso-contour for disease definition (d). 
a)  
b) c) d)  
Figure 2-5: Prostate cancer patient demonstrating whole-body segmentation of skeletal 
disease (see text above for descriptors) 
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PET Quantification Features – Definitions  
For all the patients, there were many VOIs created which had individual quantification parameters.  
Single pixels were also segmented by the image processing, which may represent clinically 
relevant bone metastases, or may represent noise.  Smaller lesions are more likely to be 
influenced by partial volume effects and noise.  A correction factor was applied to calculate the 
whole-body parameters (apart from the volumetric parameters) based on the VOI size, with the 
aim of including all voxels, but reducing the impact of noise on the measured parameter: 
𝑃𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟𝑊𝐵 =  ∑ 𝑉𝑂𝐼 𝑃𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟 𝑥 
𝑉𝑂𝐼 𝑉𝑜𝑙𝑢𝑚𝑒 (𝑡𝐷𝑉)
𝑉𝑜𝑙𝑢𝑚𝑒 𝑎𝑙𝑙 𝑉𝑂𝐼𝑠 (𝑡𝐷𝑉𝑊𝐵)
 
• SUV Histogram Parameters – SUVmeanWB, SUVmaxWB, SUVpeakWB (weighted as above) 
• SUV Volumetric Parameters – MTVWB (sum of all VOIs), TLAWB (MTVWB x SUVmeanWB).   
• SUV Heterogeneity Parameters - SUVentropyWB, SUVenergyWB (weighted as above)  
• SUV Kinetic Parameter - KiWB.(weighted as above) 
The parameters are reported from the baseline scan, the second scan (at 8 weeks), and %Δ. 
Statistical Analyses 
• Descriptive statistics 
• Response analysis, comparing distributions between response groups with non-
parametric Mann-Whitney U tests (none of data met assumptions necessary for a 
parametric approach). 
• OS and PFS analysis – Cox univariate regression analysis and KM analysis 
Results – See Chapter 8 
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2.3.8 DW-MRI – Per-Lesion Analysis – Response Analysis 
Hypothesis – Quantification parameters from the baseline scan and changes in parameters 
between scans will be identified to be predictive of 24-week treatment response. 
VOI definitions  
It was felt necessary to ensure the same target lesions were used between imaging modalities.  
The same largest definable bone metastasis was identified on all imaging modalities, and the MRI 
sequences used to identify the lesion on DW-MRI imaging, ensuring cross reference between the 
imaging modalities to ensure anatomical accuracy. 
The target lesions were manually delineated using the calculated high-b-value image (b-1400 
mm2/s).  No threshold was applied to these volumes before quantification 
ADC Quantification Features – Definitions  
• ADC Histogram Parameters – ADCmean, ADCmedian 
• ADC Volumetric Parameter - tDV.   
• ADC Heterogeneity Parameters - ADCentropy, ADCenergy.   
 
The parameters are reported from the baseline scan, the second scan (at 8-12 weeks), and %Δ. 
Statistical Analyses 
• Descriptive statistics of parameters 
• Comparison of parameter distributions between response groups with Mann-Whitney U 
tests 
Results – See Chapter 9 
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2.3.9 DW-MRI – Per-Lesion Analysis – Survival Analysis 
Hypothesis – Quantification parameters from the baseline scan and changes in parameters 
between scans will be identified to be associated with OS and PFS. 
VOI definitions  
Up to 5 lesions were identified in each patient.  The same lesions were identified and quantified 
on the other imaging modalities, confirming the malignant status of the target lesions.  The largest 
and/or most avid discrete bone lesions were selected for all modalities, ensuring cross reference 
between the imaging modalities to ensure anatomical accuracy. 
The target lesions were manually delineated using the calculated high-b-value image (b-1400 
mm2/s).  No threshold was applied to these volumes before quantification 
ADC Quantification Features – Definitions – as described in “DW-MRI – Per-Lesion Analysis 
– Response Analysis” section 
Statistical Analyses 
• OS Analysis 
o Cox regression univariate analysis 
o KM Analysis with Log Rank analysis 
• PFS Analysis 
o Cox regression univariate analysis 
o KM Analysis with Log Rank analysis 
• Results – See Chapter 10 
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2.3.10 DW-MRI – Per-Patient Analysis – Response Analysis 
Hypothesis – Quantification parameters from the baseline scan and changes in parameters 
between scans will be identified to be predictive of 24-week treatment response. 
VOI definitions  
Up to 5 lesions were identified in each patient.  The same lesions were identified and quantified 
on the other study imaging modalities.  The largest and/or most avid discrete bone lesions were 
selected for all modalities, ensuring cross reference between the imaging modalities to ensure 
anatomical accuracy.   
The target lesions were manually delineated using the b=1400 mm2/s image.  
ADC Quantification Features – Definitions  
ADCmean -  the average SUVmean of VOI(s).  
ADCmedian - the average SUVmedian of VOI(s).   
tDV – total diffusion volume = sum of individual VOI volumes 
ADCentropy – the average SUVentropy of VOI(s).     
ADCenergy – the average SUVenergy of VOI(s).   
The parameters are reported from the baseline scan, the second scan (at 8-12 weeks), and %Δ. 
Statistical Analysis 
• Response Assessment 
• Non-parametric Mann-Whitney U test to compare the parameter distributions 
between response groups (a non-parametric approach is used because of small 
sample size) 
Where appropriate, generation of Receiver Operating Characteristic (ROC) curves. 
Results See Chapter 11. 
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2.3.11 DW-MRI – Per-Patient Analysis – Survival Analysis 
Hypothesis – Quantification parameters from the baseline scan and changes in parameters 
between scans will be identified to be associated with OS and PFS. 
VOI definitions – see Chapter 2.3.10 
Statistical Analysis 
• OS Analysis 
o Cox regression univariate analysis 
o KM Analysis with Log Rank test for comparison 
• PFS Analysis 
o Cox regression univariate analysis 
o KM Analysis with Log Rank test for comparison 
Results – See Chapter 12 
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2.3.12 DW-MRI Whole-Body Quantification of Bone Metastases – 
Methodology, Response Analysis and Survival Analysis 
Hypothesis – Parameters representing the whole PET skeletal volume will be quantified.  
Parameters will be identified predicting 24-week treatment response, and prognostic of PFS and 
OS. 
It has been necessary to develop a method for identifying and defining the full skeletal metastatic 
burden to enable whole-body quantification of the bone metastases. 
Extrapolated b=1400s/mm2 images were generated for each DW-MRI scan.  This high diffusion 
gradient strength exaggerates the signal from restricted diffusion by suppressing the T2 shine 
through effect, reducing the influence of capillary perfusion on the image signal189.  A high b-value 
DW-MRI image produces stronger diffusion-weighting and more suppression of benign tissue 
signal.   have proved their utility for detecting malignancy.  These images were therefore selected 
for VOIWB definition.  
It is not currently feasible to segment the skeleton out of an MRI image, and therefore I have 
worked to find a solution for whole-body selection of only bony metastatic disease.  This is 
complicated by the significant physiological signal on DW-MRI scanning, and still present on the 
high b-value images. 
A small preliminary study involved the manual delineation of 14 known bone metastases.  These 
were confirmed as sites of metastatic disease in prostate cancer patients, and CT imaging was 
used to identify the area of sclerosis.  Bone lesions clearly distinguishable from surrounding 
normal bone and surrounding structures were identified.  The corresponding anatomical sites 
were identified on the DW-MRI imaging, using all sequences to aid identification of the site of 
disease.  A manual VOI was then drawn around the lesion, using Osirix on an Apple Mac 
computer.  The volumes of the CT defined sclerotic disease was compared with the manual high-
b signal VOI with a paired samples t-test, showing where t(8)=-1.338 p=0.218, concluding there 
was no significant difference in the volume of disease characterised on each imaging modality.  
The high-b value image signal data was analysed by comparing the signal intensity maximum.  
The data can be seen in the following table and box-plot comparing the benign and malignant 
lesions. 
Inclusion of all malignant tissue was identified as the priority, rather than exclusion of all benign 
tissue.  The distributions of the high b-value image overlap, and therefore there is no perfect 
distinguishing cut-off.  Selecting a high b-value imaging intensity of 14 was identified on ROC 
analysis as the most differentiating value, with a sensitivity of 100% (meaning all malignant lesions 
would be identified if the VOI contained a high b-value signal intensity of 14).   
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Table 2-8: High b-value DW-MRI imaging analysis; benign vs malignant bone lesions 
For this feasibility study this threshold was used for initial image preparation, but the high b-value 
images required manual deletion of physiological and non-malignant image signal.  Firstly, all 
voxel values in the high b-value image were made binary: all voxels of intensity<14 were set to 0 
(black), and all remaining voxels set to 1000 (white) to ensure all residual voxels were clearly 
distinguishable.  Slice by slice non-malignant non-bone signal was deleted, using other 
sequences image-fused for anatomic guidance. 
The final modified b-value image was then used as a mask to place over the ADC map, and each 
lesion was then quantified using in-house image analysis software. 
   
a) b) c) 
Figure 2-6: Whole-body DW-MRI VOI Segmentation: Study Patient FAP03 Baseline Scan.  
(99mTC Bone Scan showing sites of prostate cancer bone metastases and 18F-Fluoride 
PET scan showing uptake at sites of bone metastases can be reviewed in whole-body 
18F-Fluoride methodology) a) extrapolated high b-value (1400s/mm2) image of same 
patient b) high-b value image with segmented pathological bone signal mask overlaid c) 
pathological bone signal mask which will be applied to ADC map for whole-body 
quantification) 
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ADC Quantification Features – Definitions  
The images after processing demonstrated image noise, including numerous single pixels.  Some 
studies have only quantified lesions >2cm.  For this study a weighting was applied to create the 
Whole-body (WB) parameter, minimising the impact of individual pixels/small volumes more likely 
to represent image noise.   
𝑃𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟𝑊𝐵 =  ∑ 𝑉𝑂𝐼 𝑃𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟 𝑥 
𝑉𝑂𝐼 𝑉𝑜𝑙𝑢𝑚𝑒 (𝑡𝐷𝑉)
𝑉𝑜𝑙𝑢𝑚𝑒 𝑎𝑙𝑙 𝑉𝑂𝐼𝑠 (𝑡𝐷𝑉𝑊𝐵)
 
ADCmeanWB –  As previously described, weighted as above 
ADCmedianWB - As previously described, weighted as above. 
tDVWB – total diffusion volume = volume of VOI(s) 
ADCentropyWB – As previously described, weighted as above 
ADCenergyWB – As previously described, weighted as above  
The parameters are reported from the baseline scan, the second scan (at 8-12 weeks), and %Δ. 
Statistical Analysis 
• Tumour group analysis 
o Comparison of distributions of parameters between tumour groups made using 
independent samples t-tests (where assumptions for a parametric approach were 
not met, Mann-Whitney U tests used) 
• Response Analysis 
o Comparison of distributions of parameters between response groups made using 
independent samples t-tests (or non-parametric, Mann-Whitney U tests) 
• OS Analysis 
o Cox regression univariate analysis 
o KM Analysis 
• PFS Analysis 
o Cox regression univariate analysis 
o KM Analysis 
Results – See Chapter 13 
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2.4 Patients 
At the time of this data analysis, 20 patients had been recruited to the three studies.  The patient 
demographics and clinical details can be seen in the summary table on the following page. 
5 women with breast cancer have been included, all of whom were treated with hormone therapies 
and bisphosphonates.  The average Ca15-3 was 167 (range 14-484).  The breast cancer patients 
were of average age 65 years (range 40-78 years). 
15 men with prostate cancer have been included.  6 patients were treated with docetaxel 
chemotherapy, and 9 with Abiraterone and prednisolone.  The average PSA was 308 (range 7-
2891).  The prostate cancer patients were of average age 74 years (range 60-90 years). 
14 patients had baseline 18F-Fluoride PET imaging, and 12 successfully completed the second 
imaging, with an average 69 days between the scans (range 53-93 days). 
20 patients had baseline DW-MRI imaging, and 19 successfully completed the second imaging, 
with an average of 71 days between the scans (range 55-86 days). 
 
 












































































































































































































1 FAB-B Breast 40 
Letrozole and 
bisphosphonates 
13 484 N/A ✓ ✓ 57 10/07/13 03/09/13 55 Alive Progressed No Response 
2 FAB-B Breast 75 Letrozole and zometa 33 14 N/A ✓ ✓ 58 09/09/13 06/11/13 58 Alive Not Progressed Response 
3 FAB-B Breast 68 Letrozole + zometa 7 47 N/A ✓ ✓ 62 30/10/13 07/01/14 69 Alive Not Progressed Response 
4 FAB-B Breast 78 Tamoxifen 14 87 N/A ✓ ✓ 62 20/01/14 20/03/14 59 Alive Progressed No Response 
5 FAB-B Breast 65 Faslodex+Denosumab 15 205 N/A ✓ ✓ 77 07/04/14 18/06/14 72 Alive Not Progressed Response 
6 FAB-P Prostate 66 Docetaxel (+GCSF) 2  475 ✓  n/a 01/10/12 03/12/12 63 Dead Progressed No Response 
7 FAB-P Prostate 72 Docetaxel 4  2891 ✓ ✓ 63 21/01/13 04/04/13 73 Alive Progressed No Response 
8 FAB-P Prostate 79 DOCETAXEL 17  173 ✓ ✓ 93 11/02/13 26/04/13 74 Dead Progressed No Response 
9 FAB-P Prostate 74 DOCETAXEL 6  137 ✓ ✓ 68 30/08/13 01/11/13 63 Alive Not Progressed Response 
10 FAB-P Prostate 90 ABIRATERONE+PRED 4  76 ✓ ✓ 53 28/01/14 25/03/14 56 Alive Progressed No Response 
11 FAB-P Prostate 68 DOCETAXEL 18  39 ✓ ✓ 84 24/03/14 06/06/14 74 Alive Progressed No Response 
12 FAB-P Prostate 79 ABIRATERONE+PRED 9  76 ✓ ✓ 85 04/04/14 26/06/14 83 Alive No Progressed n/a 
13 FAB-P Prostate 77 DOCETAXEL 1  8 ✓ ✓ 70 08/04/14 05/06/14 58 Dead Progressed No Response 
14 FAB-P Prostate 64 ABIRATERONE+PRED 21  263 ✓ x n/a 10/04/14 n/a N/A Alive Not reached Not reached 
15 FAB-IE Prostate 82 ABIRATERONE+PRED 4  157    08/07/13 30/09/13 84 Dead Progressed No Response 
16 FAB-IE Prostate 60 ABIRATERONE+PRED 2  29    12/08/13 06/11/13 86 Alive Progressed No Response 
17 FAB-IE Prostate 79 ABIRATERONE+PRED 11  7    19/08/13 12/11/13 85 Alive Progressed No Response 
18 FAB-IE Prostate 63 ABIRATERONE+PRED 1  213    30/09/13 20/12/13 81 Dead Progressed No Response 
19 FAB-IE Prostate 83 ABIRATERONE+PRED -2  37    12/11/13 28/01/14 77 Alive Progressed No Response 
20 FAB-IE Prostate 74 ABIRATERONE+PRED 1  42    20/11/13 14/02/14 86 Alive Not Progressed Response 
Table 2-9: Patient demographics 
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Chapter 3  18F-Fluoride PET – Per-Lesion Analysis.  Image 
quantification for response assessment of patients with bone 
metastases from breast or prostate cancer 
The methods of this chapter and the statistical approaches for this section can be reviewed in 
Chapter 2.3.2.  
3.1 Results 
14 patients had data suitable for inclusion, with 62 bone metastases identified.  5 breast cancer 
patients have yielded 24 bone metastases, and 38 lesions from 9 prostate cancer patients.  
Response data was available for 55 lesions (12 patients, 24 breast lesions, 31 prostate lesions).  
2/5 (40%) breast cancer patients (representing 10/24 lesions) had PD.  6/7 (86%) prostate cancer 
patients (29/31 lesions) had PD.  With only 2 prostate lesions in patients with a treatment 
response, response analysis of the prostate cancer lesions only is not feasible. 
3.1.1 Baseline Scan 
3.1.1.1 SUV Parameters 



























Figure 3-1: 18F-Fluoride Per-lesion analysis; Baseline SUV Parameters 
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Fig.3-1 demonstrates the heterogeneity of SUV parameters.  The whole-population statistics are 
recorded in Tbl.3-1 and Fig.3-2: 
 SUVmean SUVmax SUVpeak 
 















































































Table 3-1: 18F-Fluoride PET Per-lesion analysis; Descriptive statistics of baseline scan; 
SUV Parameters 

















   












   
 p=0.404 p=0.643 p=0.470 
Figure 3-2: 18F-Fluoride PET Per-lesion analysis; Descriptive statistics of baseline scan; 
SUV Parameters; Comparisons with Mann-Whitney U tests (B - Breast cancer patients; P 
– Prostate cancer) 
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The mean of the SUV parameter distributions are significantly higher for the prostate cancer 
lesions (Mann Whitney U tests: SUVmean p=0.066; SUVmax p=0.011; SUVpeak p=0.008).  Prostate 
cancer lesions are predominantly osteoblastic, and it is expected they would have increased 
avidity for 18F-Fluoride.  The standard deviation of the groups distributions is smaller for breast 
cancer lesions (4.29) compared with the prostate cancer lesions (14.69) suggesting more inter-
lesion heterogeneity in the prostate cancer lesions measured. 
There is no demonstrable association between the baseline SUV parameters for these lesions -
and the subsequent 24-week response (Mann-Whitney U tests – see Figure 3-2), although this 
highest SUV parameters were identified in lesions with PD. 
Response analysis of just the breast lesions also shows no association between the baseline 
SUV and 24-week treatment response (Mann-Whitney U tests: SUVmean p=1.0; SUVmax p=0.752; 
SUVpeak p=0.709).  
The baseline SUV parameters have no utility for predicting a treatment response in these patients.   
3.1.1.2 Volumetric Parameters 











Figure 3-3: 18F-Fluoride Per-lesion analysis; Baseline Volumetric Parameters  
Fig.3-3 shows the range of volumetric parameters identified; the prostate patients yielded the 
largest measurements.  The population data and tumour group data is recorded Tbl.3-2 and Fig.3-
4. 
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 MTV TLA 
 




All lesions n=62 
39.7 (27.94-51.46)  
[2.25-241.7]  
{27.29; 46.32}  
|3.04; 10.18| 
647.17 (359-935.35)  
[15.77-6494.17]  




25.04 (17.17-32.91)  
[2.25-67.09]  
{23.62; 18.63}  
|1.03; 0.61| 
249.6 (162.76-336.45)  
[15.77-907.08]  




(7 did not have response analysis 
data) 
48.96 (30.67-67.24)  
[2.35-241.7]  
{32.68; 55.63}  
|2.47; 5.94| 
898.27 (441.71-1354.82)  
[22.86-6494.17]  









835.83 (385.79-1285.87)  
[15.77-6494.17]  









233.45 (152.81-314.08)  
[59.93-575.12]  
{244.38; 151.32}  
|0.88; 0.6| 
Table 3-2: 18F-Fluoride PET Per-lesion analysis; Descriptive statistics of baseline scan; 
Volumetric Parameters 
 






































 p=0.09 p=0.04 
Figure 3-4: 18F-Fluoride PET Per-lesion analysis; Descriptive statistics of baseline scan; 
Volumetric Parameters (B - Breast cancer patients; P – Prostate cancer) 
There is a demonstrable difference in the distribution of MTV and TLA between the tumour 
groups, with larger lesions and higher TLA identified in the prostate cancer patients (Mann 
Whitney U tests:  MTV p=0.035; TLA p=0.002). 
There is a significant and expected correlation between the TLA and the MTV (Spearman’s rank 
analysis: ρ=0.749, p<0.00001); TLA is the product of the MTV and the SUVmean. 
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There is a notable difference in the distribution of the baseline volumetric parameters between 
response groups, with lesions in patients with PD having a higher MTV (p=0.09) and TLA 
(p=0.04).  However, analysis of the breast cancer lesions alone does not identify an (Mann 
Whitney U tests: MTV p=0.752; TLA p=0.977).  Prostate cancer lesions are larger and were more 
likely to have PD. 
3.1.1.3 Heterogeneity Parameters 






















Figure 3-5: 18F-Fluoride Per-lesion analysis; Baseline SUV Heterogeneity Parameters 
 SUVentropy SUVenergy 
 




All lesions  
n=62 
2.92 (2.75-3.09)  
[1.81-4.72]  
{2.75; 0.68}  
|0.72; -0.02| 
0.0805 (0.0692-0.0918)  
[0.0098-0.2082]  




2.7 (2.51-2.88)  
[1.81-3.34]  
{2.73; 0.45}  
|-0.29; -0.7| 
0.0883 (0.0709-0.1056)  
[0.0393-0.2082]  




3.06 (2.81-3.31)  
[2.01-4.72]  
{2.84; 0.76}  
|0.51; -0.84| 
0.0756 (0.0603-0.0909)  
[0.0098-0.1719]  




2.96 (2.72-3.21)  
[2.01-4.72]  
{2.72; 0.75}  
|0.75; -0.47| 
0.0774 (0.063-0.0917)  
[0.0098-0.1719]  




2.75 (2.5-3)  
[1.81-3.33]  
{2.77; 0.47}  
|-0.75; -0.1| 
0.0866 (0.0624-0.1109)  
[0.0425-0.2082]  
{0.0716; 0.0455}  
|1.6685; 2.6197| 
Table 3-3: 18F-Fluoride PET Per-lesion analysis; Descriptive statistics of baseline scan; 
SUV Heterogeneity Parameters 
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 p=0.670 p=0.670 
Figure 3-6: 18F-Fluoride PET Per-lesion analysis; Descriptive statistics of baseline scan; 
SUV Heterogeneity Parameters (B - Breast cancer patients; P – Prostate cancer) 
There is no demonstrable difference in the distribution of the baseline SUV heterogeneity 
parameters between the tumour groups (Mann-Whitney U tests: SUVentropy p=0.140 and for 
SUVenergy p=0.319), or response groups (Mann-Whitney U tests: SUVentropy p=0.670 and for 
SUVenergy p=0.0670).  The highest SUVentropy and lowest SUVenergy measurements were in lesions 
representing PD.  Analysis of the breast cancer lesions only also demonstrates no predictive utility 
(p=1.0 for both parameters). 
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3.1.1.4 Ki 
All lesions Distribution within patients 
  
Figure 3-7: 18F-Fluoride Per-lesion analysis; Baseline Ki 
 Ki 
 




All lesions  
n=62 
0.22 (0.18-0.27)  
[0.06-1.09]  




0.18 (0.14-0.22)  
[0.06-0.37]  




0.25 (0.18-0.32)  
[0.06-1.09]  




0.24 (0.17-0.3)  
[0.06-1.09]  




0.17 (0.13-0.21)  
[0.06-0.31]  
{0.16; 0.08}  
|0.28; -0.79| 
Table 3-4: 18F-Fluoride PET Per-lesion analysis; Descriptive statistics of baseline scan; Ki 
All lesions Tumour subgroups Response Groups 
   
 p=0.479 p=0.541 
Figure 3-8: 18F-Fluoride PET Per-lesion analysis; Descriptive statistics of baseline scan; Ki 
(B - Breast cancer patients; P – Prostate cancer) 
Fig.3-7 and Tbl.3-4 report the data of the baseline Ki parameter, showing the inter-lesion 
heterogeneity.  There is no demonstrable statistically significant difference in the distribution of Ki 
between tumour subgroups (Mann-Whitney U test: p=0.479), or 24-week response groups (Mann-
Whitney U test, p=0.541).  There is no significant difference between the response groups when 
only the breast cancer lesions are analysed (p=0.709). 
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Correlations between parameters 
 SUVmean SUVmax SUVpeak MTV TLA SUVentropy SUVenergy Ki 
SUVmean 
1 - - - - - - - 
SUVmax 0.843 
(<0.0001) 





























































Table 3-5: 18F-Fluoride PET Per-lesion analysis; Baseline Parameters; Correlations 
between parameters (Spearman’s Correlation coefficient (p-value)) 
To complicate the analysis, there are significant correlations between most of the baseline 
parameters (Tbl.3-5).   
The correlation between the SUV parameters was anticipated because they are all describing the 
same histogram.  TLA is the product of MTV and SUVmean, and therefore the correlation between 
TLA and the SUV parameters is also to be expected.  MTV is not significantly correlated with any 
of the other parameters (other than TLA).  The heterogeneity parameters are significantly and 
strongly correlated with the SUV parameters; SUVentropy is positively correlated with the SUV 
parameters, and SUVenergy negatively correlated.  Ki is significantly and strongly correlated with 
all the parameters other than MTV.  MTV seems to be the most independent parameter used in 
this study. 
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3.1.2 Second Scan 
 






14.95 (12.53-17.37)  
[4.18-39.57]  




39.48 (33.41-45.56)  
[7.66-104.96]  




30.05 (25.37-34.73)  
[5.21-77.8]  




40.7 (29.23-52.17)  
[2.4-220.09]  






















0.21 (0.17-0.24)  
[0.06-0.52]  
{0.16; 0.12}  
|0.9; -0.22| 
 
Table 3-6: 18F-Fluoride PET Per-lesion analysis; Descriptive statistics of second scan; All 
Parameters  
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3.1.3 %Δ Parameters 
3.1.3.1 %ΔSUV Parameters 

































Figure 3-9: 18F-Fluoride Per-lesion analysis; %Δ SUV Parameters 
 %ΔSUVmean %ΔSUVmax %ΔSUVpeak 
 






10.59 (-1.98-23.16)  
[-56.01-147.59]  
{0.92; 45.61}  
|1.21; 1.14| 
2.2 (-10.16-14.57)  
[-56.87-173]  
{-11.07; 44.87}  
|1.64; 3.5| 
1.89 (-9.12-12.9)  
[-57.97-169.57]  




15.33 (-7.35-38.01)  
[-56.01-130.28]  
{4.74; 51.15}  
|0.79; -0.11| 
20.66 (-5.7-47.01)  
[-44.84-173]  
{-3.44; 59.44}  
|1; 0.38| 
13.71 (-10-37.42)  
[-47.58-169.57]  




7.23 (-8.1-22.56)  
[-46.01-147.59]  
{-1.5; 41.79}  
|1.7; 3.37| 
-10.89 (-19.79--1.99)  
[-56.87-31.76]  
{-12.05; 24.27}  
|-0.14; -0.74| 
-6.5 (-15.41-2.4)  
[-57.97-31.25]  





5.93 (-7.74-19.6)  
[-46.01-130.28]  
{-1.41; 39.18}  
|1.61; 2.67| 
1.48 (-16.41-19.37)  
[-56.87-173]  
{-14.72; 51.27}  
|1.79; 3.21| 
-0.55 (-15.47-14.37)  
[-57.97-169.57]  





3.24 (-24.3-30.78)  
[-56.01-109.53]  
{-7.26; 47.7}  
|0.89; 0.21| 
-2.92 (-22.72-16.89)  
[-44.84-67.29]  
{-5.21; 34.3}  
|0.72; -0.09| 
-0.03 (-22.62-22.56)  
[-47.58-75.85]  
{-6.93; 39.12}  
|0.69; -0.45| 
Table 3-7: 18F-Fluoride PET Per-lesion analysis; Descriptive statistics of %ΔSUV 
Parameters 
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 p=0.634 p=0.785 p=0.838 
Figure 3-10: 18F-Fluoride PET Per-lesion analysis; Descriptive statistics of %ΔSUV 
Parameters (B - Breast cancer patients; P – Prostate cancer) 
Fig.3-9, Fig.3-10, and Tbl.3-7 show lesions with both increases and decrease in the %ΔSUV 
parameters have been identified.  Within individual patients there are lesions with opposing 
changes.  
There is no statistically significant difference in the distribution of the %ΔSUV Parameters 
between the response groups (Fig.3-24).  Within each response group there are lesions for which 
the parameter has increased and for which the parameter has fallen.   
Analysis of only the breast cancer lesions demonstrates a trend towards significance for 
identification of the 24-week response group from the %Δ SUV parameters (Fig.3-11)). 
 %ΔSUVmean 
Breast lesions only 
%ΔSUVmax 
Breast lesions only 
%ΔSUVpeak 















   
 p=0.069 p=0.05 p=0.228 
Figure 3-11: 18F-Fluoride PET Per-lesion analysis; Descriptive statistics of %ΔSUV 
Parameters; Breast lesions only; comparisons with Mann-Whitney U tests 
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Statistical significance is only reached at the 0.05 level for %ΔSUVmax.  The %ΔSUVmean data 
approaches significance (p=0.069), but although the box-plots suggest a similar separation of the 
%ΔSUVpeak data, no statistically significant difference has been identified (p=0.228). 
The ROC data (Fig.3-12) can be used to identify the accuracy shown by these two parameters 
for the prediction of PD by 24-weeks. 
 
%ΔSUVmean 
Breast lesions only 
%ΔSUVmax 
Breast lesions only 
ROC 
  
AUC 0.733 0.750 





Sensitivity Specificity AUC 
p-
value 
%ΔSUVmean >+1.25% 80% 58% 0.733 0.065 
%ΔSUVmax >+19.91% 60% 75% 0.775 0.048 
Figure 3-12: 18F-Fluoride PET Per-lesion analysis; Response analysis of %Δ ADC 
parameters with ROC analysis for prediction of PD; Breast lesions only 
The %Δ in SUVmean shows increased sensitivity for predicting PD, but the %Δ SUVmax shows a 
higher specificity. 
Despite this association, there were lesions within each response group showing inconsistency 
in the direction of SUV parameter change.  The heterogeneous change in these parameters can 
be visualised using waterfall plots (Fig.3-13). 
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Figure 3-13: 18F-Fluoride PET Per-lesion analysis; Response analysis of %Δ SUV 



















































%Change SUVpeak and treatment response
Response Progression
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3.1.3.2 %Δ Volumetric Parameters 















Figure 3-14: 18F-Fluoride Per-lesion analysis; %Δ Volumetric Parameters  
 %ΔMTV %ΔTLA 
 




All lesions  
n=53 
24.24 (0.25-48.23)  
[-76.47-522.66]  
{1.98; 87.03}  
|3.94; 20.78| 
21.3 (6.02-36.58)  
[-56.09-192.47]  




37.94 (-13.46-89.33)  
[-76.47-522.66]  
{9.18; 115.92}  
|3.77; 16.01| 
32.73 (5.78-59.67)  
[-50.71-173.9]  




14.52 (-7.14-36.19)  
[-70.51-208.24]  
{0.86; 59.05}  
|1.64; 3.49| 
13.19 (-5.44-31.82)  
[-56.09-192.47]  





18.43 (-0.61-37.47)  
[-49.12-208.24]  
{0.25; 54.57}  
|1.86; 4.18| 
20.56 (1.03-40.09)  
[-56.09-192.47]  





55.51 (-26.66-137.68)  
[-76.47-522.66]  




{14.63; 62.56}  
|1.23; 1.15| 
Table 3-8: 18F-Fluoride PET Per-lesion analysis; Descriptive statistics of %Δ Volumetric 
Parameters 







































 p=0.276 p=0.964 
Figure 3-15: 18F-Fluoride PET Per-lesion analysis; Descriptive statistics of %Δ Volumetric 
Parameters (B - Breast cancer patients; P – Prostate cancer) 
There is a wide spread of results, even within individual patients (Fig.3-14).  Tbl.3-8 and Fig.3-15 
report this data and compares the tumour groups and response groups. 
There is no demonstrable statistically significant difference between the distributions of the %Δ 
volumetric parameters and the response group (Mann-Whitney U Tests: %ΔMTV p=0.367; 
%ΔTLA p=0.271).  There is also no difference when only the breast cancer lesions are analysed 
(Mann-Whitney U Tests: %ΔMTV p=0.180; %ΔTLA p=0.254).  Both response groups contain 
lesions with increases and decreases in volumetric parameter (Fig.3-16). 
 
Figure 3-16: 18F-Fluoride PET Per-lesion analysis; Response analysis of %Δ Volumetric 






























%Change TLA and treatment response
Response Progression
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3.1.3.3 %Δ Heterogeneity Parameters 




























Figure 3-17: 18F-Fluoride Per-lesion analysis; %Δ SUV Heterogeneity Parameters 
 %ΔSUVentropy %ΔSUVenergy 
 




All lesions  
n=53 
0.99 (-3.33-5.31)  
[-29-46.4]  
{0.26; 15.67}  
|0.54; 0.17| 
11.19 (-2.02-24.39)  
[-74-121.23]  




2.27 (-6.03-10.56)  
[-23.81-46.4]  
{1.76; 18.71}  
|0.61; -0.2| 
12.73 (-9.45-34.91)  
[-47.65-106.89]  






{-0.27; 13.37}  
|0.22; -0.01| 
10.09 (-7.22-27.39)  
[-74-121.23]  





-0.42 (-4.99-4.15)  
[-29-27.01]  
{-1.55; 13.1}  
|0.27; -0.25| 
12.61 (-2.75-27.97)  
[-66.83-121.23]  





-0.94 (-12.56-10.68)  
[-23.81-46.4]  
{-0.55; 20.13}  
|1.07; 0.98| 
22.45 (-9.51-54.4)  
[-46.5-106.89]  
{1.64; 55.34}  
|0.24; -1.7| 
Table 3-9: 18F-Fluoride PET Per-lesion analysis; Descriptive statistics of %Δ SUV 
Heterogeneity Parameters 
As for the other %Δ parameters, a full range of change has been identified in these study lesions, 
and there is again a heterogeneous change within individual patients (Fig.3-17).  Table 3-9 reports 
the full data.  There is no demonstrable difference identified in the distribution of the %Δ 
heterogeneity parameters between the tumour subgroups (Fig.3-18). 
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[independent samples t-test] 
p=0.928  
















 p=0.634 p=0.785 
Figure 3-18: 18F-Fluoride PET Per-lesion analysis; Descriptive statistics of %Δ SUV 
Heterogeneity Parameters (B - Breast cancer patients; P – Prostate cancer) 
There is no statistically significant difference in the distribution of the %Δ heterogeneity 
parameters between the 24-week response groups for these lesions (Tbl.3-18).  Analysis of just 
the breast cancer lesions can be reviewed below (Fig.3-19). 
 %ΔSUVentropy 
Breast lesions only 
%ΔSUVenergy 
















 p=0.140 p=0.093 
Figure 3-19: 18F-Fluoride PET Per-lesion analysis; Descriptive statistics of %Δ SUV 
Heterogeneity Parameters; breast lesions only; comparisons with Mann-Whitney U tests 
There is a trend towards significance for PD being predicted for the breast cancer lesions with an 
increase in SUVentropy between scans (p=0.140) and a decrease in SUVenergy (p=0.093), i.e. when 
treatment results in a more heterogeneous SUV voxel distribution. 
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Again, for both response groups there are lesions showing an increase in the heterogeneity 
parameter, but also lesions for which the heterogeneity parameter fell with treatment.  This can 
be more clearly seen in the waterfall plots below: 
 
Figure 3-20: 18F-Fluoride PET Per-lesion analysis; Response analysis of %Δ SUV 








































%Change SUVenergy and treatment response
Response Progression
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3.1.3.4 %Δ Ki 






Figure 3-21: 18F-Fluoride Per-lesion analysis; %Δ Ki 
 %ΔKi 
 




All lesions  
n=48 
11.56 (-0.49-23.6)  
[-53.77-148.76]  




17.4 (-5.91-40.71)  
[-30.83-148.76]  




8.35 (-6.18-22.89)  
[-53.77-138.52]  




0.79 (-9.66-11.24)  
[-53.77-69.96]  




27.09 (-14.16-68.34)  
[-25.07-148.76]  
{9.51; 53.66}  
|1.57; 3| 
Table 3-10: 18F-Fluoride PET Per-lesion analysis; Descriptive statistics of %Δ Ki 
All Lesions Tumour Subgroups Response Groups 
   
 p=0.674 p=0.198 
Figure 3-22: 18F-Fluoride PET Per-lesion analysis; Descriptive statistics of %Δ Ki (B - 
Breast cancer patients; P – Prostate cancer) 
As for the other parameters in this study, a full range of changes in Ki has been identified, 
including within individual patients (Fig.3-21).  Table 3-10 reports the data. 
Statistical comparison of the distributions of %ΔKi between the response group does not reach 
significance (Fig.3-22), but the Ki seemed higher in lesions from patients with a treatment 
response at 24-weeks.  There is no statistically significant difference identified when only breast 
cancer lesions are analysed (p=0.417). 
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The heterogeneous change in parameter seen with the other parameters has also been identified 
in these lesions, with positive and negative changes seen in each response group.  This can be 
seen clearly on the following waterfall plot: 
 
Figure 3-23: 18F-Fluoride PET Per-lesion analysis; Response analysis of %ΔKi; Waterfall 
plots for all lesions 
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Table 3-11: 18F-Fluoride PET Per-lesion analysis; %Change Parameters; Correlations 
between parameters (Spearman’s Correlation coefficient (p-value)) 
There are significant correlations between most of the %Δ parameters (Table 3-11).  The SUV 
parameters are describing the same histogram and are closely correlated.  TLA is the product of 
MTV and SUVmean, and the correlation between TLA and the SUVmean parameters is also to be 
expected.  There is a trend towards a weak association for the other SUV parameters. 
MTV was not significantly correlated with the other parameters (apart from TLA) at the baseline 
scan, but the %Δ MTV parameter shows a weak but significant correlation with the other 
parameters.  The heterogeneity parameters are significantly and strongly correlated with the SUV 
parameters; SUVentropy is positively correlated with the SUV parameters, and SUVenergy negatively 
correlated.  Ki is significantly and strongly correlated with all the parameters other than MTV.   
%Δ MTV still seems to be the most independent parameter used in this study, but still shows 
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3.2 Discussion 
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Table 3-12: 18F-Fluoride PET Per-lesion analysis; All Parameters; Summary Table 
Although the clinical use of 18F-Fluoride PET for assessment of bone metastases is widespread, 
there is no evidence for assessment other than qualitative analysis for these scans.  Hiller et al. 
reported 59% of patients in their retrospective study had treatment decisions changed following 
addition information from the 18F-Fluoride PET190;  it is not clear what information was used to 
effect these changes. 
At the time of the study design there was little evidence to show 18F-Fluoride PET quantification 
from baseline imaging had validity for response prediction.  Zukotynski et al.191, demonstrated no 
utility for predicting treatment outcome from baseline volumetric or SUV parameters in 9 prostate 
cancer patients with bone metastases.  A non-cancer study reviewing the use of 18F-Fluoride to 
monitor bone healing following complex orthopaedic procedures suggested 18F-Fluoride could 
predict non-response to the orthopaedic interventions (surgical procedures rather than medical 
therapy)192. 
To my knowledge there is no literature reporting the successful quantification of baseline 18F-
Fluoride PET scans for prediction of a treatment response of bone metastases; the limited studies 
published have indeed found no value.  This study has also demonstrated no value from the 
baseline parameters for prediction of the clinical treatment response.   
There is more literature describing the clinical application of quantifying the changes in 18F-
Fluoride parameters.  Responses to therapy for non-malignant bone conditions has been reported   
(e.g. osteopenia patients had an increase in Ki following anabolic therapy193, and a rat model 
demonstrated a negative correlation with Ki and positive correlation with SUV following 
inducement of osteoporosis194).  A decrease in 18F-Fluoride uptake with successful therapy 
(correlated with the changes in tumour markers and markers of bone turnover) was shown in 
prostate cancer metastases by Cook et al., following therapy with Alpharadin140, hypothesising 
the utility of 18F-Fluoride PET for monitoring therapy of bone metastases.  Apolo et al. confirmed 
a significant correlation between the SUV changes of 18F-Fluoride PET, repeated at 6 and 12 
months after initiating therapy, with PSA changes195.  Takalkar et al. reported a decrease in 18F-
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Fluoride SUVmax after 2 and 6 cycles of Alpharadin for bone metastases from breast cancer196, 
suggesting a treatment response can be assessed at a clinically useful time. 
A recent publication compared 18F-Fluoride and 18F-FDG PET imaging for 34 patients with 
multiple myeloma who were imaged before and after autologous stem cell transplantation.  The 
authors report Ki, SUVaverage and SUVmax from 18F-Fluoride PET all decreased following treatment.  
They report persistence of 81.5% of the baseline 18F-Fluoride positive lesions despite 65% of 
these lesions becoming 18F-FDG negative.  The performance of 18F-Fluoride PET was limited, 
and did not have accuracy for identifying response to therapy197.  However, myeloma has a 
predominantly osteolytic action in bone, and although there will be osteoblast activity to some 
degree; bone scans and 18F-Fluoride PET has limited utility for imaging myeloma. 
Yu et al. reported a decrease in SUVmax 12 weeks after initiation of a tyrosine kinase inhibitor for 
prostate cancer bone metastases.  A correlation between an increased SUVmax and a lower risk 
of PD was shown198; this may represent a flare response.  Another group demonstrated a fall in 
SUVmax identified after 8-weeks and 24-weeks of Radium-223 for bone metastases from breast 
cancer in one patient with a treatment response196. 
In a study to compare the utility of 18F-Fluoride and 18F-FDG PET imaging for bone metastases 
from prostate cancer before and after therapy, Simoncic et al. reported a correlation between the 
changes in 18F-Fluoride and 18F-FDG199.  There was no clinical correlation with treatment 
response.  Interestingly the authors concluded up to an 80% discordance in spatial overlap of 
uptake from the two tracers; the stromal bone response resulting in 18F-Fluoride uptake is not 
necessarily where the tumour cells are, indicated by the 18F-FDG uptake199. 
In this study, an increase in SUV between the scans predicts for the treatment response for the 
breast cancer lesions (there were too few responses for analysis of the prostate 
lesions).  %ΔSUVmax and %ΔSUVmean have shown the most utility.  A similar pattern in the data 
is seen for SUVpeak, but this does not approach statistical significance.  This might suggest it is 
the SUV extremes (e.g. SUVmax, or the description of the whole SUV histogram with SUVmean) 
with predictive clinical utility.  Healing bone metastases are often associated with increased 
sclerosis from osteoblastic repair.  6 of the 14 (43%) patients with a clinical treatment response 
at 24-weeks had a measurable increase in SUVmean between the scans; the literature suggests 
6-23% of prostate cancer patients have a demonstrable flare response on a bone scan200-203, and 
12-29% of breast cancer patients with bone metastases127,129. 
The changes in SUV heterogeneity parameters also appear to suggest potential utility for 
predicting a treatment response in breast cancer lesions, with a decrease in SUVentropy and 
increase in SUVenergy suggesting a better outcome (i.e. a shift towards image homogeneity).  This, 
however, is difficult to interpret.  There is a strong and significant correlation between the %Δ 
SUV heterogeneity parameters and the %Δ SUV parameters.  It is not clear what features of the 
image are contributing to the changes in the heterogeneity parameters, and they may simply be 
another way to measure a decrease in the range of SUV values across a VOI. 
The changes in the volumetric parameters have demonstrated no utility.  Although the %Δ 
SUVmean predicted treatment response, this effect was not strong enough to overcome the lack of 
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association of the MTV with treatment response, and therefore TLA has not shown predictive 
benefit.  18F-Fluoride PET uptake is an indirect measure of the tumour within bone; although a 
decrease in the number and extent of tumour cells following a treatment response might be 
expected, this may not translate into a change in the volume of bone influenced by the tumour 
and treatment activity.  Indeed, a healing bone metastasis will still demonstrate osteoblastic 
activity for healing. 
A fall in Ki has been demonstrated by other groups following successful therapy.  Sachpekidis et 
al. measured a fall in Ki of bone lesions following therapy for myeloma197.  In contrast, Yu et al. 
did not identify a difference in the Ki between tumour and normal bone following therapy198.  They 
identified SUVmax as a better indicator of 18F-Fluoride incorporation, but were not expecting this 
finding, attributing image noise to the limited precision of Ki estimates. 
In conclusion, the per-lesion analysis of 18F-Fluoride PET of breast cancer bone metastases has 
shown a 24-week treatment response can be identified at 8 weeks with an increase in SUVmean 
and SUVmax between scans, probably representing a flare response of osteoblastic repair activity 
is being identified.  Significant differences in the parameters between breast and prostate cancer 
have been identified.  
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Chapter 4  18F-Fluoride PET – Per-Lesion Analysis.  Image 
quantification for survival analysis of patients with bone metastases 
from breast or prostate cancer 
The methods of this chapter and the statistical approaches for this section can be reviewed in 
Chapter 2.3.3.  
4.1 OS Analysis 
62 lesions have been analysed (24 breast (no deaths), 38 prostate (15/38 in 3 patient deaths). 
4.1.1 Tumour Group Analysis 





Figure 4-1: 18F-Fluoride PET Per-lesion analysis; KM OS analysis comparing tumour 
groups (B=Breast cancer P=Prostate cancer) (p-values from Log Rank analysis) 
4.1.2 Baseline Scan 
4.1.2.1 SUV Parameters 
 SUVmean SUVmedian SUVpeak 
 










Table 4-1: 18F-Fluoride PET Per-lesion analysis; Baseline Scan; SUV Parameters; OS 
Analysis with univariate Cox regression analysis 
A higher SUV is correlated with an increased risk of death (see Cox regression results in Tbl.4-
1).  KM OS analysis (Fig.4-2), show a significant OS advantage for lesions with a lower baseline 
SUV. 
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SUVmean SUVmax SUVpeak 
   
p=0.029 
Low (1) - blue line 
High (2) - green line 
p=0.018 
Low (1) - blue line 
High (2) - green line 
p=0.018 
Low (1) - blue line 
High (2) - green line 
Figure 4-2: 18F-Fluoride PET Per-lesion analysis; Baseline Scan SUV Parameters; OS 
analysis with KM analysis and log rank for comparison; All lesions 
Multivariate analysis is not feasible, but the prostate cancer lesions (higher SUV and poorer OS) 
can be interrogated separately (see Tbl.4-2 and Fig.4-3). 
 SUVmean 
Prostate lesions only 
SUVmedian 
Prostate lesions only 
SUVpeak 
Prostate lesions only 
 











Table 4-2: 18F-Fluoride PET Per-lesion analysis; Baseline Scan; SUV Parameters; OS 
Analysis with univariate Cox regression analysis; Prostate lesions only 
SUVmean 
Prostate lesions only 
SUVmax 
Prostate lesions only 
SUVpeak 
Prostate lesions only 
   
Dichotomised at 17.66 
Low (1) - blue line 
High (2) - green line 
Dichotomised at 56.8 
Low (1) - blue line 
High (2) - green line 
Dichotomised at 53.48 
Low (1) - blue line 
High (2) - green line 
p=0.048 p=0.074 p=0.036 
Figure 4-3: 18F-Fluoride PET Per-lesion analysis; Baseline Scan SUV Parameters; OS 
analysis with KM analysis and log rank for comparison; Prostate lesions only 
For the prostate cancer lesions, a higher baseline SUV correlates significantly with a higher risk 
of death (results in Tbl.4-2), confirmed with KM analysis (Fig.4-3).  
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4.1.2.2 Volumetric Parameters 
 MTV TLA 
 








Table 4-3: 18F-Fluoride PET Per-lesion analysis; Baseline Scan; Volumetric Parameters; OS 
Analysis with univariate Cox regression analysis 
Cox regression analysis (Tbl.4-3) shows no correlation between the volumetric parameters and 




Low (1) - blue line 
High (2) - green line 
p=0.131 
Low (1) - blue line 
High (2) - green line 
Figure 4-4: 18F-Fluoride PET Per-lesion analysis; Baseline Scan Volumetric Parameters; 
OS analysis with KM analysis and log rank for comparison; All lesions 
There is no significant separation of the survival curves for either parameter.  Analysis of the 
prostate cancer lesions separately does not indicate prognostic benefit from the baseline 
volumetric parameters (Cox regression analysis HR 1.0 p=0.696). 
4.1.2.3 Heterogeneity Parameters 
 SUVentropy SUVenergy 
 
Cox regression p-value 
[HR (95%CI)] 





Table 4-4: 18F-Fluoride PET Per-lesion analysis; Baseline Scan; SUV Heterogeneity 
Parameters; OS Analysis with univariate Cox regression analysis 
With Cox regression analysis (Tbl.4-4) a higher SUVentropy correlates with a higher risk of heath 
(p=0.001); a higher SUVenergy correlates with a lower risk of death (p=0.01), suggesting an OS 
benefit for patients with a less random and more uniform SUV distribution.  These findings are 
corroborated by KM OS analysis (Fig.4-5).  However, subgroup analysis of the prostate cancer 
patients demonstrates no association.  The baseline heterogeneity parameters demonstrated no 
significant difference in the distribution of the SUV heterogeneity parameters between the tumour 
types, and analysis of the prostate cancer lesions alone may be impaired by a reduction of the 
sample group; multivariate analysis is not feasible with so few data to analyse this further. 
  




Dichotomised at 3.294 
Low (1) - blue line 
High (2) - green line 
Dichotomised at 0.0384 
Low (1) - blue line 
High (2) - green line 
p=0.0002 p=0.0004 
Figure 4-5: 18F-Fluoride PET Per-lesion analysis; Baseline Scan SUV Heterogeneity 




Cox regression p-value 
[HR (95%CI)] 
n=62, 15 events 
0.001  
[21.29 (3.802-119.2)] 
Table 4-5: 18F-Fluoride PET Per-lesion analysis; Baseline Scan; Ki; OS Analysis with 
univariate Cox regression analysis 
A higher Ki is correlated with an increased risk of death (Tbl.4-5 - HR 21.29, p=0.001).  The data 
has been dichotomised at the median, and KM analysis (Fig.4-6)) demonstrates a statistically 
significant separation of the survival curves (p=0.018) with a survival advantage for patients with 
lesions with a lower baseline PET Ki. 
 
p=0.018 
Figure 4-6: 18F-Fluoride PET Per-lesion analysis; Baseline Scan Ki; OS analysis with KM 
analysis and log rank for comparison; All lesions 
Cox regression analysis of only the prostate cancer patients identifies consistency of this finding 
(HR 8.276 (1.332-51.414 95%CI), p=0.023, indicating a higher Ki is associated with a significantly 
increased risk of death for the prostate patients.  
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4.1.3 %Δ Between Scans 
4.1.3.1 %ΔSUV Parameters 
 %ΔSUVmean %ΔSUVmax %ΔSUVpeak 
 
Cox regression p-value 
[HR (95%CI)] 








Table 4-6: 18F-Fluoride PET Per-lesion analysis; %Δ SUV Parameters; OS Analysis with 
univariate Cox regression analysis 
For these lesions, there is no correlation between the size of change of SUVmean between the 
scans and the risk of death (Tbl.4-6).  However, %ΔSUVmax and %ΔSUVpeak appear to be 
predictive parameters; an increase in the SUV parameters between scans is associated with a 
lower risk of death.  This may represent a flare response.  KM analysis has been performed using 
the data (Fig.4-7). 
%ΔSUVmean %ΔSUVmax %ΔSUVpeak 
   
Dichotomised at 1.405% 
Low (1) - blue line 
High (2) - green line 
Dichotomised at -13.38% 
Low (1) - blue line 
High (2) - green line 
Dichotomised at 4.75% 
Low (1) - blue line 
High (2) - green line 
p=0.016 p=0.001 p=0.014 
Figure 4-7: 18F-Fluoride PET Per-lesion analysis; %Δ SUV Parameters; OS analysis with 
KM analysis and log rank for comparison; All lesions 
Increases greater than 1.405% in SUVmean (p=0.016), increases in SUVmax (or decreases smaller 
than 13.28%) (p=0.001), and SUVpeak increases above 4.75% (p=0.014) are all associated with 
better OS. 
However, the breast cancer patients on average had a larger increase in the SUV parameters 
between the scans.  KM analysis of just the prostate cancer lesions can be reviewed in Fig.4-8, 
demonstrating persistence of the OS benefit for lesions with an increase in SUV between the 
scans.  The findings are statistically significant for %Δ SUVmax and %Δ SUVpeak (p=0.002 and 
0.014, respectively), although the survival curves do meet, and with so few events this would 
require a larger sample for ratification.  This probably represents healing osteoblastic activity 
secondary to a treatment response.  
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%ΔSUVmean 
Prostate lesions only 
%ΔSUVmax 
Prostate lesions only 
%ΔSUVpeak 
Prostate lesions only 
   
Dichotomised at +1.5% 
Low (1) - blue line 
High (2) - green line 
Dichotomised at -13.37% 
Low (1) - blue line 
High (2) - green line 
Dichotomised at -3.72% 
Low (1) - blue line 
High (2) - green line 
p=0.232 p=0.002 p=0.014 
Figure 4-8: 18F-Fluoride PET Per-lesion analysis; %Δ SUV Parameters; OS analysis with 
KM analysis and log rank for comparison; Prostate lesions only 
4.1.3.2 %Δ Volumetric Parameters 
 %ΔMTV %ΔTLA 
 
Cox regression p-value 
[HR (95%CI)] 






Table 4-7: 18F-Fluoride PET Per-lesion analysis; %Δ Volumetric Parameters; OS Analysis 
with univariate Cox regression analysis 
Cox regression (Tbl.4-7) does not show any correlation between %Δ volumetric parameters and 
the risk of death.  KM analysis has been performed (Fig.4-9), but no significant separation of the 
survival curves is identified.  The volumetric parameters have no predictive benefit in these lesions 
for assessing patient OS.  Analysis of just the prostate cancer lesions only also identifies no utility 
(%Δ MTV p=0.396 log rank analysis, %Δ TLA p=0.358). 
%ΔMTV %ΔTLA 
  
Low (1) - blue line 
High (2) - green line 
Low (1) - blue line 
High (2) - green line  
p=0.508 p=0.853 
Figure 4-9: 18F-Fluoride PET Per-lesion analysis; %Δ Volumetric Parameters; OS analysis 
with KM analysis and log rank for comparison; All lesions 
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4.1.3.3 %Δ Heterogeneity Parameters 
 %ΔSUVentropy %ΔSUVenergy 
 
Cox regression p-value 
[HR (95%CI)] 
n=53 (B=22, P=31) 





Table 4-8: 18F-Fluoride PET Per-lesion analysis; %Δ SUV Heterogeneity Parameters; OS 
Analysis with univariate Cox regression analysis 
Cox regression analysis (Tbl.4-8) suggests a correlation between the %ΔSUVentropy and OS, 
although the hazard-ratio confidence interval and does not quite achieve statistical significance 
(p=0.09).  The trend suggests a higher %ΔSUVentropy and lower %Δenergy is associated a decreased 
risk of death.  This may be identifying a flare response in responding lesions causing more 




Dichotomised at +0.6% 
Low (1) - blue line 
High (2) - green line 
Dichotomised at +29.8% 
Low (1) - blue line 
High (2) - green line 
p=0.04 p=0.008 
Figure 4-10: 18F-Fluoride PET Per-lesion analysis; %Δ SUV Heterogeneity Parameters; OS 
analysis with KM analysis and log rank for comparison; All lesions 
A %Δ SUVentropy >0.6% (p=0.04) and %ΔSUVenergy ≤ 29.8% (p=0.008) is associated with an OS 
benefit (p=0.04).  The breast cancer lesions had a larger increase in the SUV heterogeneity 
parameters between the scans, although this not statistically significant.  Analysis of the prostate 
cancer patients alone reveals an OS advantage for patents with a lower %ΔSUVenergy  (Fig.4-11).  
However, the curves meet, and with so few events conclusions cannot be confidently drawn.  
Further analysis with sufficient data for multivariate analysis is necessary.  
%ΔSUVentropy 
Prostate lesions only 
%ΔSUVenergy 
Prostate lesions only 
  
Dichotomised at +0.82% 
Low (1) - blue line 
High (2) - green line 
Dichotomised at +29.8% 
Low (1) - blue line 
High (2) - green line 
p=0.264 p=0.005 
Figure 4-11: 18F-Fluoride PET Per-lesion analysis; %Δ SUV Parameters; OS analysis with 
KM analysis and log rank for comparison; Prostate lesions only 
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4.1.3.4 %Δ Ki 
 %ΔKi 
 
Cox regression p-value 
[HR (95%CI)] 
n=48, 10 events 
0.205  
[0.986 (0.965-1.008)] 
Table 4-9: 18F-Fluoride PET Per-lesion analysis; %Δ Ki; OS Analysis with univariate Cox 
regression analysis 
There is no demonstrable statistically significant correlation between the size of change of the Ki 
parameter and the risk of death (Tbl.4-9).  KM analysis has also not demonstrated statistically 
significant separation of the survival curves (Fig.4-12).  There is also no evidence of OS prediction 
utility when only the prostate cancer lesions are analysed (p=0.880).  The change in Ki has not 
been a valuable OS predictor for these lesions 
 
Low (1) - blue line 
High (2) - green line 
p=1.0 
Figure 4-12: 18F-Fluoride PET Per-lesion analysis; %Δ Ki; OS analysis with KM analysis 
and log rank for comparison; All lesions 
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4.2 PFS Analysis 
4.2.1 Tumour Group Analysis 
60 lesions (24 breast (10/24 in 2 patients with PD), 38 prostate cancer lesions (35/38 in 6 patients 
with PD) have been analysed.  KM PFS analysis based on the tumour group (Fig.4-13; p=0.0004) 




Figure 4-13: 18F-Fluoride PET Per-lesion analysis; KM PFS analysis comparing tumour 
groups (B=Breast cancer P=Prostate cancer) (p-values from Log Rank analysis) 
4.2.2 Baseline Scan 
4.2.2.1 SUV Parameters 
 SUVmean SUVmedian SUVpeak 
 
Cox regression p-value 
[HR (95%CI)] 







Table 4-10: 18F-Fluoride PET Per-lesion analysis; Baseline Scan SUV Parameters; PFS 
Analysis with univariate Cox regression analysis 
Cox regression analysis (Tbl.4-10) shows no correlation between the magnitude of the baseline 
SUV parameters and the PFS.  KM analysis can be reviewed below (Tbl.4-11).  There is a 
significant separation when using SUVmax (p=0.034) and SUVpeak (p=0.022), a PFS benefit for 
those lower SUV.  However, KM analysis of the prostate cancer lesions only does not reveal PFS 
predictivity utility using the baseline SUV parameters ((SUVmean p=0.868, SUVmax p=0.511, 
SUVpeak p=0.761), nor for the breast cancer lesions (SUVmean p=0.248, SUVmax p=0.440, SUVpeak 
p=0.614).  The SUV parameters are not independent predictors of PFS for these lesions. 
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 SUVmean SUVmedian SUVpeak 
 Median PFS in days (95% CI) 
KM 
   
Cut-off 16.57 56.96 40.47 
(1) ≤ 136 (113.4-158.6) 141 (111.6-170.4) 141 (111.8-170.2) 
(2) > 117 (108.9-125.1) 117 (107.5-126.5) 117 (112.8-121.2) 
p-Value (Log 
Rank) 
0.141 0.034 0.022 
Table 4-11: 18F-Fluoride PET Per-lesion analysis; Baseline SUV Parameters; PFS analysis 
with KM analysis and log rank for comparison; All lesions 
4.2.2.2 Volumetric Parameters 
 MTV TLA 
 









Table 4-12: 18F-Fluoride PET Per-lesion analysis; Baseline Scan Volumetric Parameters; 
PFS Analysis with univariate Cox regression analysis 
Cox regression analysis (Tbl.4-12) does not identify a correlation between the size of the 
volumetric parameters and the risk of PD.  The data has been dichotomised for KM analysis 
(Tbl.4-13). 
 MTV TLA 
 Median PFS in days (95% CI) 
KM 
  
Cut-off 27.80 268.35 
(1) ≤ 136 (107.4-164.6) 136 (76.8-195.2) 
(2) > 117 (91.1-142.9) 117 (98.7-135.3) 
p-Value (Log 
Rank) 0.045 0.05 
Table 4-13: 18F-Fluoride PET Per-lesion analysis; Baseline Volumetric Parameters; PFS 
analysis with KM analysis and log rank for comparison; All lesions 
A small but significant 19-day benefit in PFS for lesions smaller than 27.8cm3 (p=0.045) and for 
lesions with a TLA ≤ 268.35 (0.05) has been identified.  The prostate cancer lesions, on average, 
had higher MTV and TLA parameters than the breast cancer lesions.  Analysis of the breast 
cancer lesions suggests a trend for a PFS benefit (median 19-day) for the smaller breast cancer 
lesions (p=0.093), and the lesions with a lower calculated TLA (p=0.126) – see Tbl.4-14.   
  






 Median PFS in days (95% CI) 
KM Plots 
  
Median (cut-off) 23.62cm3 210.55 
(1) ≤ 136 (107.9-164.1) 136 (105.9-166.1) 
(2) > 117 (89.6-144.4) 117 (99.9-134.1) 
p-Value (Log Rank) 0.093 0.126 
Table 4-14: 18F-Fluoride PET Per-lesion analysis; Baseline SUV Parameters; PFS analysis 
with KM analysis and log rank for comparison; Breast lesions only 
4.2.2.3 Heterogeneity Parameters 
 SUVentropy SUVenergy 
 
Cox regression p-value 
[HR (95%CI)] 





Table 4-15: 18F-Fluoride PET Per-lesion analysis; Baseline Scan SUV Heterogeneity 
Parameters; PFS Analysis with univariate Cox regression analysis 
Cox regression analysis (Tbl.4-15) does not demonstrate any significant correlation for these 
lesions.  The data has been dichotomised at the median for KM PFS analysis (Tbl.4-16)), but no 
significant PFS prognostic utility has been identified.  Analysis of the breast cancer lesions 
independently does not demonstrate significant separation of the KM PFS curves.   
There is no demonstrable PFS predictive benefit for these lesions using the baseline SUV 
heterogeneity parameters. 
 SUVentropy SUVenergy 






(1) ≤   136 (97.8-174.2) 117 (109.7-124.3) 





Table 4-16: 18F-Fluoride PET Per-lesion analysis; Baseline SUV Heterogeneity Parameters; 
PFS analysis with KM analysis and log rank for comparison; All lesions 
  





Cox regression p-value 
[HR (95%CI)] 
n=60, 44 events 
0.302  
[2.249 (0.483-10.461)] 
Table 4-17: 18F-Fluoride PET Per-lesion analysis; Baseline Scan Ki; PFS Analysis with 
univariate Cox regression analysis 
There is no correlation identified with Cox regression analysis (Tbl.4-17).  KM analysis (Tbl.4-18)) 
has also not demonstrated an association between Ki and PFS. 
 Ki 
 Median PFS in days (95% CI) 
KM Plots 
 
Median (cut-off) 0.16 
(1) ≤ 136 (91.5-180.5) 
(2) > 117 (109.7-124.3) 
p-Value (Log Rank) 0.911 
Table 4-18: 18F-Fluoride PET Per-lesion analysis; Baseline Ki; PFS analysis with KM 
analysis and log rank for comparison; All lesions 
Analysis of the prostate cancer and breast cancer lesions independently also does not 
demonstrate a significant separation of the PFS curves (breast cancer, p=0.911).). 
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4.2.3 %Δ Parameters Between Scans 
53 lesions (22 breast (10/22 in 2/5 patients with PD), 31 prostate cancer lesions (29/31 in 6/7 
patients with PD) have been analysed.  
4.2.4 %ΔSUV Parameters 
 %ΔSUVmean %ΔSUVmedian %ΔSUVpeak 
 











Table 4-19: 18F-Fluoride PET Per-lesion analysis; %Δ SUV Parameters; PFS Analysis with 
univariate Cox regression analysis 
For these lesions, no correlation between the size of change in the SUV parameters between 
scans and the risk of PD has been identified (Tbl.4-19). 
KM analysis has been performed for all the lesions together, revealing no significant separation 
of the dichotomised PFS survival curves (Tbl.4-20).  
 %ΔSUVmean %ΔSUVmedian %ΔSUVpeak 
 Median PFS in days (95% CI) 
KM 
Plots 
   
Median  0.92% -11.07% -7.67% 
(1) ≤  141 (126.7-155.3) 117 (110.2-123.8) 117 (86.1-147.9) 
(2) >  136 (115.2-156.8) 136 (118.5-153.5) 136 (117-155) 
p-
Value 0.432 0.461 0.998 
Table 4-20: 18F-Fluoride PET Per-lesion analysis; %Δ SUV parameters; PFS analysis with 
KM analysis and log rank for comparison; All lesions 
There is no PFS benefit identified when only the prostate cancer lesions are analysed 
(%ΔSUVmean p=0.665, %ΔSUVmax p=0.243, %ΔSUVpeak p=0.397), or the breast cancer lesions 
((%ΔSUVmean p=0.298, %ΔSUVmax p=0.204, %ΔSUVpeak p=0.204). 
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4.2.4.1 %Δ Volumetric Parameters 
For these lesions, the percentage change in the volumetric parameters between scans has no 
demonstrable role in predicting for PFS.  The results of Cox regression analyses (Tbl.4-21) and 
KM analyses (Tbl.4-22) can be reviewed below. 
 %ΔMTV %ΔTLA 
 
Cox regression p-value 
[HR (95%CI)] 





Table 4-21: 18F-Fluoride PET Per-lesion analysis; %Δ Volumetric Parameters; PFS Analysis 
with univariate Cox regression analysis 
 %ΔMTV %ΔTLA 
 Median PFS in days (95% CI) 
KM Plots 
  
Median (cut-off) 1.98% 15.04% 
(1) ≤ 136 (110.3-161.7) 141 (135.3-146.7) 
(2) > 136 (109.7-162.3) 117 (105.2-128.8) 
p-Value (Log Rank) 0.610 0.355 
Table 4-22: 18F-Fluoride PET Per-lesion analysis; %Δ Volumetric parameters; PFS analysis 
with KM analysis and log rank for comparison; All lesions 
There is no demonstrable predictive utility for these lesions using the %Δ volumetric parameters 
of 18F-Fluoride PET.  There is also no utility identified when only the prostate cancer lesions were 
analysed (%ΔMTV p=0.175, %ΔTLA p=0.409).  The analysis (Tbl.4-23) of just the breast cancer 
lesions shows a trend towards significance for a PFS benefit for the lesions with a more negative 








Low (1) - blue line 
High (2) - green line 
Median  +9.18%% +21.91%% 
p-value (log rank) 0.411 0.078 
Table 4-23: 18F-Fluoride PET Per-lesion analysis; %Δ Volumetric parameters; PFS analysis 
with KM analysis and log rank for comparison; Breast lesions only 
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4.2.4.2 %Δ Heterogeneity Parameters 
The %ΔSUV heterogeneity parameters have no demonstrable role in predicting for PFS.  The 
results of Cox regression analyses (Tbl.4-24) and KM analyses (Tbl.4-25) can be reviewed below. 
 %ΔSUVentropy %ΔSUVenergy 
 
Cox regression p-value 
[HR (95%CI)] 





Table 4-24: 18F-Fluoride PET Per-lesion analysis; %Δ SUV Heterogeneity Parameters; PFS 
Analysis with univariate Cox regression analysis 
 %ΔSUVentropy %ΔSUVenergy 
 Median PFS in days (95% CI) 
KM PFS Plots 
  
Median (cut-off) 0.26% 3.84% 
(1) ≤ 141 (119.1-162.9) 117 (92-142) 
(2) > 136 (115.2-156.8) 141 (111-171) 
p-Value (Log Rank) 0.657 0.747 
Table 4-25: 18F-Fluoride PET Per-lesion analysis; %Δ SUV Heterogeneity parameters; PFS 
analysis with KM analysis and log rank for comparison; All lesions 
KM analysis of the breast cancer patients also shows no statistically significant association 
between the %Δ SUV heterogeneity parameters and PFS, but there is perhaps a trend towards 
a PFS benefit for lesions with a decrease in SUVentropy and increase in SUVenergy between the 






 Median PFS in days (95% CI) 
KM PFS plots 
  
Key 
Low (1) - blue line 
High (2) - green line 
Median (cut-off) +1.76% +1.92% 
p-Value (Log Rank) 0.204 0.298 
Table 4-26: 18F-Fluoride PET Per-lesion analysis; %Δ SUV Heterogeneity parameters; PFS 
analysis with KM analysis and log rank for comparison; Breast lesions only 
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4.2.4.3 %ΔKi 
For these lesions, the %ΔKi has no demonstrable role in predicting PFS.  The results of Cox 
regression analysis (Tbl.4-27) and KM analysis (Tbl.4-28) can be reviewed below. 
 %ΔKi 
 











 Median PFS in days (95% CI) 
KM Plot 
 
Median (cut-off) 0.15% 
(1) ≤ 117 (108.7-125.3) 
(2) > 136 (116.4-155.6) 
p-Value (Log Rank) 0.539 
Table 4-28: 18F-Fluoride PET Per-lesion analysis; %Δ Ki; PFS analysis with KM analysis 
and log rank for comparison; All lesions 
There is no demonstrable predictive utility identified either with %ΔKi when only the prostate 
cancer lesions are analysed (median dichotomisation for KM analysis, p=0.361), or breast cancer 
lesions (p=0.383). 
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4.3 Discussion 
 SUVmean SUVmax SUVpeak MTV TLA SUVentropy SUVenergy Ki 
↑OS 
↓ 






























↑PFS X X X 
PCa – X 
BCa - ↓ 
p=0.093 
PCa – X 
BCa - ↓ 
p=0.126 
X X X 














































Table 4-30: 18F-Fluoride PET Per-lesion analysis; Survival Analyses; %Δ Parameters; 
Summary Table 
This chapter has suggested prognostic utility from 18F-Fluoride PET scans of bone metastases, 
both from the pre-treatment scans, and with %Δ parameters.  There is limited corroborative 
evidence in the literature to compare these findings. 
Yu et al. published in 2015 a study of 17 patients (12 with a second 18F-Fluoride PET scan at 12 
weeks following treatment) with bone metastases from prostate cancer, due to start treatment 
with a tyrosine kinase inhibitor.  The baseline SUVmax and Ki did not correlate with the PFS of 
these patients, but an increase in SUVmax between scans was associated with a lower risk of PD 
(HR 0.91, p=0.056)198. 
In the same year, another study of prostate cancer bone metastases was published by 
Etchebehere et al.  They performed an 18F-Fluoride PET before treatment with the radionuclide 
treatment Alpharadin.  They concluded no prognostic utility of SUVmean and SUVmax, but the 
measures of skeletal burden were independent OS predictors (HR 5.99, p=0.02)204.  Prognostic 
utility of volumetric parameters was also shown by Lindgren Belal et al. in 2017; a study of 48 
prostate cancer patients showed baseline measurements of the full skeletal burden of bone 
metastases predicted an OS benefit for patients with less than 39% of skeletal involved 
involvement205. 
The lack of prognostic utility of 18F-Fluoride quantification parameters before therapy has also 
been suggested by Piccardo et al.  They compared the role of baseline 18F-Fluoride and 18F-FDG 
PET imaging of 32 breast cancer patients with bone metastases; despite the higher diagnostic 
sensitivity of the 18F-Fluoride imaging, none of the 18F-Fluoride quantification parameters were 
associated with PFS or OS206. 
18F-Fluoride PET Per-Lesion Analysis Survival Analysis 
95 
SUV quantification parameters have been shown to have possible utility.  Apolo et al. reported a 
prospective pilot study of 30 patients with prostate cancer, imaging them with 18F-Fluoride PET 
before treatment, at 6 months and again at 12 months.  The patients were treated with a wide 
range of therapies.  Baseline SUVmax was not a significant predictor of OS, but the maximal 
change at 6 months correlated with survival (HR 1.23, p=0.017).  The change in SUV of the bone 
metastases correlated with the change in patients’ PSA at 6 and 12 months, and an increase in 
SUV greater than 57% at 6 months correlated with PD.  A significant increase in SUV between 6 
and 12 months was seen in those patients who had PD at 12 months195. 
This thesis seems unique in identifying prognostic utility from semi-quantitative parameters from 
baseline 18F-Fluoride PET of bone.  31 prostate cancer lesions have been imaged before 
treatment and again after 8 weeks of therapy.  For the prostate cancer lesions a higher 
SUVmean/max/peak at baseline was correlated with OS (SUVmean HR 1.03, p=0.038, SUVmax HR 1.014 
p=0.029).  These hazard ratios are small, but statistically significant, suggesting a signal with 
clinical relevance can be quantified.  The baseline imaging also demonstrated OS prediction from 
a decrease in SUVentropy (p=0.0002) (towards image homogeneity), rise in SUVenergy (0.0004) 
(towards image homogeneity) and an increase in Ki (p=0.023).  However, there are strong and 
significant correlations between all these parameters (negative correlation for SUVenergy) and the 
SUV parameters.  There are too few lesions and events to warrant a multivariate analysis, and 
therefore it is unclear which of these parameters yields more prognostic accuracy.   
24 breast cancer lesions were imaged with baseline imaging, and 22 had data available for 
calculation of the %Δ parameters.  The baseline parameters suggested no utility of the SUV 
parameters for PFS prognostication, but the smaller lesions, measured with MTV, had a trend 
towards a PFS benefit (p=0.093).  The whole skeletal burden of bone metastases has been shown 
to have prognostic relevance204,205.  It is not clear if the size of individual lesions correlates with 
the skeletal burden.  Up to 5 lesions per patient were identified; the largest and most avid lesions 
were selected.  The total skeletal burden of disease in these patients could be assessed 
retrospectively to assess whether the individual size of the lesions is an independent predictor of 
PFS.  The TLA parameter also shows a possible association with PFS, but TLA is closely 
correlated with MTV, being the product of MTV and SUVmean, and tumour volume probably has 
the dominant prognostic effect for these lesions. 
The %Δ parameters do show an association with OS of the prostate cancer lesions.  An increase 
in SUV mean/max/peak suggests an OS benefit (p=0.048, 0.074, 0.036 respectively); this may 
represent a flare osteoblastic response.  An increase in SUVentropy and decrease in SUVenergy 
(towards image homogeneity) also suggest OS prognostication, but there is a strong and 
significant correlation between these parameters and the SUV parameters (negative correlation 
for %Δ SUVenergy), and it is not possible with so few patients and lesions to perform multivariate 
analysis. 
The change in SUV parameters between scans also have not predicted PFS.  The change in 
MTV has not shown utility, but the TLA suggests a fall in TLA between scans predicts PFS of the 
breast cancer lesions (p=0.078).  Response analysis (See Ch.3) showed an increase in SUV 
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between scans suggested a treatment response, and there was no demonstrable difference 
between the MTV of those with a treatment response and those with no response to treatment.  
Therefore, a fall in TLA being associated with PFS benefit was unexpected.  This may be a 
statistical anomaly; the lesions were identified in only 5 patients, and the PFS analysis of the 
lesions will be unduly influenced by the prolonged PFS of even one patient.  None of the %Δ 
parameters are associated with PFS in this analysis. 
This study has identified novel prognostic information from 18F-Fluoride PET quantification of 
bone metastases.  Prostate cancer metastases with a higher baseline SUV, or with heterogeneity 
parameters measuring more homogeneity, have a significant OS benefit .  An increase in SUV by 
8-weeks of the prostate cancer lesions has shown a significant OS benefit, corroborating the 
literature195.
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Chapter 5  18F-Fluoride PET Per-Patient Analysis: Impact of VOI 
segmentation on image quantification of bone metastases 
The methods of this chapter and the statistical approaches for this section can be reviewed in 
Chapter 2.3.4.  
5.1 Baseline Scan 
14 patients had baseline 18F-Fluoride PET imaging, 5 with breast cancer, 9 with prostate cancer. 
5.1.1 SUV Parameters 























































Table 5-1: 18F-Fluoride PET; Per-Patient Analysis; Baseline Scan; SUV Parameters; 
Descriptive statistics for all VOI methods and all patients 
SUVmean SUVmax SUVpeak 
   
Figure 5-1: 18F-Fluoride PET; Per-Patient Analysis; Baseline Scan; SUV Parameters; 
Descriptive statistics for all VOI methods and all patients - Boxplots 
The choice of VOI definition technique affects the SUV parameters differently, with SUVmean 
seeming to be more impacted than the other two parameters (see Tbl.5-1 and Fig.5-1).  
SUVmean increases as lower value voxels are excluded from the VOI by increasing the 
segmentation threshold.  The lowest SUVmean was calculated from VOImanual; this reflects inclusion 
of marginal low value voxels.  In addition, the range of SUVmean is smallest using VOImanual.  The 
volume of the lower value voxels around the circumference of the VOI will have a greater impact 
on the overall SUVmean than single higher intensity voxels in the middle of the VOI. 
There is an absolute difference of 7.9 between the population average SUVmean identified with 
VOImanual compared to VOI50; this represents a 234% difference.  There is a maximum difference 
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of 131% (absolute SUV difference of 5.0) between the VOI techniques where an SUV threshold 
has been applied.  This difference is statistically significant (a non-parametric Friedman’s 
Variance test: where χ2 = 53.2 (4 d.f.), p< 0.001).  The distributions of SUVmean calculated using 
VOIFLAB is closest to the distributions achieved using VOI27. 
Clearly, when using SUVmean, the choice of thresholding technique will have a significant impact 
on the size of the calculated parameter. 
SUVmax is more consistent, demonstrating smaller variations between the threshold methods.  
Although this was anticipated there are small differences.  With application of a segmentation 
threshold, a single VOI can be separated into two or more smaller volumes the largest residual 
volume has been selected for analysis.  This VOI may not contain the highest SUVmax voxel, 
thereby affecting the overall metric in this analysis.  The differences identified in SUVmax across 
all the threshold techniques in these patients is not statistically significant (Friedman’s Variance 
test, where χ2 = 3 (4 d.f.), p=0.558). 
A statistically significant difference is identified between the distributions of SUVpeak between the 
VOI (Friedman Test; where χ2 =140.00 (4d.f.), p=0.007).  The differences are small, with a 
maximum absolute difference of 0.66 (1.9%) between the average SUVpeak for each VOI threshold 
method.  The methodology of this study has resulted in this impact on SUVpeak in the same way 
identified for SUVmax. 
The distributions of the SUV parameters between the tumour groups have been compared using 
Mann-Whitney tests (see Tbl.5-2).  There is no demonstrable statistically significant difference 
identified in these patients between the distributions of the SUV parameters tested of breast 
cancer and prostate cancer bone metastases, but there is a definite trend towards a higher SUV 
for the prostate cancer patients, particularly when the per-lesion analysis is considered which a 
significant difference.  SUVpeak has more discriminating for these patients, but none of the 
parameters have met statistical significance.  A larger sample would improve the statistical power 
of this analysis, and enable better comparison of the quantification parameters and VOI methods. 
Prostate cancer metastases are usually more osteoblastic than those from breast cancer, and a 
higher 18F-Fluoride uptake is physiologically expected. 
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 SUVmean SUVmax SUVpeak 
















































































































   
Table 5-2: 18F-Fluoride PET; Per-Patient Analysis; Baseline Scan; SUV Parameters; 
Comparison between tumour groups for all VOI methods and all patients (Mann-Whitney 
U tests for comparison) 
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5.1.2 Volumetric Parameters 







































[2016.58; 2941.37]  
Box Plots 
  
Table 5-3: 18F-Fluoride PET; Per-Patient Analysis; Baseline Scan; Volumetric Parameters; 
Descriptive statistics for all VOI methods and all patients 
The volumetric parameters will be affected by the threshold techniques; this is clearly 
demonstrated in the comparison of the MTV and TLA parameters (Tbl.5-3).   
For MTV the differences in the distribution of the parameter across the threshold techniques is 
statistically significant (Friedman test (non-parametric): where χ2=56.00, 4d.f., p<0.00001).  The 
VOIs defined by the higher SUV thresholds are smaller because a larger volume of lower-value 
voxels are excluded from the final VOIs.  However, the threshold used for VOI definition is of vital 
significance when calculating these volumetric parameters. 
A similar effect is seen in the distributions of TLA, but to a smaller degree.  TLA is the product of 
the MTV and SUVmean.  TLA is therefore also linked inextricably with the MTV, and the VOI 
methodology.  This is confirmed using a Friedman Test (when χ2=55.26, 4 d.f., p<0.00001).  With 
increased severity of the threshold SUVmax used for VOI definition SUVmean increases and MTV 
decreases; the effect on their product (TLA) is therefore blunted.  
Table 5-4 gives an impression of the magnitude of the differences in the median of the 
distributions between the VOI definition methods.  Large differences are shown in the distributions 
of the volumetric parameters depending on which VOI method is applied for calculating the 
parameters.  They are essentially separate parameters – volumetric parameters without 
knowledge of the segmentation methods applied are not comparable.  The distributions of the 
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MTV 100 45 30 21 52 
TLA 100 72 52 39 80 
Table 5-4: 18F-Fluoride PET; Per-Patient Analysis; Baseline Scan; Volumetric Parameters; 
Comparison (%) of median of distributions with VOImanual 
 
The volumetric parameters have been compared between the tumour groups in Table 5-5. 
 MTV TLA 



















































































Table 5-5: 18F-Fluoride PET; Per-Patient Analysis; Baseline Scan; Volumetric Parameters; 
Comparison between tumour groups for all VOI methods and all patients (Mann-Whitney 
U tests for comparison) 
The distributions of MTV and TLA between the tumour groups have been compared with Mann-
Whitney U tests for each threshold technique pair.  These results are shown in Table 5-5.  For 
MTV, it is only the manual delineation with a significant difference between the tumour groups; 
this could suggest a difference in the penumbra of lower value pixels in the VOI, eliminated by 
applying a threshold relative to the SUV, and perhaps this is greater for prostate cancer 
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metastases.  There is a trend for a larger MTV for the prostate patients using the other VOI 
methods, and this was identified at the per-lesion analysis, adding validity. 
The TLA comparisons between breast and prostate cancer patients shows a likely significant 
difference irrespective of threshold technique.  TLA is the product of MTV and SUVmean; neither 
of these parameters have individually shown a difference between tumour types, and it is only 
the combination in a TLA returning significance.  Both distributions of SUVmean and MTV are 
empirically larger for these prostate cancer patients and this effect has been emphasised by the 
calculation of TLA.  There is no VOI method showing superiority.  The VOI27 iso-contour produces 
distributions of these SUV parameters most similar to the FLAB methodology. 
At the per-patient analysis TLA seems more discriminatory when comparing the tumour groups, 
emphasising the higher baseline SUVmean and MTV of the prostate lesions.  The next chapter 
interrogates the potential predictive and prognostic role for these parameters.   
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5.1.3 Heterogeneity Parameters 








[2.67; 0.53]  
0.1  
(0.04-0.16)  




[2.68; 0.63]  
0.08  
(0.02-0.14)  











[2.79; 0.65]  
0.09  
(0.03-0.16)  




[2.69; 0.58]  
0.1  
(0.03-0.17)  
[0.09; 0.04]  
Box Plots 
  
Table 5-6: 18F-Fluoride PET; Per-Patient Analysis; Baseline Scan; SUV Heterogeneity 
Parameters; Descriptive statistics for all VOI methods and all patients 
There is a small but significant difference in the distribution of SUVentropy between the threshold 
techniques (Friedman Test: where χ2=17.13 (4 d.f.), p=0.002).  This represents a maximum 
absolute difference of 0.17 between the mean SUVentropy measurements.  The clinical significance 
of this size of difference is undetermined and will be interrogated in the next chapters.  As the iso-
contour threshold increases, entropy falls suggesting the VOI becomes more uniform as lower 
value voxels are excluded.  
A significant difference also exists between the distributions of SUVenergy between the threshold 
methods.  Using a parametric approach, where F=4.703, p=0.019 and ƞ2=0.299.  There is a 
maximum difference of 0.02 between the means of these populations, but the clinical significance 
of a difference of this magnitude is undetermined. 
The heterogeneity parameters seem much more consistent across the VOI methods than the 
other parameters.  The per-lesion analysis demonstrated strong correlations between the SUV 
parameters and the SUV heterogeneity parameters; where the SUV parameters have shown 
inconsistencies across the VOI methods, the SUV heterogeneity parameters may record the 
same information in a method less reliant on the underlying VOI methodology. 
The data suggests the distribution mean of SUVentropy is higher for prostate cancer bone 
metastases (see Tbl.5-7), but no statistically significant difference has been identified with non-
parametric Mann Whitney U tests.  No difference between the tumour groups has been shown 
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for SUVenergy.  The per-lesion analysis also showed no difference in the SUV heterogeneity 
parameters between the tumour groups. 
 SUVentropy SUVenergy 














































































Table 5-7: 18F-Fluoride PET; Per-Patient Analysis; Baseline Scan; SUV Heterogeneity 
Parameters; Comparison between tumour groups for all VOI methods and all patients 
(Mann-Whitney U tests for comparison) 
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5.1.4 Ki 




























Table 5-8: 18F-Fluoride PET; Per-Patient Analysis; Baseline Scan; Ki; Descriptive statistics 
for all VOI methods and all patients 
The calculation of Ki is affected by the choice of VOI method (Tbl.5-8).  This can be demonstrated 
statistically (non-parametric Friedman Test: where χ2 =45.267 (4 d.f.), p<0.00001).  The tissue 
time-activity curve created for Patlak Ki analysis will be affected by the VOI threshold techniques 
– if only higher value voxels remain after segmentation, the average activity will be greater for a 
given VOI.  The calculated Ki will therefore be higher.  For this data, VOIFLAB yields a Ki distribution 
most similar to VOI27. 
Comparison between the tumour groups has been performed (see Tbl.5-9).  13 patients had data 
for analysis, but only 12 with the VOI50 threshold.  No statistically significant difference of the Ki 
between the tumour groups has been demonstrated (see table above).  No difference was 
identified with the per-lesion analysis either (data not included for brevity). 
It is not feasible from this analysis to identify a superior VOI methodology, but the differences in 
the quantified measurements are clear.  The next chapter will review the clinical implications of 
the VOI methods. 
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 Ki 















































Table 5-9: 18F-Fluoride PET; Per-Patient Analysis; Baseline Scan; Ki; Comparison between 
tumour groups for all VOI methods and all patients (Mann-Whitney U tests for comparison) 
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5.2 Percentage Change (Δ%) Between Scans 
12 patients had imaging pairs suitable for analysis of the percentage change (Δ%) between the 
baseline scan and the second scan.   
5.2.1 Δ%SUV Parameters 
The table below summaries the data for the SUV parameters (Tbl.5-10). 











[1.07; 41.35]  
-0.13 
(-43.62-94.64) 







[-3.98; 38.76]  
0.09  
(-47.41-99.69)  
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[30.73; 64.16]  
8.31  
(-75.01-414.16)  







[38.62; 58.11]  
2.15  
(-78.45-425.73)  
[-39.9; 136.56]  
-13.61 
(-79.99-303.64)  
[-35.95; 102.72]  
Table 5-10: 18F-Fluoride PET; Per-Patient Analysis; %ΔSUV Parameters; Descriptive 
statistics for all VOI methods and all patients 
Δ%SUVmean Δ%SUVmax Δ%SUVpeak 
   
Figure 5-2: 18F-Fluoride PET; Per-Patient Analysis; %ΔSUV Parameters; Descriptive 
statistics for all VOI methods and all patients – Box-Plots 
I hypothesised the difference between the two scans might be consistent between the VOI 
methods applied; i.e. so long as there was consistency of the threshold method applied between 
scans, the change in parameter might be comparable between different techniques.   
For SUVmean this hypothesis can be tested using a parametric one-way ANOVA.  There is a 
statistically significant difference between the distributions of Δ%SUVmean between the VOI 
methods (when F=11.579, p=0.001, η2=0.51).  Much of this difference is caused by the 
Δ%SUVmean calculated using the absolute-SUV threshold methods for the second scan (VOI27BL, 
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VOI40BL, VOI50BL).  Absolute differences in the Δ%SUVmean from the VOI methods can be 
compared to those of Δ%VOImanual can through pairwise examination performed during the one-
















VOI27 -13.9% (0.157) -5.0% +0.2% 
VOI40 -13.8% (0.169) -6.2% -0.9% 
VOI50 -12.3%(0.182) -7.8% -2.1% 
VOIFLAB -10.5% (0.251) -4.1% -0.8% 
VOI27BL 35.4% (0.045) 13.5% -0.7% 
VOI40BL 37.0% (0.033) 1.7% -9.2% 
VOI50BL 39.4% (0.023) -4.5% -13.5% 
Table 5-11: 18F-Fluoride PET; Per-Patient Analysis; %ΔSUV Parameters; Difference 
between Δ% SUV Parameters by VOI method 
There is a statistically significant difference between the distributions of Δ%SUVmean as calculated 
from the manual VOI technique and the SUVmean calculated using VOIs defined by an absolute 
SUV threshold related to the baseline imaging.  The differences recorded for the relative threshold 
methods are not statistically significant, but do demonstrate variation compared to manual 
delineation, with relative Δ%SUVmean values of between 31% and 50% of those of VOImanual.  In 
absolute terms, there is consistency between the Δ%SUVmean between the relative-SUV VOI 
methods, with only 3.4 percentage points difference between them. 
The VOI methods based on the baseline scan SUV give dramatically different values for 
Δ%SUVmean; for several cases a decline in SUVmean by one threshold method corresponds to an 
increase in SUVmean by another.  This might affect the outcome of a concluded ‘metabolic 
response’ (MR); if a decrease in SUVmean is used as a definition of a metabolic response, there 
were 11 ‘metabolic non-responders’ (MNR) and only one MR with all relative VOI methods, but 
all patients were deemed to have an MR with the absolute SUV methods.  
The differences between the distributions of Δ%SUVmax from the threshold methods can be tested 
statistically, showing a real difference exists for these patients (Friedman Test: where χ2=35.417 
(7 d.f.), p=0.000009).  However, the real differences are small between the relative-SUV methods 
used to define the VOI, with only 3.7 percentage points between the calculated values of 
Δ%SUVmax.  A 13% difference is noted for Δ%SUVmax50BL compared to Δ%SUVmaxVOImanual. 
A Friedman Test of the distributions of SUVpeak between the threshold techniques shows, where 
χ2=44.472 (7 d.f.), p<0.00001.  However, the relative SUV threshold methods are all within 2.3% 
of each other, and this is a small absolute difference in the calculated Δ%SUVpeak and likely has 
little clinical significance.  Again, the absolute SUV methods have produced values more different 
from Δ%SUVpeakVOImanual with a 13% difference noted compared with Δ%SUVpeakVOI50BL.  
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5.2.2 Δ% Volumetric Parameters 
The data for the %Δ volumetric parameters can be reviewed in Table 5-12. 
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(29.55-532.61)  




[-68.02; 27.3]  
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(29.03-538.71)  




[-68.21; 26.84]  
219.46  
(24.1-536.78)  
[151.98; 174.13]  
Box Plots 
  
Table 5-12: 18F-Fluoride PET; Per-Patient Analysis; %Δ Volumetric Parameters; Descriptive 
statistics for all VOI methods and all patients 
The choice of threshold technique makes a significant difference in the measured change in MTV, 
identified using a one-way ANOVA (where F=10.693, p=0.002, η2=0.493), but no significant 
difference between the relative threshold techniques is shown from pairwise comparisons (Tbl.5-
13). The choice of threshold also affects the calculated TLA.  Where F=4.334, p=0.057, η2=0.283. 
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VOI Method 
Absolute % difference in 
Δ%MTV compared to 
Δ%VOImanual (p-value) 
Absolute % difference in 
Δ%TLA compared to 
Δ%VOImanual 
VOI27 19.33 (0.323) 9.13 (0.471) 
VOI40 22.64 (0.334) 9.86 (0.534) 
VOI50 21.71 (0.372) 8.85 (0.600) 
VOIFLAB 13.28 (0.239) 3.31 (0.352) 
VOI27BL -57.08 (0.008) -62.61 (0.064) 
VOI40BL -66.62 (0.003) -71.36 (0.035) 
VOI50BL -72.17 (0.001) -77.03 (0.023) 
Table 5-13: 18F-Fluoride PET; Per-Patient Analysis; %Δ Volumetric Parameters; Pairwise 
comparison of distributions between VOI methods 
5.2.3 Δ% SUV Heterogeneity Parameters 
The data for the %Δ SUV Heterogeneity parameters can be reviewed in Table 5-14. 







































































Table 5-14: 18F-Fluoride PET; Per-Patient Analysis; %ΔSUV Heterogeneity Parameters; 
Descriptive statistics for all VOI methods and all patients 
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The distribution of %ΔSUVentropy is not significantly different across the threshold methods (one-
way ANOVA, where F=0.562, p=0.622, ƞ2=0.086).  The differences, although not statistically 
significant, are small.  When comparing the absolute differences in the mean of the distributions 
with VOImanual,  all threshold techniques produce a result within 2.72% of each other (Tbl.5-15). 
The distributions of Δ% SUVenergy between the threshold methods approaches statistical 
significance with a non-parametric analysis (Friedman Test: when χ2 =13.095 (7 d.f.), p=0.07. 
 
 
Absolute % difference in 
mean Δ%SUVentropy compared 
to mean Δ%VOImanual (p-value) 
Absolute % difference in 
mean Δ%SUVenergy compared 
to mean Δ%VOImanual (p-value) 
VOI27 -2.30 (0.072) 8.97 (0.29) 
VOI40 0.34 (0.844) -10.5 (0.28) 
VOI50 0.78 (0.743) -9.73 (0.18) 
VOIFLAB -0.36 (0.753) -6.84 (0.39) 
VOI27BL -0.92 (0.760) 25.52 (0.09) 
VOI40BL -2.93 (0.464) 22.09 (0.26) 
VOI50BL -1.57 (0.646) 15.96 (0.44) 
Table 5-15: 18F-Fluoride PET; Per-Patient Analysis; %Δ SUV Heterogeneity Parameters; 
Pairwise comparison of distributions between VOI methods 
5.2.4 Δ% Ki 
There is a wide spread of measured %ΔKi depending on the threshold methods used (see Tbl.5-
16).  These differences are not statistically significant (Friedman Test: where χ2 =12.714 (7 d.f.), 
p=0.079); for this small number of patients the differences between the distributions are not large 
enough to be quite statistically significant (see Tbl.5-17).  The largest differences are from the 
absolute SUV threshold methods, but statistical significance is not reached, and therefore it is not 
possible to draw firm conclusions from this.  
  

















































Table 5-16: 18F-Fluoride PET; Per-Patient Analysis; %ΔKi; Descriptive statistics for 
all VOI methods and all patients 
 
 Absolute % difference in Δ%Ki compared to Δ%VOImanual (p-value) 
VOI27 -2.3 (0.07) 
VOI40 0.34 (0.84) 
VOI50 0.78 (0.74) 
VOIFLAB -0.36 (0.75) 
VOI27BL -0.92 (0.76) 
VOI40BL -2.93 (0.46) 
VOI50BL -1.57 (0.65) 
Table 5-17: 18F-Fluoride PET; Per-Patient Analysis; %ΔKi; Pairwise comparison of 
distributions between VOI methods 
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5.3 Discussion 
















X X X X X X X X 
Table 5-18: 18F-Fluoride PET Per-Patient analysis; Descriptive statistics; Baseline Scan; 
Summary Table 
 %ΔSUVmean %ΔSUVmax %ΔSUVpeak %ΔMTV %ΔTLA %ΔSUVentropy %ΔSUVenergy %ΔKi 




X X X X X X X X 
Table 5-19: 18F-Fluoride PET Per-Patient analysis; Descriptive statistics; %Δ parameters; 
Summary Table 
There is little consistency of PET quantification methodology in the literature.  Comparison of 
studies is limited due to these inconsistencies, but there is sparse evidence to document how the 
methodologies of quantification impact the resulting measurements and their clinical utility.   
Erdi et al. used phantom studies to interrogate the impact of VOI iso-contour methodology using 
18F-FDG PET imaging, showing a fixed threshold between 35-44% of SUVmax had most correlation 
with the known volume of disease, but only for target spheres greater than 4mls107.  Low 
concordance of tumour volumes has been demonstrated when different VOI threshold definition 
methods are used, with up to 41% difference in measured volumes identified 101,100 .  Tomasi et 
al. reported the reproducibility of tumour volume using 11C-Choline PET iso-contour techniques 
for definition of prostate gland tumours, including fixed and adaptive iso-contour methods, and 
FLAB.  The reproducibility of the parameters was best using FLAB with the iso-contour methods 
resulting in the least satisfactory results207. 
Phantom studies do not necessarily translate into the much more complex tissue associations in-
vivo.  There are few studies correlating the PET volume with the histological volume (e.g.208,209).  
To my knowledge there is no literature providing histological confirmation of PET delineation of 
bone metastases, or examining the impact of threshold methodology on the semi-quantification 
parameters. 
This study has demonstrated the varying impact of iso-contour and FLAB segmentation methods 
on a selection of semi-quantification parameters of bone metastases using 18F-Fluoride PET.  As 
a higher threshold for segmentation is applied, more lower value voxels are eliminated from the 
periphery of the VOI, resulting in an increase of SUVmean.  The segmentation algorithm was 
applied only to the edge of the and the centre of the VOI may still contain lower value voxels.  The 
reduction in volume, and increase in SUVmean with increasing threshold severity suggests the 
VOIs have a more avid centre, with a decreasing SUV gradient to the tumour edge; this is not 
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uniform as some VOIs were split into two more distinct VOIs by increasing iso-contour thresholds.  
The SUVmean varied by up to 8 between the methods.  The SUVmax and SUVpeak measurements 
seem more robust.  Small differences are identified because of the higher thresholds separating 
VOIs into separate volumes - the largest (not the ‘hottest’) was used for quantification. 
The SUV heterogeneity parameters are closely and strongly correlated with the SUV parameters, 
but they are much more consistent across the VOI methods than SUVmean.  SUVmean and the 
heterogeneity parameters describe the whole VOI voxel population, rather than just the selection 
measured with SUVmax and SUVpeak, and therefore may have clinical relevance; despite the strong 
and significant correlation with the SUV parameters, the lower impact of the VOI method on the 
heterogeneity parameters may suggest more robust parameters.  
For these lesions, the 27% iso-contour correlated the PET volume closest to the sclerotic 
component of the bone metastasis on the CT component of the scan.  The FLAB methodology 
has produced baseline parameters most similar to the VOI27 methodology, suggesting FLAB may 
offer a robust semi-automated segmentation technique not reliant on the SUVmax and with 
favourable repeatability99. 
The %Δ parameters shows less variation between the VOI methods than analysis of the raw data 
alone.  The SUVmean data shows only 3.4% difference in the %Δ SUVmean measurement between 
the relative-SUV VOI methods.  This provides reassurance when comparing %Δ parameters 
between studies, provided there has been consistency of the VOI methodology between scans.  
The absolute-SUV VOI methods, however produce significantly different distributions of the %Δ 
parameters, and are not directly comparable with the other VOI methods.  The choice of VOI 
method is clearly of vital significance; the direction of change of a parameter, in addition to the 
magnitude of change, is directly impacted by the VOI method, and, depending on the definition 
of metabolic response, these differences might be the difference between identifying a patient as 
a treatment responder or not.  The %ΔSUVentropy parameter seems much less impacted by the 
VOI method than other parameters.  
It has not been feasible to identify the best VOI method from this analysis.  What is clear, however, 
is the choice of VOI definition method has a significant and large impact on the quantification 
parameters.  This impact is different depending on the parameter.  The most widely used 
parameters of SUVmax and SUVpeak are less influenced by the VOI method, and this gives them a 
practical advantage.  The other parameters, however, including SUVmean, volumetric parameters, 
heterogeneity parameters and Ki are all significantly impacted by the choice of segmentation 
methodology.  An important area for further investigation would be the repeatability and 
reproducibility of the parameters as the VOI methodologies may perform differently when 
considering these.  The ground truth of where the tumour tissue starts and stops is not as clinically 
relevant with the PET parameters as the clinical information gained from quantification.  If a 
quantification method can be shown to be reproducible and repeatable, and has good diagnostic, 
predictive or prognostic accuracy, then the histological truth is perhaps less relevant.  
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Chapter 6   18F-Fluoride Per-Patient Analysis - Response analysis, 
and the impact of VOI segmentation methods  
The methods of this chapter and the statistical approaches for this section can be reviewed in 
Chapter 2.3.5.  
6.1 Baseline Scan 
12 patients (5 with breast cancer (3 with PD) , 7 with prostate cancer (6 with PD)) had 24-week 
response data for analysis. Treatment response rate, therefore, for breast cancer = 60%, for 
prostate cancer=14%.  
6.1.1 SUV Parameters  





























































































































   
Table 6-1: 18F-Fluoride PET Per-Patient Analysis; Baseline SUV Parameters; Response 
Analysis (Mann-Whitney U tests for comparison) 
The distribution of the SUV parameters measured seem higher for the patients with PD, but no 
significant difference is identified with Mann-Whitney U tests (Tbl.6-1).  There is no significant 
difference when the tumour groups are considered independently, although with such small 
numbers statistical analysis is limited (results not included for brevity). 
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No association between the baseline SUV parameters and treatment response was confirmed 
with per-lesion analysis either.  The highest SUVs were in patients with PD, and this study may 
be underpowered to identify the difference.  
6.1.2 Volumetric Parameters 




























































































Table 6-2: 18F-Fluoride PET Per-Patient Analysis; Baseline Volumetric Parameters; 
Response Analysis; (Mann-Whitney U tests for comparison) 
The data (Tbl.6-2) confirms significantly higher MTV and TLA distributions in those with 
subsequent PD.  This was also identified at the per-lesion analysis, but MTV and TLA were not 
independent of the tumour groups.  There are too few patients to perform sub-group analysis.  
Independence of these volumetric parameters as response predictors cannot be concluded.  
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6.1.3 Heterogeneity Parameters 




























































































Table 6-3: 18F-Fluoride PET Per-Patient Analysis; Baseline SUV Heterogeneity Parameters; 
Response Analysis; (Mann-Whitney U tests for comparison) 
The SUVentropy distributions (Tbl.6-3) appear to be higher in those with PD, and the SUVenergy 
distributions lower, but these differences are not statistically significant (Mann-Whitney U tests, 
Tbl.6-3).  The sample size will limit identification of a smaller difference, and sub-group analysis 
is not feasible.  Per-lesion analysis of these parameters also did not suggest response prediction 
utility.  
  





























































Table 6-4: 18F-Fluoride PET Per-Patient Analysis; Baseline Ki; Response Analysis; (Mann-
Whitney U tests for comparison) 
No statistically significant difference has been identified in the distribution of Ki between the two 
response groups (Tbl.6-4) despite the box-plot suggesting a higher Ki in the those with PD, but 
the sample number is small.  There was no demonstrable difference between the tumour 
subgroups, but the highest values were from prostate cancer patients.  Tumour subgroup analysis 
is not feasible for this data, but it is likely Ki is not an independent predictor of response.  The per-
lesion analysis also did not show predictive utility of the Ki parameter for these patients. 
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6.2 Percentage Change (%Δ) Between Scans 
n=11 (7 with PD, 4 with a treatment response) 
6.2.1 %Δ SUV Parameters 





































p-value 0.230 0.527 0.412 
VOI27 
2.48 

















































































































































   
Table 6-5: 18F-Fluoride PET Per-Patient Analysis; %Δ SUV Parameters; Response Analysis; 
(Mann-Whitney U tests for comparison) 
No statistically significant difference in %ΔSUVmean, %ΔSUVmax, or %ΔSUVpeak has been identified 
between the 24-week response groups, irrespective of the threshold technique used when 
compared with Mann-Whitney tests (Tbl.6-5). 
The per-lesion analysis showed an increase in SUV between the scans was associated with a 
treatment response.  It is not feasible to conduct tumour-subgroup analysis at the per-patient 
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level.  This analysis is underpowered due to the small number of patients, and therefore the lack 
of clinical utility of these parameters cannot be excluded. 
No VOI method has obvious superiority from this analysis. 
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6.2.2 %Δ Volumetric Parameters 
Table 6-6 reports comparison of the %Δ volumetric parameters between the 24-week response 
groups, comparing the groups with Mann-Whitney U tests for each VOI method.  None of the 
analyses approach statistical significance.  Tumour subgroup analyses are not feasible given the 
small number of patients in each tumour group.  The per-lesion analysis also did not show 
predictive utility of the %Δ volumetric parameters. No VOI method has shown superiority. 






































































































































Table 6-6: 18F-Fluoride PET Per-Patient Analysis; %Δ Volumetric Parameters; Response 
Analysis; (Mann-Whitney U tests for comparison) 
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6.2.3 %Δ Heterogeneity Parameters 
 %ΔSUVentropy %ΔSUVenergy 










































































































































p-value 0.286 0.286 
VOI50BL 
n=6 





















Table 6-7: 18F-Fluoride PET Per-Patient Analysis; %Δ SUV Heterogeneity Parameters; 
Response Analysis; (Mann-Whitney U tests for comparison) 
The response analysis data can be reviewed in Tbl.6-7.  The application of increasingly severe 
SUV thresholds for VOI definition resulted in a reduction in the number of patients with suitable 
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VOIs for quantification.  A wider range of responses are seen when measuring the %ΔSUVentropy 
in patients who subsequently had PD confirmed, and the %ΔSUVentropy is higher this group.  
However, statistical comparison does not identify any significant difference between the 
distributions, but such analysis is limited by the small sample size. 
There is no demonstrable difference identified in the distribution of %ΔSUVenergy between the 
response groups.  The per-lesion analysis a trend for a response in breast cancer lesion predicted 
with a change in SUV voxel distribution towards homogeneity (decrease entropy and increased 
energy). 
No VOI method has demonstrated predictive superiority. 
6.2.4 %ΔKi 
There is no demonstrable difference in the distribution of %ΔKi between the response groups for 
these patients, irrespective of the VOI method used for quantification (see Tbl-6-8.  The per-lesion 
analysis also did not demonstrate response predictive utility.  Tumour sub-group response 
analyses are not feasible due to the small number of patients. 
  











































































































Table 6-8: 18F-Fluoride PET Per-Patient Analysis; %Δ Ki; Response Analysis; (Mann-
Whitney U tests for comparison) 
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6.3 Discussion 
No utility has been demonstrated in this per-patient analysis of the 18F-Fluoride scan for predicting 
a treatment response.  However, with the small sample, lack of utility also cannot be concluded.  
The per-lesion analysis showed predictive utility from the behaviour of 18F-Fluoride tracer uptake 
by bone metastases.  The main limitation with this study is the size of the sample group.  The per-
lesion analysis clearly demonstrated differences between the parameter characteristics between 
breast and prostate cancer bone metastases, and analysis of all these lesions together may hide 
clinical associations.  It would be ideal to identify imaging parameters with consistency between 
tumour subtypes, but the 18F-Fluoride uptake is, by design, affected by osteoblastic activity and 
therefore will be different for tumours depending on what peri-tumour bone reaction is 
predominant.   
The VOI methods were shown in the previous chapter to be result in statistically significant 
differences of the calculated quantification parameters.  It has not been possible to demonstrate 
superiority of a VOI method given the negative nature of this analysis. 
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Chapter 7  18F Fluoride PET Per-Patient Analysis – Survival Analysis 
The methods of this chapter and the statistical approaches for this section can be reviewed in 
Chapter 2.3.6.  
7.1 OS Analysis 
7.1.1 Tumour Group Analysis 
Tumour Group OS 
 
Breast - blue line 
Prostate - green line 
p=0.142 
Figure 7-1: 18F-Fluoride PET Per Patient Analysis; KM OS Analysis; Tumour Subgroups; 
B=Breast cancer P=Prostate Cancer 
The breast cancer patients have an OS benefit, although significance has not been reached 
(p=0.142, see Fig.7-1); this benefit is real, but the small sample size has impaired statistical 
analysis.  
OS analysis has therefore not been reported at the per-patient level in this thesis due to the small 
number of patients (14) and deaths (3). 
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7.2 PFS 
7.2.1 Tumour Group Analysis 
Tumour Group PFS 
 
Breast - blue line 
Prostate - green line 
p=0.225 
Figure 7-2: 18F-Fluoride PET; KM PFS Analysis; Tumour Subgroups; B=Breast cancer 
P=Prostate Cancer 
The per-lesion analysis demonstrated the significant PFS benefit of the breast cancer patients.  
Significance is not met with per-patient analysis due to the small sample group (Fig.7-2).  
7.2.2 Baseline Scan  
13 patients (5 Breast (2 with PD), 8 Prostate (7 with PD)) had information available for PFS 
analysis.  Subgroup analysis of the breast patients is therefore not feasible. 
7.2.2.1 SUV Parameters 
The results of the Cox analysis are shown in the Table 7-1: 
 SUVmean SUVmax SUVpeak 
 Cox regression p-value [HR] 
VOImanual 0.606 [1.033] 0.633 [1.005] 0.630 [1.007] 
VOI27 0.57 [1.018] 0.657 [1.005] 0.658 [1.006] 
VOI40 0.609 [1.014] 0.657 [1.005] 0.647 [1.007] 
VOI50 0.628 [1.012] 0.657 [1.005] 0.638 [1.006] 
VOIFLAB 0.582 [1.018] 0.653 [1.005] 0.653 [1.006] 
Table 7-1: 18F-Fluoride PET Per-Patient Analysis; Baseline SUV Parameters; Cox 
regression univariate PFS Analysis; All Patients; all threshold methods. 
No significant correlation has been identified in these patients between the SUV parameters 
analysed and risk of PD.  Table 7-2 reports KM analysis; there is no statistically significant 
separation of the PFS curves for any SUV parameter. 
Analysis of the prostate cancer lesions also demonstrates no statistically significant association 
between the SUV parameters, but suggests patients with a higher baseline SUV have a trend 
towards a longer PFS (Tbl.7-3). 
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The per-lesion analysis did not reveal any association between the baseline SUV parameters and 
PFS for these patients. 
 SUVmeanVOImanual SUVmaxVOImanual SUVpeakVOImanual 
 
Median PFS in days 
(95% CI) 
 
   
Median 6.57 34.39 27.12 
≤ (1) 141 (40.49-241.51) 141 (15.25-266.75) 141 (15.25-266.75) 
> (2) 147 (101.18-192.82) Not reached Not reached 
p-Value  0.933 0.751 0.751 
Table 7-2: 18F-Fluoride PET Per-Patient Analysis; Baseline SUV Parameters; KM PFS 
Analysis; All Patients; all threshold methods. 
 SUVmean
VOImanual 
Prostate patients only 
SUVmaxVOImanual 
Prostate patients only 
SUVpeakVOImanual 
Prostate patients only 
 
   
 
Low (1) - blue line 
High (2) - green line 
p-Value 0.248 0.235 0.235 
Table 7-3: 18F-Fluoride PET Per-Patient Analysis; Baseline SUV Parameters; KM PFS 
Analysis; Prostate Patients only; all threshold methods. 
7.2.2.2  Volumetric Parameters 
 MTV TLA 
 Cox regression p-value [HR] 
VOImanual 0.272 [1.001] 0.212 [1.000] 
VOI27 0.242 [1.003] 0.167 [1.000] 
VOI40 0.211 [1.005] 0.154 [1.000] 
VOI50 0.202 [1.007] 0.152 [1.000] 
VOIFLAB 0.218 [1.003] 0.179 [1.000] 
Table 7-4: 18F-Fluoride PET Per-Patient Analysis; Baseline Volumetric Parameters; Cox 
regression univariate PFS Analysis; All Patients; all threshold methods. 
Cox regression analysis (Tbl.7-4) does not demonstrate a correlation between PFS and the 
volumetric parameters.  There is trend towards a significant separation of the KM survival curve 
for MTV (Tbl.7-5).  However, breast cancer patients had smaller lesions and a longer PFS.  KM 
analysis of the prostate patients only reveals no PFS prediction utility (p=0.629), and TMV/TLA 
are not independent predictors. 
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The per-lesion analysis suggested a PFS benefit for the breast cancer lesions with a lower MTV 
at baseline, but there are  too few breast cancer patients sub-group analysis. 
 MTVVOImanual TLAVOImanual 
 Median PFS in days (95% CI) 
 
  
Median 326.82 2520.3 
≤ Median (1) 294 (24.81-563.19) 294 (0-602.50) 
> Median (2) 117 (75.94-158.06) 141 (104.35-177.65) 
p-Value (Log Rank) 0.055 0.442 
Table 7-5: 18F-Fluoride PET Per-Patient Analysis; Baseline Volumetric Parameters; KM PFS 
Analysis; All Patients; all threshold methods. 
7.2.2.3  Heterogeneity Parameters 
 SUVentropy SUVenergy 
 Cox regression p-value [HR] 
VOImanual 0.691 [1.346] 0.718 (0.035) 
VOI27 0.713 [1.242] 0.641 (0.011) 
VOI40 0.779 [1.180] 0.708 (0.037) 
VOI50 0.560 [1.453] 0.600 (0.006) 
VOIFLAB 0.667 [1.321] 0.747 (0.061) 
Table 7-6: 18F-Fluoride PET Per-Patient Analysis; Baseline SUV Heterogeneity Parameters; 
Cox regression univariate PFS Analysis; All Patients; all threshold methods. 
For these patients, there is no demonstrable correlation between the baseline heterogeneity 
parameters and PFS using univariate Cox-Regression (Tbl.7-6).  There is no significant 
separation of the KM survival curves (Tbl.7-7).  No association with PFS was identified with per-
lesion analysis either. 
 SUVentropyVOImanual SUVenergyVOImanual 
 




Median 2.67 0.09 










p-Value (Log Rank) 0.796 0.796 
Table 7-7: 18F-Fluoride PET Per-Patient Analysis; Baseline SUV Heterogeneity Parameters; 
KM PFS Analysis; All Patients; all threshold methods. 
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VOImanual 0.833 [2.432] 
VOI27 0.768 [1.871] 
VOI40 0.803 [1.579] 
VOI50 0.656 [2.116] 
VOIFLAB 0.787 [1.822] 
Table 7-8: 18F-Fluoride PET Per-Patient Analysis; Baseline Ki; Cox regression univariate 
PFS Analysis; All Patients; all threshold methods. 
There is no demonstrable correlation between PFS and the Ki measured on the baseline scan 
(Tbl.7-8).  KM analysis is in Table 7-9; there is no significant separation of the survival curves.  
Per lesion analysis also did not demonstrate an association between baseline Ki and PFS. 
 Ki 




≤ Median (1) 141 
(40.49-241.51) 
> Median (2) Not reached 
p-Value (Log Rank) 0.553 
Table 7-9: 18F-Fluoride PET Per-Patient Analysis; Baseline Ki; KM PFS Analysis; All 
Patients; all threshold methods. 
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7.2.3 Percentage Change (Δ%) Between Scans - PFS Analysis 
n=11 (5 Breast, 6 Prostate), 8 events (2 Breast, 6 Prostate) 
7.2.3.1 Δ% SUV Parameters 
Univariate Cox regression analysis for these patients can be reviewed in Table 7-10.  No 
correlation has been identified in these patients between the time to progression and the size of 
Δ%SUV parameter. 
 Δ%SUVmean Δ%SUVmax Δ%SUVpeak 
 Cox regression p-value [HR] 
VOImanual 0.243 [0.986] 0.808 [0.997] 0.804 [1.004] 
VOI27 0.809 [1.003] 0.897 [1.002] 0.877 [1.002] 
VOI40 0.720 [1.005] 0.836 [1.002] 0.920 [1.001] 
VOI50 0.695 [1.005] 0.824 [1.002] 0.996 [1.000] 
VOIFLAB 0.737 [0.996] 0.938 [1.001] 0.814 [1.004] 
VOI27BL 0.626 [0.997] 0.362 [1.003] 0.378 [1.005] 
VOI40BL 0.627 [0.996] 0.300 [1.003] 0.323 [1.005] 
VOI50BL 0.656 [0.996] 0.244 [1.004] 0.249 [1.005] 
Table 7-10: 18F-Fluoride PET Per-Patient Analysis; %Δ SUV Parameters; Cox regression 
univariate PFS Analysis; All Patients; all threshold methods. 
KM analysis of the VOImanual data can be reviewed in Table 7-11.  The plots are similar for all 3 
parameters, showing a statistical trend for PFS benefit for patients with a more positive change 
in the SUV.  %Δ SUVmax is perhaps the more discriminating parameter, demonstrating a 177-day 
median-PFS benefit for patients with %ΔSUVmax>1.13% (p=0.056). 
 Δ%SUVmeanVOImanual Δ%SUVmaxVOImanual Δ%SUVpeakVOImanual 
 
Median PFS in days 
(95% CI) 
 
   













0.09 0.056 0.097 
Table 7-11: 18F-Fluoride PET Per-Patient Analysis; %Δ SUV Parameters; KM PFS Analysis; 
All Patients; all threshold methods. 
However, analysis of only the prostate cancer lesions reveals no association between the %Δ in 
SUV parameters and PFS (%Δ SUVmean/max/peak, p=0.607).  There are too few breast cancer 
patients for analysis.  The prostate cancer patients had a shorter PFS compared with the breast 
cancer patients; the %Δ SUV parameters are not independent predictors. 
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7.2.3.2 Δ% Volumetric Parameters 
Univariate Cox regression analysis can be reviewed in Table 7-12.  No significant correlation has 
been identified in these patients. 
 Δ%MTV Δ%TLA 
 Cox regression p-value [HR] 
VOImanual 0.637 [1.002] 0.386 [0.998] 
VOI27 0.862 [0.999] 0.391 [1.015] 
VOI40 0.802 [0.999] 0.153 [1.027] 
VOI50 0.819 [0.999] 0.083 [1.031] 
VOIFLAB 0.843 [1.001] 0.653 [0.995] 
VOI27BL 0.821 [1.003] 0.751 [0.999] 
VOI40BL 0.939 [1.001] 0.946 [1.000] 
VOI50BL 0.984 [1.000] 0.989 [1.000] 
Table 7-12: 18F-Fluoride PET Per-Patient Analysis; %Δ Volumetric Parameters; Cox 
regression univariate PFS Analysis; All Patients; all threshold methods. 
KM analysis (Tbl.7-13) demonstrates a statistically significant PFS advantage for patients with an 
increase in TLA between the scans, with a 193-day median-PFS advantage noted in the patients 
with greater than 5.8% increase between the scans (p=0.011).  The change in MTV does not 
demonstrate a significant separation of the survival curves (p=0.296).  TLA is the product of the 
MTV and SUVmean – an increase in SUVmean confers PFS advantage, and this effect is being 
translated through to %ΔTLA.  In these patients, it seems %ΔTLA is more discriminating than %Δ 
SUVmean. 
 Δ%MTVVOImanual Δ%TLAVOImanual 
 




Median -0.35% +5.82% 





> Median (2) 110 (62.0-158.0) 294 (64.7-523.3) 
p-Value (Log Rank) 0.296 0.011 
Table 7-13: 18F-Fluoride PET Per-Patient Analysis; %Δ Volumetric Parameters; KM PFS 
Analysis; All Patients; all threshold methods. 
Analysis of only the prostate cancer patients demonstrates no significant separation of the KM 
curve for %ΔMTV (p=0.951), but the survival curve separation with %ΔTLA is preserved and 
significant (Tbl.7-14). 
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 Δ%TLAVOImanual 





≤ Median (1) 101 (54.6-147.4) 
> Median (2) 147 (137.4-156.6) 
p-Value (Log Rank) 0.025 
Table 7-14: 18F-Fluoride PET Per-Patient Analysis; %Δ SUV Parameters; KM PFS Analysis; 
Prostate Patients only; all threshold methods. 
A 46-day median PFS benefit is predicted for prostate cancer patients with a decrease greater 
than 3% in the TLA between scan (p=0.025); this was shows for breast cancer lesions at per-
lesion analysis. 
7.2.3.3 Δ% SUV Heterogeneity Parameters 
 Δ%SUVentropy Δ%SUVenergy 
 Cox regression p-value [HR] 
VOImanual 0.492 [0.925] 0.133 [1.029] 
VOI27 0.728 [0.976] 0.095 [1.025] 
VOI40 0.449 [1.060] 0.711 [0.989] 
VOI50 0.237 [1.069] 0.767 [0.993] 
VOIFLAB 0.857 [1.040] 0.359 [1.017] 
VOI27BL 0.246 [1.075] 0.896 [0.998] 
VOI40BL 0.495 [1.032] 0.362 [0.990] 
VOI50BL 0.235 [0.905] 0.211 [1.022] 
Table 7-15: 18F-Fluoride PET Per-Patient Analysis; %Δ SUV Heterogeneity Parameters; Cox 
regression univariate PFS Analysis; All Patients; all threshold methods. 
Univariate Cox regression analysis of the parameters (Tbl.7-15), does not demonstrate any 
statistically significant correlation. 
Table 7-16 reports the outcome of KM PFS analysis for these data.  There is no statistically 
significant separation of the survival curves for either %Δ SUV parameter.  However, there is the 
suggestion of a more negative change (less than +12.86%) being associated with a prolonged 
PFS (177 days for these patients, p=0.195).  This is a shift towards the SUV voxel distribution 
having less uniformity (towards heterogeneity).  
Analysis of the prostate cancer patients does not suggest an association between the %Δ 
heterogeneity parameters and PFS (log rank analysis: %ΔSUVentropy/energy p=0.277 and 0.988 
respectively). 
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The per-lesion analysis demonstrated no confirmed association between these parameters and 
PFS, but suggests a trend for a PFS benefit for the breast cancer lesions with a decrease in 
SUVentropy and increase in SUVenergy between scans.   
 Δ%SUVentropyVOImanual Δ%SUVenergyVOImanual 




Dichotomisation 0.915 12.86 





> Dichotomisation (2) Not reached 
117 
(44.99-189.01) 
p-Value (Log Rank) 0.558 0.195 
Table 7-16: 18F-Fluoride PET Per-Patient Analysis; %Δ SUV Heterogeneity Parameters; KM 
PFS Analysis; All Patients; all threshold methods. 





VOImanual 0.088 [1.005] 
VOI27 0.289 [1.002] 
VOI40 0.603 [0.995] 
VOI50 0.879 [1.001] 
VOIFLAB 0.975 [1.000] 
VOI27BL 0.871 [1.000] 
VOI40BL 0.363 [0.997] 
VOI50BL 0.139 [1.010] 
Table 7-17: 18F-Fluoride PET Per-Patient Analysis; %Δ Ki; Cox regression univariate PFS 
Analysis; All Patients; all threshold methods. 
The Cox regression analysis (Tbl.7-17) does not demonstrate any significant correlation. 
The KM analysis (Tbl.7-18) does not demonstrate a statistically significant separation of the 
survival curves, but there is perhaps the suggestion of a PFS benefit from a decrease in Ki 
between scans (p=0.152). 
However, analysis of the prostate cancer patients only does not demonstrate an association 
between %Δ Ki and PFS (p=0.988).  There are too few breast patients for useful analysis, but it 
is likely Ki analysis in not independent to the tumour types. 
Per-lesion analysis did not demonstrate any PFS prognostic utility for these patients. 
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 Δ%Ki 




≤ Median (1) 
294 
(20.53-567.47) 
> Median (2) 
117 
(49.38-184.62) 
p-Value (Log Rank) 0.152 
Table 7-18: 18F-Fluoride PET Per-Patient Analysis; %Δ Ki; KM PFS Analysis; All Patients; 
all threshold methods. 
7.3 Discussion 
The per-lesion analysis of these patients showed prognostic utility of the quantification 
parameters; this has not been elicited with per-patient analysis. 
The %Δ parameters at the per-lesion analysis suggested a PFS benefit for breast cancer patients 
with a decrease in TLA between scans, a fall in SUVentropy and an increase in SUVenergy.  The 
breast cancer patients cannot be analysed at the per-patient level, but the prostate cancer 
patients have been shown to have a PFS advantage from an increase in TLA between the scans 
(p=0.025) which is contradictory to what analysis the breast cancer lesions suggested.  The TLA 
is a product of the MTV and SUVmean, and the change in neither of these parameters have shown 
prognostic utility.  The %ΔTLA of the per-patient analysis has not shown an association with 
treatment response.  An increase in TLA will be caused by an increase in MTV or an increase in 
SUVmean.  The MTV for the 18F-Fluoride PET is not a direct measure of the tumour deposit size, 
but is a volume of bone with an osteoblastic reaction due to the interaction of the tumour cells; a 
flare response of a healing bone metastasis might cause both an increased tracer uptake 
(therefore SUVmean) and may show an increased volume of reactive bone, and hence MTV.  This 
needs to be examined further with a larger patient population, including both breast and prostate 
cancer patients to examine the differences between the tumour types. 
The per-patient survival analysis has therefore been disappointing, the likelihood of 
prognostication from 18F-Fluoride PET having been suggested with the per-lesion analysis.  This 
study is likely to be underpowered to identify differences if they are smaller, even if real clinically 
relevant information does exist.  The multiple analyses should be statistically corrected for due to 
the increased risk of identifying an association through chance alone; this correction has not been 
applied to this analysis.  However, this analysis provides data for generating new hypothesis, and 
for taking forward methods into subsequent prospective trials for further evaluation. 
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Chapter 8  18F-Fluoride PET Whole-Body Quantification - Appraisal 
of novel whole-skeletal 18F-Fluoride PET quantification parameters for 
predictive and prognostic utility in the assessment of bone 
metastases from breast and prostate cancer. 
The methods of this chapter and the statistical approaches for this section can be reviewed in 
Chapter 2.3.7.  This chapter is presented in 4 sections: 8.1-Descriptive statistics and response 
analysis; 8.2-OS Analysis; 8.3-PFS Analysis; 8.4-Discussion. 
8.1  Response Analysis 
8.1.1 Baseline Scan 
14 patients had baseline 18F-Fluoride PET imaging ( BCa-5, PCa-9).  12 patients had data for 
response analysis (BCa-5, PCa-7).  4 patients had a treatment response (including stable 
disease) maintained at 24-weeks (BCa-3,PCa-1)   
8.1.1.1 SUV Parameters 
The whole-population distributions (Tbl.8-1) of the SUV parameters are significantly different from 
each other (Friedman’s Variance test, p<0.0001).  The distributions medians of SUVmax and 
SUVpeak are higher than SUVmean; SUVmean will involve more lower value voxels.  No statistical 
difference in the parameter distributions is identified between tumour groups, but the distribution 
mean for the prostate patients is higher than the breast patients; there are too few patients to 
statistically confirm this. 
There is no demonstrable difference in the distributions of the SUV parameters between the 
response groups (Mann-Whitney U tests: SUVmean/max/peak p=1.0, 0.933, 0.93 respectively).   
The individual patient response data for each parameter split can be seen in the waterfall plots 
(Figs.8-1,8-2,8-3).  The highest SUVWB measurements were from patients with PD, but the SUVWB 
was lower in some PD patients compared to those a response; identifying a discriminating 
threshold is not possible. 
Response analysis of only the breast cancer patients does not demonstrate an significant 
difference in the distributions between the response groups (p=1.0 for all parameters), but with 
so few patients this does not exclude a difference. 
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p=0.298 p=0.147 p=0.147 
Progression 
n=8 
(BCa 2; PCa 6) 
Response 
n=4 
(BCa 3; PCa 1) 
Progression 
n=8 
(BCa 2; PCa 6) 
Response 
n=4 
(BCa 3; PCa 1) 
Progression 
n=8 
(BCa 2; PCa 6) 
Response 
n=4 



















   
p=1.00 p=0.933 0.933 
Table 8-1: 18F-Fluoride PET; Whole-Body Analysis; Baseline Scan SUV parameters; all 
patients; Descriptive statistics and response analyses; Mann-Whitney U tests for 
comparisons between distributions (B=Breast, P=Prostate) 
  
18F-Fluoride PET  Whole-Body Analysis 
138 
 
Figure 8-1: 18F-Fluoride PET; Whole-Body Analysis; Baseline SUVmeanWBVOI27; all patients 
split into response groups (Progression=Green; Response=Blue) 
 
Figure 8-2: 18F-Fluoride PET; Whole-Body Analysis; Baseline SUVmaxWBVOI27; all patients 
split into response groups (Progression=Green; Response=Blue) 
 
Figure 8-3: 18F-Fluoride PET; Whole-Body Analysis; Baseline SUVpeakWBVOI27; all patients 
split into response groups (Progression=Green; Response=Blue) 
8.1.1.2 Volumetric Parameters 
Table 8-2 reports the data; there is no statistical difference in the MTVWB between the tumour 
groups (p=0.298), but there is a trend suggesting larger MTVs for prostate patients.  TLAWB is 
significantly larger for the prostate patients (p=0.042); combining the higher baseline SUVmeanWB 
and higher MTVWB for the prostate lesions, neither of which were discriminating in themselves, to 
create a more discriminating parameter. 
The mean MTVWB is greater for those with PD, but this is not significant (p=0.570).  The largest 
MTVWB values were identified in patients with PD.  Similarly, the calculated TLAWB is larger in 
those with PD, but this is not significant (p=0.368).   







Baseline SUVmeanWB and Response
Progression VOI27 Response VOI27







Baseline SUVmaxWB and Response
Progression VOI27 Response VOI27







Baseline SUVpeakWB and Response
Progression VOI27 Response VOI27
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Figures 9-4 and 9-5 represent the individual patient data for MTVWB and TLAWB as waterfall plots. 
It is not possible to identify values of MTVWB or TLAWB to accurately predict a treatment response 
in these patients.  The prostate cancer patients had a larger MTV and TLA compared to the breast 
patients; these differences are significant for TLA (p=0.042) but not for MTV (p=0.298).  The 
prostate patients were much less likely to have a treatment response.   
Response analyses for just the breast cancer patients can be seen in Table 8-3.  Statistical 
comparisons are compromised by the small number of patients, but the breast patients with PD 




































(BCa 2; PCa 6) 
Response 
n=4 
(BCa 3; PCa 1) 
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n=8 
(BCa 2; PCa 6) 
Response 
n=4 















Table 8-2: 18F-Fluoride PET; Whole-Body Analysis; Baseline Scan Volumetric Parameters; all 
patients; Descriptive statistics and response analyses; Mann-Whitney U tests for comparisons 
between distributions (B=Breast, P=Prostate) 
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Figure 8-4: 18F-Fluoride PET; Whole-Body Analysis; Baseline MTVWBVOI27; all patients split 
into response groups (Progression=Green; Response=Blue) 
 
Figure 8-5: 18F-Fluoride PET; Whole-Body Analysis; Baseline TLAWBVOI27; all patients split 
































Table 8-3: 18F-Fluoride PET; Whole-Body Analysis; Baseline Scan Volumetric Parameters; Breast 
Patients Only; Descriptive statistics and response analyses; Mann-Whitney U tests for comparisons 
between distributions 
8.1.1.3 Heterogeneity Parameters 
The data is recorded in Table 8-4.  There is a wider range of whole-body SUV heterogeneity 
parameters in those patients with PD, but there were twice the number of patients in this group.   
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Baseline TLAWB and Response
Progression VOI27 Response VOI27
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The prostate cancer patients had a higher ADCentropy and lower ADCenergy than the breast cancer 
patients; these differences do not reach statistical significance (p=0.190 and 0.083 respectively), 
but this suggests a trend.  No statistically significant difference has been identified in the 
distributions of parameters between the response groups.  Both the highest and lowest 
parameters were identified in patients with PD; it is not possible to identify a value to usefully 
predict treatment response.  The waterfall plots (Figs.8-6,8-7) display the individual patient data 
for comparison. 
The distribution of the breast cancer heterogeneity parameters are also not significantly different 
between the response groups (p=1.0 for each parameter), but with so few patients it is not 
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Table 8-4: 18F-Fluoride PET; Whole-Body Analysis; Baseline Scan SUV Heterogeneity Parameters; 
all patients; Descriptive statistics and response analyses; Mann-Whitney U tests for comparisons 
between distributions (B=Breast, P=Prostate) 
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Figure 8-6: 18F-Fluoride PET; Whole-Body Analysis; Baseline SUVentropyWBVOI27; all patients 
split into response groups (Progression=Green; Response=Blue) 
 
Figure 8-7: 18F-Fluoride PET; Whole-Body Analysis; Baseline SUVenergyWBVOI27; all patients 
split into response groups (Progression=Green; Response=Blue) 
8.1.1.4 KiWB 
11 patients had data suitable for analysis, 5 breast patients and 6 prostate patients.  The data is 
displayed in Table 8-5. 
There is no demonstrable difference in the KiWB between the tumour groups (p=1.0).  Baseline 
KiWB does not differentiate between patients who subsequently are defined as responders and 
those with PD (p=0.788). 
The waterfall plot (Fig.8-8) shows the highest KiWB values were recorded in patients with PD, but 
this response group also included patients with the lowest KiWB measurements from the baseline 
scan.  No useful cut off to accurately separate patients into response groups cannot be identified.  
Breast cancer lesions have not been analysed separately because there is no demonstrable 
difference in the KiWB between the tumour groups. 
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Baseline SUVenergyWB and Response
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Figure 8-8: 18F-Fluoride PET; Whole-Body Analysis; Baseline KiWBVOI27; all patients split into 











(BCa 2; PCa 5) 
Response 
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(BCa 3; PCa 1) 
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Table 8-5: 18F-Fluoride PET; Whole-Body Analysis; Baseline Scan Ki; all patients; Descriptive 
statistics and response analyses; Mann-Whitney U tests for comparisons between distributions 
(B=Breast, P=Prostate) 
 







Baseline KiWB and Response
Progression VOI27 Response VOI27
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8.1.2 Second Scan 
n=12 (5 breast cancer patients, 7 prostate cancer patients). 














































Table 8-6: 18F-Fluoride PET; Whole-Body Analysis; Second Scan All Parameters; all patients; 
Descriptive statistics 
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8.1.3 Percentage Change (%Δ) Between Scans 
12 patients had data for %Δ analysis ( BCa-5, PCa-7).  11 patients had data for response analysis 
(BCa-5, PCa-6).  4 patients had a treatment response (including stable disease) maintained at 
24-weeks (BCa-3(60%),PCa-1(16%))   
8.1.3.1 %Δ SUV Parameters 












































   
p=0.639 p=0.343 p=0.432 
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p=0.927 p=1.00 p=0.788 
Table 8-7: 18F-Fluoride PET; Whole-Body Analysis; %Δ SUV Parameters; all patients; Descriptive 
statistics and response analyses; Mann-Whitney U tests for comparisons between distributions 
(B=Breast, P=Prostate) 
The %Δ SUV parameters show more agreement between them than the baseline parameters 
(Tbl.8-7); there is no demonstrable significant difference between the distributions (Friedman’s 
variance test, p=0.558). 
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Each response group contains patients with increases and decreases in the SUV parameter.  The 
following waterfall plots (Figs.8-9,8-10,8-11) show the %Δ in the parameters for every patient. 
 
Figure 8-9: 18F-Fluoride PET; Whole-Body Analysis; %ΔSUVmeanWBVOI27; all patients split 
into response groups 
 
Figure 8-10: 18F-Fluoride PET; Whole-Body Analysis; %ΔSUVmaxWBVOI27; all patients split 
into response groups 
 
Figure 8-11: 18F-Fluoride PET; Whole-Body Analysis; %ΔSUVpeakWBVOI27; all patients split 
into response groups 
There are no consistent findings from analysis of the %Δ SUVWB parameters.  No utility has been 
shown for identifying a treatment response using 18F-Fluoride PET 8-weeks after treatment 
initiation with these whole-body parameters (Mann-Whitney U tests to compare the response 
groups: %Δ SUVmean/max/peak p=0.927/1.0/0.788). 
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p=0.4 p=0.8 p=1.0 
Table 8-8: 18F-Fluoride PET; Whole-Body Analysis; %Δ SUV Parameters; Breast Patients Only; 
Descriptive statistics and response analyses; Mann-Whitney U tests for comparisons between 
distributions 
None of the differences between the %Δ SUV parameters distributions reach statistical 
significance (%Δ SUVmean/max/peak p=0.4/0.8/1.0), but there is a suggestion of a greater increase in 
SUV between scans for those patients with PD by 24-weeks.  A larger sample would be necessary 
to interrogate this further. 
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Table 8-9: 18F-Fluoride PET; Whole-Body Analysis; %Δ Volumetric Parameters; all patients; 
Descriptive statistics and response analyses; Mann-Whitney U tests for comparisons between 
distributions (B=Breast, P=Prostate) 
There is no statistically significant difference in the distributions of the %Δ volumetric parameters 
between the tumour groups (Tbl.8-9) (Mann-Whitney U tests for comparison: %Δ MTV p=0.432, 
%ΔTLA p=0.530).  More of the prostate patients had PD, but there is no significant difference in 
%ΔMTV or %ΔTLA between the response groups (p=0.788, 0.412 respectively). 
There is heterogeneity of changes in the whole-body parameters within each response groups.  
The following charts plot the patient data for each response group (Figs.8-12,8-13).  Most 
patients, irrespective of the response group, had an increase in the parameters between scans.   
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Figure 8-12: 18F-Fluoride PET; Whole-Body Analysis; %ΔMTVWBVOI27; all patients split into 
response groups (Progression=Grey; Response=Blue) 
 
Figure 8-13: 18F-Fluoride PET; Whole-Body Analysis; %ΔTLAWBVOI27; all patients split into 
response groups (Progression=Grey; Response=Blue) 
The %Δ volumetric parameters have not shown utility for prediction treatment response at the 
per-lesion analysis (see earlier results chapter), nor per-patient target lesions analysis (see earlier 
results chapter).  It is not clear why the volumetric parameters have increased for most patients, 
irrespective of the response group.  The largest increase was in a patient deemed to have had a 
treatment response at 24-weeks; the increase in volume of 18F-Fluoride uptake, as defined by the 
27% iso-contour, may represents a flare response to treatment.  
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Table 8-10: 18F-Fluoride PET; Whole-Body Analysis; %Δ SUV Heterogeneity Parameters; all patients; 
Descriptive statistics and response analyses; Mann-Whitney U tests for comparisons between 
distributions (B=Breast, P=Prostate) 
There is no demonstrable statistically significant difference in the %Δ heterogeneity parameters 
between the tumour types (%ΔSUVentropy p=0.539, %ΔSUVenergy p=0.432; Tbl.8-10), or response 
groups (p=1.0 for both parameters).  The waterfall plots (Figs.8-14,8-15) show patients with 
increases and others with decreases in the parameters within each response group. 
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Figure 8-14: 18F-Fluoride PET; Whole-Body Analysis; %ΔSUVentropyWBVOI27; all patients split 
into response groups 
 
Figure 8-15: 18F-Fluoride PET; Whole-Body Analysis; %ΔSUVenergyWBVOI27; all patients split 
into response groups  
Response analysis of the breast cancer patients only (Tbl.8-11) does not identify a statistically 
significant difference in the %Δ parameters between the response groups, although the patients 
with the greater increase in SUVentropy and greatest decrease in SUVenergy between scan who did 






























Table 8-11: 18F-Fluoride PET; Whole-Body Analysis; %Δ SUV Heterogeneity Parameters; 
Breast Patients Only; Descriptive statistics and response analyses; Mann-Whitney U tests 
for comparisons between distributions 
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8.1.3.4 %Δ Uptake Rate Constant (KiWB) 
Only 8 patients had data suitable for %ΔKi analysis, 4 breast cancer patients (2 with a treatment 
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Table 8-12: 18F-Fluoride PET; Whole-Body Analysis; %Δ Ki; all patients; Descriptive 
statistics and response analyses; Mann-Whitney U tests for comparisons between 
distributions (B=Breast, P=Prostate) 
The KiWB distribution seems higher in those with a treatment response(Tbl.8-12), but this is not 
confirmed statistically (p=0.343).  The waterfall plot (Fig.8-16) demonstrates the individual patient 
data; the change in KiWB is inconsistent and does not appear to predict treatment response in 
these patients.  There are too few patients for response analysis of the breast cancer patients 
only. 
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8.2 OS Analysis 
As previously discussed, there are too few deaths in this data to warrant meaningful OS analysis. 
8.3 PFS Analysis 
PFS analysis with Cox regression analysis is more valid than OS analysis in these patients 
because of the increased number of events. 
12 patients had PFS data available for analysis, 5 breast cancer patients and 7 prostate cancer 
patients.  2 breast cancer patients had PD at the point of data analysis, and 7 prostate cancer 
patients. 
8.3.1 Tumour Group Analysis 
 
Breast cancer (B) - blue line 
Prostate cancer (P) - green line 
p=0.153 
Figure 8-17: 18F-Fluoride PET; Whole-Body Analysis; KM PFS Analysis of tumour groups 
(Log rank analysis; B=Breast cancer; P=Prostate cancer) 
There is no statistically significant PFS benefit for the breast cancer patients has been identified 
(Fig.8-24), although this most likely represents the small number of patients and events. 
8.3.2 Baseline Scan PFS Analysis 
8.3.2.1 SUVWB Parameters 
The results of the Cox analysis (Tbl.8-19) show is no demonstrable correlation between the 
baseline SUVWB parameters and the risk of progression: 
 SUVmeanWB SUVmaxWB SUVpeakWB 
p-value [HR] 0.932 [1.002] 0.84 (1.003) 0.75 (1.006) 
Table 8-13: 18F-Fluoride PET; Whole-Body Analysis; Baseline Scan SUV Parameters; Cox 
regression PFS Analysis; All Patients 
Table 8-20 reports the KM PFS analyses.  Using an SUVmeanWB/SUVmaxWB/SUVpeakWB cut-off at 
12/21.08/16.6 (respectively) the same 3 patients have been selected, creating identical KM 
analysis for all three parameters.  There is significant separation of the PFS curves (p=0.037), 
with a 55-day median-PFS benefit for the patients with the higher baseline SUV parameters.  
Analysis of the prostate cancer patients only does not demonstrate a predictive association with 
these baseline SUV parameters (SUVmeanWB/SUVmaxWB/SUVpeakWB p=0.475, 0.909, 0.153 
respectively).  The analysis of all the patients together is most likely influenced by the tumour 
subgroup, and an association between these parameters and PFS cannot be concluded. 
18F-Fluoride PET  Whole-Body Analysis 
154 
 SUVmeanWB SUVmaxWB SUVpeakWB 
 Median PFS in days (95% CI) 
 
   
Cut-off 12.0 21.08 15.6 
≤ (1) 92 (59.99-124.01) 92 (59.99-124.01) 92 (59.99-124.01) 
> (2) 147 (0-300.12) 147 (0-300.12) 147 (0-300.12) 
p-Value (Log 
Rank) 
0.037 0.037 0.037 
Table 8-14: 18F-Fluoride PET; Whole-Body Analysis; Baseline Scan SUV Parameters; KM 
PFS Analysis; All Patients 
8.3.2.2 Whole-Body SUV Volumetric Parameters 
Cox regression analysis (Tbl.8-21) does not demonstrate a correlation between the size of the 
baseline whole-body volumetric parameters and PFS in these patients. 
 MTVWB TLAWB 
p-value [HR] 0.683 (1) 0.794 (1) 
Table 8-15: 18F-Fluoride PET; Whole-Body Analysis; Baseline Scan Volumetric Parameters; 
Cox regression PFS Analysis; All Patients 
The data has been dichotomised for KM analysis – see Tbl.8-22: 
 MTVWB TLAWB 
 Median PFS in days (95% CI) 
 
  
Cut-off 52.51 2148.66 
≤ (1) Not reached Not reached 
> (2) 117 (74.3-159.7) 141 (91.77-190.23) 
p-Value (Log Rank) 0.137 0.445 
Table 8-16: 18F-Fluoride PET; Whole-Body Analysis; Baseline Scan Volumetric Parameters; 
KM PFS Analysis; All Patients 
The KM analysis does not identify significant separation of the PFS curves.  Of the 4 patients with 
an MTVWB less than 52.5cm3 only one had progressed at the time of data analysis, suggesting a 
lower tumour burden at baseline is associated with a prolonged PFS; however, the log rank 
analysis of the curves is not significant, and the numbers are small.   
Analysis of the prostate cancer patients (Tbl.8-23) shows a significant separation of the PFS 
curves for MTVWB (p=0.048) shows a PFS advantage for patients with larger MTVWB 
measurements.  No significant separation is identified with TLAWB.  The per-lesion analysis did 
not identify an association between baseline MTV and PFS.  This might suggest the whole-body 
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quantification has unveiled prognostic information about these patients, not shown from individual 
lesion analysis; perhaps a larger burden of osteoblastic mediated prostate cancer bone 
metastases indicates a different disease biology with a slower progression trajectory.  With this 





 Median PFS in days (95% CI) 
 
  
Dichotomisation 108.56 4212.65 
≤ (1) 92 (60-124) 92 (60-124) 
> (2) 141 (95.9-186.1) 117 (77.8-156.2) 
p-Value (Log Rank) 0.048 0.400 
Table 8-17: 18F-Fluoride PET; Whole-Body Analysis; Baseline Scan Volumetric Parameters; 
KM PFS Analysis; Prostate patients only 
8.3.2.3 SUVWB Heterogeneity Parameters 
The Cox regression analysis below does not identify a significant correlation between the 
magnitude of the baseline SUVWB heterogeneity parameters and the PFS of these patients (Tbl.8-
24).  
 SUVentropyWB SUVenergyWB 
p-value [HR] 0.728 [0.794] 0.439 [79.315] 
Table 8-18: 18F-Fluoride PET; Whole-Body Analysis; Baseline Scan SUV Heterogeneity 
Parameters; KM PFS Analysis; All Patients 
The data has been dichotomised for KM analysis (Tbl.8-25).   
 SUVentropyWB SUVenergyWB 
 Median PFS in days (95% CI) 
 
  
Dichotomisation 2.12 0.0803 
≤ (1) 92 (59.99-124.01) 147 (101.18-192.82) 
> (2) 147 (0-300.12) 141 (15.25-266.75) 
p-Value (Log Rank) 0.037 0.842 
Table 8-19: Median PFS times from KM analysis with optimised dichotomisation; Whole-
Body Heterogeneity Parameters; 18F-Fluoride PET; Baseline Scan; WBCT Analysis; All 
Patients; VOI27 only. 
There is a significant separation of the PFS curves using SUVentropyWBVOI27 – patients with 
SUVentropyWBVOI27 greater than 2.12 have a median PFS benefit of 55 days (p=0.037).  Patients 
with more a more heterogeneous whole-body measurement have a better PFS.  This is not 
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maintained after analysis of only the prostate cancer patients (p=0.909); SUVentropy has not been 
shown to be an independent predictor of treatment response. 
There is no significant separation of the survival curves for SUVenergyWBVOI27 (p=0.842 for all 
patients, p-0.909 for prostate cancer patients only, KM analysis). 
8.3.2.4 KiWB 
n=11, 8 events 
 KiWB 
p-value [HR] 0.747 [3.168] 
Table 8-20: 18F-Fluoride PET; Whole-Body Analysis; Baseline Scan Ki; Cox regression PFS 
Analysis; All Patients 
Cox regression univariate analysis demonstrates no correlation between the KiWB and the risk of 
PD (Tbl.8-26). The data has been dichotomised for KM analysis (Tbl.8-27). 
 KiWB 




≤ Median (1) 141.00 (35.79-246.21) 
> Median (2) 110.00 (65.83-154.17) 
p-Value (Log Rank) 0.636 
Table 8-21: 18F-Fluoride PET; Whole-Body Analysis; Baseline Scan Ki; KM PFS Analysis; 
All Patients 
No significant separation of the PFS curves (p=0.636 for all patients, p=0.832 for prostate cancer 
patients only).  KiWB has shown no PFS prognostic utility. 
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8.3.3 %Δ Whole-Body Parameters - PFS Analysis 
11 patients had data suitable for analysis with the %Δ parameters, 5 breast and 6 prostate cancer 
patients.  8 patients had PD at the time of data analysis (2 breast cancer patients and all 6 prostate 
cancer patients. 
8.3.3.1 %ΔSUVWB Parameters 
Table 8-28 details the outcomes from Cox regression analyses.  There is no demonstrable 
correlation between the PFS and the size of change in the SUVWB parameters.   
 %Δ SUVmeanWB %Δ SUVmaxWB %Δ SUVpeakWB 
p-value [HR] 0.388 (0.985) 0.398 (0.986) 0.33 (0.984) 
Table 8-22: 18F-Fluoride PET; Whole-Body Analysis; %Δ SUV Parameters; Cox regression 
PFS Analysis; All Patients 
The data has been dichotomised for KM analysis.  There is no statistically significant separation 
of the PFS curves (Tbl.8-29). 
 %ΔSUVmeanWB %ΔSUVmaxWB %ΔSUVpeakWB 
 Median PFS in days (95% CI) 
 
   
Cut-off 20.20 0.139 2.837 
≤ (1) 141 (70.88-211.12) 117 (99.04-134.96) 117 (99.04-134.96) 
> (2) Not reached Not reached Not reached 
p-Value (Log 
Rank) 
0.364 0.227 0.227 
Table 8-23: 18F-Fluoride PET; Whole-Body Analysis; %Δ SUV Parameters; KM PFS 
Analysis; All Patients 
No statistically significant separation of the PFS curves has been identified using the %Δ SUV 
parameters.  The patients with higher positive changes in the SUV parameters were those with 
longer PFS. 
Table 8-30 documents KM analysis of the prostate patients only, showing a statistically significant 
separation of the PFS curves only with %ΔSUVmeanWB (p=0.025), with a 46-day median PFS 
benefit for patients with an increase in SUVmeanWB between scans.  This is not replicated with the 
other %Δ SUV parameters.  The per-lesion analysis did not demonstrate this association for the 
prostate cancer lesions.  An increase in SUV mean might suggest a flare response in patients, 
which could suggest a flare response.  There were too few prostate cancer patients to compare 
the %ΔSUVmeanWB between the response groups, but an increase in SUVmeanWB was suggested in 
the breast cancer patients with a treatment response, and there was a statistical trend of this 
association with per-lesion analysis. 
  








 Median PFS in days (95% CI) 
KM Plot 
   
Cut-off -7.50% -4.62% -7.91% 
≤ (1) 101 (54.6-147.4) 117 (45-189) 117 (45-189) 
> (2) 147 (137.4-156.6) 141 (77-205) 141 (77-205) 
p-Value  0.025 0.486 0.486 
Table 8-24: 18F-Fluoride PET; Whole-Body Analysis; %Δ SUV Parameters; KM PFS 
Analysis; Prostate patients only 
8.3.3.2 %Δ WB Volumetric Parameters 
Table 8-31 details the outcomes from Cox regression analyses.  There is no demonstrable 
statistically significant association between the size of change of the volumetric parameters and 
PFS.  
 %ΔMTVWB %ΔTLAWB 
p-value [HR] 0.607 (1.003) 0.947 (0.999) 
Table 8-25: 18F-Fluoride PET; Whole-Body Analysis; %Δ Volumetric Parameters; Cox 
regression PFS Analysis; All Patients 
The data has been dichotomised for KM analysis (Tbl.8-32).  There is no statistically significant 
separation of the PFS curves (%ΔMTVWB p=0.151, %ΔTLAWB p=0.304).  There is the suggestion 
of a PFS advantage for those patients with a smaller increase (<41%) and decrease in MTV 
between scans, and perhaps with a larger study group this might have been confirmed. 
 %ΔMTVWBVOI27 %ΔTLAWBVOI27 
 
  













Table 8-26: 18F-Fluoride PET; Whole-Body Analysis; %Δ Volumetric Parameters; KM PFS 
Analysis; All Patients 
The analysis for the prostate cancer patients is in Table 8-33 showing a trend towards a PFS 
benefit for patients with a smaller increase (or decrease) in MTVWB between scans (p=0.198), and 
a statistically significant 46-day median PFS benefit for the prostate patients with a smaller 
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increase (or decrease) in TLAWB between scans.  This is despite an increase in SUV between 
scans being associated with an improved PFS, and most likely reflects the impact of MTV on the 
calculation of TLA.  With this small sample group, however, this association would need to be 








Median +19.99% +51.23% 
≤ (1) 
[Days (95% CI)] 
141 (n/a) 147 (137.4-156.6) 
> (2) 
[Days (95% CI)] 
101 (56.9-145.1) 101 (54.6-147.4) 
p-Value (Log Rank) 0.198 0.025 
Table 8-27: 18F-Fluoride PET; Whole-Body Analysis; %Δ Volumetric Parameters; KM PFS 
Analysis; All Patients 
8.3.3.3 %ΔSUVWB Heterogeneity Parameters 
The Cox regression analysis of this data does not a significant correlation between PFS and the 
size of change of the heterogeneity parameters (Tbl.8-34). 
 %ΔSUVentropyWB %ΔSUVenergyWB 
p-value [HR] 0.566 [1.014] 0.829 [0.998] 
Table 8-28: 18F-Fluoride PET; Whole-Body Analysis; %Δ SUV Heterogeneity Parameters; 
Cox regression PFS Analysis; All Patients 
The data for has been dichotomised for KM analysis (Tbl.8-35).   
 %ΔSUVentropyWBVOI27 %ΔSUVenergyWBVOI27 
KM Plots 
  
Dichotomisation -1.86% +3.9% 
Low ≤ (1) 141 (112.2-169.8) 110 (n/a) 
High > (2) 110 (0-295.3) 141 (112.2-169.8) 
p-Value (Log Rank) 0.906 0.637 
Table 8-29: 18F-Fluoride PET; Whole-Body Analysis; %Δ SUV Heterogeneity Parameters; 
KM PFS Analysis; All Patients 
No significant separation of the PFS curves is identified with either parameter (%ΔSUVentropyWB 
p=0.906, %ΔSUVenergyWB p=0.637), and analysis of the prostate cancer patients only still identifies 
no PFS prognostic utility (p=0.486 and 0.441 respectively). 
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8.3.3.4 %ΔKiWB 
8 patients had data suitable for analysis (4 prostate, 4 breast).  6 patients had PD, all 4 prostate 
patients and 2 of the breast patients. 
The Cox regression analysis (Tbl.8-36) does not identify any correlation between the magnitude 
of %ΔKiWB and PFS in these patients. 
 %ΔKiWB 
p-value [HR] 0.183 [0.967] 
Table 8-30: Cox regression PFS Analysis; %Δ Whole-Body Ki; 18F-Fluoride PET; 
Percentage Change; WBCT Analysis; All Patients; all threshold methods. 
The data has been dichotomised for KM analysis (Tbl.8-37), but no statistically significant 





≤ Median (1) 
[Days (95% CI)] 
101.00 (0-246.04) 
> Median (2) 
[Days (95% CI)] 
110.00 (42.38-117.62) 
p-Value (Log Rank) 0.933 
Table 8-31: 18F-Fluoride PET; Whole-Body Analysis; %Δ Ki; KM PFS Analysis; All Patients 
Analysis of the prostate cancer patients (n=4) can be seen below (Tbl.8-38).  The prostate patients 
with an increase in KiWB between scans show a trend towards a significant PFS benefit (p=0.09), 








p-Value (Log Rank) 0.09 
Table 8-32: 18F-Fluoride PET; Whole-Body Analysis; %Δ Ki; KM PFS Analysis; Prostate 
patients only 






SUVmeanWB SUVmaxWB SUVpeakWB MTVWB TLAWB SUVentropyWB SUVenergyWB KiWB 
Tumour X X X X X X X X 
Response  X X X X X X X X 
↑PFS 
↑ P only 
p=0.025 
X X 
↓ P only 
p=0.198 






Table 8-33: 18F-Fluoride PET; Whole-Body Analysis; Summary Tables 
This study was designed to explore the potential predictive and prognostic utility from quantifying 
the whole-skeletal burden of 18F-Fluoride avid bone metastases.  Per-lesion analysis showed 
clinically significant information can be gleaned from the baseline parameters, and from 
parameter changes following treatment, but inter-lesion heterogeneity was evident.  The most 
clinically relevant lesion(s) for analysis is unclear; whole-body quantification perhaps results in 
parameters taking this heterogeneity into account, and this might have predictive and prognostic 
relevance.  Whole-body qualitative assessment of bone scans and PET imaging is routine in 
clinical practice; providing quantification parameters might standardise analysis, and demonstrate 
changes not identified visually. 
There is limited literature reporting similar approaches to whole-body 18F-Fluoride PET 
quantification.  When this study was conceived, I was only aware of one study exploring whole-
body quantification.  Abouzied et al. reported in a meeting abstract a study of 25 patients with 
varied malignancies, but confirmed bone metastases.  A Hounsfield unit threshold of 150 was 
used to segment the skeleton from the CT, and this was used as a mask to segment bone 
metastases from the 18F-FDG PET, segmenting with a 50% iso-contour 188.  They demonstrated 
feasibility of this approach, but they did not report clinical outcome analysis. 
More recently further data has been published addressing whole-body PET quantification, but 
primarily focusing on volumetric parameters.  Building on the knowledge of skeletal burden of 
metastatic disease predicting survival of prostate cancer patients 210, 18F-Fluoride PET imaging 
has been interrogated for the same purpose. 
Baseline 
Parameter 


















Response  X X X X X X X X 
↑PFS X X X 
All pts 
X 
↑ P only 
p=0.048 
X X X X 
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Etchebehere reported a study of 42 patients treated with Alpharadin; baseline tumour burden 
identified on 18F-Fluoride PET imaging was highly and significantly correlated with OS (HR 5.990, 
p=0.02)204.  Visual analysis, and whole-body SUVmean and SUVmax parameters were not predictive 
of OS or PFS, but the average SUV predicted for skeletal related events. 
Most recently, Lindgren Belal et al. have shown correlation between whole-skeletal metastatic 
burden metrics with comparable bone scan indices, and significant correlation with OS 205.  
Wassberg et al., in a study of repeatability of 18F-Fluoride PET for prostate cancer bone 
metastases, measured the whole-skeletal 18F-Fluoride avid metastatic burden, using a 50% iso-
contour, and calculated a parameter analogous to the TLA used in this thesis study.  They 
repeated the PET imaging within 8 days, and demonstrated reasonable repeatability coefficients 
for the whole-body parameters (23% for TLA parameter, 35% for skeletal volumetric burden), and 
reasonable performance of the per-lesion metrics of SUVmax and SUVmean (26% and 24%, 
respectively)211. 
To my knowledge this this is the first study examining the potential clinical utility of whole-body 
18F-Fluoride PET quantification for bone metastases using baseline and %Δ parameters. 
The potential clinical utility of 18F-Fluoride PET has been suggested in the per-lesion analyses of 
this thesis.  The per-lesion analysis demonstrated the different 18F-Fluoride avidity of breast and 
prostate cancer bone metastases; univariate analysis of the patients may be misleading, but the 
number of patients in this study has prevented meaningful tumour subgroup analyses.  There is, 
however, evidence of meaningful and clinically relevant image signal. 
Whole-skeletal quantification shows a trend for the prostate cancer metastases to have higher 
baseline SUV parameters than the breast patients, have a greater 18F-Fluoride avid bone 
metastasis burden (MTV), and have whole-body image heterogeneity tending away from 
homogeneity (higher SUVentropy and lower SUVenergy).  Prostate cancer metastases tend to display 
predominantly osteoblastic activity compared to the more mixed osteoblastic and osteoclastic 
qualities of breast cancer deposits.  This would account for this higher 18F-Fluoride avidity.  It is 
not clear what feature of the bone metastases is accounting for the differences in the 
heterogeneity parameters. 
The differences in SUV and volumetric parameters were also identified with the per-lesion 
analysis of these patients.  The whole-skeletal quantification technique is providing patient-
specific data discriminating features of the underlying bone pathology.  Unfortunately, this has not 
provided the ability to predict a treatment response using the baseline scans; no utility was 
identified with per-lesion analysis.  There may be no predictive information to be extracted from 
the baseline scans, but certainly the whole-skeletal quantification method has not yielded further 
discriminatory value. 
The per-lesion analysis of the change in the parameters between the scans suggested an 
association between an increased SUV and a sustained treatment response for the breast cancer 
lesions.  The whole-skeletal quantification has suggested this pattern, but this has not reached 
statistical significance (p=0.4 for SUVmeanWB).  The statistical benefit of the per-lesion analysis 
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enables significance to be concluded for smaller differences; further interrogation of the predictive 
value of the %Δ SUVWB parameters with a larger study group is indicated. 
No other %Δ parameter has suggested utility in these patients for predicting the clinical treatment 
response. 
An increase in SUVmeanWB between scans is associated with a 46-day median PFS benefit in these 
prostate cancer patients (p=0.025) suggesting a flare response of increased osteoblastic activity 
in healing bone.  This was not identified with the per-lesion or per-patient target-lesion analyses, 
and may suggest a benefit from quantification of the whole-skeleton metastatic burden.  Similarly, 
a trend towards a PFS benefit from a decrease in the MTV of prostate cancer patients (p=0.198), 
and the significant benefit from a decrease in TLA (p=0.025) was not identified with per-patient 
target-lesion analysis.  This may suggest prognostic benefit from the quantification of the whole-
skeletal metastatic burden. 
Segmentation of the skeletal PET data is readily achievable using freely available software.  The 
27% iso-contour was used to segment the skeletal uptake to select ‘malignant’ bone, but this may 
not be the most discriminatory method.  Certainly, for a per-lesion analysis an iso-contour is 
individualised for each lesion, but for a whole-body segmentation this is likely to be less specific 
for identifying malignancy.  A computational segmentation, such as FLAB, might be preferable, 
but such an approach for whole-body analysis is currently hindered by computational power.  The 
whole-body quantification is likely to be impacted by random image noise; individual voxels of 
higher uptake are not necessarily seen on qualitative assessment, but may alter the parameters.  
In this thesis, I wanted to include all segmented voxels, and applied a volumetric weighting to limit 
the impact of these small lesions.  An alternative method might be to exclude VOIs below a certain 
size.  Smaller VOIs, even if truly representing malignant bone, are more prone to partial volume 
effects and this may degrade the quantification.  The repeatability and reproducibility of these 
whole-body parameters has not been included in this thesis, but would be an essential step before 
expanding investigation of the clinical utility.  18F-Fluoride may not be the most clinically predictive 
or prognostic PET tracer; the same skeletal segmentation methodology has been used to analyse 
the initial patients recruited to the FAB-P and FAB-B studies, enabling whole-body skeletal 
quantification of 11C-Choline and 18F-FDG PET.  There were too few patients analysed for 
inclusion in this thesis, but the increased extra-skeletal physiological uptake of these tracers 
makes a methodology to segment just the skeletal PET data an attractive proposition. 
One key area of data yet to be fully analysed is generation of skeletal burden metrics; the CT 
skeletal mask can be analysed similarly to the PET scan to generate ‘whole-skeletal’ volumes 
against which the 18F-Fluoride avid volume could be compared.  Other groups have suggested 
prognostic utility of this approach, and this might provide validation of this whole-body analysis 
methodology. 
In summary, this exploratory study has demonstrated a readily applicable method for selecting 
only skeletal PET data for analysis, by applying a mask created from the CT component of the 
scan.  The predictive and prognostic utility of 18F-Fluoride PET scans suggested from per-lesion 
analysis has not been statistically confirmed using the whole-body parameters measured in this 
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study, but this has been impacted by the relatively small study population.  There is a strong 
suggestion of discriminatory signal being quantified using these whole-body parameters, and this 
certainly warrants further investigation as the trials approach full recruitment. 
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Chapter 9  DW-MRI Per-lesion Analysis – Response assessment 
using DW-MRI quantification parameters of patients with bone 
metastases from breast or prostate cancer 
The methods of this chapter and the statistical approaches for this section can be reviewed in 
Chapter 2.3.8.  
9.1 Tumour Groups 
92 lesions are included from 20 patients (BCa-5, PCa-15).  82 lesions (18 patients) had data for 
response analysis (BCa-22, PCa-60).  23 lesions were from patients with a treatment response 
(including stable disease) (BCa-12(55%), PCa-11(18%)).  59 lesions were from patients with PD 
(BCa-10(45%), PCa-49(82%)). 
9.2 Baseline Scan 
9.2.1 ADC Parameters 

























Figure 9-1: DW-MRI Per-lesion Analysis; Baseline ADC Parameters (ADCmean-left, 
ADCmedian-right); TOP – all lesions for all patients; BOTTOM – ADC distributions for all 
patients (ADC expressed as 10-3 mm2/s) (B - Breast cancer patients; P – Prostate cancer 
patients) 
Figure 9-1 shows the inter-lesion heterogeneity, both within and between patients.  Table 9-1 
summarises the parameter distributions for all lesions, including the sub-group analyses of tumour 
group and treatment response. 
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 ADCmean ADCmedian 
 
Mean (x10-3 mm2s-1) (95% CI) 
[min-max]  
{median; SD} |Skewness; Kurtosis| 
All lesions 
n=92, 20 patients 
1.16 (1.12-1.2)  
[0.71-1.69]  
{1.13; 0.19} |0.32; 0.47| 
1.08 (1.04-1.12)  
[0.67-1.62]  
{1.06; 0.19} |0.36; 0.02| 





1.27 (1.2-1.35)  
[1-1.69]  
{1.28; 0.17} |0.62; 0.1| 
1.19 (1.12-1.27)  
[0.95-1.62]  
{1.18; 0.18} |0.66; -0.04| 
Prostate cancer 
n=70 
1.12 (1.08-1.17)  
[0.71-1.61]  
{1.12; 0.18} |0.3; 0.68| 
1.05 (1.01-1.09)  
[0.67-1.51]  
{1.03; 0.18} |0.35; -0.02| 
Box Plots 
Tumour Groups  
 
  




1.16 (1.12-1.21)  
[0.71-1.61]  
{1.12; 0.18} |0.45; 0.02| 
1.09 (1.04-1.14)  
[0.67-1.51]  




1.2 (1.11-1.29)  
[0.75-1.69]  
{1.19; 0.21} |0.22; 1.21| 
1.11 (1.03-1.2)  
[0.74-1.62]  




p-value 0.363 0.601 
Table 9-1: DW-MRI Per-lesion Analysis; Baseline ADC Parameters; Descriptive statistics, 
comparison of tumour groups (Mann-Whitney U tests) and comparison of response 
groups (Mann-Whitney U tests) (ADC expressed as 10-3 mm2/s) 
ADCmean values are significantly larger than those of ADCmedian (paired samples t-test: where 
t(91)=10.837, p=4.6x10—18).  The actual difference in the median of the distribution is only 
0.08x10-3 mm2/s. 
Both ADC parameters are significantly lower for the prostate cancer lesions (independent 
samples t-tests: ADCmean, where t(90)=3.434, p=0.001; ADCmedian - t(90)=3.353, p=0.01).  This 
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suggests a difference in the underlying bone metastasis physiology between the tumour types.  
Prostate cancer metastases classically are more sclerotic than lytic, and breast cancer bone 
metastases have a more mixed reaction.  This lower ADCmean/median is likely to represent the 
increased sclerotic change within prostate cancer metastases. 
There is no demonstrable difference in the distribution of ADCmean or ADCmedian between the 
response groups (independent samples t-tests: p=0.363 and p=0.601 respectively).   
Tumour subgroup analysis demonstrates no difference in the distribution between the response 
groups for the prostate cancer patients (ADCmean/median p=0.871/0.782 respectively), or breast 
cancer patients (ADCmean/median p=1.00 /0.628 respectively). 
9.2.2 tDV  
 
Figure 9-2: DW-MRI Per-lesion Analysis; Baseline tDV (cm3); Left – all lesions for all patients; 
right – tDV distributions for all patients 
These whole-population plots (Fig.9-2) show a wide range of metastatic tumour volumes were 
identified.  Among the prostate cancer patients there were 3 significantly larger metastases 
included, larger than 200cm3.  The population statistics are recorded in tabular and graphic form 
on the next page (Tbl.9-2). 
Most lesions included were under 100cm3, but several outliers can be noted with much larger 
volumes; these were prostate cancer patients.  A statistically significant difference exists in the 
VOI volumes recorded from breast and prostate cancer metastases in this study (Mann-Whitney 
U test p=<0.0001).  The breast cancer lesions were relatively more consistent in size.   
These studies included breast and prostate cancer patients embarking on further lines of 
treatment; perhaps the prostate cancer patients had more significant disease burden at the time 
of inclusion in the study relative to the breast cancer patients.   
The lesions which subsequently were classified as being in patients with a treatment response 
had a statistically lower baseline tDV (Mann-Whitney U test, p=0.002).   
  
DW-MRI  Per-Lesion Analysis Response Analysis 
168 
 Baseline tDV 
 
Mean (cm3) (95% CI) 
[min-max]  
{median; SD} |Skewness; Kurtosis| 
All lesions 
n=92, 20 patients 
48.67 (35.71-61.62)  
[3.79-471.77]  




Breast cancer (B) 
n=22 
27.11 (13.59-40.63)  
[4.46-151.03]  
{20.08; 30.5} |3.47; 13.93| 
Prostate cancer (P) 
n=70 
55.44 (39.12-71.76)  
[3.79-471.77]  














29.42 (16.58-42.26)  
[4.46-150.11]  





Table 9-2: DW-MRI Per-lesion Analysis; Baseline tDV; Descriptive statistics, comparison 
of tumour groups (Mann-Whitney U tests) and comparison of response groups (Mann-
Whitney U tests)  
The ROC analysis (Fig.9-3) for prediction of progression demonstrates an AUC of 0.726 
(p=0.002) suggesting baseline tDV is an accurate predictor of PD. 
DW-MRI  Per-Lesion Analysis Response Analysis 
169 
 
AUC 0.726, p=0.002 
Figure 9-3: DW-MRI Per-lesion Analysis; ROC curve for prediction of 24-week response 
sub-group with baseline tDV; all patients 
tDV predicts for progression in these patients with a sensitivity of 81% and specificity of 61% (for 
lesions greater than 23.76cm3)(p=0.002).  The prostate cancer lesions were larger than the breast 
lesions, and tDV may not be independent of the tumour group. 
There is no statistically significant difference in tDV between the response groups for the prostate 
cancer patients (Mann-Whitney U test: p=0.178).  However, the box-plot (Fig.9-4) of the prostate 





Figure 9-4: DW-MRI Per-lesion Analysis; ROC curve for prediction of 24-week response 
sub-group with baseline tDV; prostate patients only 
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Figure 9-5: DW-MRI Per-lesion Analysis; Baseline ADC Heterogeneity Parameters 
(ADCentropy-left, ADCenergy-right); TOP – all lesions for all patients; BOTTOM – ADC 
distributions for all patients (ADC expressed as 10-3 mm2/s) 
The population data is recorded in Table 9-3.  Figure 9-5 demonstrates the inter-lesion 
heterogeneity and the differences between the patients. 
No difference in the ADCentropy distributions is shown between the tumour subgroups (independent 
samples t-test: where t(90)=0.768, p=0.445).  The prostate lesions showed a trend towards a 
higher ADCenergy (Mann-Whitney U test: p=0.067) than the breast metastases.   
The prostate lesion data had several outliers, all with higher ADCenergy measurements.  This, 
suggests the prostate cancer lesions were generally more uniform (with a higher ADCenergy) than 
the breast cancer lesions.  This may be reflecting the differing physiologies of the bone 
metastases; breast cancers tend to have bone lesions with a mix of osteolytic and osteoblastic 
changes, whereas prostate bone metastases tend to be much more osteoblastic, perhaps 
causing more ADC voxel distribution uniformity. 
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 Baseline ADCentropy Baseline ADCenergy 
 
Mean (95% CI) 
[min-max]  
{median; SD} |Skewness; Kurtosis| 
All lesions 
n=92, 20 patients 
5.32 (5.27-5.37) 
[4.62-5.84] 
{5.3; 0.25} |-0.24; 0.03| 
0.0085 (0.0065-0.0104) 
[0.0037-0.0809] 








{5.42; 0.26} |-0.15; -1.32| 
0.0061 (0.0053-0.0069) 
[0.0038-0.0097] 
{0.0056; 0.0018} |0.3774; -1.1955| 




{5.29; 0.24} |-0.32; 0.58| 
0.0092 (0.0066-0.0118) 
[0.0037-0.0809] 










{5.34; 0.24} |-0.05; -0.49| 
0.0078 (0.0062-0.0094) 
[0.0037-0.0411] 






{5.28; 0.25} |-0.2; -0.43| 
0.0078 (0.0052-0.0103) 
[0.0038-0.0344] 




p-value 0.141 0.971 
Table 9-3: DW-MRI Per-lesion Analysis; Baseline ADC Heterogeneity Parameters; 
Descriptive statistics, comparison of tumour groups (Mann-Whitney U tests) and 
comparison of response groups (Mann-Whitney U tests) 
Patients with a treatment response had a lower baseline ADCentropy, but similar ADCenergy 
compared to those in patients with PD, but these differences are not statistically significant 
difference (ADCentropy tested with independent samples t-test, where t(80)=1.486, p=0.141; 
ADCenergy tested with a non-parametric Mann Whitney U test, p=0.971).  The tumour sub-group 
analyses can be reviewed in Figure 9-6 (data not included for brevity). 
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No response: 5.47 (5.31-5.64) 
Response 5.25 (5.09-5.41) 
p=0.059 
Mean (95%CI) 
No response: 0.0053 (0.0042-0.0064) 
Response 0.0067 (0.0056-0.0079) 
Figure 9-6: DW-MRI Per-lesion Analysis; Baseline Scan ADC Heterogeneity Parameters; 
Response Assessment; Tumour groups separately (comparison with Mann-Whitney U 
tests). 
A lower baseline ADCentropy and higher ADCenergy (a more homogeneous picture) how a statistical 
trend for prediction of a treatment response (p=0.069 and 0.059 respectively). 
9.2.4 Baseline Parameters Correlations 
Table 9-4 summarises pairwise correlation analysis between the baseline scan parameters 
(analysed using Spearman Rank correlation tests). 
 ADCmean ADCmedian tDV ADCentropy ADCenergy 
ADCmean 1 - - - - 
ADCmedian 0.93 
(<0.001) 






















Table 9-4: DW-MRI Per-lesion Analysis; Baseline Parameters; Correlations (and p-values) 
using Spearman Rank analysis; All lesions 
A strong correlation is identified between ADCmean and ADCmedian, as would be anticipated as they 
are describing the average of the same VOIs.  There is no correlation between tDV and the other 
parameters.  There is a only a weak positive correlation between ADCentropy and the ADC 
parameters, and a weak negative correlation between ADCenergy and the ADC parameters.  The 
ADC heterogeneity parameters have a close negative correlation (correlation coefficient -0.78, 
p<0.001).   
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9.3 Second Scan 
 
Mean (x10-3 mm2s-1) (95% CI) 
[min-max]  




1.21 (1.16-1.27)  
[0.65-2.44]  










50.68 (37.66-63.69)  
[3.09-388.51]  
{35.75; 61.05} |3.57; 14.62| 
 
ADCentropy 
5.3 (5.25-5.35)  
[4.31-5.72]  
{5.31; 0.24} |-1.08; 3.01| 
 
ADCenergy 
0.0104 (0.0065-0.0143)  
[0.0038-0.1191]  
{0.0064; 0.0183} |5.2485; 28.4132| 
 
Table 9-5: DW-MRI Per-lesion Analysis; Second Scan ADC Parameters; Descriptive 
statistics (ADC expressed as 10-3 mm2/s) 
DW-MRI  Per-Lesion Analysis Response Analysis 
174 
9.4 % Change Between Scans 
9.4.1 %ΔADC Parameters 

























Figure 9-7: DW-MRI Per-lesion Analysis; %ΔADC Parameters (%ΔADCmean-left, 
%ΔADCmedian-right); TOP – all lesions for all patients; BOTTOM – ADC distributions for all 
patients 
A wide range of percentage changes in the ADC parameters can be seen (Fig.9-7).  Inter-lesion 
heterogeneity within individual patients is evident; within a single patient some lesions have an 
increased ADC, and others a decrease, suggesting a differential treatment effect.  The population 
statistics are recorded in Table 9-6. 
There is no demonstrable statistical difference in the distributions of the %Δ ADC parameters 
between the tumour groups (Mann Whitney U tests: %ΔADCmean p=0.838; %ΔADCmedian, 
p=0.598).   
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 %ΔADCmean %ΔADCmedian 
 
% change (95% CI) 
[min-max]  






{5.47; 19.12} |0.79; 3.46| 
7.24 (2.4-12.07) 
[-52.63-115.74] 









{3.97; 26.5} |1.27; 3.08| 
13.29 (-1.38-27.96) 
[-40.97-115.74] 






{5.81; 15.98} |-0.33; -0.08| 
5.19 (0.79-9.59) 
[-52.63-45.42] 













{4.16; 15.82} |-0.11; 0.26| 
3.73 (-0.97-8.43) 
[-52.63-45.42] 







{11.18; 24.74} |0.85; 3.45| 
18.27 (5.23-31.31) 
[-40.97-115.74] 





p-value 0.018 0.024 
Table 9-6: DW-MRI Per-lesion Analysis; %Δ ADC Parameters; Descriptive statistics, 
comparison of tumour groups (Mann-Whitney U tests) and comparison of response 
groups (Mann-Whitney U tests) 
There has been a more positive change in ADC parameters between scans in the lesions from 
patients with a treatment response.  These differences are statistically significant (%ΔADCmean 
data compared with an independent samples t-test: t(80)=-2.415, p=0.018; %ΔADCmedian data 
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compared with an independent samples Mann Whitney U test: p=0.024).  Tumour subgroup 
analysis can be seen in Figure 9-8. 










 p=0.283 p=0.159 
Figure 9-8: DW-MRI Per-lesion Analysis; %ΔADC Parameters; Response Assessment; 
Tumour groups separately  
All the box-plots suggest higher ADCs in the response group, but only with ADCmean for the 
prostate cancer lesions is statistical significant met (p=0.029). 
ROC analysis shows a treatment response can be predicted for the prostate cancer lesions with 
a sensitivity of 81.8% and specificity of 67.3% with an increase in ADCmean >8.53% between scans 
(p=0.029) (Fig.9-9). 










Figure 9-9: DW-MRI Per-lesion Analysis; %ΔΔADC Parameters; ROC analysis for 
predicting a treatment response; Prostate cancer lesions only  
The individual lesion data can be used to construct waterfall plots (Figure 9-10).  Despite the clear 
and demonstrable difference at a population level, the individual lesion data is more complex with 
a heterogeneous response.  There are lesions showing a decrease in patients with a treatment 
response, and lesions showing less restriction in patients who have clinically PD. 




Figure 9-10: DW-MRI Per-lesion Analysis; Waterfall plots for %ΔADC Parameters; 
Response analysis 
9.4.2 %Δ tDV 
%Δ tDV - All lesions %Δ tDV – All patients 
  
Figure 9-11: DW-MRI Per-lesion Analysis; %ΔtDV 
The second scan tDV whole-population statistics suggested there was little difference with 
baseline imaging (there was no demonstrable statistical significance).  Figure 9-11 shows the 
population analysis masked the underlying individual per-lesion changes.  There is significant 
inter-lesion heterogeneity of response between lesions within the same patient; some lesions 
were larger on the second scan and others smaller.  These changes will be compared with clinical 
response in a later section.  The population statistics for %ΔtDV are recorded in Table 9-7. 
On a study population level, there is no demonstrable difference in the %ΔtDV between the 
prostate cancer and breast cancer metastases (Mann Whitney U test: p=0.639). 
There is no statistically significant difference in the distribution of %ΔtDV between the response 






















































Mean (95% CI) 
[min-max]  
{median; SD} |Skewness; Kurtosis| 
All lesions 
n=82, 19 patients 
11.7 (0.09-23.32) 
[-87.06-243.99] 








{-3.87; 54.65} |0.98; -0.13| 

























Table 9-7: DW-MRI Per-lesion Analysis; %Δ tDV; Descriptive statistics, comparison of 
tumour groups (Mann-Whitney U tests) and comparison of response groups (Mann-
Whitney U tests) (ADC expressed as 10-3 mm2/s) 
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Figure 9-12: DW-MRI Per-lesion Analysis; Response Analysis using %ΔtDV; Tumour 
subgroup analyses (comparison with Mann-Whitney U tests) 
Although the distribution of %Δ tDV between the response groups does not reach statistical 
significance for either tumour subgroup, it is striking to identify an increase in tDV in patients with 
a clinical response.  This is an unexpected finding.  Similarly, there are lesions with a decrease 
in tDV from patients who overall had no treatment response.  There is considerable inter-lesion 
heterogeneity of response.  This heterogeneity in response using this parameter can be more 
clearly seen with a waterfall plot (Fig.9-13).  There were some significant increases in measured 
tDV in both response groups, with some measured lesions doubling in size. 
There may indeed be a truly heterogeneous response within patients with some lesions increasing 
in size and others decreasing.  The clinical response assessment considers other clinical and 
radiological parameters (as per the PCWG2 guidelines), and the individual lesion changes may 
not impact the clinical response assessment i.e. they are not clinically dominant lesions.  
Alternatively, the tDV may not be measuring the true tumour volume.  DW-MRI is assessing the 
water diffusion of the tumour cells but also the bone stroma in which the tumour deposits are 
growing.  Sclerosis causes restricted diffusion, and sclerosis is a known treatment response of 
healing bone metastases.  The tDV is defined by the area of image restriction, and perhaps the 
peri-tumour bone undergoing sclerosis results in a larger defined tDV.  It is not possible to 
separate the DW-MRI signal from tumour and bone stroma.  
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Figure 9-13: DW-MRI Per-lesion Analysis; Waterfall plot for %ΔtDV Parameters; Response 
analysis 
9.4.3 %Δ ADC Heterogeneity Parameters 

























Figure 9-14: DW-MRI Per-lesion Analysis; %ΔADC Parameters (%ΔADCmean-left, 
%ΔADCmedian-right) 
Like the other parameters discussed so far, the comparison of population statistics between 
baseline and second imaging did not show significant changes, but lesion based analysis shows 
a wide range of change in the ADC heterogeneity parameters, with inter-lesion variation between 
patients, and again within patients (Fig.9-14).  There are contradictory changes in parameter 
within individual patients, with measured values increasing in some lesion and decreasing in 
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 %ΔADCentropy %ΔADCenergy 
 
% change (95% CI) 
[min-max]  






{-0.22; 5.37} |0.03; 1.87| 
24.95 (0.6-49.29) 
[-90.47-797.16] 









{-0.84; 5.45} |0.08; -0.87| 
13.6 (-10.28-37.49) 
[-40.75-197.7] 






{0.01; 5.37} |0.01; 2.91| 
28.78 (-3.06-60.63) 
[-90.47-797.16] 













{0.02; 4.91} |-1.02; 1.4| 
30.46 (-3.87-64.78) 
[-65.89-797.16] 







{-0.22; 6.45} |0.96; 1.29| 
17.44 (-11.5-46.38) 
[-87.32-197.7] 





p-value 0.631 0.617 
Table 9-8: DW-MRI Per-lesion Analysis; %Δ ADC Heterogeneity Parameters; Descriptive 
statistics, comparison of tumour groups (Mann-Whitney U tests) and comparison of 
response groups (Mann-Whitney U tests) (ADC expressed as 10-3 mm2/s) 
At a whole-population level, there is no demonstrably statistically significant difference between 
tumour groups of the distribution of %ΔADCentropy (Mann Whitney U test, p=0.703) or %ΔADCenergy 
(p=0.675).   
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There is no clear observable pattern in the distributions of the %ΔADC heterogeneity parameters 
between the two response groups (Mann-Whitney U tests: %ΔADCentropy p=0.631; %ΔADCenergy 
p=0.617). 
Tumour subgroup analysis can be seen below (Fig.9-15): 










 p=0.159 p=0.381 
Figure 9-15: DW-MRI Per-lesion Analysis; %ΔADC Heterogeneity Parameters; Response 
Assessment; Tumour groups separately  
There is no statistically significant difference identified using either %ΔADC heterogeneity 
parameter between the response groups, but there is perhaps a trend towards significance for 
%ΔADCenergy for the prostate cancer lesions (p=0.091) with the responding lesions tending 
towards a larger increase in ADCenergy, i.e. a move towards uniformity of the ADC voxel 
distributions within the VOIs. 
As with the other parameters examined, there is considerable variation in how the ADC 
heterogeneity parameters responded to treatment in these target lesions.  The waterfall plots 
(Fig.9-16) display the individual lesion changes separated into the 24-week response assessment 
groups. 
  




Figure 9-16: DW-MRI Per-lesion Analysis; Waterfall plots for %ΔADC Heterogeneity 
Parameters; Response analysis 
9.4.4 %Change Parameters Correlations 
Table 9-9 summarises pairwise correlation analysis between the %Δ parameters (analysed using 
Spearman Rank correlation tests). 
 %ΔADCmean %ΔADCmedian %ΔtDV %ΔADCentropy %ΔADCenergy 
%ΔADCmean 1  - - - - 
%ΔADCmedian 0.95  
(<0.001) 
1 - - - 
%ΔtDV 0.19  
(0.075) 
0.14  
(0.2088) 1 - - 
















Table 9-9: DW-MRI Per-lesion Analysis; Baseline Parameters; Correlations (and p-values) 
using Spearman Rank analysis; All lesions 
A strong correlation is identified between %ΔADCmean and %ΔADCmedian parameters, as would be 
anticipated as they are describing the average of the same VOIs.  There is no correlation between 
%ΔtDV and the other parameters.  There is only a weak but significant positive correlation 
between %ΔADCentropy and the %ΔADC parameters, and a weak but significant negative 
correlation between %ΔADCenergy and the %ΔADC parameters.  The %ΔADC heterogeneity 





























































































































Table 9-10: DW-MRI Per-lesion Analysis; All Response Analyses; Summary Table 
Inter-lesion heterogeneity has been identified at the per-lesion level, irrespective of the 
quantification factor measured.  Within individual patients there are bone metastases with notably 
different measurements, and the %Δ parameters following treatment do not provide a consistent 
direction or magnitude of response in individual patients.  Inter-lesion heterogeneity and 
inconsistency of changes with treatment within individual patients has been described in bone 
metastases assessed with DW-MRI152. 
This inter-lesion heterogeneity within patients is clearly seen with the baseline ADC data.  Despite 
the heterogeneity, patterns can be demonstrated.  Prostate cancer lesions demonstrate more 
diffusion restriction at baseline (ADCmean Breast 1.27 (+/-0.04), Prostate 1.12 (+/- 0.04), p=0.001, 
ADCmedian Breast 1.19 (+/-0.07), Prostate 1.05 (+/-0.04), p=0.01).  This probably reflects the 
difference in the physiology of the bone metastases; although all bone metastases cause both 
lytic and sclerotic changes within the bone, prostate cancer metastases generally result in a 
significantly osteoblastic sclerotic response whereas breast cancer can be more variable.  
Sclerotic bone can result in more restriction of water diffusion, measured as a lower ADC164,212.  
Tumours cause restriction of water diffusion because of higher cell density and tumour tissue 
disorganisation. However, imaging bone metastases includes measurement of the tumour as well 
as the changes within the surrounding bone. 
None of the baseline parameters predicted for the 24-week reference standard treatment 
response.  There is no evidence in the literature to suggest ADC measurements predict the 
ultimate clinical treatment response of bone metastases.  An increasing body of evidence 
suggests a lower pre-treatment ADC in tumour tissue (not necessarily bone metastases) is 
associated with an increased response rate145,213-219.  The correlation of ADC with the underlying 
histology is more complicated.  A lower ADC of primary prostate cancer correlates with a higher 
Gleason grade, indicating a more aggressive and proliferative histology220, and there is an 
association between the Gleason Grade and PFS221.  Others have demonstrated no difference in 
the baseline ADC measurements of bone metastases from prostate cancer between responders 
and non-responders152. 
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There is evidence suggesting the prognostic value of the volume of osseous disease in prostate 
cancer222,223, but there is no evidence showing utility for predicting a treatment response. This 
study has found no association either. 
There is more evidence in the literature of the possible utility of baseline ADC heterogeneity 
parameters.  There is a correlation between heterogeneity and the prostate cancer Gleason 
Grade (increase in Gleason grade is associated with a higher ADCentropy and lower 
ADCenergy172,176,177,224 – this suggests the more aggressive tumours (higher Gleason grade) have 
a more heterogeneous ADC voxel distribution.  This might translate into a predictor of treatment 
response.  In this study the ADC heterogeneity parameters have only suggested utility for 
predicting the treatment response for the breast cancer metastases.  A treatment response was 
more likely for patients with a lower ADCentropy and higher ADCenergy (i.e. more homogeneous ADC 
voxel distributions); this finding was approaching statistical significance for ADCenergy (p=0.067). 
Interpreting the literature is complicated by significant variations in the definition of a treatment 
response and the timing of the response assessment.  Most studies use the RECIST criteria for 
determining a treatment response in a soft tissue tumour citing a partial response with at least a 
30% reduction in the tumour volume215,216,219,225, including a study of bone metastases, where soft 
tissue response as assessed with the RECIST criteria was used as a surrogate marker of 
treatment response152.  This study, by Messiou et al., is most comparable to the analyses in this 
thesis, with MRI repeated at 12 weeks after initiation of chemotherapy for bone-predominant 
metastatic prostate cancer; 26 men were analysed, but there was no demonstrable difference in 
the ADC of the bone lesions before therapy when the group was dichotomised into the 12-week 
response group152.  Treatment related changes in ADC quantification occur before any significant 
tumour volumetric change.  An early response may not translate into a clinically relevant sustained 
response for the patient; identifying a gold-standard for response definition is difficult, particularly 
for bone metastases not amenable to size assessment.  
This data shows a larger increase in the ADC parameters between scans predicts for a treatment 
response.  Subgroup analysis suggests this relationship exists for both tumour types, but the 
differences only reach statistical significance for the prostate cancer lesions and with %ΔADCmean 
(p=0.029).  
A treatment response associated with a rise in measured ADC has been reported by several other 
groups in non-bone and non-prostate cancers142,143,215,217-219,226-228; an increase in ADC appears 
to be prognostic.  This has also been demonstrated in malignancies involving the 
skeleton58,148,157,229-231, and specifically prostate cancer bone metastases151-153,232,233.  This finding 
in this study could therefore be anticipated.  However, there do appear to be differences in both 
the measurements, and how the parameters change with treatment, depending on the tumour 
type and the specific pathophysiological processes within the peri-tumour bone environment. 
Graham et al. (2014) examined a preclinical model of prostate cancer bone metastases, 
assessing the ADC changes following treatment with Cabozantinib.  They also showed an 
increase in ADC is associated with a treatment response, attributing this change with increased 
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necrosis232.  Increased necrosis and a corresponding rise in measured ADC has been 
demonstrated histologically in osteogenic sarcomas148. 
The inter-lesion heterogeneity of change in ADC parameters in individual patients is significant, 
not only with magnitude of parameter change, but also direction of change.  This heterogeneous 
response was reported by Messiou et al., 2011 in their study of prostate cancer bone metastases, 
and is therefore directly relatable to this current study.  This group attributed the heterogeneous 
response to varying effects of treatment on the composition of the bone marrow152 – a different 
impact will result depending on the haematopoietic cell composition within the bone being 
quantified.  Bone marrow is composed of fat cells and, in varying proportions, haematopoietically 
active marrow which contains more water than the adjacent less active marrow and the fat cells, 
and thus demonstrates more free movement of water and a higher ADC.  An increase in 
haematopoietic cells has been shown to result in a corresponding decrease in the more diffusion 
restricting fat cells, and vice versa152.  With PD the measured bone ADC may counterintuitively 
increase after replacement of tumour cells with normal fatty marrow; progression of an osteolytic 
component of disease will result in a higher measured ADC; the healing sclerotic reaction of a 
treatment response in bone can result in a fall in ADC152.  Reishauer et al. also noted a 
heterogeneous response, and identified areas of ADC fall within ‘responding’ tumours with 
repeated imaging, suggesting an effect of post-treatment fibrosis, or repopulation of the tumour 
area by fatty tissue and/or red marrow, or indeed could represent areas of sclerosis suggesting 
healing bone153.  An ADC response is subject to numerous conflicting variables, and this perhaps 
explains the heterogeneous changes seen in these patients. 
Assessment of bone metastases is significantly complicated by the unavoidable influence of the 
peri-tumour bone architecture, the function of which is constantly impacted by the tumour, by the 
therapy, and by subsequent healing or damage. 
The %Δ tDV in these patients has not demonstrated any utility for predicting treatment response.  
There is significant intra-patient heterogeneity of %ΔtDV.  An increase in tDV of bone metastases 
from breast and prostate cancer is associated with non-response of the disease154, although these 
changes in tDV were measured after an interval of 12-38 weeks (mean of 22 weeks).  The 8-12-
week interval between scans in this study might be too short to identify significant changes in the 
tDV.  Many studies showing prognostic utility of DW-MRI have defined response by reduction in 
the size of soft tissue malignancies  With this analysis of DW-MRI perhaps tumour and abnormal 
peri-tumour bone is included in the quantification, complicating quantification analysis.  
The %Δ ADC Heterogeneity parameters have not demonstrated a prognostic utility in this study, 
for either tumour group, but the now familiar inter-lesion heterogeneity in individual patients is 
clearly demonstrated. 
In summary, per-lesion analysis has clearly shown intra-patient inter-lesion heterogeneity, and 
the parameters from prostate cancer metastases are different from breast cancer; the sclerosis 
of prostate cancer bone metastases probably results in a lower ADC.  A larger increase in ADC 
between scans, measured at 8-12 weeks, predicts the 24-week treatment response.  
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Chapter 10  DW-MRI Per-lesion Analysis - Survival assessment 
using DW-MRI quantification parameters of patients with bone 
metastases from breast or prostate cancer 
The methods of this chapter and the statistical approaches for this section can be reviewed in 
Chapter 2.3.9. 
10.1 Lesion Based Analysis – OS Analysis 
10.1.1 Tumour Analysis 
 
Figure 10-1: DW-MRI Per-lesion Analysis; KM OS Analysis; Tumour Groups  
The breast cancer patients in this study had a significantly better OS than the prostate cancer 
patients – none of the breast cancer patient had died at the time of data analysis, but 5 of the 
prostate cancer patients had (log rank p=0.002, Fig.10-1)). 
10.1.2 Baseline Scan  
10.1.2.1 ADC Parameters  
 ADCmean ADCmedian 
 








Table 10-1: DW-MRI Per-lesion Analysis; Baseline ADC Parameters; OS Cox regression 
analysis 
Cox regression analysis (Tbl.10-1) does not demonstrate correlation between the ADCmean/median 
with the length of OS.  The data can also be examined with KM analysis - these plots are displayed 
in Figure 10-2. 
Lesions with a baseline ADCmean greater than 1.197 or ADCmedian greater than 1.14 have a 
statistically longer OS than those with lower values.  
The baseline ADC parameters did not show utility in predicting the response for these patients, 
and an OS benefit was not anticipated.  The baseline ADC parameters were significantly higher 
for the breast cancer patients, and this survival benefit could simply be selection of the lesions 
from breast cancer patients.  KM analysis of the prostate patients confirms this statistically; a 
lower baseline ADC predicts for a longer OS (ADCmean p=0.047; ADCmedian p=0.005) (Fig.10-3).  
Baseline ADC parameters predict OS for prostate cancer lesions.  Sclerosis in bone results in 
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Dichotomised at 1.1966 
Low (≤) – Blue 
High (>) - Green 
Dichotomised at 1.138 
Low (≤) – Blue 
High (>) - Green 
p=0.03 p=0.054 







Dichotomised at 1.073 
Low (≤) – Blue 
High (>) - Green 
Dichotomised at 0.913 
Low (≤) – Blue 
High (>) - Green 
p=0.047 p=0.005 
Figure 10-3: DW-MRI Per-lesion Analysis; KM OS analysis; baseline ADC parameters; 










Table 10-2: DW-MRI Per-lesion Analysis; Baseline tDV; OS Cox regression analysis 
Cox regression analysis (Tbl.10-2) of the baseline tDV data does not demonstrate a significant 
correlation between tDV and OS.  There is a statistically significant separation of the two KM 
survival curves (Fig.10-4) (Log rank, p=0.044).  Patients with smaller lesions at baseline had a 
significantly better OS. 
  




Dichotomised at 33.5 (median) 
Low (≤) – Blue 
High (>) - Green 
p=0.044 
Figure 10-4: DW-MRI Per-lesion Analysis; KM OS Analysis; baseline tDV; All Patients 
However, the baseline tDV discriminated between the breast and prostate cancer lesions; 
prostate lesions were larger, and the prostate patients had a shorter OS.  KM analysis with only 
the prostate cancer patients does not identify utility of baseline tDV for predicting OS 
(dichotomisation at 31.92cm3, p=0.354).  Analysis of just the breast cancer patients is not feasible 
as there were no deaths. 
Therefore, tDV has not been shown to be an independent predictor of OS. 
10.1.2.3 Heterogeneity Parameters 
 ADCentropy ADCenergy 
 








Table 10-3: DW-MRI Per-lesion Analysis; Baseline ADC Heterogeneity Parameters; OS Cox 
regression analysis 
Cox regression analysis (Tbl.10-3) does not indicate a significant association between the 
baseline ADC heterogeneity parameters and the OS.  KM analysis produces the survival curves 




Dichotomised at 5.3 
Low (≤) – Blue 
High (>) - Green 
Dichotomised at 0.007 
Low (≤) – Blue 
High (>) - Green 
p=0.501 p=0.401 
Figure 10-5: DW-MRI Per-lesion Analysis; KM OS Analysis; baseline ADC heterogeneity 
parameters; All patients 
Analysing both tumour groups together is perhaps misleading because the prostate cancer 
patients had a slightly higher baseline ADCenergy than the breast cancer patients (p=0.067).  KM 
analysis of the prostate cancer lesions only demonstrates a statistically significant separation of 
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the OS curves for ADCenergy, with a survival advantage noted (p=0.019) for patients with a higher 
measurement (i.e. more uniform ADC distribution within the VOIs) (Fig.10-6).  No association 






Dichotomised at 5.24 
Low (≤) – Blue 
High (>) - Green 
Dichotomised at 0.00643 
Low (≤) – Blue 
High (>) - Green 
p=0.214 p=0.019 
Figure 10-6: DW-MRI Per-lesion Analysis; KM OS Analysis; baseline ADC heterogeneity 
parameters; Prostate patients only 
10.1.3 %Δ Parameters OS Analysis 
10.1.3.1 %ΔADC Parameters  
 %ΔADCmean %ΔADCmedian 
 








Table 10-4: DW-MRI Per-lesion Analysis; %ΔADC Parameters; OS Cox regression analysis 
There is no correlation between %ΔADCmean or %ΔADCmedian and OS (Tbl.10-4).   
KM analysis of the data shows statistically significant separation of the %ΔADCmean curves 
(p=0.037), and for %ΔADCmedian (p=0.007), showing a survival advantage for lesions with a 
decrease (or lower increase) in ADC between the scans (Fig.10-7).   
%ΔADCmean %ΔADCmedian 
  
Dichotomised at +5.94% 
Low (≤) – Blue 
High (>) - Green 
Dichotomised at +4.79% 
Low (≤) – Blue 
High (>) - Green 
p=0.037 p=0.007 
Figure 10-7: DW-MRI Per-lesion Analysis; KM OS Analysis; %ΔADC parameters; all lesions 
The ADC parameters are difficult to interpret.  For the prostate cancer lesions, a lower ADC at 
baseline was indicative of a longer OS.  The breast cancer lesions had on average a higher 
baseline ADC and at the time of data analysis none of the breast patients had died.  Inclusion of 
the breast lesions for baseline KM analysis showed the clear OS advantage of the breast patients, 
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and thus it seemed a higher ADC was prognostic.  However, by the second scan, a lower ADC 
was associated with an OS advantage for all the lesions (data not included), suggesting the higher 
ADC of the breast lesions had decreased.  A decrease in ADC would be expected to be 
associated with an OS benefit, as shown in this analysis.  
The breast lesions are contributing to the separation of the KM OS curves.  Separation is still 
demonstrated when analysing just the prostate cancer lesions (Figure 10-8), reaching statistical 
significance for %ΔADCmedian (p=0.015), but not quite with %Δ ADCmean (p=0.006) %ΔADCmedian 
is more discriminating for these lesions. 







Dichotomised at +5.94% 
Low (≤) – Blue 
High (>) - Green 
Dichotomised at +7.51% 
Low (≤) – Blue 
High (>) - Green 
p=0.06 p=0.015 
Figure 10-8: DW-MRI Per-lesion Analysis; KM OS Analysis; %ΔADC parameters; Prostate 
lesions only 
For the prostate cancer patients at least, an increase in ADC confers a poorer OS.  It is unclear 
what change in the bone architecture the ADC is most affected by, but it might be sclerosis is a 
significant contributing factor; an increase in sclerosis may cause further restriction and a fall in 
ADC between scans, but may suggest a treatment response and osteoblastic reaction resulting 
in a prolonged OS.  OS analysis of just the breast cancer lesions is not possible as all the patients 
were alive at the time of data analysis. 
10.1.3.2 %ΔtDV  
 %ΔtDV 
 






Table 10-5: DW-MRI Per-lesion Analysis; %ΔADC Heterogeneity Parameters; OS Cox 
regression analysis 
There is no demonstrable correlation in these patients between the change in size of the lesions 
(%ΔtDV) and the OS when analysed by Cox regression (Tbl.10-5).  Using KM analysis there is 
no demonstrable association for these lesions between the change in size of the lesions between 
scans and the OS (Fig.10-9). 
  




Dichotomised at 0 
Low (≤) – Blue 
High (>) - Green 
p=0.514 
Figure 10-9: DW-MRI Per-lesion Analysis; KM OS Analysis; %ΔtDV  
OS analysis of just the prostate cancer lesions also demonstrates no significant separation of the 
KM survival curves (p=0.817) concluding for these patients the %Δ tDV has no OS predictive 
utility. 
10.1.3.3 %ΔADC Heterogeneity Parameters 
 %ΔADCentropy %ΔADCenergy 
 








Table 10-6: DW-MRI Per-lesion Analysis; %ΔADC Heterogeneity Parameters; OS Cox 
regression analysis 
There is no demonstrable statistically significant correlation between the %ΔADC heterogeneity 
parameters when analysed using Cox regression (Tbl.10-6).  The KM OS curves can be reviewed 
below (Fig.10-10):   
%ΔADCentropy %ΔADCenergy 
  
Dichotomised at -1.127% 
Low (≤) – Blue 
High (>) - Green 
Dichotomised at +8.239% 
Low (≤) – Blue 
High (>) - Green 
p=0.023 p=0.002 
Figure 10-10: DW-MRI Per-lesion Analysis; KM OS Analysis; %ΔADC Heterogeneity 
Parameters 
Lesions with a more negative change in ADCentropy (≤ -1.127%, p=0.023) and more positive 
change in ADCenergy (> +8.239%, p=0.002) were found in patients with longer OS, i.e. a change 
in lesions to a more uniform, less heterogeneous state in terms of ADC values.  Median OS had 
not been reached at the time of data analysis. 
The separation of the survival curves is maintained when only the prostate cancer lesions are 
analysed (Figure 10-11), although statistical significance is only reached with %Δ ADCenergy 
(p=0.015).  







Dichotomised at -2.2% 
Low (≤) – Blue 
High (>) - Green 
Dichotomised at +8.78% 
Low (≤) – Blue 
High (>) - Green 
p=0.09 p=0.015 
Figure 10-11: DW-MRI Per-lesion Analysis; KM OS Analysis; %ΔADC Heterogeneity 
Parameters; Prostate patients only 
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10.2 Lesion Based Analysis – PFS Analysis 
10.2.1 Tumour Groups 
 
 Tumour Groups 
KM plot  
 
Breast lesions n/a 
Prostate lesions 141 (120.2-161.8) 
p-Value  
(Log Rank) 0.039 
Table 10-7: DW-MRI Per-lesion Analysis; PFS Table for tumour groups; All lesions 
The breast cancer patients have a PFS advantage over the prostate patients, seen above in the 
KM analysis (Tbl.10-7, p=0.039).  Median PFS for the breast patients has not been reached.  
Median PFS for the prostate cancer patients is 141 days from initiation of therapy. 
10.2.2 Baseline Scan  
10.2.2.1 ADC Parameters 
 ADCmean ADCmedian 
 








Table 10-8: DW-MRI Per-lesion Analysis; Baseline ADC Parameters; PFS Cox regression 
analysis 
There is no demonstrable statistically significant correlation between the magnitude of the 
baseline ADC parameters measured with these lesions and PFS of the patients when analysed 
using Cox regression (Tbl.10-8). 
KM analysis of the data (Tbl.10-9) shows little separation of the survival plots, but for ADCmean 
there is an identified 6-days PFS benefit in the lesions with higher ADCmean (p=0.049).  There is 
no statistically significant separation of the ADCmedian survival curves.   
Although this suggests a statistically significant separation of the survival curves, there is only a 
6-day difference in PFS.  There is no clinically relevant observed difference in PFS identified using 
baseline ADC parameters. 
  
DW-MRI  Per-Patient Analysis Survival Analysis 
195 
 ADCmean ADCmedian 
KM plot  
  
Dichotomisation 1.1437 1.06 
Median PFS in days (95% CI) 
≤ 141 (109.1-172.9) 141 (111.2-170.8) 
> 147 (106-188) 147 (117.7-176.3) 
p-Value  
(Log Rank) 0.049 0.268 
Table 10-9: DW-MRI Per-lesion Analysis; KM PFS Analysis; Baseline ADCmean; All lesions 
The baseline imaging showed a higher ADC of the breast cancer lesions, and this had an impact 
on OS analysis.  The breast cancer patients have a PFS advantage.  When analysing the prostate 
lesions alone, there is no significant separation of the KM PFS curves (ADCmean p=0.897, 
ADCmedian p=0.524, plots not shown).  PFS analysis with only the breast cancer lesions suggests 
a lower ADC is prognostic of a longer PFS, although this does not reach statistical significance 






KM plot  
  
Dichotomisation 1.298 1.224 
Median PFS in days (95% CI) 
≤ n/a n/a 
> 110 (74.9-145.1) 110 (74.9-145.1) 
p-Value  
(Log Rank) 0.106 0.106 
Table 10-10: DW-MRI Per-lesion Analysis; KM PFS Analysis; baseline ADCmean; Only Breast 
Cancer lesions 
The PFS KM analysis including all the lesions is misleading.  The breast cancer lesions had a 
higher baseline ADC than the prostate lesions, and separate analysis suggests a PFS benefit for 
the breast cancer lesions with a lower baseline ADC.  The prostate lesions had a lower baseline 
ADC, and no difference in PFS has been identified in these patients by KM analysis.  However, 
analysis using baseline ADC suggested an OS benefit for the prostate cancer lesions (see earlier 
results).  
  





Cox regression p-value 
[HR (95%CI)] 
n=87, 64 events 
0.211 
[1.002 (0.999-1.005)] 
Table 10-11: DW-MRI Per-lesion Analysis; Baseline tDV; PFS Cox regression analysis 
There is no significant correlation between the baseline tDV and the PFS for these lesions (Tbl.10-
11).  The data has been analysed with the KM PFS method (Tbl.10-12). 
 tDV 
KM plot  
 
Dichotomisation 38.1cm3 
Median PFS in days (95% CI) 
≤ 147 (139.2-154.8) 
> 117 (87.1-146.9) 
p-Value  
(Log Rank) 0.031 
Table 10-12: DW-MRI Per-lesion Analysis; KM PFS Analysis; Baseline tDV  
There is a significant separation of the survival curves for these lesions.  Lesions smaller than 
38.1cm3 have a 30-day PFS benefit (p=0.031) using these data.  The breast cancer lesions were 
smaller than the prostate cancer lesions, and this may simply be identifying the breast cancer 
lesions (and the breast patients have a PFS advantage). 
KM PFS analysis of only the prostate cancer lesions does not demonstrate significant separation 
of the PFS curves (p=0.177), but smaller breast lesions have a PFS benefit (≤ 23.98cm3, 
p=0.038,– see Fig.10-12).  This suggests a PFS advantage for smaller breast cancer deposits, 
which would be biologically anticipated. 
tDV (breast lesions only) 
 
Dichotomised at 23.98cm3 
Low (≤) – Blue 
High (>) - Green 
p=0.038 
Figure 10-12: DW-MRI Per-lesion Analysis; KM PFS Analysis; Baseline tDV; Breast lesions 
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10.2.2.3 Heterogeneity Parameters 
 ADCentropy ADCenergy 
 








Table 10-13: DW-MRI Per-lesion Analysis; Baseline ADC Heterogeneity Parameters; PFS 
Cox regression analysis 
There is no significant correlation in the data for these lesions between baseline ADC 
heterogeneity parameters and PFS using Cox regression (Tbl.10-13).  The data has been 
dichotomised for KM analysis (Tbl.10-14).  
 ADCentropy ADCenergy 
KM plot  
  
Dichotomisation 5.162 0.0048 
Median PFS in days (95% CI) 
≤ 
141 (105.8-176.2) 101 (77-125) 
> 
141 (116.5-165.5) 147 (120.8-173.2) 
p-Value  
(Log Rank) 0.340 0.004 
Table 10-14: DW-MRI Per-lesion Analysis; KM PFS Analysis;  Baseline ADC heterogeneity 
parameters 
There is no significant separation of the survival curves for ADCentropy for these data.  ADCenergy 
however shows a statistically significant separation, with a PFS benefit of median 46 days in those 
patients with baseline ADCenergy of greater than 0.0048 (p=0.004) suggesting the more uniform 
lesions (higher ADCenergy) progressed later than more heterogeneous lesions. 
The prostate lesions had a trend towards having a higher ADC energy on baseline imaging.  The 
prostate cancer patients had a shorter PFS, and the benefit shown in the KM PFS analysis above 
is most from the breast cancer lesions.  Indeed, PFS analysis of only the prostate cancer lesions 
shown no significant separation of the PFS curves (dichotomisation 0.0066, p=0.710).   
The same analysis for the breast cancer lesions is shown in Figure 10-13, demonstrating a 
significant separation of the KM PFS curves, with a clear benefit for lesions with a higher baseline 
ADCenergy (>0.0049). 
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ADCenergy  
(breast lesions only) 
 
Dichotomised at 0.0049 
Low (≤) – Blue 
High (>) - Green 
p=0.001 
Figure 10-13: DW-MRI Per-lesion Analysis; KM PFS Analysis; Baseline ADCenergy; Breast 
lesions only 
 
10.2.3 %Δ Parameters 
10.2.3.1 %ΔADC Parameters  
 %ΔADCmean %ΔADCmedian 
 








Table 10-15: DW-MRI Per-lesion Analysis; %ΔADC Parameters; PFS Cox regression 
analysis 
Cox regression analysis of the %ΔADC parameters has not identified significant correlation 
between the size of change and the length of PFS (Table 10-15). 
KM PFS analysis has not identified significant separation of the survival curves (Table 10-16). 
 %ΔADCmean %ΔADCmedian 
KM plot  
  
Dichotomisation +5.71% +5.84% 
Median PFS in days (95% CI) 
≤ 147 (124.7-169.3) 173 (133.8-212.2) 
> 141 (116.5-165.5) 117 (97.4-136.6) 
p-Value  
(Log Rank) 0.762 0.395 
Table 10-16: DW-MRI Per-lesion Analysis; KM PFS Analysis; %ΔADC parameters; All 
lesions 
The PFS KM analysis for the separate tumour groups can be reviewed in Tables 10-17 and 10-
18. 
  







KM plot  
  
Dichotomisation -2.06 -3.49 
Median PFS in days (95% CI) 
≤ 177 (151.7-202.3) 177 (151.7-202.3) 
> 117 (96.9-137.1) 117 (96.9-137.1) 
p-Value  
(Log Rank) 0.088 0.088 







KM plot  
  
Dichotomisation +3.97% +13.13% 
Median PFS in days (95% CI) 
≤ 110 (70.4-149.6) 110 (66.5-153.5) 
> n/a n/a 
p-Value  
(Log Rank) 0.078 0.052 
Table 10-18: DW-MRI Per-lesion Analysis; KM  PFS Analysis; %ΔADC parameters; Prostate 
lesions only 
Neither of the parameters reaches statistical significance for either tumour group, but there is 
certainly a trend.  The tumour groups seem to have different characteristics.  A fall in ADC 
between scans is associated with a PFS benefit for the prostate cancer lesions, but an increase 
in ADC is associated with a PFS benefit for the breast cancer lesions.  This reflects a difference 
in the pathophysiology of a treatment response on the metastases and surrounding bone between 
the tumour types. 
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10.2.3.2 %ΔtDV  
 %ΔtDV 
 Cox regression p-value 
[HR (95%CI)] 
n=87, 64 events 0.478  
[0.998 (0.993-1.003)] 
Table 10-19: DW-MRI Per-lesion Analysis; %ΔtDV; PFS Cox regression analysis 
There is no demonstrable correlation between the size of change in tDV and the PFS for these 
lesions (Table 10-19).  KM analysis can be reviewed in the table below (Table 10-20). 
 %ΔtDV 






≤ 141 (114.3-167.7) 
> 177 (n/a) 
p-Value  
(Log Rank) 0.027 
Table 10-20: DW-MRI Per-lesion Analysis; KM PFS Analysis; %ΔtDV; All lesions 
Lesions with a greater than +46% increase in volume are associated with a 36-day PFS benefit 
(p=0.027) when all the lesions are considered together.  Tumour-specific analysis can be 
reviewed in Tables 10-21 and 10-22. 
 %ΔtDV  







≤ 147 (94.2-199.8) 
> 141 (119.4-162.6) 
p-Value  
(Log Rank) 0.819 
Table 10-21: DW-MRI Per-lesion Analysis; KM PFS Analysis; %ΔtDV; Breast lesions only 
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 %ΔtDV  
(breast lesions only) 






≤ 110 (87.2-132.8) 
> n/a 
p-Value  
(Log Rank) 0.071 
Table 10-22: DW-MRI Per-lesion Analysis; KM PFS Analysis; %ΔtDV; Breast lesions only 
There is no association between the change in tDV and PFS for the prostate cancer lesions 
(p=0.819).  A PFS benefit is seen for the breast cancer lesions with an increase in tDV.  This is 
an unexpected finding, and the separation of the PFS curves does not reach statistical 
significance.  There is a different pathophysiology demonstrated in this per-lesion analysis 
between the tumour groups, and this finding for the breast cancer lesions most likely reflects a 
change in the bone metastasis or the surrounding bone.  The breast cancer patients in this study 
had a PFS benefit, and significant OS benefit, and therefore the measured increase in tDV is 
unlikely to represent an increase in the size of the tumour deposit, and tDV may not be a true 
measure of just the tumour deposit in the bone, and is more likely to represent the tumour and 
the surrounding bony architecture.   
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10.2.3.3 %ΔADC Heterogeneity Parameters  
 %ΔADCentropy %ΔADCenergy 
 








Table 10-23: DW-MRI Per-lesion Analysis; %ΔADC Heterogeneity Parameters; PFS Cox 
regression analysis 
There is no significant correlation for these lesions between the change in the ADC heterogeneity 
parameters and the length of PFS (Tbl.10-23).  The data has been dichotomised for KM PFS 
analysis (Tbl.10-24). 
 %ΔADCentropy %ΔADCenergy 
KM plot  
  
Dichotomisation +5.564% -0.03% 
Median PFS in days (95% CI) 
≤ 141 (115.5-166.5) 141 (112.9-169.1) 
> 177 (81.8-272.2) 177 (135-219) 
p-Value  
(Log Rank) 0.074 0.053 
Table 10-24: DW-MRI Per-lesion Analysis; KM PFS Analysis; %ΔADC Heterogeneity 
Parameters; All lesions 
Lesions with a more negative change in ADCentropy between scans have a better PFS, although 
this does not quite reach statistical significance (p=0.074).  There is a 36-day PFS benefit in 
lesions with a greater positive change in ADCenergy (p=0.053).  These data therefore suggest a 
change towards homogeneity confers a PFS benefit.  
The tumour subgroup analyses show contradictory findings depending on the tumour type being 
assessed (Tbls.10-25/10-26).  For the prostate cancer lesions, there is significant separation of 
both PFS curves (%ΔADCentropy p=0.006, %ΔADCenergy p=0.0002) showing at least a 60-day PFS 
benefit for less heterogeneous lesions (decrease in ADCentropy and increase in ADCenergy).  The 
exact opposite is demonstrated by the breast cancer lesions, where an increase in ADCentropy and 
decrease in ADCenergy is associated with a PFS benefit (p=0.052). 
The number of breast patients is small, and the log rank analysis does not quite reach the level 
of statistical significance, particularly when repeated testing is considered, but this suggests a 
fundamental difference at the physiological level about the behaviour of the prostate and breast 
cancer lesions in these patients. 
  









Dichotomisation -0.108% +6.245% 
Median PFS in days 
(95% CI) 
≤ 177 (149.3-204.7) 110 (93.3-126.7) 
> 117 (85.9-148.1) 177 (170.9-183.1) 
p-Value  
(Log Rank) 0.006 0.0002 
Table 10-25: DW-MRI Per-lesion Analysis; KM PFS Analysis; %ΔADC Heterogeneity 
Parameters; Prostate lesions only 
 
%ΔADCentropy (breast lesions 
only) 




Dichotomisation +1.52% -1.52% 
Median PFS in days 
(95% CI) 
≤ 110 (66.5-153.5) n/a 
> n/a 110 (66.5-153.5) 
p-Value  
(Log Rank) 0.052 0.052 
Table 10-26: DW-MRI Per-lesion Analysis; KM PFS Analysis; %ΔADC Heterogeneity 
Parameters; Breast lesions only 
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10.3 Discussion 































































Table 10-27: DW-MRI Per-lesion Analysis; All Survival Analyses; Summary Table 
Useful prognostic information has been identified by imaging tumour deposits with DW-MRI.  For 
prostate cancer, a negative correlation between ADC and Gleason grading has been identified 
220.  Histological correlates of a poor response have been identified for other tumours.  Breast 
primary tumours with a low ADC at baseline are associated with a higher tumour grade and 
invasiveness, and with a worse prognosis236.  A high baseline ADC in head and neck primary 
tumours predicts a poorer outcome217, and is associated histologically with poor prognostic 
features (higher stromal content, low cellularity (suggesting lower proliferation), and 
micronecrosis), and poorly differentiated tumours have a lower ADC than well-differentiated 
ones237-239. 
The per-lesion response analysis for this study was not able to demonstrate predictive benefit 
using the baseline ADC parameters, but the %Δ ADC parameters suggested an increase in ADC 
with treatment predicted a clinical treatment response for the prostate cancer lesions.   
None of the breast cancer patients had died at the time of data analysis for this study, and this 
OS advantage (p=0.002) and PFS advantage (p=0.039), for the breast cancer patients has 
impacted interpretation of the data. 
Lower baseline ADC parameters (mean and median) predict OS (p=0.047 and 0.005 respectively, 
but median OS was not reached for comparison) for the prostate lesions.  Other studies have 
shown a lower baseline ADC is predictive of a treatment response, and OS might similarly be 
expected to be prolonged.  There is little in the literature to support this supposition.  Sclerotic 
bone metastases have a better prognosis235, but sclerosis is not the confirmed cause of the lower 
ADC in these lesions.  Sclerosis does return a lower ADC measurement 234.  ADCmedian is more 
predictive for these lesions. 
The baseline ADC parameters have not shown a statistically significant PFS prognostic benefit. 
This difference between the tumour groups persists through to analysis of the %ΔADC 
parameters, where a fall in ADC between scans is associated with a non-statistically significant 
PFS benefit for prostate cancer patients (ADCmean/median p=0.088 for both), but an increase in ADC 
DW-MRI  Per-Patient Analysis Survival Analysis 
205 
between scans of the breast cancer lesions confers a non-statistically significant PFS benefit 
(ADCmean/median p=0.078/0.052).  There is currently no histological correlate of what the changes 
in ADC are measuring in these tumour metastases, but there are fundamental differences in the 
pathophysiology of the bone metastases from breast and prostate cancer.  Inclusion of mixed 
bone pathologies in future studies may mask or distort the findings; bone metastases differ in 
phenotypic and biological behaviour.  
There has been some evidence to suggest the volume of bony metastatic disease has prognostic 
benefit.  Perez-Lopez et al. reported in 2016 a study of 43 metastatic prostate cancer patients, 
showing the baseline tDVWB was associated with OS, and a greater tumour burden in the bone 
had a negative impact on OS240.  Vargas et al. demonstrated an increased number of prostate 
cancer bone metastases was associated with a shorter survival241 but it is not clear if this is directly 
analogous to tDV.  The bone scan index is a measure of the proportion of the skeleton replaced 
by metastatic disease, and has been shown to predict prostate cancer survival, with a poorer 
survival from a higher burden222,223,242. 
No PFS prognostic utility has been identified using tDV for the prostate cancer lesions.  The breast 
cancer lesions tell a different tale: smaller (lower tDV) breast cancer metastases are associated 
with an improved PFS (scan1/scan2 p=0.038/0.0002).  The %ΔtDV for the breast cancer lesions 
does not quite reach statistical significance, but there is a trend towards a PFS benefit for lesions 
with an increase in tDV between the scans (p=0.071).  This is clearly an unexpected finding, and 
an explanation is difficult.  This could be a statistical phenomenon, suggesting there may be a 
difference, or simply random error.  The tDV may not just measuring viable tumour volume, but 
might also be measuring pathophysiological changes in the bony architecture; the responses and 
changes with treatment may be causing a halo-effect of change within the surrounding bone, 
volume on the high b-value image and resulting in an increased VOI volume.  This again indicates 
the impact of the underlying bone metastasis pathophysiology on the quantification parameters. 
It has already been described how the ADC heterogeneity parameters have been associated with 
markers of poorer prognosis for several tumours, including prostate cancer176 and breast 
cancer172.  A higher entropy and lower energy (i.e. a more heterogeneous ADC voxel distribution 
within the VOIs) is associated with more poor prognosis histological features, and associations 
with OS and PFS it would be expected. 
ADCenergy seems to have more prediction utility for these patients.  A higher baseline ADCenergy 
predicts better OS for the prostate cancer patients (p=0.019).  Both %Δ ADC heterogeneity 
parameters have successfully predicted the OS for the prostate cancer lesions: a decrease in 
ADCentropy and increase in ADCenergy between scans shows an OS benefit for the prostate cancer 
lesions (p=0.023 and 0.002 respectively).  A change towards a more homogeneous ADC voxel 
distribution confers an OS benefit.  The underlying bone physiology being measured is unknown, 
but this may represent a return to a more homogeneous normal bone architecture, or a move 
towards sclerosis, which may result in a more homogeneous ADC voxel distribution.  There is no 
histological correlate in the literature. 
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The ADC heterogeneity parameters also show performance for PFS analysis for these patients.  
ADCenergy offers more prognostic value.  For the breast cancer lesions, only a higher ADCenergy at 
baseline is associated with a PFS benefit (p=0.001).  No such benefit was identified for the 
prostate cancer lesions.  The PFS of the %Δ in ADC parameters is more difficult to interpret as 
the underlying tumour type demonstrates conflicting outcomes.  For the breast cancer lesions, an 
increase in ADCentropy and decrease in ADCenergy (i.e. towards heterogeneity) is associated with a 
PFS benefit (p=0.006 and 0.0002, respectively).  However, for the prostate cancer lesions, a 
decrease in ADCentropy and increase in ADCenergy (i.e. towards homogeneity) is associated with a 
PFS benefit (p=0.052 for both).  The changes in the parameters for the prostate cancer lesions 
seem to fit with expectation, and agree with the OS analysis, where survival is indicated by a 
move of the ADC distribution within VOIs towards homogeneity.  The move towards heterogeneity 
for PFS benefit of the breast cancer lesions suggests a different underlying pathophysiological 
response of the tumour and bony architecture to the endocrine therapy. 
In summary, prognostication of OS has been demonstrated with a lower baseline ADC and higher 
ADCenergy (showing more homogeneity of ADC voxels) of the prostate cancer lesion.  Breast and 
prostate metastases show different parameter characteristic changes with treatment; for the 
prostate cancer lesions a fall in ADC is associated with a PFS benefit, but the opposite is 
demonstrated for the breast cancer lesions.  Similar conflicting data is shown for PFS 
prognostication using the %Δ heterogeneity parameters.  This suggests the different biology of 
the tumour types is affecting quantification different.  
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Chapter 11  DW-MRI Per-Patient Analysis – Response Analysis 
The methods of this chapter and the statistical approaches for this section can be reviewed in 
Chapter 2.3.10. 
11.1 Baseline Scan 
11.1.1 Tumour Group 
n=20 (BCa-5, PCa-15).  18 patients had data for response analysis (BCa-5 (PD-2, Response 
3/5(60%), PCa-13 (PD-11, Response 2/13(15.4%)). 
The breast cancer patients had a higher response rate. 
11.1.2 ADC Parameters 
There is a clear demonstrable difference in the distributions (Tbl.11-1) between the two 
parameters (paired samples t-test: when t(19)=7.316, p=<0.00001).  Although ADCmean and 
ADCmedian are correlated, there is a significant difference in their distributions.  The distributions 
are wider for the prostate cancer patients, suggesting more intra-patient heterogeneity.  The 
distribution means of the ADC parameters for the prostate cancer metastases are significantly 
lower than those for breast cancer (Mann Whitney U tests: ADCmean, p=0.028; ADCmedian p=0.058 
suggesting a trend). 
The box-plots suggests a lower baseline ADC parameters might predict PD, but this difference is 
not statistically significant (independent samples t-test: ADCmean, where t(16)=-1.653, p=0.118; 
ADCmedian, p=0.154).   
The breast cancer patients have a higher baseline ADC, and these patients have a better 
treatment response rate.   
Tbl.11-2 summarises the tumour-specific response analysis, comparing the groups with 
independent sample Mann Whitney U tests (data not recorded here for brevity).  This analysis is 
complicated by the small number of patients.  Only 2 prostate cancer patients had a treatment 
response; 2 of the 5 breast cancer patients had PD.  The box-plots demonstrate no statistically 
significant difference between the response groups, but a treatment response is suggested by a 
higher baseline ADC.  The per-lesion analysis suggested an association between a higher 
baseline ADC and a treatment response, but did not reach statistical significance.   
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 ADCmean ADCmedian 
 











































































Table 11-1: DW-MRI Per-Patient Analysis; Baseline Scan ADC Parameters; Descriptive 
statistics and box-plots; All Patients (ADC expressed as 10-3 mm2/s); Tumour groups 
(B=Breast cancer, P=Prostate Cancer) 
Prostate Breast 









Table 11-2: DW-MRI Per-Patient Analysis; Response Analysis; Baseline ADC Parameters; 
Tumour Subgroup Analysis 
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11.1.3  Volumetric tDV 
n=20 (5 Breast, 15 Prostate) 
































































Table 11-3: DW-MRI Per-Patient Analysis; Baseline Scan tDV; Descriptive statistics and 
box-plots; All Patients; Tumour groups (B=Breast cancer, P=Prostate Cancer) 
The prostate cancer patients have larger tumour volumes selected for quantification than the 
breast cancer patients (Tbl.11-3) (Mann-Whitney U test: p=0.033).  Patients with a larger tDV 
were more likely to have PD by 24-weeks (Mann-Whitney U test: p=0.007).  
The prostate patients had larger volume disease, and were more likely to have PD.  The subgroup 
analyses are plotted in Table 11-4, with independent samples Mann Whitney U tests used to 
compare the response groups (raw data not included for brevity). 
  








Table 11-4: DW-MRI Per-Patient Analysis; Response Analysis; Baseline tDV; 
Tumour Subgroup Analyses 
Statistical analysis of the tumour subgroup response groups is difficult because of the small 
number of patients as previously described.  None of these analyses meet statistical significance, 
but there seems to be a trend towards patients with larger tDV measurements being more likely 
to have PD.   
The per-lesion analysis demonstrated no predictive utility of the baseline tDV, only suggesting 
tDV identified the tumour group and therefore the inherent treatment response superiority of the 
breast cancer patients included in this study. 
11.1.4 ADC Heterogeneity Parameters 
Table 11-5 summaries the data for the ADC heterogeneity parameters.  There is no demonstrably 
significant statistical difference in the distribution of ADCentropy between breast cancer and prostate 
cancer bone metastases (Mann-Whitney U test: p=0.395). 
The population distribution mean of ADCentropy is lower in patients with a treatment response (see 
Table 11-5), suggesting the lesions with a more uniform ADC distribution are the lesions with a 
resposne.  This difference is not statistically significant (independent samples t-test: when 
t(16)=0.863, p=0.562)   
Patients with a treatment response had bone metastases seem to have a slightly higher ADCenergy 
distribution (i.e. less heterogeneous tumours).  This small difference is not statistically significant 
(Mann-Whitney U test: p=0.775).   
Particularly for ADCentropy there is the suggestion of a difference in the parameter between the 
response groups, with more homogeneous lesions being more likely to have a treatment 
response.  This is not proven statistically; there may be no real difference or the sample size was 
too small to statistically detect the difference. 
Table 11-6 displays the tumour-specific response analysis, with Mann-Whitney U tests for 
comparisons.  None of the statistical comparisons of the tumour subgroup response analyses 
reach statistical significance, but there are only a small number of patients.  The patients with a 
treatment response seem to have a lower baseline ADCentropy and higher ADCenergy, i.e. are more 
homogeneous before treatment.  The per-lesion analysis also demonstrated no difference in the 
baseline ADC heterogeneity parameters between the response groups.  
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 p=0.562 p=0.467 
Table 11-5: DW-MRI Per-Patient Analysis; Baseline Scan ADC Heterogeneity Parameters; 
Descriptive statistics and box-plots; All Patients; Tumour groups (B=Breast cancer, 
P=Prostate Cancer) 
Prostate Breast 









Table 11-6: DW-MRI Per-Patient Analysis; Response Analysis; Baseline ADC 
Heterogeneity Parameters; Tumour Subgroup Analysis 
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11.1.5 Baseline Parameters Correlations 
Tbl.11-7 summarises pairwise correlation analysis between the baseline scan parameters 
(analysed using Spearman Rank correlation tests). 
 ADCmean ADCmedian tDV ADCentropy ADCenergy 
ADCmean 1 - - - - 
ADCmedian 0.95  
(0) 
1 - - - 




1 - - 
















Table 11-7: DW-MRI Per-lesion Analysis; Baseline Parameters; Correlations (and p-values) 
using Spearman Rank analysis; All lesions 
A strong correlation is identified between ADCmean and ADCmedian parameters, as would be 
anticipated as they are describing the average of the same VOIs.  This was also identified with 
the per-lesion analysis.  There is no correlation between tDV and the other parameters, just as 
identified with the per-lesion analysis.  A moderate negative correlation exists between ADCenergy 
and the ADC parameters.  The ADC heterogeneity parameters have a close negative correlation.  
These correlations are similar to those identified with the per-lesion analysis. 
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11.2 Second Scan 
n= 19 (5 Breast, 14 Prostate) 
 VOI  
 

































Table 11-8: DW-MRI Per-Patient Analysis; Second Scan Parameters; Descriptive statistics 
and box-plots 
 
DW-MRI  Per-Patient Analysis Survival Analysis 
214 
11.3 Percentage Change (%Δ) Between Scans 
n= 19 (5 Breast, 14 Prostate) (18 with data for response analysis, 5 breast, 13 prostate) 
11.3.1 %Δ ADC Parameters 
 %ΔADCmean %ΔADCmedian 
 










































































 p=0.018 p=0.001 
Table 11-9: DW-MRI Per-Patient Analysis; %Δ ADC Parameters; Descriptive statistics and 
box-plots; All Patients; Tumour groups (B=Breast cancer, P=Prostate Cancer) 
Table 11-9 summaries the data for the %Δ ADC parameters.  Independent samples t-tests were 
used to compare the %ΔADCmean distributions for the breast and prostate cancer patients, but no 
significant difference has been identified (see Tbl.11-9 for results). 
The patients with a subsequent treatment response had a more positive change in the ADC 
parameters between scans.  This is what would be anticipated with a treatment response, and 
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this difference is statistically significant in this analysis (%ΔADCmean, when t(16)=-1.985, p=0.018; 
%ΔADCmedian, where t(16)=-2.084, p=0.001).  
Tumour subgroup analysis is complicated for these data due to the small number of prostate 
cancer patients with a treatment response (n=2), and the small number of breast cancer patients.  
The raw data is not displayed, but the plots in Tbl.11-10 display the tumour subgroup response 
analysis, using Mann-Whitney U tests to compare the distributions: 
Prostate Breast 









Table 11-10: DW-MRI Per-Patient Analysis; Response Analysis; %Δ ADC Parameters; 
Tumour Subgroup Analysis 
As anticipated with such small numbers none of the differences in the distributions reach statistical 
significance.  The largest influence on the response analysis is the influence of the tumour type.  
While not statistically significant, the breast cancer patients in this study population had, on 
average, a larger increase in ADC between scans, and were more likely to have a treatment 
response. 
The per-lesion analysis suggested a treatment response was associated with an increase in ADC 
between the scans (particularly %Δ ADCmean), but this was only observed for prostate cancer 
bone metastases.  There are too few prostate cancer patients in this study to have sufficient with 
a treatment response for useful comparisons to be made.  No predictive utility of the %Δ ADC 
parameters has been demonstrated independent to tumour group analysis, but a lack of utility 
has not been proven. 
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11.3.2 %Δ tDV 
 %Δ tDV 
 


























































Table 11-11: DW-MRI Per-Patient Analysis; %Δ tDV; Descriptive statistics and box-plots; 
All Patients; Tumour groups (B=Breast cancer, P=Prostate Cancer) 
Table 11-11 summaries the %ΔtDV data.  There no significant difference between the %Δ tDV of 
breast cancer and prostate cancer patients (independent samples t-test: where t(17)=-0.137, 
p=0.893).   
Patients with a treatment response seem to have shown a larger increase in tDV between scans.  
This is counterintuitive - a treatment response would be expected to result in smaller lesions.  This 
difference is not statistical significance (where t(16)=-1.288, p=0.216), and may represent a data 
anomaly, or may suggest influence of the difference between the tumour types.  Tumour sub-
group response analysis can be reviewed in Table 11-12. 

































Table 11-12: DW-MRI Per-Patient Analysis; Response Analysis; %ΔtDV; Tumour Subgroup 
Analysis 
Between the breast patients there is no demonstrable significant difference in the distribution of 
%ΔtDV between response groups, but with only 5 patients for analysis, statistical comparison is 
of limited value.   
An increase in tDV between scans is predictive of a sustained treatment response for the prostate 
cancer patients (p=0.026).  ROC analysis of only the prostate cancer patients suggests a 
treatment response can be identified with a sensitivity of 100% and specificity of 100% for lesions 
with a %ΔtDV> +36.15% (AUC=1.00, p=0.03 using Mann-Whitney U tests for comparison). 
This is an unexpected finding, and was also identified with per-lesion analysis.  There was 
significant inter-lesion heterogeneity identified within individual patients during per-lesion 
analysis, showing some lesions increased in size in patients with overall responsive disease.  
Healing bone metastases undergo a sclerotic reaction, and sclerotic bone restricts the DW-MRI 
image further.  The sclerotic nature of prostate cancer metastases explains the lower measured 
ADC parameters of the prostate cancer bone lesions relative to the breast cancer lesions.  The 
high b-value images have been used for VOI definition because of the exaggeration of restricted 
diffusion, which has been used as a surrogate for identifying the extent of the bone metastases.  
The sclerotic reaction in bone metastases may extend beyond the true edge of the metastasis, 
and a treatment response, with healing sclerosis, might result in a larger area of restriction on the 
high b-value image, and a larger VOI and tDV. 
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11.3.3 %ΔADC Heterogeneity Parameters 
 %ΔADCentropy %ΔADCenergy 
 







































































Table 11-13: DW-MRI Per-Patient Analysis; %Δ ADC Heterogeneity Parameters; 
Descriptive statistics and box-plots; All Patients; Tumour groups (B=Breast cancer, 
P=Prostate Cancer) 
Table 11-13 summarises the data for the %ΔADC Heterogeneity parameters.  No statistically 
significant difference can be identified in the distribution of the %Δ heterogeneity parameters 
between the tumour groups (Mann-Whitney U tests: %ΔADCentropy p=0.687; %ΔADCenergy 
p=0.622).   
There is no statistically significant difference identified in these patients in the distribution of the 
%Δ heterogeneity parameters between the response groups (Mann Whitney U tests: 
%ΔADCentropy p=0.924; %ΔADCenergy p=0.1).  The %Δ ADC heterogeneity parameters do not 
predict treatment response for these patients.  The per-lesion analysis (see previous chapter) 
suggested %ΔADCenergy might have utility for predicting the treatment response.  The following 
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box-plots (Tbl.11-14) display the tumour-specific response analysis for these data, comparing the 
distributions with Mann-Whitney U tests: 
Prostate Breast 









Table 11-14: DW-MRI Per-Patient Analysis; Response Analysis; %Δ ADC Heterogeneity 
Parameters; Tumour Subgroup Analysis 
There is no statistically significant difference in the distributions between the response groups for 
either tumour group.  However, with such small numbers this is to be expected.  The distributions 
of the parameters for both response group overlap, and there is no clear pattern to suggest an 
association in these patients. 
11.4 %Δ Parameters Correlations 
Table 11-15 summarises pairwise correlation analyses between the baseline scan parameters 
(analysed using Spearman Rank correlation tests). 
 %ΔADCmean %ΔADCmedian %ΔtDV %ΔADCentropy %ΔADCenergy 
%ΔADCmean 1 - - - - 
%ΔADCmedian 0.96  
(<0.001) 
1 - - - 




1 - - 
















Table 11-15: DW-MRI Per-Patient Analysis; %Δ Parameters; Correlations (and p-values) 
using Spearman Rank analysis; All lesions 
The correlations between the parameters are similar to the baseline imaging, and similar to the 
correlations identified with per-lesion analysis. 
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11.5 Discussion 
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Table 11-16: DW-MRI; Per-Patient Analysis; Response Analysis; summary table 
The per-lesion analysis of these data considerable intra-patient inter-lesion heterogeneity.  This 
per-patient analysis attempts to translate the clinical associations of the parameters identified 
from per-lesion analysis into a clinically relevant per-patient methodology. 
The per-lesion analysis did not identify utility of the baseline parameters for predicting the 
treatment response.  The per-patient analysis has also failed to confirm predictive information 
from these parameters.   
A lower baseline ADC has been identified in other soft tissue tumours as a predictor of therapeutic 
response213 2016,218,219.  There is no evidence supporting the predictive utility for bone metastases.  
A lack of association between the baseline ADC and treatment response of bone metastases 
from prostate cancer has been identified by Messiou et al.152.  No association has been 
statistically confirmed in this study between the baseline ADC and the treatment response for 
either tumour group; the non-statistically significant suggestion of a lower baseline ADC in those 
with PD is likely to be largely influenced by the lower baseline ADC identified for the prostate 
patients, possibly due to the more sclerotic nature of these deposits.  The prostate cancer patients 
were much more likely to have PD compared to the breast cancer patients.  There are too few 
data to enable meaningful tumour subgroup analysis.  There are demonstrable differences in the 
ADC parameters of the tumour groups, and predictive utility of the baseline ADC parameters 
cannot be discounted as this study group has been too small to interrogate fully. 
The baseline tDV has no predictive utility in these patients, at either the per-lesion or per-patient 
level.  The volume of osseous disease is prognostic for prostate cancer222,223, with a smaller 
volume of disease being associated with a better prognosis.  However, there is no evidence 
showing and association between smaller volume of bone metastases and treatment response. 
The baseline ADC heterogeneity parameters have also failed to yield treatment response 
prognostic value.  The per-lesion analysis suggested, for the breast cancer lesions, a lower 
ADCentropy and higher ADCenergy predicted for a treatment response.  The per-patient box-plots for 
breast cancer suggest this association is evident at the patient level, but the differences do not 
meet statistical significance.  There were only 2 breast cancer patients with PD, and therefore 
meaningful conclusions cannot be drawn from this analysis, but an association between baseline 
ADC heterogeneity parameters cannot be excluded for the breast cancer patients and warrants 
further investigation. 
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The %Δ parameter analysis has also been hampered by the relatively small sample size.  There 
are clear differences identified in the ADC parameters between the tumour types, and drawing 
conclusions from analysis of all the patients together is likely to be misleading.  An example is the 
%ΔADC parameters – a statistically significant association is identified between the response 
groups, but it is unlikely this is independent of the tumour subgroup (breast cancer patients had 
a higher baseline ADC, had a larger increase in ADC between scans, and 60% of the breast 
cancer patients had a sustained response at 24-weeks).  The tumour sub-group analyses do not 
reveal a significant association between the %Δ ADC and treatment response for either tumour 
group, but in both tumour groups one of the response groups contains only 2 patients (2 prostate 
patients had a treatment response and 2 breast patients had PD).  In the per-lesion analysis, 
prostate cancer patients with an increase in ADC between scans was associated with a treatment 
response.  The absence of this relationship at the per-patient level cannot be concluded and 
needs to be interrogated with a larger study population.  
The %Δ tDV behaved in a surprising manner during the per-lesion analysis, showing an increase 
was associated with a treatment response.  For the prostate cancer patients, there is a positive 
association between an increase in tDV between scans and the likelihood of a treatment response 
(p= 0.026).  The inter-lesion heterogeneity was demonstrated with the per-lesion analysis; 
perhaps the target lesions have not been representative of the clinically relevant disease.  
Alternatively, the tDV may not represent accurately the size of the tumour deposit within the bone.  
It is not possible to separate the influence of the tumour and bone stroma signal from the ADC 
data, but both will inevitably have impact.  A treatment response and associated up-regulation of 
osteoblastic activity and sclerosis may extend beyond the extent of the bone metastasis, causing 
a halo of increased image restriction around the target volume, but included within the VOI volume 
on the high b-value image.   
The %Δ ADC heterogeneity parameters have shown no utility for prediction of the treatment 
response.  No association was identified either at the per-lesion analysis.  In summary, the 
differences in the parameters between breast and prostate cancer lesions are comparable with 
those identified at per-lesion analysis, but no clear utility for prediction of treatment response has 
been identified, apart from an increase in tDV between scans for the prostate cancer patients; 
this may represent an increased volume of ADC restriction from the healing osteoblastic response 
in the bone. 
In summary, the parameter characteristics are different between breast and prostate cancer 
metastases, as identified with per-lesion analysis.  No parameter has suggested utility for 
predicting the treatment response apart from an increase in tDV for prostate cancer patients 
between cans.  This suggests that tDV is also measuring the peri-tumour bone architecture and 
associated changes with therapy.  Although per-lesion analysis suggested more predictive utility 
of the parameters, this has not been seen with per-patient analysis; this may reflect the smaller 
sample size, or a dilution of the signal due to inter-lesion heterogeneity. 
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Chapter 12  DW-MRI Per-Patient Analysis – Survival Analysis  
The methods of this chapter and the statistical approaches for this section can be reviewed in 
Chapter 2.3.12. 
12.1 OS Analyses 
20 patients from this study had data available for OS analysis, 5 breast cancer patients and 15 
prostate cancer patients.  No breast cancer patients had died at the time of data analysis, and 5 
prostate cancer patients had died (33.3%). 
12.1.1 Tumour Group Analysis 
KM OS analysis of the tumour groups can be seen below (Fig.12-1).  There is no statistically 
significant separation of the survival curves (p=0.154), but certainly a trend towards a significant 
dichotomisation. 
Tumour Group OS Analysis 
 
P – Prostate Cancer 
B- Breast Cancer 
p=0.154 
Figure 12-1: DW-MRI Per-Patient Analysis; KM OS Analysis of tumour groups; All Patients; 
Log Rank Analysis 
12.1.2 Baseline Scan OS Analysis 
12.1.2.1 ADC Parameters 
The Cox regression analysis for the baseline ADC parameters does not demonstrate a significant 
correlation between the parameters and the OS (Tbl.12-1). 
 ADCmean ADCmedian 






Table 12-1: DW-MRI Per-Patient Analysis; Cox regression OS Univariate Analysis; Baseline 
ADC Parameters 
KM OS analysis is recorded in Figure 12-2. 
  




Dichotomised at 1.23 
Low (1) - blue line 
High (2) - green line 
Dichotomised at 1.18 
Low (1) - blue line 
High (2) - green line 
p=0.021 p=0.109 
Figure 12-2: DW-MRI Per-Patient Analysis; KM OS Analysis; Baseline ADC Parameters 
For both parameters, the survival curves separate, suggesting a survival benefit for patients with 
a higher baseline ADC (ADCmean, p=0.021).  There were no patients with a baseline ADCmean 
lower than 1.23 who had died at the time of data analysis.  The survival plot for ADCmedian shows 
a similar separation, but this has not reached significance (p=0.109), but suggests a trend.  
The prostate cancer patients were more likely to have died, and they had a lower baseline ADC.  






Dichotomised at 1.03 
Low (1) - blue line 
High (2) - green line 
Dichotomised at 0.96 
Low (1) - blue line 
High (2) - green line 
p=0.155 p=0.238 
Figure 12-3: DW-MRI Per-Patient Analysis; KM OS Analysis with Log Rank test for 
comparison; Baseline ADC Parameters; Prostate patients only 
These plots contradict the analysis of the whole patient group, suggesting the tumour subgroup 
has a larger impact on survival.  Although the separation of the curves does not reach statistical 
significance, the prostate cancer patients with a higher baseline ADC were more likely to have 
died.  The per-lesion analysis also demonstrated this for the prostate cancer lesions.  Increased 
sclerosis of bone metastases has been associated with a survival benefit235, and increased 
sclerosis causes results in a lower measured ADC due to restricted water diffusion234. 
  








Table 12-2: DW-MRI Per-Patient Analysis; Cox regression OS Univariate Analysis; Baseline 
tDV 
Cox regression analysis of baseline tDV does not show any correlation between the volume of 
lesion(s) and OS (Tbl.12-2).  The data has been dichotomised for KM OS analysis (Fig.12-4): 
tDVVOI5 
 
Dichotomised at 165.04cm3 
Low (1) - blue line 
High (2) - green line 
p=0.115 
Figure 12-4: DW-MRI Per-Patient Analysis; KM OS Analysis with Log Rank test for 
comparison; Baseline tDV 
There is clear separation of the survival plots, suggesting an OS advantage for patients with 
smaller volume disease, but this separation does not reach statistical significance (p=0.115), 
concluding a trend.  
The prostate cancer lesions were larger than the breast cancer lesions, and deaths were only in 
prostate cancer patients; it is not clear that tDV is an independent predictor of OS.  KM analysis 
of the prostate cancer patients (Fig.12-5) does not show significant prognostic utility, implying tDV 




Dichotomised at 258.17cm3 
Low (1) - blue line 
High (2) - green line 
p=0.413 
Figure 12-5: DW-MRI Per-Patient Analysis; KM OS Analysis with Log Rank test for 
comparison; Baseline tDV; Prostate patients only 
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12.1.2.3 Heterogeneity Parameters 








Table 12-3: DW-MRI Per-Patient Analysis; Cox regression OS Univariate Analysis; Baseline 
ADC Heterogeneity Parameters 
Cox regression analysis of the heterogeneity parameters from the baseline imaging do not 
demonstrate any significant correlation between the heterogeneity parameter and OS (Tbl.12-3). 
KM analyses are in Figure 12-6. 
ADCentropy ADCenergy 
  
Dichotomised at 5.22 
Low (1) - blue line 
High (2) - green line 
Dichotomised at 0.0079 
Low (1) - blue line 
High (2) - green line 
p=0.227 p=0.198 
Figure 12-6: DW-MRI Per-Patient Analysis; KM OS Analysis with Log Rank test for 
comparison; Baseline ADC Heterogeneity Parameters 
The patients with higher entropy and/or lower energy (i.e. a wider, more random distribution of 
ADC voxels and/or a less uniform distribution of ADC voxels) on their pre-treatment DW-MRI 
seem to have a shorter OS, but this is not proven statistically (ADCentropy/ADCenergy 
p=0.227/0.198).  
Subgroup analysis of the prostate cancer patients can be seen in Figure 12-7.  Prostate cancer 
patients with a lower baseline ADCentropy and higher baseline ADCenergy (i.e. more homogeneous 
ADC voxel distribution) have an OS benefit, although this has not reached statistical significance, 






Dichotomised at 5.28 
Low (1) - blue line 
High (2) - green line 
Dichotomised at 0.00695 
Low (1) - blue line 
High (2) - green line 
p=0.129 p=0.113 
Figure 12-7: DW-MRI Per-Patient Analysis; KM OS Analysis with Log Rank test for 
comparison; Baseline ADC Heterogeneity Parameters; Prostate patients only  
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12.1.3 %ΔOS Analysis 
12.1.3.1 %ΔADC Parameters 
 %ΔADCmean %ΔADCmedian 






Table 12-4: DW-MRI Per-Patient Analysis; Cox regression OS Univariate Analysis; %Δ ADC 
Parameters 
There is no demonstrable correlation between the %ΔADC parameters and OS when analysed 
using Cox regression (Tbl.12-4).  The following plots (Fig.12-8) display the KM survival analysis 
of %ΔADC parameters. 
%ΔADCmean %ΔADCmedian 
  
Dichotomised at +4.45% (median) 
Low (1) - blue line 
High (2) - green line 
Dichotomised at +3.36% (median) 
Low (1) - blue line 
High (2) - green line 
p=0.129 p=0.129 
Figure 12-8: DW-MRI Per-Patient Analysis; KM OS Analysis with Log Rank test for 
comparison; %ΔADC Parameters 
There is no statistically significant separation of the OS curves for either %ΔADCmean or 
%ΔADCmedian.  There was a significant impact from the tumour group on survival analysis using 
the ADC parameters from the baseline scan.  The plots below (Fig.12-9) record the KM analysis 






Dichotomised at -1.30% 
Low (1) - blue line 
High (2) - green line 
Dichotomised at -1.91% 
Low (1) - blue line 
High (2) - green line 
p=0.057 p=0.057 
Figure 12-9: DW-MRI Per-Patient Analysis; KM OS Analysis with Log Rank test for 
comparison; %Δ ADC Parameters; Prostate patients only 
The OS curves separate in the same direction as for the whole-population analysis, but for just 
the prostate cancer patients it seems the %Δ ADC parameters have prognostic utility for OS.  The 
separations do not quite reach statistical significance at the 0.05 level (p=0.057 for both 
DW-MRI  Per-Patient Analysis 
227 
parameters), but a trend suggests patients with a larger decrease in ADC between scans have a 
survival advantage.  This confirms the findings from the per-lesion analysis.  
12.1.3.2 %ΔtDV 
 %ΔtDV 




Table 12-5: DW-MRI Per-Patient Analysis; Cox regression OS Univariate Analysis; %Δ tDV 
Cox regression analysis does not identify significant correlations the %ΔtDV and the OS (Tbl.12-
5).  Figure 12-10 reports the KM OS analysis for these patients. 
%ΔtDVVOI5 
 
Dichotomised at -7.9% (median) 
Low (1) - blue line 
High (2) - green line 
p=0.091 
Figure 12-10: DW-MRI Per-Patient Analysis; KM OS Analysis; %Δ tDV 
There is separation of the survival curves; patients with a more positive change or increase of the 
tDV between scans have a better OS.  Neither of these findings reach statistical significance, but 
there is a trend towards significance (%ΔtDV p=0.091).  This is not the anticipated result.  Patients 
with an increase in tumour burden were expected to have a poorer OS.  However, throughout this 
analysis the impact on analysis of the tumour subgroups has been significant.  The KM OS 
analysis of just the prostate cancer lesions can be reviewed in Table 12-11, showing a significant 
separation of the survival curves, with a survival advantage for the prostate cancer patients with 




Dichotomised at -3.41%  
Low (1) - blue line 
High (2) - green line 
p=0.028 
Figure 12-11: DW-MRI Per-Patient Analysis; KM OS Analysis; %Δ tDV; Prostate patients 
only 
The tDV has been assumed to be a proxy measure of the tumour within the bone, but this finding 
suggests the target volumes are also including the surrounding bony architecture influenced by 
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both the tumour and by the treatment response.  Sclerosis causes restriction of the DW-MRI 
image, and healing bone metastases undergo sclerosis.  This sclerotic reaction may extend to 
include peri-tumour bone.  The volumes have been defined using the high b-value images, 
exaggerating the impact of differences in diffusion between the tissues, and it is possible the 
volume of image restriction of a metastasis increases when the sclerotic reaction is considered.  
This was also demonstrated with the response analysis of these patients (see previous chapter) 
where an increase in tDV predicted a treatment response. 
12.1.3.3 %Δ Heterogeneity Parameters 
 %ΔADCentropy %ΔADCenergy 






Table 12-6: DW-MRI Per-Patient Analysis; Cox regression OS Univariate Analysis; %Δ ADC 
Heterogeneity Parameters 
There is no significant correlation between the magnitude of the %ΔADC heterogeneity 
parameters and OS when using Cox regression analysis (Tbl.12-6).  
There is no significant separation of survival curves when using KM analysis - the plots can be 
seen below (Fig.12-12). 
%ΔADCentropy %ΔADCenergy 
  
Dichotomised at -0.62% (median) 
Low (1) - blue line 
High (2) - green line 
Dichotomised at -0.09% (median) 
Low (1) - blue line 
High (2) - green line 
p=0.601 p=0.809 
Figure 12-12: DW-MRI Per-Patient Analysis; KM OS Analysis; %Δ ADC Heterogeneity 
Parameters 






Dichotomised at +0.49% 
Low (1) - blue line 
High (2) - green line 
 
Dichotomised at +17.3% 
Low (1) - blue line 
High (2) - green line 
p=0.595 p=0.071 
Figure 12-13: DW-MRI Per-Patient Analysis; KM OS Analysis; %Δ ADC Heterogeneity 
Parameters; Prostate patients only 
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None of the OS curves reach statistical significance, but there is a trend towards significance for 
%ΔADCenergy (p=0.071) suggesting patients with a greater increase in image uniformity (i.e. a shift 
towards homogeneity) had a survival benefit.  This was identified for the prostate cancer lesions 
with per-lesion analysis.  
12.2 PFS Analyses 
19 patients from this study had data available for PFS analysis, 5 breast cancer patients and 14 
prostate cancer patients.  Only 2 breast cancer patients had progressed at the time of data 
analysis (40%), and 12 prostate cancer patients had PD (73.7%).  18 patients had data available 
using the %Δ parameters (5 breast patients and 13 prostate cancer patients). 
12.2.1 Tumour Analysis 
KM PFS analysis of these patients dichotomising the data into the tumour groups can be seen 
below (Fig.12-14).  There is no statistically significant separation of the PFS curves (p=0.242).  
The breast cancer patients have a median PFS of 110 days from treatment initiation, and the 
prostate cancer patients have a median survival of 136 days (91-180 days 95% CI).  The breast 
patient group, however, contains two patients with much longer PFS (no progression at the time 
of data analysis). 
Tumour Group PFS Analysis 
 
P – Prostate Cancer 
B- Breast Cancer 
p=0.242 
Figure 12-14: DW-MRI Per-Patient Analysis; KM PFS Analysis of tumour groups 
12.2.2 Baseline Scan PFS Analysis 
12.2.2.1 ADC Parameters 
 ADCmean ADCmedian 






Table 12-7: DW-MRI Per-Patient Analysis; Cox regression PFS Univariate Analysis; 
Baseline Scan ADC Parameters 
Cox analysis (Tbl.12-7) demonstrates a trend towards a significant correlation between ADCmean 
and the time to PD (ADCmean HR 0.034, p=0.063).  A higher ADCmean is correlated with a lower 
risk of progression.  For these patients, there is no significant correlation between the ADCmedian 
parameters and time to progression.   
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 ADCmean ADCmedian 
KM plot 
  
Dichotomisation 1.24 1.0626 
Median PFS 
in days (95% 
CI) 
≤ 110 (91.9-128.1) 136 (87.24-184.8) 
> 185 (164.5-205.5) 147 (46.96-247.04) 
p-Value  
(Log Rank) 0.046 0.358 
Table 12-8: DW-MRI Per-Patient Analysis; KM PFS Analysis; Baseline ADC Parameters 
The KM plots can be reviewed in Table 12-8, corroborating the Cox regression analysis.  There 
is a significant 75 day median PFS benefit for those with an ADCmean>1.24(p=0.046).  The 
ADCmedian analyses show some separation of the survival curves, again with an OS benefit 
suggested for patients with higher baseline ADC measurements, but the separation does not 
meet statistical significance (p=0.358).   
For these patients the ADC parameters were lower for prostate cancer lesions and more prostate 
patients suffered PD.  KM analysis of the ADC parameters for the prostate cancer patients can 








Dichotomisation 1.24 1.14 
Median PFS 
in days (95% 
CI) 
≤ 117 (76.7-157.3) 110 (85.2-134.8) 
> 147 (64.7-229.3) 177 (139.8-214.2) 
p-Value  
(Log Rank) 0.08 0.279 
Table 12-9: DW-MRI Per-Patient Analysis; KM PFS Analysis; Baseline ADC Parameters; 
Prostate patients only 
 








Table 12-10: DW-MRI Per-Patient Analysis; Cox regression PFS Univariate Analysis; 
Baseline Scan tDV 
There is a nearly significant correlation between tDV and PFS in these patients (Cox regression 
– Tbl.12-10), suggesting a higher baseline tDV is correlated with a higher risk of progression (HR 





Dichotomisation 165.03cm3 (median) 
Median PFS in 
days (95% CI) 
≤ n/a 
> 136 (99.6-172.4) 
p-Value  
(Log Rank) 0.064 
Table 12-11: DW-MRI Per-Patient Analysis; KM PFS Analysis; Baseline tDV 
There is separation of the survival curves, showing a trend towards a PFS benefit for patients 
with a tDV ≤165.03cm3 (p=0.064).   
The prostate cancer patients had larger tDV values.  Analysis of the prostate patients (Tbl.12-12) 
suggests a PFS benefit for smaller lesions, but no statistically significant benefit is demonstrated, 
possibly due to the small number of patients.  The per-lesion analysis did not identify an 
association between the baseline tDV and PFS for the prostate cancer patients. 




Median PFS in 
days (95% CI) 
≤ 136 (52.8-219.2) 
> 101 (42.2-159.8) 
p-Value  
(Log Rank) 0.117 
Table 12-12: DW-MRI Per-Patient Analysis; KM PFS Analysis; Baseline tDV; Prostate 
patients only 
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12.2.2.3 Heterogeneity Parameters 
 ADCentropy ADCenergy 






Table 12-13: DW-MRI Per-Patient Analysis; Cox regression PFS Univariate Analysis; 
Baseline Scan ADC Heterogeneity Parameters 
Cox regression analysis (Tab.12-13) of the baseline heterogeneity parameters does not identify 
any significant correlation between the magnitude of the parameters and the length of PFS of 
these patients. 
KM PFS plots for the ADC heterogeneity parameters have been reported in Table 12-14.  There 
is no significant separation of the survival curves (p=0.317), but the plot suggests a small PFS 
advantage for those patients with lower ADCentropy (i.e. more homogeneous lesions).  The curves 
for ADCenergy do not separate. 
 ADCentropy ADCenergy 
KM plot 
  
Dichotomisation 5.3 (median) 0.0069 
Median PFS in 
days (95% CI) 
≤ 141 (90-192) 117 (96.5-137.5) 
> 110 (96.9-123.1) 141 (125.8-156.2) 
p-Value  
(Log Rank) 0.317 0.741 
Table 12-14: DW-MRI Per-Patient Analysis; KM PFS Analysis; Baseline ADC heterogeneity 
parameters 
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12.2.3 %ΔPFS Analysis 
12.2.3.1 %ΔADC Parameters 
 %ΔADCmean %ΔADCmedian 






Table 12-15: DW-MRI Per-Patient Analysis; Cox regression PFS Univariate Analysis; %Δ 
ADC Parameters 
Cox regression analysis (Tbl.12-15) does not identify any significant correlation between the 
magnitude of the ADCmean and ADCmedian parameters with PFS in these patients.  The graphs and 
survival tables below (Tbl.12-16) demonstrate KM analysis of the ADC data. 
 %ΔADCmean %ΔADCmedian 
KM plot 
  
Dichotomisation +8.949% +4.71% 
Median PFS in 
days (95% CI) 
≤ 110 (70.4-149.6) 136 (86.4-185.6) 
> n/a 141 (n/a) 
p-Value  
(Log Rank) 0.085 0.152 
Table 12-16: DW-MRI Per-Patient Analysis; KM PFS Analysis; %Δ ADC Parameters 
There is no demonstrable statistically significant separation of the PFS curves for the %ΔADC 
parameters, but there is a trend towards significance for %Δ ADCmean (p=0.085), suggesting a 
larger increase in ADC between the scans is associated with a PFS benefit.  However, analysis 
of just the prostate cancer patients does not demonstrate any PFS predictive utility from the %Δ 







Dichotomisation 8.95 4.71 
Median PFS 
in days (95% 
CI) 
≤ 136 (60-212) 136 (60-212) 
> 141 (89.5-192.5) 141 (89.5-192.5) 
p-Value  
(Log Rank) 0.237 0.219 
Table 12-17: DW-MRI Per-Patient Analysis; KM PFS Analysis; %ΔADC Parameters; 
Prostate patients only  
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12.2.3.2 %Δ Volumetric Parameters 
 %ΔtDV 




Table 12-18: DW-MRI Per-Patient Analysis; Cox regression PFS Univariate Analysis; 
%ΔtDV 
There is no correlation identified in these patients between the percentage change in the tDV and 
the PFS (Cox regression – Tbl.12-18).  The KM graphs and survival table below (Tbl.12-19) record 





Median PFS in days 
(95% CI) 
≤ 136 (99.6-172.4) 
> 177 (45.7-308.3) 
p-Value  
(Log Rank) 0.239 
Table 12-19: DW-MRI Per-Patient Analysis; KM PFS Analysis; %ΔtDV 
There is no significant separation of the KM PFS curves (p=0.239) but there is the suggestion of 
a PFS with an increase in tDV between scans.  This unexpected finding was also identified with 
OS analysis.  The KM PFS analysis of just the prostate cancer patients (Tbl.12-23) confirms this 
finding, although there is only a trend towards statistical significance (p=0.062).  tDV is probably 







Median PFS in 
days (95% CI) 
≤ 117 (76.7-157.3) 
> 177 (0-0) 
p-Value  
(Log Rank) 0.062 
Table 12-20: DW-MRI Per-Patient Analysis; KM PFS Analysis; %ΔtDV; Prostate patients 
only 
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12.2.3.3 %Δ Heterogeneity Parameters 
 %ΔADCentropy %ΔADCenergy 






Table 12-21: DW-MRI Per-Patient Analysis; Cox regression PFS Univariate Analysis; %Δ 
ADC Heterogeneity Parameters 
Cox regression analysis (Table 12-21) does not demonstrate a significant correlation between the 
magnitude of the heterogeneity parameters and the PFS of these patients. 
KM analysis for the %ΔADC heterogeneity parameters is recorded in Table 12-22.  There is no 
significant separation of the survival curves.  There is perhaps a suggestion of a small PFS benefit 
for patients with an increase in ADCenergy between the scans but a larger patient population would 
be necessary to interrogate this further. 
 %ΔADCentropy %ΔADCenergy 
KM plot 
  
Dichotomisation -2.16 +7.6% (median) 
Median PFS 
in days (95% 
CI) 
≤ 136 (103.6-168.4) 185 (0-427.6) 
> 177 (82.8-271.2) 136 (92-180) 
p-Value  
(Log Rank) 0.449 0.2 
Table 12-22: DW-MRI Per-Patient Analysis; KM PFS Analysis; %ΔADC Parameters 
The same KM PFS analysis has been performed below for only the prostate cancer patients 
(Tbl.12-23); no significant separation is identified, but, again, perhaps an increase in ADCenergy 







Dichotomisation -1.6 17.3 
Median PFS 
in days (95% 
CI) 
≤ 117 (76.7-157.3) 117 (6.3-227.7) 
> 177 (66.3-287.7) 136 (88-184) 
p-Value  
(Log Rank) 0.486 0.215 
Table 12-23: DW-MRI Per-Patient Analysis; KM PFS Analysis; %Δ ADC heterogeneity 
parameters; Prostate patients only 
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12.3 Discussion 

















All pts p=0.227 
PCa p=0.129 
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Table 12-24: DW-MRI Per-Patient Analysis; Survival analyses; Summary table 
The previous chapter demonstrated little predictive utility from the DW-MRI in these patients.  
However, there appears to be more useful information for prognosis. 
The statistical analysis of the OS and PFS for the two tumour groups does not identify a 
statistically significant difference, but this is probably misleading; only one breast cancer patient 
had died at the time of data analysis, and only 2 of the breast patients developed PD.  With so 
few events in the study group it is difficult to draw firm conclusions about the OS/PFS of each of 
the tumour groups in this study.   
The baseline OS analysis of the ADC parameters is difficult to interpret.  When analysing all the 
patients together the ADC parameters predict OS, with a benefit identified for patients with a 
higher baseline ADC.  However, analysis of the prostate patients only shows an OS benefit for 
those with a lower baseline ADC; ADC parameters are not independent to the tumour type.  This 
OS benefit for prostate cancer lesions was also demonstrated with the per-lesion.  There is no 
direct evidence in the literature to support or refute this finding.  Increased sclerosis causes more 
diffusion restriction and a lower ADC234.  There is an association between increased sclerosis of 
bone metastases and a better prognosis235 in breast cancer metastases. 
The %Δ in ADC parameters have no utility in these patients for predicting OS over and above the 
differentiation of the tumour sub-groups.  With the per-lesion analysis there was a trend of an 
association between a fall in ADC and a PFS benefit for the prostate cancer lesions.  This effect 
has not been translated through to per-patient analysis. 
The baseline tDV data suggests an OS benefit from smaller lesions, but the impact of the tumour 
types is likely to be significant, and analysis of the prostate patients only is non-significant.  The 
PFS analysis also only suggests a trend towards a PFS benefit for the prostate cancer patients, 
but this again is not significant.  A greater burden of bone metastases in prostate cancer is a 
marker of shorter OS240, and the development of the bone scan index as a measure of total 
skeletal burden indicate a worse survival with a higher burden of disease222,223,242.  The per-lesion 
analysis of these patients did not demonstrate a significant association between baseline tDV and 
PFS for the prostate cancer patients. 
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The %Δ tDV parameter for OS and PFS analysis is more difficult to justify.  tDV is used as a 
measure of disease burden within the bone, but it is likely, certainly with the methodology utilised 
in this study, peri-tumour bone is included in the volume, and this is impacted by both the tumour 
and changes in bone architecture with treatment.  An increase in tDV between the scans is 
associated with an OS and PFS benefit.  This is still identified when just prostate cancer patients 
are interrogated.  The per-lesion analysis also demonstrated this finding for the breast cancer 
lesions.  tDV probably encompasses treatment changes in peri-tumour bone architecture. 
Increased tumour heterogeneity was anticipated to be associated with a poorer prognosis172,176.  
The per-lesion analysis demonstrated an OS benefit was associated with a lower ADCentropy and 
higher ADCenergy for the prostate cancer lesions, and a higher baseline ADCenergy was associated 
with a PFS benefit for the breast cancer lesions.  There is no evidence in the literature reporting 
how the ADC heterogeneity parameters of bone metastases behave following treatment. 
The per-patient analyses show a trend for prognostic utility of the ADC heterogeneity parameters.  
A lower ADCentropy and high ADCenergy are associated with an OS benefit for the whole patient 
population, and this relationship persists when prostate cancer patients alone are analysed.  
There is a demonstrable PFS benefit using the baseline ADC heterogeneity parameters; a lower 
ADCentropy (p=0.129) and higher ADCenergy (p=0.113) are associated with this benefit. 
The %ΔADC heterogeneity parameters do not show a strong association with OS, but there is a 
trend towards an increase in ADCenergy being associated with a OS benefit (p=0.071).  An increase 
in ADCenergy between scans was also predicted a median 75-day PFS benefit with per-lesion 
analysis, and this association also persists through to analysis of the prostate cancer patients 
only.  This suggests a prognostic benefit for patients with tumours with a more homogeneous 
ADC voxel distribution before treatment, and those becoming more homogeneous with treatment.   
The previous chapter has not identified predictive utility from the baseline or %ΔADC 
heterogeneity parameters. 
In summary, lower baseline ADC measurements in prostate cancer patients indicate an OS and 
PFS benefit.  The ADC parameters are not independent of the tumour groups; breast and prostate 
cancer quantification parameters behave differently following treatment.  Per-patient analysis 
does not elicit the prognostic utility identified with per-lesion analysis.  This may be because of 
inter-lesion heterogeneity diluting the signal, or the smaller sample size.  
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Chapter 13  DW-MRI - Whole-Body Quantification of Bone 
Metastases 
The methods of this chapter and the statistical approaches for this section can be reviewed in 
Chapter 2.3.5.  This chapter is presented in 4 sections: 13.1-Descriptive statistics and response 
analysis; 13.2-OS Analysis; 13.3-PFS Analysis; 13.4-Discussion. 
13.1 Descriptive Statistics and Response Analysis 
13.1.1 Baseline Scan  
13.1.1.1 ADCWB Parameters 
The baseline ADCWB Parameters are summarised in Table 13-1.  There is no significant difference 
in the distribution of ADCmeanWB and ADCmedianWB (Paired samples t-test: where (t(19)=1.287, 
p=0.214).  The two parameters are closely correlated (Pearson correlation: r=0.998, p<0.0001).  
A correlation would be expected as these two parameters are describing the distribution of the 
same voxels in this study group, and the per-lesion and per-patient target lesion analysis also 
demonstrate a close correlation between these two parameters. 
The box-plots show the means of ADCWB parameter distributions are higher for breast cancer 
patients, but these differences are not statistically significant (non-parametric Mann-Whitney U 
tests: ADCmeanWB p=0.672; ADCmedianWB p=0.735). 
The per-lesion and per-patient target lesion analyses demonstrate the baseline ADC parameters 
were lower for the prostate cancer patients.  Perhaps with a larger study group this would have 
been identified with whole-body analysis, but the whole-body parameters are less sensitive for 
differentiation between the tumour groups using ADC. 
The box-plots of treatment response have similar appearances between the baseline ADC 
parameters.  Those with a treatment response perhaps had higher baseline ADCWB 
measurements, but these differences are not statistically significant (Mann-Whitney U tests: 
ADCmeanWB p=0.849; ADCmedianWB p=0.924).  Analysis of the prostate cancer lesions only does not 
demonstrate any significant difference in the ADC parameters between the response groups 
(ADCmeanWB p=0.513; ADCmedianWB p=0.513).  The baseline ADC parameters from the per-lesion 
and per-patient target lesion analyses also demonstrated no utility in predicting the treatment 
response. 
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 ADCmeanWB ADCmedianWB 
 


































































































 p=0.849 p=0.924 
Table 13-1: WB DW-MRI; Baseline Scan; WB ADC Parameters; All Patients; Descriptive 
statistics (ADC expressed as 10-6 mm2/s) 
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13.1.1.2  tDVWB 




































Table 13-2: WB DW-MRI; Baseline Scan; WB tDV; All Patients; Descriptive statistics 
The box-plots (Tbl.13-2) suggest the breast patients had a larger volume of tDVWB identified, but 
this is not statistically significant (Mann-Whitney U test: p=0.553).   
The data also suggests larger tDVWB measurements were more likely to be associated with PD, 
but again this difference is not significant (Mann-Whitney U test: p=0.633).  When analysing the 
prostate patients independently, there is no demonstrable difference in the tDVWB distribution 
between the response groups (p=0.410). 
The baseline tDVWB does not predict treatment response for these patients. 
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13.1.1.3  ADCWB Heterogeneity Parameters 




































































































 p=0.173 p=0.633 
Table 13-3: WB DW-MRI; Baseline Scan; WB ADC Heterogeneity Parameters; All 
Patients; Descriptive statistics 
The box-plots (Tbl.13-3) suggest the prostate cancer patients have a lower ADCentropyWB and a 
higher ADCenergyWB than the breast cancer patients, suggesting the whole-body parameters are 
tending towards more homogeneity for the prostate cancer patients.  However, these differences 
are not statistically significant (Mann-Whitney U tests: ADCentropyWB p=0.197, ADCenergyWB 
p=0.230). 
There is no demonstrable difference in the distribution of the ADCWB parameters between the 
response groups (Mann-Whitney U tests: ADCentropyWB, p=0.173, ADCenergyWB p=0.633). 
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Sub-group analysis of the tumour groups also shows no significant difference in the between the 
response groups (Prostate: ADCentropyWB p=0.103; ADCenergyWB p=0.410; Breast: ADCentropyWB 
p=0.2; ADCenergyWB p=0.1).   
Baseline Parameters Correlations 
The table below (Tbl.13-4) summarises pairwise correlation analysis between the baseline scan 
parameters (analysed using Spearman Rank correlation tests). 
 ADCmeanWB ADCmedianWB tDVWB ADCentropyWB ADCenergyWB 
ADCmeanWB 1 - - - - 
ADCmedianWB 0.99  
(<0.0001) 
1 - - - 




1 - - 
















Table 13-4: DW-MRI Per-lesion Analysis; Baseline Parameters; Correlations (and p-values) 
using Spearman Rank analysis; All lesions 
A strong correlation is identified between ADCmean and ADCmedian parameters, as would be 
anticipated as they are describing the average of the same VOIs.   
There is a strong negative correlation between tDV and ADCentropyWB (correlation coefficient -0.75, 
p=0.0001), and a strong correlation between tDV and ADCenergyWB (correlation coefficient 0.68 
p=0.0009).   
There is a strong negative correlation between ADCenergyWB and ADCentropyWB (correlation 
coefficient -0.89, p=<0.0001).  
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Table 13-5: WB DW-MRI; Second Scan; WB Parameters; All Patients; Descriptive 
statistics  
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13.1.3 Percentage Change (%Δ) Between Scans 
13.1.3.1 %Δ ADCWB Parameters 




































































































 p=0.387 p=0.387 
Table 13-6: WB DW-MRI; %Δ WB ADC Parameters; All Patients; Descriptive 
statistics 
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Table 13-6 summarises the data for the %Δ whole-body ADC parameters.  There is no statistically 
significant difference in the distributions between the response groups (Mann-Whitney U tests: 
%ΔADCmeanWB p=0.387; %ΔADCmedianWB p=0.387).  There is no predictive utility identified when 
only the prostate cancer patients are analysed (p=0.513 for both parameters). 
The per-lesion analysis showed for the prostate cancer patents an increase in ADCmean between 
scans could predict a treatment response.  This has not been shown with the whole-body 
quantification. 
An examination of the waterfall plots (Figs.13-1/13-2) of the individual patient data suggests the 
changes in whole-body ADCmean and ADCmedian have not been discriminatory in these patients for 
identifying a treatment response.  Most of the patients had a measured increase in the parameter, 
irrespective of the response group.  The largest fall in the ADC parameters was in the PD group, 
but this group also had the patient with the largest measured increase. 
 
Figure 13-1: WB DW-MRI; %Δ ADCmeanWB Parameters; Response Analysis; Waterfall plot of 
all patients 
 
Figure 13-2: WB DW-MRI; %Δ ADCmedianWB Parameters; Response Analysis; Waterfall plot 
of all patients 
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13.1.3.2 %Δ tDVWB 


































Table 13-7: WB DW-MRI; %Δ WB tDV; All Patients; Descriptive statistics 
A wide range of %Δ tDV values have been found in these patients (Tbl.13-7).  The range of 
responses is wider for the prostate cancer patients.  The breast cancer patients mostly had a 
decrease in size of tDV, and the breast cancer patients were more likely to have a clinical 
response.  There is no significant difference in the distribution of %ΔtDV between the tumour 
groups (Mann-Whitney U test: p=0.823). 
Within the progression group there were some lesions with increases and other with decreases 
in tDV.  In the response group, most patients had a decrease in tDV, which would be more in 
keeping with a pathophysiological response of a tumour deposit.  The differences in the 
distributions between the response groups does not meet statistical significance (Independent 
samples t-test, where t(16)=0.049, p=0.289).  When analysing the prostate cancer patients, no 
predictive utility for response is shown (p=0.769). 
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The per-lesion and per-patient target lesion analysis suggested an increase in tDV was 
associated with a treatment response, probably because of a sclerotic reaction in healing 
metastases.  The whole-body parameter has not demonstrated utility in identifying a treatment 
response for these patients. 
The waterfall plot of the individual data (Fig.13-3) shows the change in tDV in these patients 
appears to be unhelpful in identifying a treatment response – there are patients with both increase 
and decreases in tDV in both response groups. 
 
Figure 13-3: WB DW-MRI; %Δ tDVWB Parameters; Response Analysis; Waterfall plot of all 
patients 
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13.1.3.3 %Δ ADCWB Heterogeneity Parameters 





































































































Table 13-8: WB DW-MRI; %Δ WB ADC Heterogeneity Parameters; All Patients; Descriptive 
statistics 
Table 13-8 reports the data for the baseline ADC heterogeneity parameters.  The baseline 
imaging suggested the breast cancer patients had a smaller range of ADCentropyWB.  The box-plots 
show only small changes in ADCentropyWB were noted for the breast patients following treatment.  
There is no statistically significant difference in the distributions of %ΔADCentropyWB between the 
tumour groups (Mann-Whitney U test: p=1.00).  The box plot suggests a larger range of change 
in parameter recorded for the prostate cancer patients, perhaps with a trend towards a larger 
decrease in entropy (i.e. towards homogeneity). 
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Similarly, the distributions of %ΔADCenergyWB suggest there was little demonstrable change in the 
whole-body measurement of ADCenergyWB for the breast cancer patients.  More change (in both 
directions) was identified for the prostate cancer patients.  However, for these data there is 
demonstrate no statistically significant difference in the distributions between tumour groups 
(p=0.823).  The prostate patients perhaps had more of an increase in ADCenergyWB, i.e. a move 
towards uniformity of ADC voxel distribution. 
There is no significant difference between the response groups for either %Δ ADCWB response 
parameter (Mann-Whitney U tests: %ΔADCentropyWB p=0.246, %ΔADCentropyWB p=0.246).  Analysis 
of the prostate cancer patients alone does not identify a utility for predicting the treatment 
response (%ΔADCentropyWB p=0.308, %ΔADCentropyWB p=0.769). 
The waterfall plot below (Figs.13-4/13-5) demonstrates the range of changes within the response 
groups.  Within both response groups there were patients with increases and decreases in the 
heterogeneity parameters, confirming no utility has been identified for detecting a treatment 
response. 
 
Figure 13-4: WB DW-MRI; %Δ ADCentropyWB Parameters; Response Analysis; Waterfall plot 
of all patients 
 
 
Figure 13-5: WB DW-MRI; %Δ ADCenergyWB Parameters; Response Analysis; Waterfall plot 
of all patients 
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13.1.3.4 %Δ Parameters Correlations 
The table below (Tbl.13-9) summarises pairwise correlation analysis between the baseline scan 
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Table 13-9: DW-MRI Per-lesion Analysis; Baseline Parameters; Correlations (and p-values) 
using Spearman Rank analysis; All lesions 
A strong correlation is identified between %ΔADCmean and %ΔADCmedian parameters, as would be 
anticipated as they are describing the average of the same VOIs. 
There is a strong negative correlation between %ΔtDV and %ΔADCentropyWB (correlation coefficient 
-0.93, p<0.0001), and a strong correlation between %ΔtDV and %ΔADCenergyWB (correlation 
coefficient 0.88 p<0.0001).   
There is a strong negative correlation between %ΔADCenergyWB and %ΔADCentropyWB (correlation 
coefficient -0.90, p=<0.0001).  
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13.2 OS Analysis 
13.2.1 Tumour Group 
20 patients from this study had data available for OS analysis, 5 breast cancer patients and 15 
prostate cancer patients.  No breast cancer patients had died at the time of data analysis, and 5 
prostate cancer patients had died (33.3%). 
Chapter 12.1 demonstrated the trend for an OS benefit for the breast cancer patients (KM plot 
can be seen in Fig.13-6). 
Tumour Group OS Analysis 
 
P – Prostate Cancer 
B- Breast Cancer 
p=0.154 
Figure 13-6: DW-MRI Per-Patient Analysis; KM OS Analysis of tumour groups; All Patients; 
Log Rank Analysis 
13.2.2 Baseline Scan  
13.2.2.1 ADCWB Parameters 
 ADCmeanWB ADCmedianWB 






Table 13-10: WB DW-MRI; OS Analysis; Baseline Scan; WB ADC Parameters; All Patients; 
Cox regression analysis 
The Cox regression analysis (Tbl.13-10) does not identify any correlation between the baseline 
ADCWB parameters and the risk of death for these patients.  
ADCmeanWB ADCmedian 
  
Dichotomised at 878.95 
Low (1) - blue line 
High (2) - green line 
Dichotomised at 877.81 
Low (1) - blue line 
High (2) - green line 
p=0.422 p=0.341 
Figure 13-7: WB DW-MRI; OS Analysis; Baseline Scan; WB ADC Parameters; All Patients; 
KM Analysis (ADC expressed as 10-6 mm2/s) 
DW-MRI  Whole-Body Analysis 
252 
Log rank analysis of the KM survival curves (Fig.13-7) does not identify any statistically significant 
separation for either ADCmeanWB or ADCmedianWB.  Although this whole-body analysis has not 
demonstrated a difference in the ADC parameter distributions between the tumour groups, the 
per-lesion level showed a lower ADC for the prostate lesions compared to the breast cancer 
lesions.  KM analysis of only the prostate cancer lesions shows a trend towards an OS benefit for 







Dichotomised at 849.71 
Low (1) - blue line 
High (2) - green line 
Dichotomised at 859.14 
Low (1) - blue line 
High (2) - green line 
p=0.212 p=0.064 
Figure 13-8: WB DW-MRI; OS Analysis; Baseline Scan; WB ADC Parameters; Prostate 
patients only; KM Analysis (ADC expressed as 10-6 mm2/s) 
13.2.2.2 tDVWB 
 tDVWB 




Table 13-11: WB DW-MRI; OS Analysis; Baseline Scan; WB tDV; All Patients; Cox 
regression analysis 
Cox regression analysis (Tbl.13-11) does not identify a significant correlation between tDVWB and 
the risk of death.  The KM analysis below (Fig.13-19) does not demonstrate significant separation 
of the survival curves (p=0.134).  There is however the suggestion of a survival advantage for 







Dichotomised at 210.41cm3 (median) 
Low (1) - blue line 
High (2) - green line 
Dichotomised at 167.23cm3 
Low (1) - blue line 
High (2) - green line 
 
p=0.134 p=0.164  
Figure 13-9: WB DW-MRI; OS Analysis; Baseline Scan; tDV; KM Analysis 
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Analysis of only the prostate cancer patients also suggest an OS advantage for the patients with 
a smaller tDV (Fig.13-9), but again the separation of the survival curves does not reach statistical 
significance (p=0.164). 
13.2.2.3 WB Heterogeneity Parameters 
 ADCentropyWB ADCenergyWB 






Table 13-12: WB DW-MRI; OS Analysis; Baseline Scan; WB ADC Heterogeneity 
Parameters; All Patients; Cox regression analysis 
Cox regression analysis (Fig.13-12) does not identify a correlation between the baseline whole-




Dichotomised at 4.99 
Low (1) - blue line 
High (2) - green line 
Dichotomised at 0.0208 
Low (1) - blue line 
High (2) - green line 
p=0.281 p=0.328 
Figure 13-10: WB DW-MRI; OS Analysis; Baseline Scan; WB ADC Heterogeneity 
Parameters; All Patients; KM Analysis 
There is no significant separation of the survival curves for either parameter when comparing 
using log-rank analysis.  The data has also been analysed for the prostate cancer patients only, 






Dichotomised at 4.988 
Low (1) - blue line 
High (2) - green line 
Dichotomised at 0.0225 
Low (1) - blue line 
High (2) - green line 
p=0.376 p=0.328 
Figure 13-11: WB DW-MRI; OS Analysis; Baseline Scan; WB ADC Heterogeneity 
Parameters; Prostate patients only; KM Analysis 
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13.2.3 %Δ Parameters  
n=19, 5 deaths (all prostate patients)  
13.2.3.1 %ΔADCWB Parameters 
 %ΔADCmeanWB %ΔADCmedianWB 






Table 13-13: WB DW-MRI; OS Analysis; %Δ WB ADC Parameters; All Patients; Cox 
regression analysis 
There is no correlation identified in these patients between the size of change of the ADC 
parameters and OS analysis when compared with Cox regression analysis (Tbl.13-13).  KM 
analysis is reported in Figure 13-12.  
%ΔADCmeanWB %ΔADCmedianWB 
  
Dichotomised at +3.9% 
Low (1) - blue line 
High (2) - green line 
Dichotomised at +4.07% 
Low (1) - blue line 
High (2) - green line 
p=0.011 p=0.032 
Figure 13-12: WB DW-MRI; OS Analysis; %Δ WB ADC Parameters; All Patients; KM 
Analysis 
Significant separation of the OS curves has been identified using the %Δ ADCWB parameters 
suggesting OS benefit for patients with a more negative, or decrease, in the ADC parameters 
between the scans.  There was no demonstrable difference in the %Δ ADC parameters between 
the tumour groups for these patients, but subgroup analysis of the prostate cancer patients shows 
these survival curve separations persist to show OS benefit for a fall in ADC, although with fewer 






Dichotomised at +3.9% 
Low (1) - blue line 
High (2) - green line 
Dichotomised at +4.07% 
Low (1) - blue line 
High (2) - green line 
p=0.049 p=0.128 
Figure 13-13: WB DW-MRI; OS Analysis; %Δ WB ADC Parameters; All Patients; KM 
Analysis  








Table 13-14: WB DW-MRI; OS Analysis; %Δ WB tDV; All Patients; Cox regression analysis 
There is no demonstrable correlation in these patients between the change in tDVWB and OS 
analysis when Cox regression analysis is used (Tbl.13-14).  KM analysis of the data can be 
reviewed below (Fig.13-14). 
%tDVWB 
 
Dichotomised at -31.145% 
Low (1) - blue line 
High (2) - green line 
p=0.371 
Figure 13-14: WB DW-MRI; OS Analysis; %Δ WB tDV; All Patients; KM Analysis 
There is no significant separation of the survival curves using %ΔtDVWB (p=0.371).  Analysis of 
only the prostate cancer patients (Fig.13-15) also demonstrates no utility for these patients for 
predicting their OS. 
%tDVWB (prostate only)  
 
Dichotomised at -67.4% 
Low (1) - blue line 
High (2) - green line 
p=0.343 
Figure 13-15: WB DW-MRI; OS Analysis; %Δ WB tDV; Prostate patients only; KM Analysis 
13.2.3.3 %Δ WB Heterogeneity Parameters 
 
 %ΔADCentropyWB %ΔADCenergyWB 






Table 13-15: WB DW-MRI; OS Analysis; %Δ WB ADC Heterogeneity Parameters; All 
Patients; Cox regression analysis 
There is a demonstrable correlation between the size of change of the whole-body heterogeneity 
parameters and OS, compared using Cox regression analysis (Tbl.13-15).  This is particularly 
noted for %ΔADCentropyWB.  A HR of 0.957 (p=0.045) suggests an increase in ADCentropyWB between 
images is associated with a lower risk of death.  For ADCenergyWB, a fall in the parameter between 
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scans is associated with an OS benefit (HR 1.002 (p=0.093; which is approaching statistical 
significance).  The data has been split at the median for KM OS analysis (Fig.13-16). 
%ΔADCentropyWB %ΔADCenergyWB 
  
Dichotomised at -2.36% 
Low (1) - blue line 
High (2) - green line 
Dichotomised at +8.03% 
Low (1) - blue line 
High (2) - green line 
p=0.017 p=0.067 
Figure 13-16: WB DW-MRI; OS Analysis; %Δ WB ADC Heterogeneity Parameters; All 
Patients; KM Analysis  
For these patients, there has been a significant separation of the KM OS curves using both %Δ 
ADCWB Heterogeneity parameters.  An OS advantage has been noted for patients with a more 
positive change in ADCentropy (a move towards heterogeneity), and a more negative change in 






Dichotomised at +2.25% 
Low (1) - blue line 
High (2) - green line 
Dichotomised at +28.15% 
Low (1) - blue line 
High (2) - green line 
p=0.087 p=0.598 
Figure 13-17: WB DW-MRI; OS Analysis; %Δ WB ADC Heterogeneity Parameters; Prostate 
patients only; KM Analysis  
The KM plots (Fig.13-17) show the analysis for just the prostate cancer patients.  There was no 
demonstrable difference identified in these patients between the %Δ ADC parameters between 
the tumour groups, and subgroup analysis limits the statistical validation with a small study group.  
This analysis suggests persistence of the OS benefit for prostate cancer patients with an increase 
in ADCentropyWB between the scans, but not for %ΔADCenergyWB.  The %Δ ADC heterogeneity 
parameters are strongly correlated with the %ΔtDV but not the other parameters measured.  
%ΔtDV did not show OS predictive utility.  Multivariate analysis is not feasible due to the small 
number of patients to examine if the %Δ heterogeneity parameters are independent predictors of 
OS. 
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13.3 PFS Analysis 
19 patients from this study had data available for PFS analysis, 5 breast cancer patients and 14 
prostate cancer patients.  Only 2 breast cancer patients had progressed at the time of data 
analysis (40%), and 12 prostate cancer patients had PD (73.7%).  18 patients had data available 
using the %Δ parameters (5 breast patients and 13 prostate cancer patients). 
13.3.1 Tumour Group 
The PFS analysis of the tumour groups has been previously recorded (Chapter 12.2.1).  KM PFS 
analysis shows no significant separation of the PFS curves (p=0.242), but the survival curves 
show a trend for PFS benefit for the breast patients (Fig.13-18).  
Tumour Group PFS Analysis 
 
P – Prostate Cancer 
B- Breast Cancer 
p=0.242 
Figure 13-18: DW-MRI Whole-Body Analysis; KM PFS Analysis of tumour groups 
13.3.2 Baseline WB Scan 
13.3.2.1 WB ADCWB Parameters 
 ADCmeanWB ADCmedianWB 






Table 13-16: WB DW-MRI; PFS Analysis; Baseline Scan; WB ADC Parameters; All Patients; 
Cox regression analysis 
There is no correlation in these patients between the size of the baseline ADCWB parameters and 
PFS (Cox regression analysis – Tbl.13-16).  KM analysis can be reviewed in Table 13-17.   There 
is no significant separation of the PFS survival curves for either baseline ADCWB parameter noted 
on the KM PFS plots.  Analysis of just the prostate cancer lesions (Fig.13-19) also demonstrates 
no significance.  There is no demonstrable difference in the baseline whole-body ADC parameters 
identified for these but at the per-lesion analysis prostate cancer metastases had a lower ADC 
than the breast cancer lesions.  The breast cancer patients had a PFS benefit. 
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 ADCmeanWB ADCmedianWB 
KM plot 
  
Dichotomisation 878.95 861.86 
Median PFS in days (95% CI) 
≤ 177 (166.7-187.3) 173 (117.2-228.8) 
> 141 (101-181) 147 (95.7-198.3) 
p-Value 
(Log Rank) 0.557 0.576 
Table 13-17: WB DW-MRI; PFS Analysis; Baseline Scan; WB ADC Parameters; All Patients; 
KM Analysis & Survival Table (ADC expressed as 10-6 mm2/s) 
ADCmeanWB (prostate only) ADCmedianWB (prostate only) 
  
Dichotomised at 846.195 
Low (1) - blue line 
High (2) - green line 
Dichotomised at 861.86 
Low (1) - blue line 
High (2) - green line 
p=0.817 p=0.589 
Figure 13-19: WB DW-MRI; PFS Analysis; Baseline Scan; WB ADC Parameters; All 
Patients; KM Analysis (ADC expressed as 10-6 mm2/s) 
13.3.2.2 tDV 
 tDVWB 




Table 13-18: WB DW-MRI; PFS Analysis; Baseline Scan; WB tDV; All Patients; Cox 
regression analysis 
Cox regression analysis (Tbl.13-18) does not identify a significant correlation between the 
baseline tDVWB and the ultimate PFS of these patients.  The data has been dichotomised for KM 
analysis (Tbl.13-19).  The PFS plots for all patients analysed together suggest a PFS benefit for 
the smaller skeletal burden of disease (p=0.066).  There is no significant difference in these 
patients between the tDV of the tumour types, but at the per-lesion analysis the prostate cancer 
lesions were on average larger than the breast cancer lesions, and the prostate cancer patients 
had a worse PFS.  Subgroup analysis of the prostate cancer lesions is therefore appropriate.  The 
separation of the PFS curves persists when only the prostate cancer lesions are analysed 
(p=0.036). 
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≤ 185 (171.8-198.2) 185 (172.2-197.8) 
> 110 (82.8-137.2) 117 (70.3-163.7) 
p-Value 
(Log Rank) 0.066 0.036 
Table 13-19: WB DW-MRI; PFS Analysis; Baseline Scan; WB tDV; KM Analysis Survival 
Table 
13.3.2.3 Heterogeneity Parameters 
 ADCentropyWB ADCenergyWB 






Table 13-20: WB DW-MRI; PFS Analysis; Baseline Scan; WB ADC Heterogeneity 
Parameters; All Patients; Cox regression analysis 
Cox regression analysis (Tbl.13-20) demonstrates no significant correlation between the baseline 
ADCWB heterogeneity parameters and risk of progression.  The data has also been analysed with 
KM PFS analysis.  The plots and survival table can be seen below (Tbl.13-21): 
 ADCentropyWB ADCenergyWB 
KM plot 
  
Dichotomisation 4.945 0.0183 
Median PFS in days (95% CI) 
≤ 294 (174-414) 110 (86.9-133.1) 
> 101 (71.6-130.4) 185 (167.5-202.5) 
p-Value 
(Log Rank) 0.0002 0.022 
Table 13-21: WB DW-MRI; PFS Analysis; Baseline Scan; WB ADC Heterogeneity 
Parameters; All Patients; KM Analysis Survival Table 
KM PFS analysis of the baseline ADCentropyWB parameters for all patients shows a clear and 
significant separation of the survival curves, with a median 193-day PFS benefit for patients with 
more homogeneous parameters (lower ADCentropyWB and higher ADCenergyWB) (p=0.0002 and 0.022 
respectively).  There was no significant difference in the distribution of the ADC heterogeneity 
parameters identified at the whole-body analysis, but analysis of the prostate cancer patients only 
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shows persistence of this association (Tbl.13-22, p=0.017 for ADCentropyWB, and 0.116 for 








Dichotomisation 4.76 0.0226 
Median PFS in days (95% CI) 
≤ 294 (0-0) 117 (75.9-158.1) 
> 141 (89.9-192.1) 177 (168.9-185.1) 
p-Value 
(Log Rank) 0.017 0.116 
Table 13-22: WB DW-MRI; PFS Analysis; Baseline Scan; WB ADC Heterogeneity 
Parameters; Prostate patients only; KM Analysis Survival Table 
Correlation assessment has shown strong correlations between tDVWB and the ADC 
heterogeneity parameters; multivariate analysis to test whether the ADC heterogeneity 
parameters are independent predictors of OS is not possible due to the small number of patients 
included. 
 
13.3.3 %Δ Parameters 
13.3.3.1 %Δ ADCWB Parameters 
 %ΔADCmeanWB %ΔADCmedianWB 






Table 13-23: WB DW-MRI; PFS Analysis; %Δ WB ADC Parameters; All Patients; Cox 
regression analysis  
There is no statistically significant correlation identified in these patients between the size of the 
change in the ADCWB parameters and the patients’ PFS (Cox regression – Tbl.13-23).  The data 
has been dichotomised at the median for KM analysis (Tbl.13-24).  There is a trend towards a 
significant separation for the %ΔADCWB parameters, with the suggestion on a 63-day median PFS 
benefit in patients with an increase in the ADCWB parameters between scans.   
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 %ΔADCmeanWB %ΔADCmedianWB 
KM plot 
  
Dichotomisation +1.626% +1.8% 
Median PFS in days (95% CI) 
≤ 0 (0-0) 0 (0-0) 
> 141 (91.7-190.3) 141 (91.7-190.3) 
p-Value 
(Log Rank) 0.144 0.144 
Table 13-24: WB DW-MRI; PFS Analysis with optimised dichotomisation; %Δ WB ADC 
Parameters; All Patients; KM Analysis Survival Table 
KM analysis of the prostate cancer lesions only (Fig.13-20) demonstrates no significant 
separation of the survival curves, showing no utility in these patients for prediction of PFS with 






Dichotomised at +3.05% 
Low (1) - blue line 
High (2) - green line 
Dichotomised at +4.07% 
Low (1) - blue line 
High (2) - green line 
p=0.528 p=0.528 
Figure 13-20: WB DW-MRI; PFS Analysis; %Δ WB ADC Parameters; Prostate patients only; 
KM Analysis 
  








Table 13-25: WB DW-MRI; PFS Analysis; %Δ WB tDV; All Patients; Cox regression analysis 
No significant statistical correlation has been identified using a Cox regression (Tbl.13-25) for 
these patients between the size of change of the whole-body tDV and their PFS.  The data has 








≤ 141 (70.9-211.1) 
> 177 (92.2-261.8) 
p-Value 
(Log Rank) 0.955 
Table 13-26: WB DW-MRI; PFS Analysis; %Δ WB tDV; All Patients; KM Analysis Survival 
Table 
No significant separation of the PFS curve has been identified for these patients using log rank 
analysis.  Analysis of just the prostate cancer patients also demonstrates no significant separation 
of the survival curves (p=0.165).   
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13.3.3.3 %Δ Heterogeneity Parameters 
 %ΔADCentropyWB %ΔADCenergyWB 






Table 13-27: WB DW-MRI; PFS Analysis; %Δ WB ADC Heterogeneity Parameters; All 
Patients; Cox regression analysis 
No significant correlation between the size of the %Δ whole-body heterogeneity parameters and 
the patients’ PFS has been identified using Cox regression analysis (Tbl.13-27).   
 %ΔADCentropyWB %ΔADCenergyWB 
KM plot 
  
Dichotomisation -0.71% -11.2 
Median PFS in days (95% CI) 
≤ 117 (96.5-137.5) 173 (0-359.2) 
> 177 (160.9-193.1) 141 (96.4-185.6) 
p-Value 
(Log Rank) 0.186 0.460 
Table 13-28: WB DW-MRI; PFS Analysis; %Δ WB ADC Heterogeneity Parameters; All 
Patients; KM Analysis Survival Table 
There is no significant separation of the PFS curves either %Δ ADC heterogeneity parameter 
(Tbl.13-28).  Analysis of only the prostate cancer patients (Tbl.13-29) has also failed to 








Dichotomisation 0.88 6.41 
Median PFS in days (95% CI) 
≤ 117 (70.3-163.7) 177 (170.4-183.6) 
> 177 (170.6-183.4) 117 (61.6-172.4) 
p-Value  
(Log Rank) 0.361 0.716 
Table 13-29: WB DW-MRI; PFS Analysis; %Δ WB ADC Heterogeneity Parameters; Prostate 
patients only; KM Analysis Survival Table  



















 Tumour  X X X X X 
Response  X X X X X 
↑OS  
↓ 
P pts - p=0.212 
↓ 
P pts - p=0.064 
↓ 
All pts – p=0.134 
P Pts – p=0.164 
X X 
↑PFS X X 
↓ 
P pts – p=0.036 
↓ 
All pts – p=0.0002 
P pts – p=0.017 
↑ 
All pts – p=0.022 




Tumour  X X X X X 
Response  X X X X X 
↑OS  
↓ 
All pts p=0.011 
P pts – p=0.049 
↓ 
All pts p=0.032 
P pts – p=0.128 
X 
↑ 
Pts – p=0.087 
X 
↑PFS X X X X X 
Table 13-30: WB DW-MRI: Summary Table 
In this technical development study, successful whole-body quantification of DW-MRI has been 
achieved.  The parameters used in this analysis have demonstrated their individual utility for bone 
metastases at the lesion level, but also at the patient level when target lesions have quantified 
within patients. 
Target lesion selection is often arbitrary, and quantification of an isolated lesion does not 
necessarily take into account the inter-lesion heterogeneity known to exist in patients with bone 
metastases.  Whole-body quantification gives an opportunity to consider tumour burden and the 
impact of inter-lesion heterogeneity. 
The per-lesion analysis identified the ADC of individual breast and prostate cancer bone 
metastases were statistically different, with a lower ADC identified with prostate cancer 
metastases.  However, no such difference has been identified with the whole-body analysis.  This 
may represent the known heterogeneity of bone metastases within individual patients; within all 
patients there will be bone metastases with relatively high and low ADC parameters and the 
whole-body parameter may be diluted by this heterogeneity.  The known differences between the 
breast and prostate cancer metastases may also be hidden by noise in the whole-body parameter.  
Within the whole-body segmentation there are probably voxels not associated with bone 
metastases.  No utility for predicting a treatment response has been shown for these patients 
from the baseline ADC WB parameters. 
The per-lesion analysis for these patients demonstrated a predictive utility from the %Δ ADC 
parameters; prostate cancer bone metastases with a more positive change in ADC between the 
scans more likely to be in patients with a treatment response.  However, the whole-body 
parameters have not demonstrated an association with the 24-week treatment response.  The 
per-lesion analysis also clearly demonstrated the heterogeneous response of individual bone 
metastases within individual patients.  Whole-body quantification was embarked upon as a 
quantification method incorporating this heterogeneity, but perhaps correlating the more dominant 
change in ADC within the skeleton with the whole-body ADC parameters with the patient’s overall 
clinical outcome.  This has not been demonstrated with the whole-body ADC parameters.  This 
may be due to inter-lesion heterogeneity or and image noise diluting the predictive data. 
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However, the whole-body ADC parameters have a trend towards significance for predicting 
overall-survival; in this group of patients, those with a lower baseline ADCmedianWB had a prolonged 
OS.  This association was also found with per-lesion analysis.  The lower ADC of the prostate 
cancer lesions suggest ADC is lower with sclerosis234.  This OS advantage may suggest the 
degree of sclerosis in these prostate cancer patients is a predictor of OS. This has been shown 
in breast cancer patients previously235.  A decrease in ADC after treatment was associated with 
an OS benefit with per-lesion analysis, perhaps reflecting further sclerosis associated with healing 
bone metastases.  This has been also demonstrated significantly with the whole-body ADC 
parameters; patients with a decrease in ADCmeanWB between the scans have an OS benefit 
(p=0.011). 
Although the ADCWB parameters have predicted for OS, there is no evidence to demonstrate they 
predict PFS for these patients, either from the baseline imaging or percentage change between 
the scans.  The per-lesion analysis also failed to identify an association from the baseline imaging, 
but there was a trend towards prediction of PFS.  Prostate cancer patients with decrease in ADC 
tended towards a PFS benefit; this has not been identified with whole-body analysis. 
The whole-body volume of bone metastatic burden has failed to show prognostic utility for these 
patients.  The per-lesion analysis did not show a statistically significant association between the 
baseline tDV and 24-week treatment response, but the largest lesions were in patients who failed 
to have a sustained treatment response.  Whole-body quantification was expected to amplify this 
measure, resulting in a clinically useful parameter.  However, this has not been demonstrated.  
Similarly, no association between the change in whole-body tDV and the 24-week treatment 
response for these patients. 
The baseline tDVWB shows a trend for prognosis in the prostate cancer lesions; lower skeletal 
burden of disease predicts an OS and PFS benefit.  No predictive utility for OS or PFS has been 
identified by the change in tDV between the scans.  Biologically a prolonged OS might be 
expected in patients with a lower skeletal burden of disease; Perez-Lopez et al showed, for 
prostate cancer patients, a lower baseline tDV was associated with an OS benefit240.  Other 
imaging modalities have shown the disadvantageous effect of bone metastasis burden on 
OS222,223,242.  The prediction of PFS is difficult to explain; the tDV parameters have not shown 
utility for predicting the overall clinical response to treatment, but perhaps a lower baseline volume 
of disease is associated with a less aggressive behaviour of tumour resulting in a prolonged time 
to clinically confirmed progression. 
The baseline or %Δ ADCWB heterogeneity parameters in these patients did not predict the 
treatment response.  The per-lesion analysis also did not show utility. 
The %Δ ADC heterogeneity parameters however seem to show predictive utility for anticipating 
the OS; patients with an increase in ADCentropyWB or fall in ADCenergyWB have an OS benefit 
(p=0.017 and 0.067 respectively).  This statistical significance is not maintained when only the 
prostate cancer patients are analysed.  For the prostate cancer analysis, there is a trend towards 
an OS benefit with %Δ ADCentropyWB (p=0.087).  There was no demonstrable difference in the %Δ 
ADC heterogeneity parameters between the tumour groups identified for these patients, and the 
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tumour subgroup analysis limits statistical comparisons by decreasing the sample size.  The 
patients with a change in the whole-body heterogeneity parameters towards heterogeneity have 
an OS advantage.  A fall in whole-body ADC is associated with an OS benefit, and it might be the 
same underlying processes are influencing the quantification parameters; sclerosis may be 
causing increased image restriction, and resulting in a more heterogeneous voxel distribution 
within the VOI. 
PFS for these patients has been predicted with the baseline whole-body ADC heterogeneity 
parameters, showing a 193-day median PFS benefit for the patients with more homogeneous 
whole-body parameters (lower ADCentropyWB (p=0.0002) and higher ADCenergyWB (70-day PFS 
benefit p=0.022)).  This association was maintained for the prostate cancer patients, although 
with fewer patients at sub-group analysis the statistical associations are not as strong.  However, 
the change in ADC heterogeneity parameters between the scans have not demonstrated PFS 
predictive utility. 
This study has demonstrates successful segmentation of only bone metastases from the whole 
imaged skeleton for quantification.  The inter-lesion heterogeneity of bone metastases is clear, 
and has been demonstrated with the per-lesion analysis of these patients.  Functional imaging 
modalities give the opportunity to interrogate the metabolic characteristics of tumours and the 
peri-tumour environment, and perhaps offer assessment of treatment responses of tumours 
before morphological changes take place.  Quantification of DW-MRI images can identify 
predictive and prognostic behaviours of malignancies.  Quantification in the clinical environment 
requires selection of a target lesion (or a few target lesions) to act as a surrogate marker.  Which 
lesions are the most representative of the clinically most relevant disease is unknown.  Whole-
body quantification might eliminate the necessity for arbitrary selection of lesions, allowing 
quantification of all bone lesions. 
This study has not, however, shown as much predictive and prognostic utility of the whole-body 
parameters as was suggested with the per-lesion analysis or per-patient target lesion analysis, 
and therefore with this methodology and these parameters the whole-body quantification does 
not show utility.  However, the parameters do show trends towards those seen with the per-lesion 
and per-patient analyses.  The prognostic discrimination has been diluted from the per-lesion 
analysis and perhaps improvement of the methodology could improve the clinical information 
gained from whole-body quantification.   
There is likely to be significant noise in the image, with voxels included not represent bone 
metastases.  The segmentation methodology was based on a small study using a high b-value 
image (b value = 1400) to auto-segment areas of high signal within the scan.  This segmentation 
technique was based on per-lesion analysis.  The method used for this study then required 
manual slice-by-slice deletion of non-bone voxels.  This process was too time consuming to have 
clinical utility, and is likely to have introduced error.  Identification of all bone metastatic disease 
was the aim, but there is no gold standard against which to compare the methodology.  For this 
study the individual VOI parameters were weighted based on the volume of the VOI; other 
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methods might be to exclude VOIs below a certain threshold to try and reduce the impact of image 
noise. 
Blackledge et al. have developed a semi-automatic segmentation method using statistical 
methods to segment bone metastases from whole-body diffusion weighted imaging, aiming to 
provide global measurement of tDV and ADC, specifically examining the bone metastases of 
breast and prostate cancer.  Their initial feasibility study as published in 2014, after the design of 
the study reported in this thesis.  They reported on 11 patients with breast or prostate cancer 
bone metastases, and identified an increase in global ADC (gADC) after treatment compared to 
non-responding patients, and non-responding patients demonstrated an increase in tDV154.  None 
of the parameters in this study demonstrate an association with the 24-week treatment response.  
The Blackledge study had a much greater time between MRI images than was designed into this 
thesis study with an average of 22 weeks (range 10.5 - 38weeks).  The time for response 
assessment is not reported in their paper.  The scans at 8-12 weeks might be too early to 
demonstrate clinically relevant changes in signal.   
In 2016 the same group published inter- and intra-observer repeatability of their semi-automatic 
segmentation methodology, concluding excellent repeatability for gADC and gtDV.  I have not 
assessed the reproducibility and repeatability of the technique used in this study; this would be 
more relevant had more clinically relevant utility been identified. 
A limiting factor in this analysis has been the small sample size; small differences in the 
parameters may have clinical relevance, but the recruitment thus far is underpowered to 
demonstrate such differences.  The studies are still open for recruitment, and there are now more 
patients who could be included for future analysis.  It would be clinically relevant to correlate the 
parameter changes with PSA, markers of bone turn over (e.g. ALP), and it would be relevant to 
quantify the sclerotic nature of the metastases (e.g. recording the Hounsfield Units of the CT 
component of the scans). 
The underlying physical and morphological characteristics resulting in the parameter changes are 
unclear.  Histological comparisons of the ADC parameters with prostate cancers have shown 
correlation with Gleason grade and more aggressive histology220.  However, the image signal 
from bone metastases is complicated by the associated bone stroma and marrow, both of which 
will influence the DW-MRI signal, and will be affected by the treatment, and by the mode of 
treatment.  The per-lesion analysis demonstrated significant differences between the 
characteristics of the parameters from prostate and breast bone metastases.  It is unclear if the 
differences are down to the tumour interaction with bone, or if the cytotoxic therapy has a different 




Chapter 14  Discussion 
Bone metastases are common sequelae of malignancy, and cause patients significant morbidity.  
Effective treatments are available, and more are being developed.  Whereas soft tissue metastatic 
deposits can be assessed by changes in size, assessing treatment responses in bone metastases 
in an accurate and timely manner is much more complicated because morphological responses 
to therapy are slow and inconsistent.  Bone metastases are commonly excluded from inclusion 
as index lesions in clinical studies; patients with metastatic disease confined to the bone are 
therefore poorly represented by clinical trials. 
The three prospective clinical trials, FAB-P, FAB-IE and FAB-B have been designed to interrogate 
modern functional imaging techniques and the potential predictive and prognostic data quantified 
from the images. 
This thesis has reported the initial patients recruited to these studies, focusing on 18F-Fluoride 
PET imaging and DW-MRI, with the primary aims of demonstrating the predictive and prognostic 
utility from these images, identifying clinically applicable quantification parameters, and 
developing quantification methods which can be used for the final data analyses of the FAB 
studies. 
What is evident from all the analyses is the differences in imaging characteristics between the 
breast and prostate cancer pathologies.  The pre-treatment functional imaging characteristics are 
different between these diagnoses, and how the quantification parameters change with treatment 
are significantly different.  Future studies should be recommended to focus on individual 
pathologies, or ensure a sufficient population to enable multivariate analysis (which has not been 
possible with this analysis).  Prostate bone metastases are primarily osteoblastic.  Breast cancer 
lesions usually cause a mixed osteoblastic/osteolytic pattern of disease; the underlying biology 
contributing to these phenotypes is likely to be the largest contributing factor to the differences 
identified. 
Intra-patient inter-lesion heterogeneity is noted throughout these results, both at the baseline 
scans, and also heterogeneity of responses to therapy.  Within one patient lesions can be 
identified with diametrically opposed changes of quantification parameters with treatment.  If a 
single lesion were to be used as the clinical index marker quite different conclusions could be 
drawn depending on the selection of the lesion.  Which lesion is the most clinically relevant is 
unclear.  For both the 18F-Fluoride PET and DW-MRI, clear associations between the 
quantification parameters and clinical outcomes were made with per-lesion analysis, but much of 
this utility was not identified at the per-patient level.  This may reflect the much smaller study 
sample of the per-patient analysis affecting the size of difference identifiable with statistical 
comparisons, but the inter-lesion heterogeneity may also have a larger impact when per-patient 
or whole-body analysis is used.  However, it is this level of analysis required for clinical 
application.  Better approaches to per-patient analysis may be necessary to extract the clinical 
predictive and prognostic signal identified with per-lesion analysis. 
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The 18F-Fluoride PET per-lesion analysis provided 62 metastases for analysis, with 24 breast 
cancer lesions and 38 prostate cancer lesions.  Only 2 of the prostate cancer lesions represented 
a patient with a treatment response, which has limited some of the tumour-subgroup analyses.  
No baseline 18F-Fluoride parameter has been shown in this analysis to predict the 24-week 
treatment response.  However, an increase in SUVmax (p=0.048) (trend with SUVmean (p=0.065)) 
after 8 weeks of treatment was predictive of the 24-week treatment response for the breast cancer 
lesions.  The change in 18F-Fluoride metabolic volume did not predict treatment response, and 
for some patients with a treatment response the volume of tracer uptake increased, which was 
unexpected and may reflect a healing osteoblastic driven response within the peri-tumour bone.  
For the breast cancer lesions, there was a trend towards significance for using the heterogeneity 
parameters to identify a treatment response at 8 weeks, with a response more likely in those with 
a change towards homogeneity (decrease in SUVentropy (p=0.140) and increase in SUVenergy 
(p=0.093).  Ki is not predictive.  There is significant correlation between %Δ SUV parameters and 
heterogeneity parameters, but there are too few cases for multivariate analysis to identify if they 
perform as independent predictors. 
The baseline 18F-Fluoride scan, with per-lesion analysis, showed there is prognostic information 
to be elicited.  Lesions with lower SUVmean/max/peak (p=0.0002), lower SUVentropy (p=0.0002) and 
higher SUVenergy (p=0.0004) (suggesting a less random and more uniform distribution of SUV 
voxels), and a lower Ki (p=0.001) were associated with a longer OS.  There is significant and 
strong correlation between these parameters, but multivariate analysis to identify independent 
prognostic factors is not feasible with this study size.  This effect seemed independent of tumour 
subgroup analysis.  These parameters were not shown to be prognostic of PFS.   
How these 18F-Fluoride parameters changed with treatment was also associated with OS 
prognostication. Lesions with an increase in SUVmean/median/peak (p=0.016,0.001,0.014), increase in 
SUVentropy (p=0.014) and fall in SUVenergy (p=0.008) were associated with an OS benefit; these 
associations were also identified when only the prostate lesions were analysed.  As previously 
mentioned, these parameters are all closely correlated, and further analysis of a larger study 
group would be necessary to identify independence of these prognosticators.  Volumetric 
parametersi demonstrated no utility for these patients.  An increased 18F-Fluoride avidity 
demonstrates increased osteoblastic activity, and the association with OS might suggest healing 
of the metastatic deposits, although there was no association for these parameters with the 24-
week response assessment or PFS.  This may reflect a different biology of the underlying 
malignancies, with a longer course of the disease despite no demonstrable benefit in PFS 
following this line of therapy. 
None of this predictive and prognostic utility was carried through to the per-patient analysis.  There 
were too few patients to perform tumour-subgroup analyses.  Differences were suggested 
between the response groups, a larger study group might confirm these differences.  Whether 
these differences were due the tumour group or the biology of the tumour deposits, the per-patient 
analysis measured these differences.   If there is clinically predictive or prognostic utility a larger 
group might identify this.  It is not clear if it is the target lesion selection, inter-lesion heterogeneity, 
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or the reduction in sample size preventing the predictive and prognostic utility shown at per-lesion 
analysis being continued through to analysis at the patient level. 
The per-patient analysis of the 18F-Fluoride PET did however provide an opportunity to 
demonstrate the significant impact the VOI definition method has on the resulting parameters.  As 
expected, SUVmax and SUVpeak are much less affected by the choice of VOI definition method 
than the other parameters.  SUVmean, with the potential benefit of representing the full VOI voxel 
population (rather than just a sample, such as SUVmax or SUVpeak) is significantly affected by the 
choice of iso-contour.  The statistical FLAB method for VOI definition has produced parameters 
most similar to the 27% iso-contour, used as the method felt most likely to represent the PET 
volume matching the sclerotic component on CT imaging.   
The %Δ 18F-Fluoride PET parameters show less variation across the VOI methods than the 
baseline parameters for the relative iso-contour methods based on the SUVmax of each lesion.  
The parameters measured using the same SUV iso-contour applied to the baseline imaging 
showed much greater differences.  
It had been an aim to identify the VOI method showing the best clinical utility; unfortunately, due 
to the lack of predictive or prognostic associations identified with per-patient analysis, it has not 
been possible to select the better methodology.  However, consistency of methodology is clearly 
a priority.  The higher degree of consistency of the %Δ parameters between relative iso-contour 
VOI methods suggests these parameters might be more comparable between studies irrespective 
of the chosen iso-contour for VOI definition, providing the same method is used for the baseline 
and subsequent scan for calculating the percentage change.  The FLAB method most similar to 
the 27% iso-contour is shown to best match sclerosis.  Others have shown FLAB to be more 
reproducible than iso-contour methods - a clear advantage.  Current computation limitations 
restrict the use of FLAB for whole-body analysis. 
There is limited evidence against which to compare the findings of the 18F-Fluoride analysis.  
Changes in 18F-Fluoride SUV of prostate bone metastases correlates with PSA140,195, and 
deceases in breast cancer metastasis SUV following successful treatment196.  Others have shown 
no predictive utility191, nor prognostic use 204,206.  The skeletal burden of disease can predict OS204.  
The baseline per-lesion analysis of the DW-MRI scans has suggested more predictive and 
prognostic potential than the 18F-Fluoride scans, but this analysis had the benefit of a larger study 
population.  The ADC parameters (mean and median) of the baseline imaging were significantly 
different between the breast and prostate tumours.  This may represent the increased sclerotic 
component expected in osteoblastic prostate cancer metastases.  The prostate lesions on 
average had a lower baseline ADC, perhaps with the sclerotic reaction causing diffusion 
restriction.  These baseline ADC parameters have not been shown to predict treatment response, 
but the heterogeneity parameters showed a trend towards predictive utility.  Breast lesions with a 
lower ADCentropy (p=0.069) and higher ADCenergy (p=0.059) (i.e. more homogeneity of SUV voxel 
distribution) were more likely to be identified in patients with a treatment response. 
An increase in ADC following successful treatment has predicted a treatment response for the 
prostate cancer lesions (p=0.029).  A similar trend was suggested for the breast cancer lesions, 
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but there were too few to achieve statistical significance.  Others have reported an increase in 
ADC following successful therapy in skeletal malignancies 58,148,157,229-231, and specifically prostate 
cancer bone metastases151-153,232,233.  Volumetric parameters have shown no predictive utility from 
per-lesion analysis of the DW-MRI data. 
The DW-MRI data, at the per-lesion analysis level, has also shown great promise for clinical 
prognostic application.  A lower baseline ADC predicts for an OS benefit of the prostate cancer 
lesions (p≤0.05), but did not predict PFS in these patients.  ADCenergy was also shown to have 
utility, with more uniform values (higher) predicting an OS benefit for the prostate cancer lesions 
and PFS for breast cancer lesions.   
An increase in ADC predicted a clinical treatment response for the prostate cancer lesions, but in 
the same lesions a fall in ADC between scans is associated with an OS benefit (p=0.005).  An 
association between treatment response and survival might be anticipated, but this result does 
not suggest this for these patients.  Without fully understanding what is causing the ADC signal 
change in the bone metastases following treatment it is difficult to explain this finding.  There was 
a trend seen in this analysis for a PFS advantage for prostate cancer lesions showing a fall in 
ADC, but for breast cancer lesions with an increase in ADC.  Similarly, a fall in ADCentropy and rise 
in ADCenergy between scans predicts a PFS benefit for the prostate cancer lesions, but the 
converse pattern is associated with a PFS benefit for the breast cancer lesions.  The underlying 
pathophysiology of the tumour, the tumour-bone reaction and the treatment is therefore 
influencing the ADC signal, and further work will be necessary to understand the 
pathophysiological processes behind the signal changes. 
Despite the clinical utility suggested from the per-lesion analysis, the DW-MRI has proven less 
useful at the per-patient analysis.  This may be due to the much smaller study size, or may reflect 
the target-lesion selection is not representing the clinically relevant disease sufficiently.  The inter-
lesion heterogeneity may be diluting the predictive and prognostic signal when up to 5 lesions are 
quantified per patient.  The only parameter to suggest utility was the tDV, where an increase in 
tDV predicted a treatment response for the prostate cancer patients (p=0.026).  An increase in 
size suggests the tDV is not a measure of the tumour cells, but is also measuring the associated 
bone microenvironment, and changes in the bone following treatment.  A healing osteoblastic 
reaction causing sclerosis could lead to image restriction, and a larger VOI defined on the 
extrapolated b-value image. 
There is no evidence in the literature to suggest ADC measurements predict the ultimate clinical 
treatment response of bone metastases.  There is, however, an increasing body of evidence to 
suggest a lower ADC in tumour tissue (not bone metastases) before therapy is associated with 
an increased response rate145,213-219.  There is evidence to suggest the volume of osseous disease 
is prognostic in prostate cancer222,223, but there is no evidence showing the baseline volume of 
bone metastases is predictive of treatment response.  A correlation between heterogeneity and 
the prostate cancer Gleason grade has been reported172,176,177,224, and Gleason grading is 
predictive of the clinical course of the disease.  Others have reported a rise in ADC following a 
Discussion 
272 
treatment response in malignancies involving the skeleton58,148,157,229-231, and specifically prostate 
cancer bone metastases151-153,232,233. 
The whole-body analyses were an attempt to identify methods for segmenting out all the skeletal 
disease; hypothesising clinical utility for quantification of the majority of skeletal disease because 
identification of a single, or few, clinically relevant target lesions is difficult and uncertain.  
The skeletal segmentation of the PET scan from the CT component of the PET/CT is perhaps 
more clinically useful, although with the 18F-Fluoride tracer this technique did not yield significant 
predictive or prognostic information.  This technique was relatively quick and easy to apply, and 
might be useful for other PET tracers where there is more non-skeletal physiologic uptake, or for 
metastatic disease with bone and soft tissue disease.  Prognostic information was gained from 
the whole-body 18F-Fluoride PET analysis not seen with the per-patent analysis.  An increase in 
SUVmeanWB between scans suggested a PFS benefit for the prostate cancer patients (p=0.025), 
as did a fall in TLA (p=0.025).  The MTV showed a trend towards benefit, but the combination of 
MTV and SUVmeanWB has resulted, for these patients, in a more discriminatory parameter in TLA.   
The whole-body DW-MRI analysis has shown a PFS benefit for patients with a lower baseline 
tDVWB, ADCentropyWB and higher ADCenergyWB (i.e. smaller tumour burden and more homogeneous 
ADC voxel distribution).  A fall in ADCmeanWB and ADCmedianWB between scans is predictive of an 
OS benefit, as identified at the per-patient analysis. 
The inter-lesion heterogeneity seen within patients is a justification for interrogating the whole-
skeletal burden. There are many other ways this data could be analysed, including descriptions 
of the whole skeletal population of disease, such as kurtosis and skewness.  These could be 
investigated in future analyses. 
However, this thesis has shown whole skeletal segmentation of functional imaging data is readily 
achievable, and this may have significant clinical relevance.  One more immediate next analysis 
will be to examine the volume of the segmented CT component of the PET/CT scans, with the 
aim of concluding the percentage skeletal burden of metastases as other groups have clearly 
demonstrated the prognostic value of this approach205. 
There are limitation with these studies.  The study population, particularly at the per-patient 
analysis, is relatively small, particularly as the influence of the tumour sub-groups is significant.  
The same patients, and lesions, have been used for all these studies; correction could be applied 
to the statistical level of significance to take these multiple analyses into account, but this has not 
been applied as the studies have been exploratory in nature.  This level of scrutiny will however 
be necessary when the trials reach full recruitment for final analysis. 
When designing imaging methodology the repeatability and reproducibility of approaches is a vital 
component; before selecting the VOI methodology for final data analysis it will be necessary to 
consider both of these.  Although the VOI methods have not shown superiority from a clinical 
perspective in these preliminary studies, there are significant differences between the resulting 




Future developments of this analysis will be to include correlation with tumour markers and 
markers of bone turnover; particularly with the differences identified between the tumour types it 
will be necessary to identify changes in bone turnover resulting in the signal changes identified.  
Sclerosis is probably impacting the ADC signal (and, by the tracer mechanism, 18F-Fluoride 
uptake); comparison of the ADC with a measure of the lesion sclerosis (for example, using 
Hounsfield unit measurements from the CT scan) may indicate further the bone changes leading 
to the signal variations.  Histological correlation would be the gold-standard in this setting.
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Chapter 15  Conclusions 
Quantification of 18F-Fluoride PET and DW-MRI images of bone metastases, it was hypothesised, 
would enable earlier prediction of the 24-week response assessment.  This initial analysis 
certainly demonstrates the ability of both imaging techniques to discern a treatment response at 
only 8 to 12 weeks after starting therapy, implying clinical utility as imaging biomarkers of early 
response.  In addition, prognostic utility has been suggested for both OS and PFS. 
Breast and prostate cancer bone metastases have demonstrably different imaging 
characteristics; the baseline parameters were different, and how parameters changed with 
treatment was dependent on the tumour-specific pathophysiology of the bone lesions.  This was 
seen with the changes in ADC; a fall in ADC was associated with a PFS benefit for prostate cancer 
lesions, but the converse was seen with breast cancer lesions.  The specific cellular processes 
affecting the ADC parameters are uncertain, but clearly tumour-specific analyses of the scans 
need to be developed, and a unified approach for all bone metastases is misguided. 
The impact on the 18F-Fluoride parameters by the VOI delineation methods is significant.  The 
parameters describing the full VOI voxel population (SUVmean, volumetric and heterogeneity 
parameters) are affected more than those describing only a sample (SUVmax and SUVpeak), 
showing a clear practical advantage for these parameters.  It has not been possible to identify a 
superior VOI method.  The per-patient study population was perhaps too small to identify the 
predictive and prognostic utility suggested from per-lesion analysis.  Consistency of methodology 
is vital for meaningful comparisons to be made. 
Intra-patient inter-lesion heterogeneity has been a predominant feature through this analysis.  
Lesions within individual patients have been shown to have diametrically opposed changes in 
parameters following therapy; quantification using only target lesions is reliant on identification of 
the most clinically relevant lesions, and the right approach to this is unclear.  The per-patient 
analysis did not show the same response and survival discrimination identified with per-lesion 
analysis.  The most clinically indicative bone metastases may not have been selected for analysis, 
or the smaller sample size may be limiting the analysis.  Inclusion of all skeletal bone metastases 
for whole-body quantification was hypothesised to address this target lesion selection problem. 
Whole-body quantification methods, producing parameters describing the whole-skeletal 
metastatic burden, have been shown to be readily achievable.  Whole-body 18F-Fluoride PET 
analysis identified discriminatory image signal, showing expected differences between the 
prostate and breast cancer lesions.  However, clinical utility was not shown, perhaps limited by 
the sample size and uncertainty of the best segmentation threshold to minimise non-malignant 
disease in the quantification. 
Whole-body DW-MRI imaging, with a larger study sample, demonstrated prognostic utility, both 
of overall and progression free survival, independent of the tumour groups.  This was not with 
greater accuracy than target lesion per-patient analysis. 
This thesis was expected to guide methodological approaches for the final data analysis of the 
FAB trials.  The parameters selected have all suggested varying degrees of utility, but describe 
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the voxel distribution in a variety of ways maximising the likelihood of extracting clinically relevant 
data from the scans.  The choice of VOI definition method for 18F-Fluoride quantification is 
fundamental, and further work will be necessary to identify the best method to take forward.  
Reproducibility and repeatability will inform this decision.  FLAB, with superior reproducibility to 
iso-contour methods, indicates an advantage.   
The next key step is to confirm quantification methodologies that translate the predictive and 
prognostic utility of these functional imaging methods, demonstrated at the per-lesion level, into 
applicable methods for prediction and prognostication of cancer patients undergoing treatments 
in the clinic. 
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Chapter 17  Appendix 1 - Trial Design 
17.1 Introduction 
The results reported in this thesis are the preliminary analyses of data from a family of three 
prospective complementary functional imaging studies (Functional Assessment of Bone 
metastases (FAB) – Prostate (FAB-P), Breast (FAB-B), and Integrin Expression (FAB-IE)).  These 
are, at the time of writing, still recruiting patients.  These three studies are aiming to identify 
functional imaging biomarkers of bone metastases to predict treatment response earlier than is 
currently achievable with standard clinical and radiological approaches. 
For completeness, the following chapter summaries the three studies from which data for this 
thesis has drawn.  The aims and objectives of these studies is not the primary focus of this thesis 
and will be achieved after full recruitment has been met. 
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17.2 FAB-P Methods 
17.2.1 FAB-P Overview 
FAB-P (Functional Assessment of Bone metastases – Prostate) is a prospective exploratory non-
randomised study, aiming to recruit 34 patients with confirmed progressive bone predominant 
metastatic prostate cancer.  At baseline, all patients will receive a whole-body MRI with DW-MRI, 
a dynamic localised 11C-choline PET/CT scan, a static whole-body 11C-Choline PET/CT scan and 
a static whole-body 18F-Fluoride PET/CT scan before starting a new line in systemic 
chemotherapy with docetaxel.  Patients will complete a clinical pain assessment questionnaire 
and have serum measurement of PSA, ALP and bone turn over markers.  Patients will have had 
imaging of their bone disease (either a bone scan or CT) to determine PD as part of their routine 
care.  The imaging and clinical assessments will be repeated eight weeks after starting the new 
treatment, with further pain assessment and blood tests at 12 and 24 weeks after initiation of 
therapy.  If patients have increased activity on the week-8 18F-Fluoride scan suggesting a possible 
flare response, a further 18F-Fluoride PET/CT scan at 12 weeks will be indicated for further 
assessment.  FAB-P has Research Ethics Committee approval (NRES Committee South East 
Coast, REC reference 12/LO/0830) and ARSAC approval (certificate reference number 
261/3186/28833) 
17.2.2 FAB-P Objectives 
The primary objective of FAB-P is to identify a treatment response or PD earlier (at 8 weeks) than 
current clinical and radiological assessment (PCWG2 guidelines) using DW-MRI and PET 
biomarkers.  Secondarily FAB-P will be used to determine the diagnostic accuracy of each 
functional imaging method in staging the skeleton before treatment starts, and enable exploration 
of difference in baseline measurements from each method between subsequent responders and 
non-responders.  Correlation of changes between scans with changes in serum biomarkers (PSA, 
ALP and bone turn over markers) will be sought. 
17.2.3 FAB-P Planned recruitment 
Sample size estimation is important to determine how many participants are necessary to 
adequately interrogate the study hypothesis.  If too few participants are recruited the results may 
not achieve statistical significance; if too many, this is an unnecessary use of trial resources and 
study participants.  Several factors contribute to the required sample size.  For a study measuring 
therapeutic response it is necessary to consider the size of response that might be clinically 
relevant, often referred to as ∂.  The smaller the change to be identified, the larger the required 
sample size necessary to prove the change is real, and not simply random error.  There needs to 
be a practical balance struck; too large a difference required to identify a ‘response’ with the 
technique or treatment under investigation may limit the clinical usefulness of the study, and make 
it an unattainably large target to achieve. 
Alman243 suggested a nomogram to help select an appropriate sample size.  He suggests the use 
of a ‘standardised difference’, a standardised measure of the relevant difference that might be 
identified.  For example, in a PET response study it might be deemed clinically relevant to expect 
a reduction in SUV of 3 Bq/ml in participants who have a treatment response.  Previous 
experience might indicate that the standard deviation (s) of SUV uptake is 2 Bq/ml, and thus the 
standardised difference can be calculated by 2/3 (s/∂).  A decision is needed as to what 
significance level is required, i.e. the probability that a finding is true (often referred to as α).  This 
is usually expected to be a two-sided significance level, representing the notion that the result 
might change in one of two directions, either getting larger or smaller.  The power of a study is 
the probability that the outcome is not a false negative.  If the probability of a false negative is β, 
power=1-β.  Accepted academic convention normally requires a significance level of 0.05 or 
lower, but if multiple variables are to be measured it might be necessary to plan for a lower 
significance level.  A power of between 80-90% is normally required243.  The greater the required 
significance level and the power, the larger sample size is necessary.  
Particularly in early exploratory research the standard deviation of the variables may not be known 
before the study starts.  Altman suggests using the initial data from a study to identify the standard 
deviation before finalising the required sample size244.  This approach, however, is not suitable 
for modern clinical studies requiring extensive regulatory oversight and pre-planning.  He also 
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suggests that a standardised difference of 1.0 can be used, signifying a difference of greater than 
1 standard deviation, irrespective of the actual value of the standard deviation244. 
At the time of writing clinically relevant differences in PET or MRI quantification parameters are 
not clearly defined in the literature that might correspond with an assessment of treatment 
response. 
Therefore, aiming for a power of 80%, a statistical significance of p=0.05, and an assumed 
standardised difference of 1.0, it is possible to read from Altman’s nomogram that a study group 
of around 30 is required.  It was therefore concluded that a study group of 34 was required, to 
allow some leeway for participants who may withdraw from the study. 
This technique could be criticised because of the number of variables to be examined and the 
different imaging techniques to be interrogated within the same study.  A Bonferroni correction 
for multiple variables would result in a lower p-value for statistical significance.  However, this 
would significantly increase the number of patients required.  This research is preliminary 
research into the response assessment of bone metastases, and therefore a practical study group 
size has been necessary. 
17.2.4 FAB-P Inclusion Criteria 
Only men over 18 years of age with histologically confirmed prostate cancer, and with active 
skeletal-predominant disease, who are treatment naïve or have PD, and are to embark on new 
docetaxel chemotherapy, who are able and willing to give written informed consent, and who are 
willing and able to comply with the scheduled visits and tests, will be included in the study. 
17.2.5 FAB-P Exclusion Criteria 
Patients with uncontrolled concomitant medical conditions, contraindications to MR imaging, or 
likely to require palliative radiotherapy within the first 8 weeks of treatment, likely to require G-
CSF support, or those commencing on concomitant bisphosphonate therapy, will be excluded 
from the study.  Bisphosphonates have anti-osteoclastic, and possibly anti-tumour, function, and 
were therefore excluded to limit response assessment to anti-tumour therapies.  
17.2.6 FAB-P PET Scan Procedure 
Both PET scans can be completed on the same day due to the short half-life of 11C.  Patients will 
be fasted for 4 hours prior to the 11C-choline PET/CT.  740MBq of 11C-choline will be administered, 
and a dynamic PET scan will be acquired over a target bone lesion identified from recent imaging 
(if possible the target lesion will be selected to allow inclusion of the mediastinal blood pool in the 
field of view.)  A whole-body 11C-choline PET scan will then be obtained from mid-thigh to skull 
base, starting 10 minutes after injection, and after a low-dose CT scan for attenuation correction 
and image fusion.  Venous blood samples (to measure plasma activity) will be taken at 11 and 40 
(exact timings will be recorded; see SOP in Appendix). 
60 minutes after the 11C-Choline injection, 250MBq of 18F-Fluoride tracer will be administered.  
18F-fluoride PET scans will be acquired from mid-thigh to the skull base at 60 minutes after tracer 
injection.  Venous blood samples will be taken at 55 and 90 minutes after 18F-Fluoride injection 
(i.e. before and after the whole-body scan) (please see SOP in Appendix). 
PET scanning will be repeated 8 weeks after initiation of the new systemic therapy.  The same 
bone lesion as baseline imaging will be imaged for the dynamic component of the 11C-Choline 
PET.  If patients are identified as having a possible flare-response on the 8 week 18F-Fluoride 
scan a further 18F-Fluoride PET/CT can be carried out at 12 weeks. 
17.2.7 FAB-P MRI Procedure 
No specific patient preparation is necessary.  Whole-Body MRI with DW-MRI will be performed 
using a 1.5T MR imaging system (Echo-planar spin-echo technique, free breathing, STIR fat 
suppression, with two b-values of 0 and 800 s/mm2, and patients will be scanned from skull base 
to mid-thigh).  Repeat DW-MRI imaging will be undertaken 8 weeks after initiation of the systemic 
therapy. 
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17.2.8 FAB-P Response Assessment 
17.2.9 FAB-P Clinical Response Assessment 
The patients will be recruited from the treatment centre prostate cancer clinics; all therapies and 
clinical follow up assessments and investigations are at the discretion of the clinical teams.   
A response assessment will be made up to 24 weeks utilising the Prostate Cancer Working Group 
(PCWG2) criteria for defining PD, alongside the clinical judgement of the clinical teams primarily 
involved with the patient.  The clinical teams, blinded to the results of the trial scans, will assess 
whether the patient has clinically responded or not.  PD by 24 weeks will be guided by the PCWG2 
criteria (see table below).   
Feature Definition of Progression 
PSA 
If PSA decline from baseline 
• ≥25% and ≥2ng/mL above nadir, 
confirmed at least 3 weeks later 
If no PSA decline from baseline  
• ≥25% and ≥2ng/mL after 12 
weeks 
(NB - Ignore early rises in PSA before 12 weeks of 
treatment, unless other evidence of progression) 
Soft Tissue 
Lesions 
As RECIST criteria 
Bone 
Lesions 
New lesions confirmed on repeat scan at 
least 6 weeks later 
Symptoms 
Clinical suspicion confirmed by 
continuation/progression of symptoms 
with second review at least 3 weeks later 
Table 17-1: Summary of PCGW2 Guidelines for defining PD132 
A response to treatment will be defined as non-progression.  There is no limitation within this 
study as to when response assessments or therapy changes might be made by the clinical teams 
17.2.10 FAB-P PET - Response Assessment 
At baseline, an independent reviewer (an experienced nuclear medicine physician), blinded to the 
conventional staging results will assess each scan, and record the disease stage and all sites of 
disease involvement, documenting the number and location of visible sites of disease that show 
increased metabolic activity greater than the background normal tissue levels.  The largest and/or 
hottest 5 lesions will undergo further analysis with measurement of SUVmean and SUVmax for each.  
The mean values from the 5 lesions will be used as the overall semi-quantitative score of 
metabolic activity in each patient, and will be compared between baseline and 8 weeks.   
PERCIST response criteria will be used to classify treatment response on the PET images83: 
1. Partial Metabolic Response (PMR) = >30% reduction in SUL (SUV corrected to lean body 
mass) peak 
2. Stable Metabolic Disease (SMD) = Neither complete metabolic response, PMD nor SMD 
3. Progressive Metabolic Disease (PMD) = >30% increase in SUL peak (with at least 
absolute rise of 0.8SUL) OR visible increase in uptake OR new metabolically active 
lesions 
The parameter Ki will also be measured for each representative lesion using the 18F-fluoride PET 
data. 
17.2.11 FAB-P DW-MRI - Response Assessment 
At baseline, independent reviewers blinded to the conventional staging results will assess each 
scan, and record sites of metastatic disease using a confidence score and subsequently 
corroborated with all available imaging findings.  An ADC map will be created for each scan, and 
for response analysis differences in mean ADC values between pre-treatment and post-treatment 
will be recorded.  ADC values will be calculated on a per patient and a per lesion basis to include 
up to the largest 5 lesions per patient.  The ADCmean value will be recorded for each of the five 
lesions, and the average of these will be recorded.  For each patient and lesion the absolute and 
percentage difference in ADCmean between baseline and post-treatment will be calculated.  
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Progressors will be defined by a greater than 12% decrease in mean ADC values.  Stable disease 
will be represented by ADC values between baseline and a 12% decrease.  Receiver operator 
characteristic analysis will be used to identify a threshold value that best dichotomises patients 
into response groups. 
17.2.12 FAB-P End Points 
• Clinical/radiological response (as per PCWG2 guidelines) at up to 24 weeks 
• 11C-Choline response (SUVmax, SUVmean, SULpeak) at 8 weeks 
• 18F-Fluoride response (SUVmax, SUVmean, SULpeak, Ki) at 8 weeks 
• DW-MRI response (ADCmean) at 8 weeks 
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17.3 FAB-IE Methods 
17.3.1 FAB-IE Overview 
FAB-IE (Functional Assessment of Bone metastases – Integrin Expression) is a prospective 
exploratory non-randomised study aiming to recruit 75 patients with confirmed progressive bony 
metastatic disease from prostate cancer (25 patients), breast cancer (25 patients), and 
progressive multiple myeloma (25 patients).  Patients who meet the inclusion criteria will be 
considered for recruitment if they are to be started on a new course of conventional systemic 
therapy.  For prostate cancer, this treatment will be Abiraterone.  For breast cancer and multiple 
myeloma patients this will be a chemotherapy regimen at the discretion of the treating oncologist.  
At baseline, before treatment starts, all patients will receive a whole-body DW-MRI scan, a DCE-
MRI of a specified target lesion, and a 99mTc-Maraciclatide SPECT-CT (consisting of a dynamic 
scan over the specified target lesion, a whole-body planar scan and a localised tomographic 
SPECT-CT of the target lesion).  All patients will also have a clinical pain assessment 
questionnaire to complete, and will have blood tests taken for serum ALP, CTX, TRAcP-5b, 
cathepsin-K and circulating tumour cell measurement.  These assessments will all be repeated 
12 weeks after the patients starts treatment. 
17.3.2 FAB-IE Planned recruitment  
For the whole FAB-IE study, requiring a power of 80%, a statistical significance level of p=0.05 
(two sided), a study population of 75 participants would equate to a clinically relevant standardised 
difference of 0.65 i.e. standard deviation of variable/clinically relevant difference243.  The study 
design stipulated, therefore, 25 patients from each tumour group (prostate cancer, breast cancer, 
and myeloma).  For the prostate cancer patients alone, 25 patients will equate to standardised 
difference of just over 1 to equate with a power of 80% and statistical significance of p=0.05, 
meaning that a change of variable greater than 1 standard deviation from the mean will be used 
to define a clinically significant change. 
17.3.3 FAB-IE Inclusion Criteria 
Only patients (over 18 years of age) with histologically confirmed prostate cancer, breast cancer 
or multiple myeloma, and with active skeletal metastatic disease (with at least 1 lesion >2cm), 
and who are to embark on new systemic therapy and are able and willing to give written informed 
consent and comply with the scheduled visits, will be included in the study. 
17.3.4 FAB-IE Exclusion Criteria 
Pregnant or lactating women will be excluded from the study.  Also, excluded will be patients with 
uncontrolled concomitant medical conditions, those with contraindications to MR Imaging, those 
likely to require palliative radiotherapy within the first 12 weeks of treatment, those likely to require 
G-CSF support during treatment, and also those with a prognosis of<6 months. 
17.3.5 FAB-IE SPECT/CT Scan Procedure 
There will be three components to the SPECT/CT scan: 
1. A dynamic planar acquisition (10-second frames, for 300 seconds following injection of 
the tracer 99mTc-maraciclatide) of a target metastatic site derived from the pre-treatment 
imaging (the same target lesion to be also used for MRI imaging) 
2. Whole-body planar scan (45 minutes after injection) 
3. SPECT-CT acquisition of target lesion (75 minutes after injection) 
17.3.6 FAB-IE DCE-MRI Procedure 
No specific patient preparation is necessary.  DCE-MRI will be performed of the same target 
metastatic site identified for SPECT-CT.  This will be performed using a 1.5T imaging system. 
17.3.7 FAB-IE DW-MRI Procedure 
No specific patient preparation is necessary.  DW-MRI will be performed using a 1.5T MR imaging 
system (Echo-planar spin-echo technique, free breathing, STIR fat suppression, with two b-values 
of 0 and 800 s/mm2, and patients will be scanned from skull base to mid-thigh. 
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17.3.8 FAB-IE Response Assessment 
FAB-IE Clinical Response Assessment 
Patients will be assessed by 2 specified oncologists/haematologists, blinded to the study scan 
results, at 12 and 24 weeks with radiological assessment using standard radiological approaches 
as felt clinically relevant, unless such investigations are clinically indicated before these times.  
Response will be based on clinical/biochemical measures 
For prostate cancer patients, PD will be concluded if there is worsening of symptoms, a need for 
palliative radiotherapy, a rise in tumour markers or ALP, or worsening imaging per the PCWG2 
guidance. 
RECIST imaging response criteria will be used to define treatment response in breast cancer 
using metastases in soft tissue rather than bone.  Progression may also be concluded if there is 
worsening of symptoms, a need for palliative radiotherapy, a rise in ALP or confirmed new sites 
of bony metastatic disease. 
For those patients recruited on the multiple myeloma arm, a standard assessment of response 
will be completed as clinically indicated (para-protein or free light chain measurement, 
haemoglobin level, or bone marrow assessment). 
FAB-IE SPECT - Response Assessment 
The perfusion index of the target lesion will be derived from the lesion uptake curve compared to 
the contralateral normal region of interest (Hermes Gold nuclear medicine analysis software, 
Sweden).  The number and distribution of skeletal metastases will be documented.   
Uptake quantification of up to 5 marker bone metastases larger than 2cm will be included, 
measuring the target-to-normal ROI ratio and the target-to-liver ratio.  Parameters from the whole-
body planar images and the SPECT-CT acquisition will be acquired. 
These parameters will be compared between baseline and the week 12 scan. 
FAB-IE DCE-MRI - Response Assessment 
AUC and Ktrans will be calculated at baseline and at 12 weeks. 
FAB-IE DW-MRI - Response Assessment 
ADC values will be compared between baseline and the 12-week scan. 
FAB-IE Serum Markers - Response Assessment 
TRAcP-5b, cathepsin-K, CTX and ALP blood levels at baseline and at 12 weeks will be compared 
to measure osteoblastic activity and global skeletal resorption. 
PSA changes will be recorded at baseline and at 12 weeks for prostate cancer patients.  Myeloma 
patients will have paraprotein levels/free light chain levels, haemoglobin and bone marrow data 
correlated with imaging outcomes. 
Circulating tumour cell numbers will be recorded at baseline and at 12 weeks. 
17.3.9 FAB-IE End Points 
Clinical/radiological response up to 24 weeks. 
Level and variability of alphavbeta3 integrin expression in bone metastases in patients with breast 
cancer, prostate cancer or multiple myeloma. 
Changes in alphavbeta3 integrin expression (measured at 12 weeks) in bone metastases in 
responders and non-responders (defined at up to 24 weeks) 
Changes in DCE/DW MRI parameters of vascularity and cellularity 
Changes in osteoclastic activity as measured by serum TRAcP-5b, cathepsin-K and bone 
resorption measured by CTX (measured at 12 weeks, compared with clinical/radiological 
response at up to 24 weeks) 
Changes in circulating tumour cell measurements (measured at 12 weeks, compared with clinic-
radiological response at up to 24 weeks) 
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17.4 FAB-B Methods 
17.4.1 FAB-B Overview 
FAB-B (Functional Assessment of Bone metastases – Breast) is a prospective exploratory non-
randomised study, aiming to recruit 34 patients with confirmed progressive bony metastatic breast 
cancer.  The patients will undergo whole-body 18F-Fluoride PET/CT, a whole-body 18F-FDG 
PET/CT and a whole-body DW-MRI before starting a new line in systemic chemotherapy.  
Patients will also complete a clinical pain assessment and quality of life measure, and will have 
serum measurement of ALP and bone turn over markers.  The imaging and clinical assessments 
will be repeated eight weeks after starting the new treatment, with further pain assessment, quality 
of life and blood tests at 12 and 24 weeks after initiation of systemic therapy.  If patients have a 
suspected flare response on the 8 week 18F-FDG PET/CT scan a further scan will be repeated 
at 12 weeks from baseline. 
17.4.2 FAB-B Objectives 
The primary objective of FAB-B is to identify a treatment response or PD earlier (at 8 weeks) than 
current clinical and radiological assessment at up to 24 weeks using DW-MRI and PET 
biomarkers.  Secondary objectives include determining the diagnostic accuracy of the functional 
imaging methods in staging the skeleton before treatment starts, and to enable exploration of the 
difference in baseline functional biomarkers between those who subsequently respond and 
progress on therapy.  It is also planned to explore differences in the functional imaging biomarkers 
between different metastatic phenotypes of bone metastases, i.e. sclerotic compared with lytic 
disease, and how the imaging biomarkers change with therapy, perhaps indicating the likely 
mechanisms involved with MRI signal changes. 
17.4.3 FAB-B Planned Recruitment 
Using the same methodology as for FAB-P (see earlier), FAB-B has been designed to require 30 
patients to achieve a power of 80% with a significance level of 0.05.  The planned recruitment is 
34 to allow for some attrition during the study. 
17.4.4 FAB-B Inclusion Criteria 
Only women over 18 years will be included in the study, and they will be required to have 
confirmed skeletal predominant metastatic breast cancer who are either treatment naïve or 
embarking on new systemic chemotherapy or endocrine therapy alongside a bone targeted 
therapy (denosumab or a bisphosphonate).  Participants will need to have a willingness to comply 
with the necessary study visits and tests. 
17.4.5 FAB-B Exclusion Criteria 
Pregnant or lactating women will be excluded from recruitment, as will those patients with 
concomitant uncontrolled medical conditions, poorly controlled diabetes mellitus, 
contraindications to PET or MRI imaging, and those patients who are likely to require palliative 
radiotherapy to bone metastases within the first 8 weeks of therapy.  Patients likely to require 
GCS-F were also excluded. 
17.4.6 FAB-B PET Scan Procedure 
The half-life of 18F requires the FDG and Fluoride PET scans to be completed on separate days 
to ensure no image contamination; a minimum of 12 hours has been stipulated for this study. 
Patients will fast for 4 hours prior to the 18F-FDG PET/CT scan.  400MBq of 18F-FDG will be 
administered and a whole-body scan from mid-thigh to skull base will be started 60 minutes after 
administration of the tracer, and take 30 minutes to acquire. 
On a separate day patients, will be prepared for the 18F-Fluoride PET/CT scan in a similar way, 
with a 4 hour fast.  150MBq of 18F-Fluoride tracer will be administered, and a whole-body scan 
(mid-thigh to skull-base) will be acquired at 60 minutes after tracer administration, taking 30 
minutes to scan. Venous blood samples will be taken at 30 minutes and 60 minutes after tracer 
injection (i.e. before and after the whole-body scan) to enable calculation of Ki. 
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17.4.7 FAB-B DW-MRI Scan Procedure 
No specific patient preparation is necessary.  Whole-Body DW-MRI will be performed using a 
1.5T MR imaging system (Echo-planar spin-echo technique, free breathing, STIR fat suppression, 
with two b-values of 0 and 800 s/mm2, and patients will be scanned from skull base to mid-thigh).  
Repeat DW-MRI imaging will be undertaken 8 weeks after initiation of the systemic therapy. 
17.4.8 FAB-B Response Assessment 
FAB-B Clinical Response Assessment 
The patients will be recruited from the treatment centre prostate cancer clinics; all therapies and 
clinical follow up assessments and investigations are at the discretion of the clinical teams. 
Assessment will be made by the patient’s oncologist, using clinical assessment and other imaging 
methods guided by the oncologist’s normal practice.  The treating oncology team will be blinded 
to the results of the trial imaging.  A clinical response assessment will be made by 24 weeks. 
FAB-B PET – Response Assessment 
At baseline, independent reviewers blinded to the conventional staging results will assess each 
scan, and record the disease stage and all sites of disease involvement, documenting the number 
and location of visible sites of disease that show increased metabolic activity greater than the 
background normal tissue levels.  The largest 5 lesions will undergo further analysis with 
measurement of SUVmean and SUVmax for each.  The mean values from the 5 lesions will be used 
as the overall semi-quantitative score of metabolic activity in each patient, and will be compared 
between baseline and 8 weeks.   
PERCIST response criteria will be used to classify treatment response on the PET images <Wahl, 
2009 #932>: 
1. Partial Metabolic Response (PMR) = >30% reduction in SUL (SUV corrected to lean body 
mass) peak 
2. Stable Metabolic Disease (SMD) = Neither complete metabolic response, PMD nor SMD 
3. Progressive Metabolic Disease (PMD) = >30% increase in SUL peak (with at least 
absolute rise of 0.8SUL) OR visible increase in uptake OR new metabolically active 
lesions 
The parameter Ki will also be measured for each representative lesion using the 18F-fluoride PET 
data. 
FAB-B DW-MRI – Response Assessment 
At baseline, independent reviewers blinded to the conventional staging results will assess each 
scan, and record sites of metastatic disease using a confidence score and subsequently 
corroborated with all available imaging findings.  An ADC map will be created for each scan, and 
for response analysis differences in mean ADC values between pre-treatment and post-treatment 
will be recorded.  ADC values will be calculated on a per patient and a per lesion basis to include 
up to the largest 5 lesions per patient.  The mean ADC value will be recorded for each of the five 
lesions, and the average of these will be recorded.  For each patient and lesion the absolute and 
percentage difference in mean ADC between baseline and post-treatment will be calculated.  
Progressors will be defined by a greater than 12% increase in mean ADC values.  Stable disease 
will be represented by ADC values between baseline and a 12% increase.  Receiver operator 
characteristic analysis will be used to identify a threshold value that best dichotomises patients 
into response groups. 
17.4.9 FAB-B End Points 
• Clinical/radiological response at up to 24 weeks 
• 18F-FDG response (SUVmax, SUVmean) at 8 weeks 
• 18F-Fluoride response (SUVmax, SUVmean, Ki) at 8 weeks 
DW-MRI response (ADC) at 8 weeks 
 
